Microbe Alteration of Active Substances

✅ Microbes that affect active substances (drugs, traditional medicines/herbs, bioactive compounds, environmental chemicals)

Click "Microbe Name" to access detailed information about the microbe active substance interaction profile and microbe abundance in human gut.

Microbe Name	Substance Name	Substance Category	Substance Subcategory	Metabolism Type	Metabolites	Effects on Substance	Experimental Organism	Experimental Disease Condition	Mebabolism Mechanism	Mebabolism Outcome	References
Unidentified gut microbes	Baicalin	Herbal Substance	Medicinal Herbal Compounds	Hydrolysis; deglycosylation	Baicalein; oroxylin A	Increase Efficacy	n.a.	Inflammation; diabetes mellitus; tumor	n.a.	Increased activity	PMID: 26569070; PMID: 22516259; PMID: 24947972; PMID: 24033282
Unidentified gut microbes	Olsalazine	Therapeutic Substance	Approved Drug	Azo reduction	5-aminosalicylclic acid	Increase Efficacy; Increase Toxicity	n.a.	Inflammatory diseases(ulcerative colitis; Crohn’s disease; rheumatoid arthritis)	n.a.	Increased activity or causing side effects(anorexia and nausea)	PMID: 26569070; PMID: 11230497
Unidentified gut microbes	Nizatidine	Therapeutic Substance	Approved Drug	N-oxide bond cleavage	n.a.	Decrease Efficacy	n.a.	Peptic ulcer disease	n.a.	Decreased intestinal absorption and systemic bioavailability	PMID: 26569070; PMID: 13481854
Unidentified gut microbes	Ranitidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	N-oxide bond cleavage	n.a.	Decrease Efficacy	n.a.	Peptic ulcer disease	n.a.	Decreased intestinal absorption and systemic bioavailability	PMID: 26569070; PMID: 13481854
Unidentified gut microbes	Flucytosine	Therapeutic Substance	Approved Drug	Deamination	5-fluorouracil	Increase Efficacy; Increase Toxicity	n.a.	n.a.	n.a.	Increased activity or toxicity	PMID: 26569070; PMID: 14768038
Unidentified anaerobic bacterium	Sulfinpyrazone	Therapeutic Substance	Approved Drug	Reduction	sulindac sulfide; sulinpyrzone sulfide	Increase Efficacy	n.a.	n.a.	n.a.	Increased activity	PMID: 26569070; PMID: 18927500
Unidentified anaerobic bacterium	Sulindac	Therapeutic Substance	Approved Drug	Reduction	sulindac sulfide; sulinpyrzone sulfide	Increase Efficacy	n.a.	n.a.	n.a.	Increased activity	PMID: 26569070; PMID: 18927500
Unidentified gut microbes	Insulin human	Therapeutic Substance	Approved Drug	Proteolysis	Peptides	Decrease Efficacy	n.a.	Type 1 diabetes mellitus	n.a.	Decreased activity	PMID: 26569070; PMID: 21051639
Unidentified gut microbes	Loperamide oxide	Therapeutic Substance	Investigational Drug	Reduction	Loperamide	Increase Efficacy	n.a.	n.a.	n.a.	Increased activity	PMID: 26569070; PMID: 21148486
Unidentified gut microbes	Nitrazepam	Therapeutic Substance	Approved Drug	Nitroreduction	7-aminonitrazepam	Increase Toxicity	n.a.	Moderate to severe insomnia	n.a.	Inducing teratogenicity	PMID: 26569070; PMID: 21156650
Unidentified gut microbes	Nitroglycerin	Therapeutic Substance	Approved Drug	Denitration	Glyceryl-1,3-dinitrate; glyceryl-1,2-dinitrate; glyceryl-1-mononitrate; glyceryl-2-mononitrate	Decrease Efficacy	n.a.	Angina pectoris	n.a.	Decreased activity	PMID: 26569070; PMID: 22902524
Unidentified gut microbes	Dihydroxyphenylalanine (DOPA)	Therapeutic Substance	n.a.	Dehydroxylation	m-tyramine; m-hydroxylphenylacetic acid	Increase Efficacy	n.a.	Parkinson’s disease	n.a.	Increased activity	PMID: 26569070; PMID: 24264989
Unidentified gut microbes	Indomethacin	Therapeutic Substance	Approved Drug	Deconjugation	n.a.	Decrease Efficacy; Increase Toxicity	n.a.	n.a.	n.a.	Decreased activity; increased side effects(diarrhea; anorexia; weight loss)	PMID: 26569070; PMID: 24264990
Unidentified gut microbes	Simvastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Hydrolysis; demethylation; hydroxylation/dehydroxylation; β-oxidation	Lactic acid; 3-hydroxybutanoic acid; cyclohexanecarboxylic acid; 2-hydroxyvaleric acid	n.a.	n.a.	Cardiovascular disease	n.a.	Altering its lipid-lowering activity	PMID: 26569070; PMID: 5913083
Unidentified gut microbes	Risperidone	Therapeutic Substance	Approved Drug	Ring cleavage; hydroxylation	Benzisoxazole ring scission; Benzisoxazole ring hydroxylation	Increase Toxicity	n.a.	n.a.	n.a.	Inducting symptoms of Parkinson’s disease	PMID: 26569070; PMID: 6836275
Unidentified gut microbes	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Amine formation; hydrolysis	p-aminphenyl-2-amino-1； 3-propanediol	Increase Toxicity	n.a.	n.a.	n.a.	Inducing bone marrow aplasia	PMID: 26569070; PMID: 8706020
Clostridium sp.	Daidzein	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	Reduction; phenolic ring opening	Dihydrodaidzein; equol; O-desmethylanolensin(ODMA）	Increase Efficacy	n.a.	Osteoporosis; menopausal symptoms; cardiovascular diseases; obesity	n.a.	Increased activity	PMID: 26569070
anaerobic bacterium 'strain 7'	Daidzein	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	Reduction; phenolic ring opening	Dihydrodaidzein; equol; O-desmethylanolensin(ODMA）	Increase Efficacy	n.a.	Osteoporosis; menopausal symptoms; cardiovascular diseases; obesity	n.a.	Increased activity	PMID: 26569070
Bacteroides uniformis	Genistein	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	Hydrogenation	Production of 5-hydroxyequol	n.a.	n.a.	Obesity; type 2 diabetes	n.a.	n.a.	PMID: 26569070
Bacteroides	Ginsenoside Rb1	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	Hydrolysis	Compound K	Increase Efficacy	n.a.	Inflammation; tumor	n.a.	Increased activity	PMID: 26569070
Bifidobacterium	Ginsenoside Rb1	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	Hydrolysis	Compound K	Increase Efficacy	n.a.	Inflammation; tumor	n.a.	Increased activity	PMID: 26569070
Eubacterium sp. GLH	Glycyrrhizin	Herbal Substance	Medicinal Herbal Compounds	Hydrolysis	18-β-glycyrrhetinic acid	Increase Efficacy	n.a.	Inflammation	n.a.	Increased activity	PMID: 26569070
Pseudocera	Hesperidin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Deglycosylation	Hesperetin	Increase Efficacy	n.a.	n.a.	n.a.	Increased activity	PMID: 26569070
Klebsiella pneumoniae	Lactulose	Therapeutic Substance	Approved Drug	Hydrolysis	Monosaccharides; lactate, acetate; butyrate	n.a.	n.a.	n.a.	n.a.	Stimulating the growth of beneficial bacteria(Bifidobacteria; Lactobacilli)	PMID: 26569070
Enterococcus faecalis	Lactulose	Therapeutic Substance	Approved Drug	Hydrolysis	Monosaccharides; lactate, acetate; butyrate	n.a.	n.a.	n.a.	n.a.	Stimulating the growth of beneficial bacteria(Bifidobacteria; Lactobacilli)	PMID: 26569070
Cronobacter sakazakii	Lactulose	Therapeutic Substance	Approved Drug	Hydrolysis	Monosaccharides; lactate, acetate; butyrate	n.a.	n.a.	n.a.	n.a.	Stimulating the growth of beneficial bacteria(Bifidobacteria; Lactobacilli)	PMID: 26569070
Enterococcus casseliflavus	Lactulose	Therapeutic Substance	Approved Drug	Hydrolysis	Monosaccharides; lactate, acetate; butyrate	n.a.	n.a.	n.a.	n.a.	Stimulating the growth of beneficial bacteria(Bifidobacteria; Lactobacilli)	PMID: 26569070
Bacteroides	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Thiazole ring opening	levametabol-I; levametabol-II; levametabol-III	Increase Efficacy	n.a.	Colon cancer	n.a.	Increased activity	PMID: 26569070
Clostridium sp.	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Thiazole ring opening	levametabol-I; levametabol-II; levametabol-III	Increase Efficacy	n.a.	Colon cancer	n.a.	Increased activity	PMID: 26569070
Clostridia	Metamfetamine	Therapeutic Substance	Approved Drug	Demethylation	Amphetamine; norephedrine; an unknown metabolite	Decrease Efficacy	n.a.	n.a.	n.a.	Decreased activity	PMID: 26569070
Enterococcus	Metamfetamine	Therapeutic Substance	Approved Drug	Demethylation	Amphetamine; norephedrine; an unknown metabolite	Decrease Efficacy	n.a.	n.a.	n.a.	Decreased activity	PMID: 26569070
Lactobacillus	Metamfetamine	Therapeutic Substance	Approved Drug	Demethylation	Amphetamine; norephedrine; an unknown metabolite	Decrease Efficacy	n.a.	n.a.	n.a.	Decreased activity	PMID: 26569070
Unidentified anaerobic bacterium	Omeprazole	Therapeutic Substance	Approved Drug	Reduction	corresponding sulfide metabolites	Decrease Efficacy	n.a.	Gastric ulcer	n.a.	Decreased activity	PMID: 26569070
Enterococcus casseliflavus	Quercetin-3-glucoside	Herbal Substance; Dietary Substance	Medicinal Herbal Compounds; Dietary Compounds	Deglycosylation	Butyrate; acetate; 3,4-dihydroxyphenylacetic acid	n.a.	n.a.	Cardiovascular disease; tumors	n.a.	n.a.	PMID: 26569070
Eubacterium ramulus	Quercetin-3-glucoside	Herbal Substance; Dietary Substance	Medicinal Herbal Compounds; Dietary Compounds	Deglycosylation	Butyrate; acetate; 3,4-dihydroxyphenylacetic acid	n.a.	n.a.	Cardiovascular disease; tumors	n.a.	n.a.	PMID: 26569070
Clostridioides difficile	Acetaminophen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	O-Sulfation; C-S cleavage of acetaminophen-3-cysteine	acetaminophen sulfate; glucuronide	Increase Efficacy; Decrease Toxicity	n.a.	n.a.	Microbial product(p-cresol) could alter the ratio of metabolites	Altered activity or toxicity	PMID: 26569070
Eggerthella lenta	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Reduction	Dihydrodigoxin; dihydrodigoxigenin	Decrease Efficacy	Human	Heart disease	n.a.	Decreased cardiac activity	PMID: 26569070
Unidentified gut microbes	Levodopa	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Dehydroxylation	m-tyrosine; m-tyramine; m-hydroxyphenylacetic acid	Decrease Efficacy	n.a.	Parkinson's disease	n.a.	Decreased activity	PMID: 26569070
Unidentified gut microbes	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Reduction	N-(2-hydroxyethyl)-oxamic acid; acetamide	Increase Toxicity	n.a.	n.a.	n.a.	Probably increase its liver toxicity	PMID: 26569070
Bacteroides fragilis	Sorivudine	Therapeutic Substance	Investigational Drug	Hydrolysis	(E)-5-(2-bromovinyl) uracil	Increase Toxicity	n.a.	n.a.	Metabolites can inactivate a key liver enzyme	Lead to lethal toxicity when co-administered with 5-fluorouracil	PMID: 26569070; PMID: 27591027
Bacteroides thetaiotaomicron	Sorivudine	Therapeutic Substance	Investigational Drug	Hydrolysis	(E)-5-(2-bromovinyl) uracil	Increase Toxicity	n.a.	n.a.	Metabolites can inactivate a key liver enzyme	Lead to lethal toxicity when co-administered with 5-fluorouracil	PMID: 26569070; PMID: 27591027
Bacteroides uniformis	Sorivudine	Therapeutic Substance	Investigational Drug	Hydrolysis	(E)-5-(2-bromovinyl) uracil	Increase Toxicity	n.a.	n.a.	Metabolites can inactivate a key liver enzyme	Lead to lethal toxicity when co-administered with 5-fluorouracil	PMID: 26569070; PMID: 27591027
Bacteroides vulgatus	Sorivudine	Therapeutic Substance	Investigational Drug	Hydrolysis	(E)-5-(2-bromovinyl) uracil	Increase Toxicity	n.a.	n.a.	Metabolites can inactivate a key liver enzyme	Lead to lethal toxicity when co-administered with 5-fluorouracil	PMID: 26569070; PMID: 27591027
Bacteroides eggerthii	Sorivudine	Therapeutic Substance	Investigational Drug	Hydrolysis	(E)-5-(2-bromovinyl) uracil	Increase Toxicity	n.a.	n.a.	Metabolites can inactivate a key liver enzyme	Lead to lethal toxicity when co-administered with 5-fluorouracil	PMID: 26569070; PMID: 27591027
Unidentified gut microbes	Mesalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Microbial arylamine N-acetyltransferases	Differences in gut microbial metabolism contribute to variations in drug efficacy	PMID: 11344150; PMID: 26972811
Unidentified gut microbes	Azo dyes	Environmental Chemicals	Industrial Chemicals and Pollutants	n.a.	n.a.	n.a.	n.a.	n.a.	Reduce azo bond	n.a.	PMID: 26972811; PMID: 14489780
Unidentified gut microbes	Enrofloxacin	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	Mouse	Enrofloxacin-or vancomycin-treated	Microbial fermentation of carbohydrates is disrupted	Decrease concentrations of amino acids and SCFAs;increase oligosaccharide levels	PMID: 18698804; PMID: 26972811
Unidentified gut microbes	Vancomycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	Mouse	Enrofloxacin-or vancomycin-treated	Microbial fermentation of carbohydrates is disrupted	Decrease concentrations of amino acids and SCFAs;increase oligosaccharide levels	PMID: 18698804; PMID: 26972811
Unidentified gut microbes	Pentobarbital	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Animal model	Germ-free,colonized	n.a.	Germ-free animals are more efficient at metabolizing drug	PMID: 19742318; PMID: 26972811
Unidentified gut microbes	Simvastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	Human	n.a.	n.a.	Treatment is positively associated with the production by the microbiota(lithocholic acid, taurolithocholic acid and glycolithocholic acid)	PMID: 22022402; PMID: 26972811
Unidentified gut microbes	Oxaliplatin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Production of reactive oxygen species	Induces apoptosis	PMID: 24264989; PMID: 26972811
Firmicutes	Cyclophosphamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Mouse	n.a.	Promote the translocation of bacteria into secondary lymphoid organs	Limit tumour growth	PMID: 24264990; PMID: 26972811
Eggerthella lenta	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	dihydrodigoxin	Decrease Efficacy	n.a.	n.a.	Cgr operon	n.a.	PMID: 6836275; PMID: 26972811
Unidentified gut microbes	Heterocyclic amines	Environmental Chemicals	Unclassified Substance	n.a.	n.a.	n.a.	n.a.	n.a.	Β-glucuronidases	Microbiota contribute to associations between the risk of CRC and the intake of heterocyclic amines	PMID: 8055651; PMID: 26972811
Unidentified gut microbes	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Microbial β-glucuronidase,liberate the sugar moiety from SN-38G	Re-activate the drug causing increased toxicity(towards intestinal epithelial cells);exacerbate the diarrhoea	PMID: 8891470; PMID: 26972811
Unidentified gut microbes	7-ethyl-10-hydroxycamptothecin	Therapeutic Substance	Investigational Drug	n.a.	SN-38G; ;cyanuric acid	Increase Toxicity	Animal model	Germ-free,colonized	n.a.	Metabolites are harmful to the host	PMID: 26972811
Fusobacteria	Acetaminophen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Microbial metabolite p-cresol competes with drug	Impede the ability to detoxify acetaminophen,accumulate the toxic metabolite NAPQI	PMID: 26972811
Clostridioides difficile	Acetaminophen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Microbial metabolite p-cresol competes with drug	Impede the ability to detoxify acetaminophen,accumulate the toxic metabolite NAPQI	PMID: 26972811
Bacteroidetes	Acetaminophen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Microbial metabolite p-cresol competes with drug	Impede the ability to detoxify acetaminophen,accumulate the toxic metabolite NAPQI	PMID: 26972811
Actinobacteria	Acetaminophen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Microbial metabolite p-cresol competes with drug	Impede the ability to detoxify acetaminophen,accumulate the toxic metabolite NAPQI	PMID: 26972811
Bifidobacterium	Anti-PD-L1 therapy	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Increase the efficacy of PD-1	PMID: 26972811
Staphylococcus	Anti-TNF antibobies	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Therapy is accompanied by a substantial increase in the abundance of bacteria	PMID: 26972811
Aspergillus nidulans	Black tea	Dietary Substance	Drinks	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Increase the abundance of A. muciniphila	PMID: 26972811
Proteobacteria	Choline-containing compounds	Environmental Chemicals	Unclassified Substance	n.a.	n.a.	n.a.	n.a.	n.a.	Microbial glycyl radical enzymes	Associate with the risk of cardiovascular disease	PMID: 26972811
Firmicutes	Choline-containing compounds	Environmental Chemicals	Unclassified Substance	n.a.	n.a.	n.a.	n.a.	n.a.	Microbial glycyl radical enzymes	Associate with the risk of cardiovascular disease	PMID: 26972811
Bacteroides fragilis	CTLA-4 blockade	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Blockade immunotherapy	PMID: 26972811
Bacteroides thetaiotaomicron	CTLA-4 blockade	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Blockade immunotherapy	PMID: 26972811
Enterococcus faecium	Daidzin	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	equol	n.a.	n.a.	n.a.	Glycosidic cleavage and reduction	n.a.	PMID: 26972811
Bifidobacterium sp.	Daidzin	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	equol	n.a.	n.a.	n.a.	Glycosidic cleavage and reduction	n.a.	PMID: 26972811
Lactobacillus mucosae	Daidzin	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	equol	n.a.	n.a.	n.a.	Glycosidic cleavage and reduction	n.a.	PMID: 26972811
Eggerthella sp.	Daidzin	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	equol	n.a.	n.a.	n.a.	Glycosidic cleavage and reduction	n.a.	PMID: 26972811
Unidentified gut microbes	Dietary phosphatidylcholine	Dietary Substance	Dietary Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Bacteria provide a link for drugs	PMID: 26972811
Gordonibacter	Ellagic acid	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Metabolize ellagitannins	PMID: 26972811
Aspergillus nidulans	Grape-derived polyphenols	Dietary Substance	Dietary Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Increase the abundance of A. muciniphila	PMID: 26972811
Unidentified gut microbes	Heterocyclic amine 2-amino-3-methylimidazo[4,5-f]quinoline (IQ)	Environmental Chemicals	Unclassified Substance	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Reactivate the compound	PMID: 26972811
Campylobacter	Isoaminile	Therapeutic Substance	Approved Drug	n.a.	cyclohexylamine	n.a.	Animal model	n.a.	n.a.	Exhibit toxicity	PMID: 26972811
Escherichia	Isoaminile	Therapeutic Substance	Approved Drug	n.a.	cyclohexylamine	n.a.	Animal model	n.a.	n.a.	Exhibit toxicity	PMID: 26972811
Enterococcus	Isoaminile	Therapeutic Substance	Approved Drug	n.a.	cyclohexylamine	n.a.	Animal model	n.a.	n.a.	Exhibit toxicity	PMID: 26972811
Clostridium	Isoaminile	Therapeutic Substance	Approved Drug	n.a.	cyclohexylamine	n.a.	Animal model	n.a.	n.a.	Exhibit toxicity	PMID: 26972811
Corynebacterium	Isoaminile	Therapeutic Substance	Approved Drug	n.a.	cyclohexylamine	n.a.	Animal model	n.a.	n.a.	Exhibit toxicity	PMID: 26972811
Firmicutes	Isoflavones	Dietary Substance	Dietary Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Metabolites bind to oestrogen receptors	May elicit protective effects against breast cancer	PMID: 26972811
Bacteroidetes	Isoflavones	Dietary Substance	Dietary Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Metabolites bind to oestrogen receptors	May elicit protective effects against breast cancer	PMID: 26972811
Actinobacteria	Isoflavones	Dietary Substance	Dietary Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Metabolites bind to oestrogen receptors	May elicit protective effects against breast cancer	PMID: 26972811
Firmicutes	Lignans	Herbal Substance; Dietary Substance	Medicinal Herbal Compounds; Dietary Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Metabolites bind to oestrogen receptors	May elicit protective effects against breast cancer	PMID: 26972811
Bacteroidetes	Lignans	Herbal Substance; Dietary Substance	Medicinal Herbal Compounds; Dietary Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Metabolites bind to oestrogen receptors	May elicit protective effects against breast cancer	PMID: 26972811
Actinobacteria	Lignans	Herbal Substance; Dietary Substance	Medicinal Herbal Compounds; Dietary Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Metabolites bind to oestrogen receptors	May elicit protective effects against breast cancer	PMID: 26972811
Unidentified gut microbes	Methotrexate	Therapeutic Substance	Approved Drug	n.a.	n.a.	Decrease Efficacy	Animal model	Germ-free,colonized	Conversion into a downstream metabolite with reduced bioactivity	n.a.	PMID: 26972811
Unidentified gut microbes	NSAIDs	Therapeutic Substance	Drug Class	n.a.	SN-38G; ;cyanuric acid	Increase Toxicity	Animal model	Germ-free,colonized	n.a.	Metabolites are harmful to the host	PMID: 26972811
Unidentified gut microbes	Phenoxyethanol	Therapeutic Substance	Approved Drug	n.a.	SN-38G; ;cyanuric acid	Increase Toxicity	Animal model	Germ-free,colonized	n.a.	Metabolites are harmful to the host	PMID: 26972811
Raoultella terrigena	Phenoxyethanol	Therapeutic Substance	Approved Drug	n.a.	cyanuric acid	n.a.	Animal model	n.a.	n.a.	Lead to increased kidney damage	PMID: 26972811
Raoultella terrigena	Phenoxyethanol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Metabolism by the bacteria	Lead to kidney stones	PMID: 26972811
Akkermansia muciniphila	Polyphenols	Herbal Substance; Dietary Substance	Medicinal Herbal Compounds; Dietary Compounds	n.a.	n.a.	n.a.	Mouse	Fed high-fat diets	Couple with substantial sevenfold-to-tenfold blooms of drug	Limit the risk of systemic inflammation	PMID: 26972811
Clostridiales bacterium	Saccharin	Therapeutic Substance; Dietary Substance; Herbal Substance	Investigational Drug; Dietary Compounds; Artificial Sweetener; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	Mouse	Colonized with gut micro organisms from NAS-treated mice,or with faecal microorganisms	n.a.	Increase the abundance of bacteria	PMID: 26972811
Unidentified gut microbes	Secoisolariciresinol	Therapeutic Substance	Investigational Drug	n.a.	enterodiol,enterolactone	n.a.	n.a.	n.a.	n.a.	Product the cancer-protective compounds	PMID: 26972811
Unidentified gut microbes	Simvastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Increase Bioavailability	n.a.	n.a.	Modulate the expression of host transporters,or directly compete with host transporters	Contribute to the absorption of simvastatin	PMID: 26972811
Unidentified gut microbes	Sulfanilamide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Increase Efficacy	Animal model	Germ-free,colonized	Conversion to bioactive form	Contribute to therapeutic concentrations	PMID: 26972811
Enterococcus faecalis	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	Antibiotic-treated or germ-free;convention	n.a.	Result in drug cleavage	PMID: 26972811
Lactobacillus sp.	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	Antibiotic-treated or germ-free;convention	n.a.	Result in drug cleavage	PMID: 26972811
Bacteroides sp.	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	Antibiotic-treated or germ-free;convention	n.a.	Result in drug cleavage	PMID: 26972811
Unidentified gut microbes	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Efficacy	Animal model	Germ-free,colonized	Conversion to bioactive form	Contribute to therapeutic concentrations	PMID: 26972811
Faecalibacterium prausnitzii	Tacrolimus	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	Human	Kidney transplant recipient	n.a.	The abundance of the gut bacterium has a positive correlation with an increase in tacrolimus dosing	PMID: 26972811
Unidentified gut microbes	TMAO	Environmental Chemicals	Human Metabolite	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Bacteria provide a link for drugs	PMID: 26972811
Clostridiales bacterium	Xylitol	Therapeutic Substance; Herbal Substance		n.a.	n.a.	n.a.	Mouse	Colonized with gut micro organisms from NAS-treated mice,or with faecal microorganisms	n.a.	Increase the abundance of bacteria	PMID: 26972811
Bacteroidales	Carboxymethylcellulose	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Mouse	n.a.	Decrease the abundance of Bacteroidales;increase the abundance of mucolytic bacteria	The shifts in microbiota are accompanied by low-grade inflammation,increased gut permeability, increased weight and adiposity, and the development of metabolic syndrome	PMID: 26972811
[Ruminococcus] gnavus	Carboxymethylcellulose	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Mouse	n.a.	Decrease the abundance of Bacteroidales;increase the abundance of mucolytic bacteria	The shifts in microbiota are accompanied by low-grade inflammation,increased gut permeability, increased weight and adiposity, and the development of metabolic syndrome	PMID: 26972811
Bacteroidales	Polysorbate 80	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Mouse	n.a.	Decrease the abundance of Bacteroidales;increase the abundance of mucolytic bacteria	The shifts in microbiota are accompanied by low-grade inflammation,increased gut permeability, increased weight and adiposity, and the development of metabolic syndrome	PMID: 26972811
[Ruminococcus] gnavus	Polysorbate 81	Environmental Chemicals	Industrial Chemicals and Pollutants	n.a.	n.a.	n.a.	Mouse	n.a.	Decrease the abundance of Bacteroidales;increase the abundance of mucolytic bacteria	The shifts in microbiota are accompanied by low-grade inflammation,increased gut permeability, increased weight and adiposity, and the development of metabolic syndrome	PMID: 26972811
Escherichia coli	Glucuronidated compound	Environmental Chemicals	Unclassified Substance	n.a.	n.a.	n.a.	Mouse	Convention,germ-free	Β-glucuronidases	Reactivate the toxic compound and augment genotoxicity	PMID: 26972811
Unidentified gut microbes	Sulfanilamide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	triamino benzene,sulfanilamide	Increase Efficacy	n.a.	n.a.	Reduce azo bond	Activate drug	PMID: 26972811
Enterococcus faecalis	Secoisolariciresinol	Therapeutic Substance	Investigational Drug	n.a.	enterodiol and entero lactone	Increase Efficacy	Rat	Germ-free,or germ-free colonized with a bacterial consortium	Metabolism by bacteria	Protective effects against breast cancer	PMID: 26972811
Eubacterium limosum	Secoisolariciresinol	Therapeutic Substance	Investigational Drug	n.a.	enterodiol and entero lactone	Increase Efficacy	Rat	Germ-free,or germ-free colonized with a bacterial consortium	Metabolism by bacteria	Protective effects against breast cancer	PMID: 26972811
[Clostridium] scindens	Secoisolariciresinol	Therapeutic Substance	Investigational Drug	n.a.	enterodiol and entero lactone	Increase Efficacy	Rat	Germ-free,or germ-free colonized with a bacterial consortium	Metabolism by bacteria	Protective effects against breast cancer	PMID: 26972811
Blautia producta	Secoisolariciresinol	Therapeutic Substance	Investigational Drug	n.a.	enterodiol and entero lactone	Increase Efficacy	Rat	Germ-free,or germ-free colonized with a bacterial consortium	Metabolism by bacteria	Protective effects against breast cancer	PMID: 26972811
Eggerthella lenta	Secoisolariciresinol	Therapeutic Substance	Investigational Drug	n.a.	enterodiol and entero lactone	Increase Efficacy	Rat	Germ-free,or germ-free colonized with a bacterial consortium	Metabolism by bacteria	Protective effects against breast cancer	PMID: 26972811
Lactonifactor longoviformis	Secoisolariciresinol	Therapeutic Substance	Investigational Drug	n.a.	enterodiol and entero lactone	Increase Efficacy	Rat	Germ-free,or germ-free colonized with a bacterial consortium	Metabolism by bacteria	Protective effects against breast cancer	PMID: 26972811
Unidentified gut microbes	Diclofenac	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Microbial β-glucuronidase	Cause mitochondrial and endo plasmic reticulum stress, compromise mucosal integrity and promote inflammation	PMID: 26972811
Unidentified gut microbes	Indomethacin	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Microbial β-glucuronidase	Cause mitochondrial and endo plasmic reticulum stress, compromise mucosal integrity and promote inflammation	PMID: 26972811
Unidentified gut microbes	Ketoprofen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Microbial β-glucuronidase	Cause mitochondrial and endo plasmic reticulum stress, compromise mucosal integrity and promote inflammation	PMID: 26972811
Bacteroides	Saccharin	Therapeutic Substance; Dietary Substance; Herbal Substance	Investigational Drug; Dietary Compounds; Artificial Sweetener; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	Mouse	Colonized with gut micro organisms from NAS-treated mice,or with faecal microorganisms	n.a.	Increase the abundance of bacteria	PMID: 26972811
Unidentified gut microbes	Tempol	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	Mouse	n.a.	n.a.	Increase the abundance of Bacteroidetes;decrease the abundance of Firmicutes	PMID: 26972811
Firmicutes	Tempol	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Reduce members of the genus Lactobacillus	PMID: 26972811
Bacteroides	Xylitol	Therapeutic Substance; Herbal Substance		n.a.	n.a.	n.a.	Mouse	Colonized with gut micro organisms from NAS-treated mice,or with faecal microorganisms	n.a.	Increase the abundance of bacteria	PMID: 26972811
Lactobacillus	Amoxicillin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Decrease expression of genes involved in antimicrobial defence	Nearly eradicated the lactobacilli	PMID: 26972811
Clostridioides difficile	Amoxicillin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Piglet	n.a.	n.a.	Promote colonization by opportunistic pathogens	PMID: 26972811
Candida albicans	Amoxicillin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Piglet	n.a.	n.a.	Promote colonization by opportunistic pathogens	PMID: 26972811
Clostridioides difficile	Antibiotic	Therapeutic Substance	Drug Class	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	n.a.	Cause antibiotic-associated diarrhoea(AAD);pseudomembranous colitis(can cause death)	PMID: 26972811
Candida albicans	Cefoperazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Total number of bacteria is reduced;overgrowth of C.albicans	Allergic-airways diease develops after challenge with mould spores	PMID: 26972811
Lactobacillus	Cephalosporins	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	Suppression of lactocilli and bifidobacterial;overgrowth of C.albicans	Increase susceptibility to asthma	PMID: 26972811
Bifidobacterium	Cephalosporins	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	Suppression of lactocilli and bifidobacterial;overgrowth of C.albicans	Increase susceptibility to asthma	PMID: 26972811
Candida albicans	Cephalosporins	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	Suppression of lactocilli and bifidobacterial;overgrowth of C.albicans	Increase susceptibility to asthma	PMID: 26972811
Lactobacillus	Kanamycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Total number of anaerobes is reduced	Clinical scores for atopic dermatitis are higher	PMID: 26972811
Bifidobacterium sp.	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	More bifidobacterium spp.	PMID: 26972811
Gram-negative bacterium B1G-1A	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	Mouse	n.a.	Reduce expression of the gene encoding REG3γ	n.a.	PMID: 26972811
Gram-negative bacterium B1G-1A	Neomycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	Mouse	n.a.	Reduce expression of the gene encoding REG3γ	n.a.	PMID: 26972811
Salmonella enterica subsp. enterica serovar Typhimurium	Streptomycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	Mouse	Streptomycin treated	Butyrate contribute to the increased infiltration of neutrophils	Result in an increased inflammatory state	PMID: 26972811
Unidentified vaginal microbes	Unspecified antibiotic	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	Loss of vaginal lactobacilli;and overgrowth of C.albicans	n.a.	PMID: 26972811
Candida albicans	Unspecified antibiotic	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	Loss of vaginal lactobacilli;and overgrowth of C.albicans	n.a.	PMID: 26972811
Unidentified gut microbes	Vancomycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Gram-negatinve populations are depleted(not being restricted by vancomycin)	PMID: 26972811
Gram-negative bacterium B1G-1A	Vancomycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	Mouse	n.a.	Reduce expression of the gene encoding REG3γ	n.a.	PMID: 26972811
Unidentified gut microbes	Nizatidine	Therapeutic Substance	Approved Drug	n.a.	hydroxyiminonizatidine	n.a.	n.a.	n.a.	Cleavage on an N-oxide bond	n.a.	PMID: 27485182; PMID: 11955801
Unidentified gut microbes	Nabumetone	Therapeutic Substance	Approved Drug	n.a.	4-(6-methoxy-2-naphthyl)-butan-2-ol (reduced nabumetone)	Decrease Efficacy	n.a.	n.a.	n.a.	Cause lower absorbtion of nabumetone and lower its bioavailability;[drug interaction:erythromycin and tetracycline suppresses the reduction of digoxin]	PMID: 23584048; PMID: 27485182
Unidentified gut microbes	Lovastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	a phosphorylated derivative and active 2-hydroxy lovastatic acid	n.a.	Rat	n.a.	Hydrolyzed	[drug interaction]:antibiotics decreases the bioavailability of the active metabolite	PMID: 27485182; PMID: 24947972
Unidentified gut microbes	Lovastatin related compounds	Therapeutic Substance	n.a.	n.a.	a phosphorylated derivative and active 2-hydroxy lovastatic acid	n.a.	Rat	n.a.	Hydrolyzed	[drug interaction]:antibiotics decreases the bioavailability of the active metabolite	PMID: 27485182; PMID: 24947972
Unidentified gut microbes	Sulfinpyrazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Human; Rabbit	Healthy volunteers and ileostomy patients;/	Microbiota seems to be only site of sulfinpyrazone reduction(in man)	n.a.	PMID: 3630204; PMID: 27485182
Unidentified gut microbes	Sulindac	Therapeutic Substance	Approved Drug	n.a.	sulindac sulfide	n.a.	Human; Rabbit	n.a.	n.a.	n.a.	PMID: 3630204; PMID: 27485182
Unidentified gut microbes	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	5-aminosalicylic acid (mesalazine)and sulfapyridine	Decrease Toxicity	n.a.	n.a.	Bacterial azoreductases	Lead to side effect	PMID: 27485182; PMID: 4147555
Unidentified gut microbes	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	p-aminophenyl-2-amin-1,3-propanediol	Increase Toxicity	human	n.a.	n.a.	Produce toxic metabolite related to risk of marrow aplasia	PMID: 27485182; PMID: 4165044
Unidentified anaerobic bacterium	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	N-(2-hydroxyethyl)-oxamic acid and acetamide	n.a.	Rat	Conventional(CV),germ-free(GF)	Reductive modification,disrupt the imidazole ring	n.a.	PMID: 27485182; PMID: 430360
Clostridium perfringens	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	N-(2-hydroxyethyl)-oxamic acid and acetamide	n.a.	Rat	Conventional(CV),germ-free(GF)	Reductive modification,disrupt the imidazole ring	n.a.	PMID: 27485182; PMID: 430360
Unidentified gut microbes	Levodopa	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	m-tyramine and m-hydroxyphenylacetic acid	n.a.	Rat	Conventional,in pathogen free	Dehydroxylation of the catechol ring	Form the metabolites	PMID: 4723308; PMID: 27485182
Unidentified gut microbes	Misonidazole	Therapeutic Substance	Investigational Drug	n.a.	amino derivative	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 6260109; PMID: 27485182
Unidentified gut microbes	Balsalazide	Therapeutic Substance	Approved Drug	n.a.	5-aminosalicylic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 27485182; PMID: 6345112
Unidentified gut microbes	Clonazepam	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	Germ-free and ex-germ-free	Nitro reduction	n.a.	PMID: 27485182; PMID: 6506755
Unidentified gut microbes	Risperidone	Therapeutic Substance	Approved Drug	n.a.	dihydroxy-risperidone and hydroxyl-ke-to-risperidone	n.a.	Rat	n.a.	n.a.	[drug interaction]:(in the liver)antibiotics decrease the bioavailability of risperidone.	PMID: 27485182; PMID: 7512019
Unidentified gut microbes	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	sulfide metabolites	n.a.	n.a.	n.a.	Reductive metabolism	n.a.	PMID: 27485182; PMID: 7629748
Unidentified gut microbes	Zonisamide	Therapeutic Substance	Approved Drug	n.a.	2-sulfamoylacetylphenol	n.a.	Mouse; Rat; Hamster; Rabbit; Guinea pig	n.a.	Reductive metabolism	[drug interaction]:antibiotics inhibit the urinary and faecal excretion of metabolites	PMID: 9231340; PMID: 27485182
Unidentified gut microbes	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	dihydrodigoxin and dihydrodigoxigenin	Decrease Efficacy	human	n.a.	Formation of inactive metabolites	Have lower cardiac activity	PMID: 27485182; PMID: 7266632
Unidentified gut microbes	Mesalazine	Therapeutic Substance	Approved Drug	n.a.	N-acetyl-5-aminosalicylic acid	n.a.	Human; Rat; Guinea pig; Dog	n.a.	Acetylated by the gut microbiota	n.a.	PMID: 27485182
Unidentified gut microbes	Sulfapyridine	Therapeutic Substance	Approved Drug	n.a.	N-acetyl-5-aminosalicylic acid	n.a.	Human; Rat; Guinea pig; Dog	n.a.	Acetylated by the gut microbiota	n.a.	PMID: 27485182
Clostridioides difficile	Acetaminophen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	p-cresol sulfate and phenylacetylglutamine	Increase Toxicity	n.a.	n.a.	O-sulfation; C-S cleavage of acetaminophen-3-cysteine	Increased toxicity	PMID: 27485182
Bacteroides	Lactulose	Therapeutic Substance	Approved Drug	n.a.	fructose and galactose	Increase Efficacy	n.a.	n.a.	Hydrolysis of enzymes of the intestinal bacteria	Lead to laxative effect of lactulose	PMID: 27485182
Lactobacillus	Lactulose	Therapeutic Substance	Approved Drug	n.a.	fructose and galactose	Increase Efficacy	n.a.	n.a.	Hydrolysis of enzymes of the intestinal bacteria	Lead to laxative effect of lactulose	PMID: 27485182
Escherichia coli	Lactulose	Therapeutic Substance	Approved Drug	n.a.	fructose and galactose	Increase Efficacy	n.a.	n.a.	Hydrolysis of enzymes of the intestinal bacteria	Lead to laxative effect of lactulose	PMID: 27485182
Clostridium sp.	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	levametabol-I,levametabol-II,and levametabol-III	Increase Efficacy	human	n.a.	Open thiazole ring	Increased activity;[drug interaction]:antibiotics increase a stronger clinical effect of levamisole	PMID: 27485182
Bacteroidetes	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	levametabol-I,levametabol-II,and levametabol-III	Increase Efficacy	human	n.a.	Open thiazole ring	Increased activity;[drug interaction]:antibiotics increase a stronger clinical effect of levamisole	PMID: 27485182
Escherichia coli ATCC 25922	Nabumetone	Therapeutic Substance	Approved Drug	n.a.	a reduced pharmacologically inactive metabolite	Decrease Efficacy	n.a.	n.a.	n.a.	Cause lower absorbtion and lower bioavailability of the drug	PMID: 27485182
[Clostridium] leptum	Nitrazepam	Therapeutic Substance	Approved Drug	n.a.	7-aminonitrazepam	n.a.	Mouse; Rat	n.a.	Nitro reduction	Produce products with teratogenic effects	PMID: 27485182
Bacteroides sp.	Sorivudine	Therapeutic Substance	Investigational Drug	n.a.	(E)-5-(2-bromovinyl) uracil	n.a.	n.a.	n.a.	n.a.	[drug interaction]:metabolites cause toxic level of anticancer drug 5-fluorouracil	PMID: 27485182
Unidentified gut microbes	Neoprontosil	Therapeutic Substance	Approved Drug	n.a.	sulfanilamide	Increase Efficacy	n.a.	n.a.	Reduction of the azo bond by azoreductases of the large intestinal microbiota	Activate prodrug,have antibacterial effect;[drug interaction]:antbiotics suppress the conversion of prontosil	PMID: 27485182
Unidentified gut microbes	Sulfanilamide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	sulfanilamide	Increase Efficacy	n.a.	n.a.	Reduction of the azo bond by azoreductases of the large intestinal microbiota	Activate prodrug,have antibacterial effect;[drug interaction]:antbiotics suppress the conversion of prontosil	PMID: 27485182
Unidentified gut microbes	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	SN-38	Increase Toxicity	n.a.	n.a.	Β-glucuronidases	Cause diarrhoea;[drug interaction]:(rat)ciprofloxacin and amoxapine can suppress diarrhoea	PMID: 21051639; PMID: 28270698
Unidentified gut microbes	CpG oligodeoxynucleotides	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	Mouse	n.a.	Bacteria regulate the immune response to chemotherapy(primes tumour-associated innate myeloid cells for inflammatory cytokine production)	[drug interaction]:antibiotic or germ-free (sterile) status attenuates this response	PMID: 24264989; PMID: 28270698
Unidentified gut microbes	Cyclophosphamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Mouse	n.a.	n.a.	Cause commensal bacteria translocation into secondary lymphoid organs;reduce the abundance of lactobacilli and enterococci;[drug interaction]:long-term antibiotics reduce the capacity of cyclophosphamide	PMID: 24264990; PMID: 28270698
Unidentified gut microbes	Doxorubicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	Mouse	n.a.	n.a.	Cause commensal bacteria translocation into secondary lymphoid organs;reduce the abundance of lactobacilli and enterococci;[drug interaction]:long-term antibiotics reduce the capacity of cyclophosphamide	PMID: 24264990; PMID: 28270698
Unidentified gut microbes	Methotrexate	Therapeutic Substance	Approved Drug	n.a.	n.a.	Decrease Toxicity	n.a.	n.a.	TLR2 signalling and drug transporter p-gp	Bacteria regulate against chemotherapy-induced small bowel injury	PMID: 25589072; PMID: 28270698
Unidentified gut microbes	Ginsenosides	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Metabolized via microbiota from compound K79	Metabolites have anti-proliferative effects in human colon cancer cells;[drug interaction]:co-treatment with 5-FU and its pro-drug intermediate 5’-deoxy-5-fluorouridine,potentiate the anticancer effects	PMID: 25625815; PMID: 28270698
Unidentified gut microbes	CTLA-4 blockade	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	Mouse	Specific pathogen-free,germ-free(GF)	n.a.	MCA205 sarcoma progression is not controlled(in germ-free mice;or those treated with broad-spectrum antibiotics)	PMID: 26541610; PMID: 28270698
Mycoplasma hyorhinis	Floxuridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Bacterium encode a thymidine phosphorylase	Restrict the cytostatic activity of pyrimidine nucleoside analogue compounds	PMID: 28270698
Mycoplasma hyorhinis	Trifluridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Bacterium encode a thymidine phosphorylase	Restrict the cytostatic activity of pyrimidine nucleoside analogue compounds	PMID: 28270698
Bifidobacterium sp.	Anti-PD-L1 therapy	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	Mouse	n.a.	Exhibit the association with antitumour T-cell responses(through dendritic cell activation)	Combination of microbiota and anti-PD-L1 improve tumour control,inducte tumour-specific T cells,increase T cells in the tumour microenvironment	PMID: 28270698
Proteobacteria	Carmustine, Etoposide, Cytarabine and melphalan combination	Therapeutic Substance	Drug Combination	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Reducte bacteria that limit inflammation,increase bacteria associated with colitis	PMID: 28270698
Firmicutes	Carmustine, Etoposide, Cytarabine and melphalan combination	Therapeutic Substance	Drug Combination	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Reducte bacteria that limit inflammation,increase bacteria associated with colitis	PMID: 28270698
Actinobacteria	Carmustine, Etoposide, Cytarabine and melphalan combination	Therapeutic Substance	Drug Combination	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Reducte bacteria that limit inflammation,increase bacteria associated with colitis	PMID: 28270698
Ruminococcus	CpG oligodeoxynucleotides	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 28270698
Alistipes	CpG oligodeoxynucleotides	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 28270698
Burkholderiales	CTLA-4 blockade	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	Mouse	n.a.	n.a.	A cocktail of bacteria ameliorate CTLA-4-blockade-induced subclinical colitis and colon inflammatory scores in antibiotic-treated mice	PMID: 28270698
Bacteroidales	CTLA-4 blockade	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	Mouse	n.a.	n.a.	A cocktail of bacteria ameliorate CTLA-4-blockade-induced subclinical colitis and colon inflammatory scores in antibiotic-treated mice	PMID: 28270698
Segmented filamentous bacteria	Cyclophosphamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Gram-positive commensals mediate accumulation of TH17 and TH1-cell response	PMID: 28270698
Lactobacillus	Cyclophosphamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Gram-positive commensals mediate accumulation of TH17 and TH1-cell response	PMID: 28270698
Pseudomonas aeruginosa	Cyclophosphamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Mouse	Fed a diet(high in protein, l-leucine, fish oil and specific oligosaccharides);an isoenergetic control die	n.a.	Reduce incidence and severity of Pseudomonas aeruginosa translocation	PMID: 28270698
Enterococcus hirae	Cyclophosphamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Mouse	Inoculated with MCA205 tumours;microbiota-depleted	As an orchestrator of cyclophosphamide effects	n.a.	PMID: 28270698
Barnesiella intestinihominis	Cyclophosphamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Mouse	Inoculated with MCA205 tumours;microbiota-depleted	As an orchestrator of cyclophosphamide effects	n.a.	PMID: 28270698
Enterococcus hirae	Cyclophosphamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs	PMID: 28270698
Lactobacillus murinus	Cyclophosphamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs	PMID: 28270698
Lactobacillus johnsonii	Cyclophosphamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs	PMID: 28270698
Enterococcus hirae	Doxorubicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs	PMID: 28270698
Lactobacillus murinus	Doxorubicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs	PMID: 28270698
Lactobacillus johnsonii	Doxorubicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs	PMID: 28270698
Unidentified gut microbes	Ellagic acid	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	urolithins	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 28270698
Mycoplasma	Gemcitabine	Therapeutic Substance	Approved Drug	n.a.	n.a.	Decrease Efficacy	n.a.	n.a.	Pyrimidine nucleoside phosphorylase and cytidine deaminase enzyme	Have deleterious effects on its therapeutic efficacy	PMID: 28270698
Bacteroidetes	Ipilimumab	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Bacterially mediated B vitamin production and polyamine transport deficiencies	Bacteria is associated with increased risk of CTLA‑4 blockade‑induced colitis	PMID: 28270698
Enterobacteriaceae	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	n.a.	Increase abundance of bacteria	Cause diarrhoea;	PMID: 28270698
Streptococcus thermophilus	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	n.a.	n.a.	Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis	PMID: 28270698
Clostridioides difficile	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	n.a.	Increase abundance of bacteria	Cause diarrhoea;	PMID: 28270698
Lactobacillus acidophilus	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	n.a.	n.a.	Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis	PMID: 28270698
Lactobacillus plantarum	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	n.a.	n.a.	Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis	PMID: 28270698
Lactobacillus paracasei	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	n.a.	n.a.	Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis	PMID: 28270698
Bifidobacterium breve	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	n.a.	n.a.	Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis	PMID: 28270698
Bifidobacterium longum	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	n.a.	n.a.	Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis	PMID: 28270698
Lactobacillus delbrueckii subsp. bulgaricus	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	n.a.	n.a.	Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis	PMID: 28270698
Bifidobacterium longum subsp. infantis	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	n.a.	n.a.	Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis	PMID: 28270698
Unidentified gut microbes	Methotrexate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Reduce diversity and shift in relative abundance associated with chemotherapy-induced diarrhoea	PMID: 28270698
Unidentified gut microbes	Methotrexate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	n.a.	n.a.	Reduce microbial abundance(decrease anaerobes and streptococci,relative increase of Bacteroides);change in microbiota is associated with diarrhoea	PMID: 28270698
Bacteroides	Methotrexate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Reduce diversity and shift in relative abundance associated with chemotherapy-induced diarrhoea	PMID: 28270698
Bacteroides	Methotrexate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	n.a.	n.a.	Reduce microbial abundance(decrease anaerobes and streptococci,relative increase of Bacteroides);change in microbiota is associated with diarrhoea	PMID: 28270698
Streptococcus	Methotrexate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Reduce diversity and shift in relative abundance associated with chemotherapy-induced diarrhoea	PMID: 28270698
Streptococcus	Methotrexate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	n.a.	n.a.	Reduce microbial abundance(decrease anaerobes and streptococci,relative increase of Bacteroides);change in microbiota is associated with diarrhoea	PMID: 28270698
Bacteroidetes	Polysaccharides (after cyclophosphamide administration)	Dietary Substance	Dietary Compounds	n.a.	n.a.	n.a.	Mouse	n.a.	n.a.	Resulte in the enrichment of bifidobacteria and a reduction in the levels of Bacteroidetes;might protect against the adverse effects of chemotherapy	PMID: 28270698
Bifidobacterium	Polysaccharides (after cyclophosphamide administration)	Dietary Substance	Dietary Compounds	n.a.	n.a.	n.a.	Mouse	n.a.	n.a.	Resulte in the enrichment of bifidobacteria and a reduction in the levels of Bacteroidetes;might protect against the adverse effects of chemotherapy	PMID: 28270698
Bacteroides fragilis	Sorivudine	Therapeutic Substance	Investigational Drug	n.a.	(E)-5-(2-bromovinyl) uracil (BVU)	n.a.	n.a.	n.a.	Gut bacterial phosphorolytic enzyme	[drug interaction]:combination with 5-FU can increase in systemic concentrations of 5-FU and is associated with the death of patients	PMID: 28270698
Bacteroides thetaiotaomicron	Sorivudine	Therapeutic Substance	Investigational Drug	n.a.	(E)-5-(2-bromovinyl) uracil (BVU)	n.a.	n.a.	n.a.	Gut bacterial phosphorolytic enzyme	[drug interaction]:combination with 5-FU can increase in systemic concentrations of 5-FU and is associated with the death of patients	PMID: 28270698
Bacteroides uniformis	Sorivudine	Therapeutic Substance	Investigational Drug	n.a.	(E)-5-(2-bromovinyl) uracil (BVU)	n.a.	n.a.	n.a.	Gut bacterial phosphorolytic enzyme	[drug interaction]:combination with 5-FU can increase in systemic concentrations of 5-FU and is associated with the death of patients	PMID: 28270698
Bacteroides vulgatus	Sorivudine	Therapeutic Substance	Investigational Drug	n.a.	(E)-5-(2-bromovinyl) uracil (BVU)	n.a.	n.a.	n.a.	Gut bacterial phosphorolytic enzyme	[drug interaction]:combination with 5-FU can increase in systemic concentrations of 5-FU and is associated with the death of patients	PMID: 28270698
Bacteroides eggerthii	Sorivudine	Therapeutic Substance	Investigational Drug	n.a.	(E)-5-(2-bromovinyl) uracil (BVU)	n.a.	n.a.	n.a.	Gut bacterial phosphorolytic enzyme	[drug interaction]:combination with 5-FU can increase in systemic concentrations of 5-FU and is associated with the death of patients	PMID: 28270698
Unidentified gut microbes	Neoprontosil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Microbiota-driven drug metabolism	Affect drug disposition and toxicity	PMID: 28270698
Unidentified gut microbes	Sulfanilamide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Microbiota-driven drug metabolism	Affect drug disposition and toxicity	PMID: 28270698
Bacteroides thetaiotaomicron	Brivudine	Therapeutic Substance	Approved Drug	n.a.	bromovinyluracil (BVU)	Increase Toxicity	Mouse	Conventional(CV),germ-free(GF)	Microbial enzymes	Conversion to hepatotoxic BVU;(GF)reduce systemic BVU exposure	PMID: 30733391
Bacteroides ovatus	Brivudine	Therapeutic Substance	Approved Drug	n.a.	bromovinyluracil (BVU)	Increase Toxicity	n.a.	n.a.	n.a.	Conversion to hepatotoxic BVU;(GF)reduce systemic BVU exposure	PMID: 30733391
Unidentified gut microbes	Clonazepam	Therapeutic Substance	Approved Drug	n.a.	aminoclonazepam (NH2-CLZ),aminohydroxyclonazepam (NH2OH-CLZ)	Increase Toxicity	Mouse	Conventional(CV),germ-free(GF)	Contribute to the reductive metabolism of CLZ	Lead to toxicity	PMID: 30733391
Bacteroides thetaiotaomicron	Sorivudine	Therapeutic Substance	Investigational Drug	n.a.	bromovinyluracil (BVU)	Increase Toxicity	Mouse	Conventional(CV),germ-free(GF)	Microbial enzymes	Metabolized by members of this genus	PMID: 30733391
Bacteroides ovatus	Sorivudine	Therapeutic Substance	Investigational Drug	n.a.	bromovinyluracil (BVU)	Increase Toxicity	n.a.	n.a.	n.a.	Metabolized by members of this genus	PMID: 30733391
Unidentified gut microbes	Lovastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	2-hydroxy lovastatic acid,2-hydroxy simvastatin acid	Increase Efficacy	Rat	n.a.	n.a.	Product an active form;drug interaction:antibiotics suppresses the pharmacologic effects	PMID: 9728898; PMID: 24947972; PMID: 25926432; PMID: 25571290
Unidentified gut microbes	Simvastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	2-hydroxy lovastatic acid,2-hydroxy simvastatin acid	Increase Efficacy	Rat	n.a.	n.a.	Product an active form;drug interaction:antibiotics suppresses the pharmacologic effects	PMID: 9728898; PMID: 24947972; PMID: 25926432; PMID: 25571290
Clostridium perfringens	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	N-(2-hydroxyethyl)-oxamic acid and acetamide	n.a.	Rat	n.a.	Reduced metabolites	n.a.	PMID: 231450; PMID: 430360; PMID: 25926432
Streptococcus pyogenes	Sulfanilamide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	sulfanilamide	Increase Efficacy	Mouse	A murine model of Streptococcus pyogenes systemic infection	The gut microbiota transformed drug by azoreductases	Exhibit potent antibacterial activity;drug interaction:antibiotics suppresses the conversion	PMID: 4405598; Peppercorn and Goldman,1976; PMID: 25926432
Unidentified gut microbes	Daidzein	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	calycosin	n.a.	n.a.	n.a.	Aromatic hydroxylase and O-methyltransferase	Drug interaction:antibiotics suppresses the transformation	PMID: 9657051; PMID: 25926432; PMID: 9781846
Unidentified gut microbes	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	SN-38	Increase Toxicity	n.a.	n.a.	The b-glucuronidases of the gut microbiota	Causes diarrhea;drug interaction:coadministration of the poorly absorbed aminoglycoside antibiotic neomycin could be advantageous for diarrhea	PMID: 25926432; PMID: 11350876
Unidentified gut microbes	Sulindac sulfide	Environmental Chemicals	Active Metabolite of Prodrug	n.a.	n.a.	n.a.	Human	Healthy,ileostomy	n.a.	Drug interaction:metronidazole decreases the formation of sulfides of sulindac ex vivo	PMID: 3630204; PMID: 25926432
Unidentified gut microbes	Neoprontosil	Therapeutic Substance	Approved Drug	n.a.	sulfanilamide	Increase Efficacy	Rat	n.a.	n.a.	Product the pharmacologically active metabolite;drug interaction:antibiotics reduced the amount of sulfanilamide excreted in the urine after oral administration	PMID: 5173017; PMID: 25926432
Unidentified gut microbes	Misonidazole	Therapeutic Substance	Investigational Drug	n.a.	1-(2-aminoimidazol-1-yl)-3-methoxypropan-2-ol	Increase Toxicity	Rat	Convention,germ-free	n.a.	Drug interaction:antibiotic inhibits misonidazole transformation and toxicity	PMID: 6260109; PMID: 25926432
Unidentified gut microbes	Clonazepam	Therapeutic Substance	Approved Drug	n.a.	7-aminoclonazepam	n.a.	Rat	Germ-free and ex–germ-free	The reductive metabolism	Drug interaction:antibiotic suppresses the reduction	PMID: 6506755; PMID: 25926432
Unidentified gut microbes	Loperamide oxide	Therapeutic Substance	Investigational Drug	n.a.	loperamide	n.a.	Rat; Dog	n.a.	Microbiota is involved in reduction	Drug interaction:absorption of orally delivered loperamide oxide is lower when administered with cotrimoxazole	PMID: 25926432; PMID: 8838438
Unidentified gut microbes	Daidzin	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	daidzein,calycosin	Increase Efficacy	n.a.	n.a.	C-glucosidases and O-glucosidases	Drug interaction:Antibiotic inhibits the metabolism of isoflavone glycosides	PMID: 9657051; PMID: 25926432
Unidentified gut microbes	Puerarin	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	daidzein,calycosin	Increase Efficacy	n.a.	n.a.	C-glucosidases and O-glucosidases	Drug interaction:Antibiotic inhibits the metabolism of isoflavone glycosides	PMID: 9657051; PMID: 25926432
Unidentified gut microbes	Fenfluramine	Therapeutic Substance	Approved Drug	n.a.	phenolic acids	n.a.	Human; Mouse	n.a.	Deglycosylating enzymes of bacteria	Metabolites might exhibit aspirin-like pharmacologic effects;drug interaction:antibiotics reduces metabolites excreted into the urine of rats	PMID: 25926432; PMID: 9875509
Unidentified gut microbes	Hesperidin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	phenolic acids	n.a.	Human; Mouse	n.a.	Deglycosylating enzymes of bacteria	Metabolites might exhibit aspirin-like pharmacologic effects;drug interaction:antibiotics reduces metabolites excreted into the urine of rats	PMID: 25926432; PMID: 9875509
Unidentified gut microbes	Naringenin	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	phenolic acids	n.a.	Human; Mouse	n.a.	Deglycosylating enzymes of bacteria	Metabolites might exhibit aspirin-like pharmacologic effects;drug interaction:antibiotics reduces metabolites excreted into the urine of rats	PMID: 25926432; PMID: 9875509
Unidentified gut microbes	Rutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	phenolic acids	n.a.	Human; Mouse	n.a.	Deglycosylating enzymes of bacteria	Metabolites might exhibit aspirin-like pharmacologic effects;drug interaction:antibiotics reduces metabolites excreted into the urine of rats	PMID: 25926432; PMID: 9875509
Unidentified gut microbes	Scutellaria baicalensis root	Therapeutic Substance	Investigational Drug	n.a.	phenolic acids	n.a.	Human; Mouse	n.a.	Deglycosylating enzymes of bacteria	Metabolites might exhibit aspirin-like pharmacologic effects;drug interaction:antibiotics reduces metabolites excreted into the urine of rats	PMID: 25926432; PMID: 9875509
Unidentified gut microbes	Wognoside	Herbal Substance	Medicinal Herbal Compounds	n.a.	phenolic acids	n.a.	Human; Mouse	n.a.	Deglycosylating enzymes of bacteria	Metabolites might exhibit aspirin-like pharmacologic effects;drug interaction:antibiotics reduces metabolites excreted into the urine of rats	PMID: 25926432; PMID: 9875509
Unidentified gut microbes	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	dihydrodigoxin,dihydrodigoxigenin	Decrease Efficacy	Human	n.a.	n.a.	Convert to the inactive metabolites;attenuates the drug’s effects;drug interaction:antibiotics（erythromycin and tetracycline）blocks the reduction of digoxin	PMID: 25926432; PMID:7266632
Unidentified gut microbes	Sulindac	Therapeutic Substance	Approved Drug	n.a.	sulindac sulfide	n.a.	Rabbit	n.a.	n.a.	n.a.	PMID: 25926432
Unidentified gut microbes	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Decrease Efficacy	n.a.	n.a.	Transform drugs and phytochemicals into bioinactive metabolites	Affect the pharmacokinetics	PMID: 25926432
Lactococcus garvieae	Daidzein	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	5-hydroxy-equol	n.a.	Human; Animal models	n.a.	n.a.	n.a.	PMID: 25926432
Adlercreutzia equolifaciens	Daidzein	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	5-hydroxy-equol	n.a.	Human; Animal models	n.a.	n.a.	n.a.	PMID: 25926432
Slackia equolifaciens	Daidzein	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	5-hydroxy-equol	n.a.	Human; Animal models	n.a.	n.a.	n.a.	PMID: 25926432
Slackia isoflavoniconvertens	Daidzein	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	5-hydroxy-equol	n.a.	Human; Animal models	n.a.	n.a.	n.a.	PMID: 25926432
Lactococcus garvieae	Genistein	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	5-hydroxy-equol	n.a.	Human; Animal models	n.a.	n.a.	n.a.	PMID: 25926432
Adlercreutzia equolifaciens	Genistein	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	5-hydroxy-equol	n.a.	Human; Animal models	n.a.	n.a.	n.a.	PMID: 25926432
Slackia equolifaciens	Genistein	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	5-hydroxy-equol	n.a.	Human; Animal models	n.a.	n.a.	n.a.	PMID: 25926432
Slackia isoflavoniconvertens	Genistein	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	5-hydroxy-equol	n.a.	Human; Animal models	n.a.	n.a.	n.a.	PMID: 25926432
Ruminococcus sp.	Ginsenoside Rb1	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	20-O-20-O-b-D-glucopyranosyl-20(S)-protopanaxadiol (compound K)	Increase Efficacy	n.a.	n.a.	n.a.	Drug interaction:antibiotics inhibits the metabolism	PMID: 25926432
Oscillibacter sp.	Ginsenoside Rb1	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	20-O-20-O-b-D-glucopyranosyl-20(S)-protopanaxadiol (compound K)	Increase Efficacy	n.a.	n.a.	n.a.	Drug interaction:antibiotics inhibits the metabolism	PMID: 25926432
Sutterella sp.	Ginsenoside Rb1	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	20-O-20-O-b-D-glucopyranosyl-20(S)-protopanaxadiol (compound K)	Increase Efficacy	n.a.	n.a.	n.a.	Drug interaction:antibiotics inhibits the metabolism	PMID: 25926432
Holdemania sp.	Ginsenoside Rb1	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	20-O-20-O-b-D-glucopyranosyl-20(S)-protopanaxadiol (compound K)	Increase Efficacy	n.a.	n.a.	n.a.	Drug interaction:antibiotics inhibits the metabolism	PMID: 25926432
Unidentified gut microbes	Ginsenoside Rb1	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	n.a.	Increase Efficacy	n.a.	n.a.	Transform drugs and phytochemicals into bioactive metabolites	Affect the pharmacokinetics	PMID: 25926432
Bacteroides	Lactulose	Therapeutic Substance	Approved Drug	n.a.	fructose,galactose	n.a.	n.a.	n.a.	n.a.	Drug interaction:combination treatment with neomycin and lactulose reduces the blood ammonia concentration in pigs	PMID: 25926432
Lactobacillus	Lactulose	Therapeutic Substance	Approved Drug	n.a.	fructose,galactose	n.a.	n.a.	n.a.	n.a.	Drug interaction:combination treatment with neomycin and lactulose reduces the blood ammonia concentration in pigs	PMID: 25926432
Escherichia coli	Lactulose	Therapeutic Substance	Approved Drug	n.a.	fructose,galactose	n.a.	n.a.	n.a.	n.a.	Drug interaction:combination treatment with neomycin and lactulose reduces the blood ammonia concentration in pigs	PMID: 25926432
Clostridium sp.	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	levametabol-I, levametabol-II, and levametabol-III	n.a.	n.a.	n.a.	n.a.	Drug interaction: Combined therapy with tetracycline and levamisole has a stronger biologic effect	PMID: 25926432
Bacteroides spp.	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	levametabol-I, levametabol-II, and levametabol-III	n.a.	n.a.	n.a.	n.a.	Drug interaction: Combined therapy with tetracycline and levamisole has a stronger biologic effect	PMID: 25926432
Unidentified gut microbes	Lovastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Increase Efficacy	n.a.	n.a.	Transform drugs and phytochemicals into bioactive metabolites	Affect the pharmacokinetics	PMID: 25926432
Unidentified gut microbes	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Decrease Efficacy	n.a.	n.a.	Transform drugs and phytochemicals into bioinactive metabolites	Affect the pharmacokinetics	PMID: 25926432
[Eubacterium] rectale	Picosulfuric acid	Therapeutic Substance	Approved Drug	n.a.	free diphenol[4,49-(pyridin-2-ylmethanediyl)diphenol]	Increase Efficacy	n.a.	n.a.	Arylsulfate sulfotransferase of bacteria	Have a laxative effect;drug interaction:antibiotics inhibits the transformation	PMID: 25926432
Unidentified gut microbes	Ranitidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Decrease Efficacy	n.a.	n.a.	Transform drugs and phytochemicals into bioinactive metabolites	Affect the pharmacokinetics	PMID: 25926432
Unidentified gut microbes	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	5-aminosalicylic acid	Increase Efficacy	n.a.	n.a.	Azoreductases produced by metabolize	Induces anti-inflammatory effects	PMID: 25926432
Unidentified gut microbes	Epicatechin	Therapeutic Substance	Investigational Drug	n.a.	phenolic acids	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 25926432
Unidentified gut microbes	Anthocyanidins	Herbal Substance	Plant Compounds	n.a.	phenolic acids	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 25926432
Unidentified gut microbes	Balsalazide	Therapeutic Substance	Approved Drug	n.a.	5-aminosalicylic acid	n.a.	Human	n.a.	n.a.	Drug interaction:antibiotic suppresses the metabolism,limit its effectiveness	PMID: 25926432
Unidentified gut microbes	Cianidanol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	phenolic acids	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 25926432
Unidentified gut microbes	Flucytosine	Therapeutic Substance	Approved Drug	n.a.	5-fluorouracil	n.a.	n.a.	n.a.	n.a.	Drug interaction:antimicrobial agents may reduce the antifungal effect of flucytosine	PMID: 25926432
Unidentified gut microbes	Glycyrrhizic acid	Therapeutic Substance	Approved Drug	n.a.	18b-glycyrrhetic acid	n.a.	Rat	Germ-free	n.a.	Drug interaction:antibiotics(amoxicillin and metronidazole)suppresses the conversion	PMID: 25926432
Unidentified gut microbes	Hesperidin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	hesperetin	n.a.	Rat	n.a.	n.a.	Suppress gut bacterial glycosidase activities;drug interaction:Antibiotic inhibits the metabolism	PMID: 25926432
Unidentified gut microbes	Levodopa	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	tyramine,m-hydroxyphenylacetic acid	n.a.	n.a.	n.a.	n.a.	Drug interaction:antibiotics(vancomycin)inhibits the dehydroxylation of bile acid by the gut microbiota	PMID: 25926432
Unidentified gut microbes	Nitrazepam	Therapeutic Substance	Approved Drug	n.a.	7-amino-nitrazepam	Increase Toxicity	Rat	n.a.	Transform drugs and phytochemicals into toxic metabolites	Affect the pharmacokinetics,product an active teratogenic substance;drug interaction: antibiotic reduced nitrazepam-induced teratogenicity	PMID: 25926432
Unidentified gut microbes	Nizatidine	Therapeutic Substance	Approved Drug	n.a.	hydroxyiminonizatidine	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 25926432
Unidentified gut microbes	Ranitidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	hydroxyiminoranitidine	n.a.	n.a.	n.a.	n.a.	Drug interaction:antibiotics(rifampicin)decreases the absorption of ranitidine	PMID: 25926432
Unidentified gut microbes	Risperidone	Therapeutic Substance	Approved Drug	n.a.	dihydroxy-risperidone,hydroxy-keto-risperidone	n.a.	Rat	n.a.	Scission of isoxazole	Drug interaction:Antibiotics(rifampin)inhibit the bioavailability of risperidone in the liver	PMID: 25926432
Unidentified gut microbes	Scutellaria baicalensis root	Therapeutic Substance	Investigational Drug	n.a.	oroxylin A	n.a.	n.a.	n.a.	Aromatic hydroxylase and O-methyltransferase	n.a.	PMID: 25926432
Unidentified gut microbes	Sennosides	Therapeutic Substance	Investigational Drug	n.a.	rheinanthrone	Increase Efficacy	n.a.	n.a.	Reductase(s) and 3- b-D-glucosidase(s)	Product a purgative compound;drug interaction:antibiotics（chloramphenicol, streptomycin, and rifampicin）inhibits the biotransformation	PMID: 25926432
Unidentified gut microbes	Sulfinpyrazone	Therapeutic Substance	Approved Drug	n.a.	sulfinpyrazone sulfide	n.a.	Rabbit	n.a.	n.a.	Drug interaction:Metronidazole decreases the extent of sulfinpyrazone reduction in rabbits in vivo	PMID: 25926432
Unidentified gut microbes	Zonisamide	Therapeutic Substance	Approved Drug	n.a.	2-sulfamoyacetylphenol	n.a.	n.a.	n.a.	Through the reduction	n.a.	PMID: 25926432
Unidentified gut microbes	Hydrazine	Environmental Chemicals	Industrial Chemicals; Medicinal chemicals	n.a.	n.a.	Decrease Toxicity	Rat	n.a.	DszA/NtaA-like oxygenase	n.a.	PMID: 19396371; PMID: 26261284
Unidentified anaerobic bacterium	Fostamatinib	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	O-demethylation and dihydroxylation by bacteria	n.a.	PMID: 26261284; PMID: 20371637
Unidentified gut microbes	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Reactivated by bacterially expressed b-glucuronidase	Result in diarrhea	PMID: 26261284; PMID: 21051639
Unidentified gut microbes	BILR355	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Bacterially mediated N-oxide reduction	Drug interaction:(with ritonavir)bacterial mediated reactions predominate	PMID: 26261284; PMID: 22393121
Unidentified gut microbes	2-chloro-5-nitro-N-phenylbenzamide	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Bacterial nitroreductases	Alter its mutagenicity	PMID: 26261284; PMID: 22450444
Unidentified gut microbes	Antiobiotics	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Drug interaction:antibiotics effect the functional activity of bacteria	PMID: 26261284; PMID: 23332745
Unidentified gut microbes	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Drug interaction:antibiotics effect the functional activity of bacteria	PMID: 26261284; PMID: 23332745
Unidentified gut microbes	Phenacetin	Therapeutic Substance	Approved Drug (Withdrawn)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Drug interaction:antibiotics effect the functional activity of bacteria	PMID: 26261284; PMID: 23332745
Unidentified gut microbes	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Drug interaction:antibiotics effect the functional activity of bacteria	PMID: 26261284; PMID: 23332745
Sulfite-reducing bacterium LF11mE1	Saturated fats	Dietary Substance	Dietary Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Excess consumption of fat leads to an increase in the growth of bacteria	Increase the formation of proinflammatory and genotoxic secondary bile acids(deoxycholate)	PMID: 26261284; PMID: 24355793
Clostridioides difficile	Saturated fats	Dietary Substance	Dietary Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Excess consumption of fat leads to an increase in the growth of bacteria	Increase the formation of proinflammatory and genotoxic secondary bile acids(deoxycholate)	PMID: 26261284; PMID: 24355793
Unidentified gut microbes	Arsenic	Environmental Chemicals	Toxic Agents	n.a.	n.a.	n.a.	Mouse	n.a.	n.a.	Alter the gut microbiota	PMID: 26261284; PMID: 24413286
Unidentified gut microbes	Phenoxyethanol	Therapeutic Substance	Approved Drug	n.a.	cyanuric acid	Increase Toxicity	n.a.	n.a.	Microbial formation of its metabolite	Lead to toxicity	PMID: 26261284; PMID: 25105361
Faecalibacterium prausnitzii	Tacrolimus	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Alter the pharmacokinetics of tacrolimus	PMID: 26261284; PMID: 25815766
Unidentified gut microbes	Astragali radix	Herbal Substance	Medicinal Herb	n.a.	n.a.	n.a.	Rat	n.a.	Calycosin-7-O-b-D-glucoside may alter the composition of the gut microbiome	Promot the growth of beneficial organisms(Lactobacillus and Bifidobacterium)	PMID: 26261284; PMID: 26101224
Unidentified gut microbes	Calycosin-7-O-b-D-glucoside	Herbal Substance	Medicinal Herbal Compounds	n.a.	n.a.	n.a.	Rat	n.a.	Calycosin-7-O-b-D-glucoside may alter the composition of the gut microbiome	Promot the growth of beneficial organisms(Lactobacillus and Bifidobacterium)	PMID: 26261284; PMID: 26101224
Unidentified gut microbes	Epimedium grandiflorum top (flavonoids)	Herbal Substance	Medicinal Herb	n.a.	n.a.	n.a.	n.a.	n.a.	Metabolized by the colonic microflora to circulate in the plasma	[disease]osteoporosis may modulate the metabolism of Epimedii and may affect its bioavailability and efficacy	PMID: 26135008; PMID: 26261284
Unidentified gut microbes	Acetaminophen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Microbial (p-cresol) may compete for a host enzyme (SULT1A1)	PMID: 26261284
Desulfovibrio desulfuricans	Arsenic	Environmental Chemicals	Toxic Agents	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Sulfate-reducing bacteria	Product a more toxic form of arsenic	PMID: 26261284
Firmicutes	Butyric Acid	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Produce relatively high levels of butyrate in the gastrointestinal tract	Limit the growth of pathogenic microorganisms	PMID: 26261284
Faecalibacterium prausnitzii	Butyric Acid	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Produce relatively high levels of butyrate in the gastrointestinal tract	Limit the growth of pathogenic microorganisms	PMID: 26261284
Escherichia coli	Curcumin	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	tetrahydrocurcumin	Increase Efficacy	n.a.	n.a.	Enzyme(identified as CurA)	n.a.	PMID: 26261284
Eggerthella lenta	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Decrease Efficacy	n.a.	n.a.	Cardiac glycoside expressed by bacteria	Drug is inactivated	PMID: 26261284
Helicobacter pylori	Levodopa	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Sequestration of bacteria	Reactivated by microbially expressed enzymes	PMID: 26261284
Escherichia coli	Nitrobenzodiazepine	Therapeutic Substance	Drug Class	n.a.	n.a.	Decrease Efficacy	n.a.	n.a.	Bacterial nitroreductase(NfsB)	n.a.	PMID: 26261284
Micrococcus luteus	Polyaromatic compounds	Environmental Chemicals	Unclassified Substance	n.a.	hydroxyl metabolites	n.a.	n.a.	n.a.	n.a.	Exhibit estrogenic activities	PMID: 26261284
Clostridioides difficile	PPIs	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Drug is associated with Clostridium difficule infections	PMID: 26261284
Unidentified gut microbes	Resveratrol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Enzyme(identified as CurA)	n.a.	PMID: 26261284
Enterobacter	Tretazicar	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Additional enzymes expressed by bacteria(capable of azo and nitro reduction)((AzoR and NfsA))	n.a.	PMID: 26261284
Staphylococcus	Tretazicar	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Additional enzymes expressed by bacteria(capable of azo and nitro reduction)((AzoR and NfsA))	n.a.	PMID: 26261284
Escherichia coli	Tretazicar	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Additional enzymes expressed by bacteria(capable of azo and nitro reduction)((AzoR and NfsA))	n.a.	PMID: 26261284
Mycobacterium	Tretazicar	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Additional enzymes expressed by bacteria(capable of azo and nitro reduction)((AzoR and NfsA))	n.a.	PMID: 26261284
Bacillus	Tretazicar	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Additional enzymes expressed by bacteria(capable of azo and nitro reduction)((AzoR and NfsA))	n.a.	PMID: 26261284
Unidentified gut microbes	Simvastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Be extensively metabolized by microbiota(demethylation, carbon-carbon bond cleavage, a or b oxidation,dihydroxylation, and cyclization of simvastatin)	n.a.	PMID: 26261284
Unidentified gut microbes	Sulfadiazine	Therapeutic Substance	Approved Drug	n.a.	5-amino 5-salicylic acid	Increase Efficacy	n.a.	n.a.	Convert drug to its pharmacologically active form by microbial enzymes	n.a.	PMID: 26261284
Unidentified gut microbes	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	SN-38	Increase Toxicity	n.a.	n.a.	Convertion to SN-38	Lead to the severe intestinal side effect of diarrhea;[drug interaction:Antibiotic/a potent inhibitor of β-glucuronidase can reduce intestinal side effect]	PMID: 26569070; PMID: 18927500
Unidentified gut microbes	Acetaminophen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	High level of a microbial metabolite(p-cresol)	Show low postdose acetaminophen sulfate to acetaminophen glucuronide;alter the bioavailability;lead to hepatotoxicity;[drug interaction]:(rat)antibiotic lead to higher level of acetaminophen glutathione conjugates	PMID: 26569070; PMID: 19667173
Unidentified gut microbes	Simvastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Several gut microbial-derived secondary bile acids	Secondary bile acids can predict effect of simvastatin	PMID: 26569070; PMID: 24947972
Firmicutes	Cyclophosphamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Alter the composition of gut microbiota;induce the translocation(Gram positive bacteria)into secondary lymphoid organs	PMID: 26569070
Unidentified anaerobic bacterium	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	sulfide metabolites	Decrease Efficacy	n.a.	n.a.	Reduction	Decreased activity	PMID: 26569070
Clostridioides difficile	Acetaminophen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Acetaminophen sulfate and glucuronide	Decrease Efficacy; Increase Toxicity	n.a.	n.a.	O-Sulfation; C-S cleavage of acetaminophen-3-cysteine	Decrease activity,or increase cellular toxicity	PMID: 26569070
Unidentified gut microbes	CpG-oligonucleotide immunotherapy	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	Mouse	Germ free,orantibiotic-treated	Disruption of gut microbiota	Microbiota impairs the therapeutic responses of tumors	PMID: 26569070
Unidentified anaerobic bacterium	Daidzein	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	Dihydrodaidzein, equol, or O-desmethylanolensin(ODMA)	Increase Efficacy	n.a.	n.a.	Reduction, phenolic ring opening	Increased activity	PMID: 26569070
Clostridium sp. HGH 136	Daidzein	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	Dihydrodaidzein, equol, or O-desmethylanolensin(ODMA)	Increase Efficacy	n.a.	n.a.	Reduction, phenolic ring opening	Increased activity	PMID: 26569070
Eggerthella lenta	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	dihydrodigoxin	Decrease Efficacy	n.a.	n.a.	Key enzyme: A cytochrome-encoding operon (termed the cardiac glycoside reductase)	Produce inactive metabolite	PMID: 26569070
Bacteroides uniformis	Genistein	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	5-hydroxyequol	n.a.	n.a.	n.a.	Hydrogenation	n.a.	PMID: 26569070
Bacteroides	Ginsenoside Rb1	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	Compound K	Increase Efficacy	n.a.	n.a.	Hydrolysis	Increased activity	PMID: 26569070
Bifidobacterium	Ginsenoside Rb1	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	Compound K	Increase Efficacy	n.a.	n.a.	Hydrolysis	Increased activity	PMID: 26569070
Eubacterium sp. GLH	Glycyrrhizic acid	Therapeutic Substance	Approved Drug	n.a.	18-β-glycyrrhetinic acid	Increase Efficacy	n.a.	n.a.	Hydrolysis	Increased activity	PMID: 26569070
Klebsiella pneumoniae	Lactulose	Therapeutic Substance	Approved Drug	n.a.	Monosaccharides	n.a.	n.a.	n.a.	Hydrolysis	Stimulating the growth of beneficial bacteria (Bifidobacteria,Lactobacilli)	PMID: 26569070
Enterococcus faecalis	Lactulose	Therapeutic Substance	Approved Drug	n.a.	Monosaccharides	n.a.	n.a.	n.a.	Hydrolysis	Stimulating the growth of beneficial bacteria (Bifidobacteria,Lactobacilli)	PMID: 26569070
Cronobacter sakazakii	Lactulose	Therapeutic Substance	Approved Drug	n.a.	Monosaccharides	n.a.	n.a.	n.a.	Hydrolysis	Stimulating the growth of beneficial bacteria (Bifidobacteria,Lactobacilli)	PMID: 26569070
Enterococcus casseliflavus	Lactulose	Therapeutic Substance	Approved Drug	n.a.	Monosaccharides	n.a.	n.a.	n.a.	Hydrolysis	Stimulating the growth of beneficial bacteria (Bifidobacteria,Lactobacilli)	PMID: 26569070
Bacteroides	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	levametabol-I, II and III	Increase Efficacy	n.a.	n.a.	Thiazole ring opening	Increased activity	PMID: 26569070
Clostridium sp.	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	levametabol-I, II and III	Increase Efficacy	n.a.	n.a.	Thiazole ring opening	Increased activity	PMID: 26569070
Clostridia	Metamfetamine	Therapeutic Substance	Approved Drug	n.a.	Amphetamine, norephedrine and an unknown metabolite	Decrease Efficacy	n.a.	n.a.	Demethylation	Decreased activity	PMID: 26569070
Enterococcus	Metamfetamine	Therapeutic Substance	Approved Drug	n.a.	Amphetamine, norephedrine and an unknown metabolite	Decrease Efficacy	n.a.	n.a.	Demethylation	Decreased activity	PMID: 26569070
Lactobacillus	Metamfetamine	Therapeutic Substance	Approved Drug	n.a.	Amphetamine, norephedrine and an unknown metabolite	Decrease Efficacy	n.a.	n.a.	Demethylation	Decreased activity	PMID: 26569070
Unidentified gut microbes	Platinum chemotherapy	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	Mouse	Germ free,orantibiotic-treated	Disruption of gut microbiota	Microbiota impairs the therapeutic responses of tumors	PMID: 26569070
Enterococcus casseliflavus	Quercetin-3-glucoside	Herbal Substance; Dietary Substance	Medicinal Herbal Compounds; Dietary Compounds	n.a.	Butyrate, acetate, 3,4-dihydroxyphenylacetic acid	n.a.	n.a.	n.a.	Deglycosylation	n.a.	PMID: 26569070
Eubacterium ramulus	Quercetin-3-glucoside	Herbal Substance; Dietary Substance	Medicinal Herbal Compounds; Dietary Compounds	n.a.	Butyrate, acetate, 3,4-dihydroxyphenylacetic acid	n.a.	n.a.	n.a.	Deglycosylation	n.a.	PMID: 26569070
Escherichia coli	Diclofenac	Therapeutic Substance	Approved Drug	Hydrolysis to diclofenac	Diclofenac glucuronide	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 27591027; PMID: 24780296; PMID: 22328575
Escherichia coli	Flucytosine	Therapeutic Substance	Approved Drug	Deamination	5-fluorouracil	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 27591027; PMID: 12714804; PMID: 3729334
Unidentified anaerobic bacterium	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Double bond reduction	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 6836275; PMID: 24637603; PMID: 27591027; PMID: 1500644; PMID: 2759492
Clostridioides difficile	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Double bond reduction	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 6836275; PMID: 24637603; PMID: 27591027; PMID: 1500644; PMID: 2759492
Eggerthella lenta	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Double bond reduction	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 6836275; PMID: 24637603; PMID: 27591027; PMID: 1500644; PMID: 2759492
Eggerthella lenta	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Double bond reduction	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 6836275; PMID: 24637603; PMID: 27591027; PMID: 1500644; PMID: 2759492
Unidentified gut microbes	Mesalazine	Therapeutic Substance	Approved Drug	Acetylation	N-acetyl-5-aminosalicylic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356
Pseudomonas aeruginosa	Mesalazine	Therapeutic Substance	Approved Drug	Acetylation	N-acetyl-5-aminosalicylic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356
Citrobacter freundii	Mesalazine	Therapeutic Substance	Approved Drug	Acetylation	N-acetyl-5-aminosalicylic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356
Klebsiella oxytoca	Mesalazine	Therapeutic Substance	Approved Drug	Acetylation	N-acetyl-5-aminosalicylic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356
Klebsiella pneumoniae subsp. ozaenae	Mesalazine	Therapeutic Substance	Approved Drug	Acetylation	N-acetyl-5-aminosalicylic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356
Morganella morganii	Mesalazine	Therapeutic Substance	Approved Drug	Acetylation	N-acetyl-5-aminosalicylic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356
Serratia marcescens	Mesalazine	Therapeutic Substance	Approved Drug	Acetylation	N-acetyl-5-aminosalicylic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356
Shigella flexneri	Mesalazine	Therapeutic Substance	Approved Drug	Acetylation	N-acetyl-5-aminosalicylic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356
Vibrio cholerae	Mesalazine	Therapeutic Substance	Approved Drug	Acetylation	N-acetyl-5-aminosalicylic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356
Plesiomonas shigelloides	Mesalazine	Therapeutic Substance	Approved Drug	Acetylation	N-acetyl-5-aminosalicylic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356
Citrobacter amalonaticus	Mesalazine	Therapeutic Substance	Approved Drug	Acetylation	N-acetyl-5-aminosalicylic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356
Klebsiella pneumoniae subsp. rhinoscleromatis	Mesalazine	Therapeutic Substance	Approved Drug	Acetylation	N-acetyl-5-aminosalicylic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356
Citrobacter farmeri	Mesalazine	Therapeutic Substance	Approved Drug	Acetylation	N-acetyl-5-aminosalicylic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356
Clostridium sporogenes	Zonisamide	Therapeutic Substance	Approved Drug	Benzisoxazole ring reduction	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 27591027; PMID: 9231340; PMID: 1615700
Unidentified gut microbes	Ranitidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	N-oxide reduction	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 27591027; PMID: 11564550
Unidentified gut microbes	Nizatidine	Therapeutic Substance	Approved Drug	N-oxide reduction	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 27591027; PMID: 11955801
Bacteroides	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Thiazole ring opening	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 27591027; PMID: 1949905
Clostridium sp.	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Thiazole ring opening	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 27591027; PMID: 1949905
Unidentified anaerobic bacterium	Fostamatinib	Therapeutic Substance	Approved Drug	O-Demethylation	metabolite R529	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 27591027; PMID: 20371637
Unidentified gut microbes	Sulfapyridine	Therapeutic Substance	Approved Drug	Acetylation	N-acetyl sulfapyridine	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 27591027; PMID: 2890356
Unidentified anaerobic bacterium	Sulfinpyrazone	Therapeutic Substance	Approved Drug	Sulfoxide reduction	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 27591027; PMID: 3630204
Unidentified anaerobic bacterium	Sulindac	Therapeutic Substance	Approved Drug	Sulfoxide reduction	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 27591027; PMID: 3630204
Escherichia coli	Irinotecan	Therapeutic Substance	Approved Drug	Glucuronide hydrolysis	SN-38 glucuronide	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 16437251; PMID: 26364932; PMID: 9744772; PMID: 11344150; PMID: 27591027
Bacteroides fragilis	Irinotecan	Therapeutic Substance	Approved Drug	Glucuronide hydrolysis	SN-38 glucuronide	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 16437251; PMID: 26364932; PMID: 9744772; PMID: 11344150; PMID: 27591027
Streptococcus agalactiae	Irinotecan	Therapeutic Substance	Approved Drug	Glucuronide hydrolysis	SN-38 glucuronide	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 16437251; PMID: 26364932; PMID: 9744772; PMID: 11344150; PMID: 27591027
Clostridium perfringens	Irinotecan	Therapeutic Substance	Approved Drug	Glucuronide hydrolysis	SN-38 glucuronide	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 16437251; PMID: 26364932; PMID: 9744772; PMID: 11344150; PMID: 27591027
Unidentified gut microbes	3,4-Dihydro-5-Methyl-Isoquinolinone	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	Mouse	Convention and germ-free	n.a.	DHQ production was dependent on bacteria	PMID: 27782392; PMID: 19234110
Unidentified gut microbes	Simvastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Drug modulate or interact with the microbiota	PMID: 21060933; PMID: 27782392
Unidentified gut microbes	Hippuric acid	Environmental Chemicals	Industrial Chemicals and Pollutants; Toxic Agents	n.a.	n.a.	Increase Efficacy	Mouse	Germ-free,or with antibiotics	n.a.	Drug concentration in urine is reduced in either germ-free mice or in mice treated with antibiotics	PMID: 27782392; PMID: 23342949
Unidentified gut microbes	Metformin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	Mouse	n.a.	Increase hat fatty acid metabolism	Contribute to metformin therapy	PMID: 25038099; PMID: 27782392
Unidentified gut microbes	Metformin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Drug modulate or interact with the microbiota	PMID: 25038099; PMID: 27782392
Unidentified gut microbes	Levocarnitine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	TMA, TMAO	n.a.	n.a.	n.a.	L-carnitine is metabolized to TMA by microbiota	Decrease AGE levels	PMID: 25636076; PMID: 27782392
Unidentified gut microbes	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Β-glucuronidase enzyme of bacteria	Cause gut inflammation and irritation;drug interaction:irinotecan with a β-glucuronidase inhibitor decreases harmful metabolites and alleviates the gastrointestinal inflammation	PMID: 27782392; PMID: 26364932
Unidentified gut microbes	Levodopa	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	m-tyramine	n.a.	Mouse	Germ-free	n.a.	(GF mice)reduce metabolism of L-DOPA,prolong L-DOPA half-life and hence activity	PMID: 4974346; PMID: 27782392
Escherichia sp.	Metformin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Cause an increase of Escherichia spp	Result in an increase of gas metabolism pathways(side effect of metformin)	PMID: 27782392
Pseudomonas aeruginosa	2,8-DHQ (including 2,4-DHQ)	Environmental Chemicals	Human Metabolite	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	n.a.	Drug is involved in the pathogenicity of bacteria	PMID: 27782392
Enterobacteriaceae	Aspartame	Therapeutic Substance; Dietary Substance; Herbal Substance	Dietary Compounds; Artificial Sweetener; Medicinal Herbal Compounds	n.a.	SCFA(propionate)	n.a.	Rat	n.a.	n.a.	Aspartame increased total bacteria	PMID: 27782392
[Clostridium] leptum	Aspartame	Therapeutic Substance; Dietary Substance; Herbal Substance	Dietary Compounds; Artificial Sweetener; Medicinal Herbal Compounds	n.a.	SCFA(propionate)	n.a.	Rat	n.a.	n.a.	Aspartame increased total bacteria	PMID: 27782392
Bifidobacterium	B-GOSr (prebiotic oligosaccharide)	Therapeutic Substance	n.a.	n.a.	SCFA(acetate)	n.a.	Human	n.a.	n.a.	Bacteria populations increases acetate	PMID: 27782392
Clostridia	Choline	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	trimethylamine (TMA)	n.a.	n.a.	n.a.	n.a.	Have a direct relationship to cardiovascular disease and atherosclerosis	PMID: 27782392
Eggerthella lenta	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	dihydrodigoxin	Decrease Efficacy	n.a.	n.a.	The cgr operon within strains of E. lenta reduce fumarate in E. lenta to reduce digoxin	Lack cardiac activity	PMID: 27782392
Bacteroides	Lactulose	Therapeutic Substance	Approved Drug	n.a.	lactic acid,acetic acid	Increase Efficacy	n.a.	n.a.	n.a.	Produce its therapeutic metabolites	PMID: 27782392
Bifidobacterium	Lactulose	Therapeutic Substance	Approved Drug	n.a.	lactic acid,acetic acid	Increase Efficacy	n.a.	n.a.	n.a.	Produce its therapeutic metabolites	PMID: 27782392
Clostridia	Sodium cyclamate	Dietary Substance	Dietary Compounds; Artificial Sweetener	n.a.	cyclohexylamine	n.a.	Human; Mouse	n.a.	n.a.	Drug interaction:antibiotic treatment reduce cyclohexylamine production	PMID: 27782392
Enterococcus	Sodium cyclamate	Dietary Substance	Dietary Compounds; Artificial Sweetener	n.a.	cyclohexylamine	n.a.	Human; Mouse	n.a.	n.a.	Drug interaction:antibiotic treatment reduce cyclohexylamine production	PMID: 27782392
Unidentified gut microbes	3,3-dimethyl-1-butanol	Environmental Chemicals	Unclassified Substance	n.a.	TMA, TMAO	n.a.	Mouse	n.a.	n.a.	Drug interaction:inhibition of TMA lyase inhibits microbial production of TMA, reducing TMAO levels	PMID: 27782392
Unidentified gut microbes	Arabinoxylan-oligosaccharides	Environmental Chemicals	Unclassified Substance	n.a.	SCFA; phenol, pcresol	n.a.	Human	n.a.	n.a.	AXOS supplementation has a long-term effect on colonic microbe community	PMID: 27782392
Unidentified gut microbes	Aryl hydrocarbon receptor activator	Environmental Chemicals	Industrial Chemicals and Pollutants; Toxic Agents	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Alter the gut microbiota community its metabolic function	PMID: 27782392
Unidentified gut microbes	Ellagic acid	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Alter the gut microbiota community its metabolic function	PMID: 27782392
Unidentified gut microbes	Arsenic	Environmental Chemicals	Toxic Agents	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Alter the gut microbiota community its metabolic function	PMID: 27782392
Escherichia coli	NSAIDs	Therapeutic Substance	Drug Class	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Cleave the glucuronide by bacteria	Yield harmful metabolites,cause the formation of ulcers in the gut;	PMID: 27782392
Unidentified gut microbes	Persistent organic pollutant	Environmental Chemicals	Industrial Chemicals and Pollutants	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Alter the gut microbiota community its metabolic function	PMID: 27782392
Unidentified gut microbes	Rifaximin	Therapeutic Substance	Approved Drug	n.a.	Hippuric acid	n.a.	Mouse	n.a.	n.a.	Drug interaction:antibiotic(rifaximin)decreases microbial metabolites(hippuric acid)	PMID: 27782392
Lactobacillus	Tempol	Therapeutic Substance	Investigational Drug	n.a.	TβMCA	n.a.	Mouse	n.a.	n.a.	Tempol reduces BSH activity of bacteria and produces antiobesity effects	PMID: 27782392
Unidentified gut microbes	Oxaliplatin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Immunomodulation	Mediated by TLR4 and reactive oxygen species production by myeloid cells	PMID: 18555978; PMID: 28270698
Mycoplasma	Floxuridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	Decrease Efficacy	n.a.	n.a.	Enzymatic degradation	Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity	PMID: 28270698
Mycoplasma	Trifluridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	Decrease Efficacy	n.a.	n.a.	Enzymatic degradation	Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity	PMID: 28270698
Bifidobacterium	Anti-PD-L1 therapy	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	Immunomodulation	Tumour‑specific T‑cell induction;increase T cells in tumour microenvironment	PMID: 28270698
Proteobacteria	Carmustine, Etoposide, Cytarabine and melphalan combination	Therapeutic Substance	Drug Combination	n.a.	n.a.	n.a.	n.a.	n.a.	Reduced diversity; ecological network function	Chemotherapy associated with reduction in bacteria that limit inflammation and increase in bacteria associated with colitis	PMID: 28270698
Firmicutes	Carmustine, Etoposide, Cytarabine and melphalan combination	Therapeutic Substance	Drug Combination	n.a.	n.a.	n.a.	n.a.	n.a.	Reduced diversity; ecological network function	Chemotherapy associated with reduction in bacteria that limit inflammation and increase in bacteria associated with colitis	PMID: 28270698
Actinobacteria	Carmustine, Etoposide, Cytarabine and melphalan combination	Therapeutic Substance	Drug Combination	n.a.	n.a.	n.a.	n.a.	n.a.	Reduced diversity; ecological network function	Chemotherapy associated with reduction in bacteria that limit inflammation and increase in bacteria associated with colitis	PMID: 28270698
Ruminococcus	CpG oligodeoxynucleotides	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	Immunomodulation	Priming of tumour‑associated myeloid inflammatory responses	PMID: 28270698
Alistipes	CpG oligodeoxynucleotides	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	Immunomodulation	Priming of tumour‑associated myeloid inflammatory responses	PMID: 28270698
Bacteroidales	CTLA-4 blockade	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	Immunomodulation	Decreased activation of splenic effector CD4 + T cells and tumour‑infiltrating lymphocytes	PMID: 28270698
Segmented filamentous bacteria	Cyclophosphamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Immunomodulation	Gram‑positive commensals mediate accumulation of TH 17 and TH 1‑cell response	PMID: 28270698
Lactobacillus	Cyclophosphamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Immunomodulation	Gram‑positive commensals mediate accumulation of TH 17 and TH 1‑cell response	PMID: 28270698
Enterococcus hirae	Cyclophosphamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Translocation	Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs	PMID: 28270698
Lactobacillus murinus	Cyclophosphamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Translocation	Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs	PMID: 28270698
Lactobacillus johnsonii	Cyclophosphamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Translocation	Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs	PMID: 28270698
Enterococcus hirae	Doxorubicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Translocation	Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs	PMID: 28270698
Lactobacillus murinus	Doxorubicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Translocation	Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs	PMID: 28270698
Lactobacillus johnsonii	Doxorubicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Translocation	Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs	PMID: 28270698
Mycoplasma	Gemcitabine	Therapeutic Substance	Approved Drug	n.a.	n.a.	Decrease Efficacy	n.a.	n.a.	Enzymatic degradation	Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity	PMID: 28270698
Bacteroidetes	Ipilimumab	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	n.a.	Bacterially mediated B vitamin production and polyamine transport deficiencies associated with increased risk of CTLA‑4 blockade‑induced colitis	PMID: 28270698
Unidentified gut microbes	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Efficacy; Increase Toxicity	n.a.	n.a.	Enzymatic degradation	Bacterial β‑glucuronidase cleaves glucuronide from inactive metabolite, releasing active metabolite (SN‑38) in the gut	PMID: 28270698
Bacteroides	Methotrexate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Reduced diversity; ecological network function	Reduced diversity and shifts in relative abundance associated with chemotherapy‑induced diarrhoea	PMID: 28270698
Streptococcus	Methotrexate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Reduced diversity; ecological network function	Reduced diversity and shifts in relative abundance associated with chemotherapy‑induced diarrhoea	PMID: 28270698
Unidentified gut microbes	Mesalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	N-acetylation by microbial N-acetyltransferases	Yield a inactive metabolite	PMID: 11344150; PMID: 28642381
Unidentified gut microbes	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	sulfapyridine;5-ASA;N-acetyl 5-ASA	Decrease Efficacy	n.a.	n.a.	Reduce	Lack anti-inflammatory	PMID: 1425876; PMID: 28642381
Unidentified gut microbes	Ginsenosides	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Inhibit cytochrome P-450s;affect host xenobiotic metabolism	PMID: 16547074; PMID: 28642381
Unidentified gut microbes	Tryptophan	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	antioxidant indole-3-propionic acid;the neurotransmitter tryptamine;indole	Increase Toxicity	n.a.	n.a.	n.a.	Generate the uremic toxin indoxyl sulfate	PMID: 17146590; PMID: 28642381
Unidentified gut microbes	Cysteine-S-conjugates of xenobiotics	Environmental Chemicals	Unclassified Substance	n.a.	thiol metabolites	n.a.	n.a.	n.a.	Cleave cysteine-S-conjugates of polychlorinated biphenyls by C-S β-lyases	Serve as a sole nitrogen,a potential role in nutrient acquisition	PMID: 20306345; PMID: 28642381
Unidentified gut microbes	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Β-glucuronidase enzymes hydrolyze SN-38G;regenerate active agent	Cause intestinal damage and severe diarrhea;drug interaction:inhibitors	PMID: 21051639; PMID: 28642381
Unidentified gut microbes	Berberine	Herbal Substance	Medicinal Herbal Compounds	n.a.	n.a.	Increase Bioavailability	n.a.	n.a.	n.a.	Allow intestinal absorption	PMID: 26174047; PMID: 28642381
Unidentified gut microbes	Sulfoxide	Environmental Chemicals	Unclassified Substance	n.a.	n.a.	n.a.	n.a.	n.a.	Reduce the sulfoxide	n.a.	PMID: 3630204; PMID: 28642381
Unidentified gut microbes	Azo dyes	Environmental Chemicals	Industrial Chemicals and Pollutants	n.a.	mutagenic bis-aniline benzidine	Increase Toxicity	Conventional mice(not GF)	n.a.	n.a.	Increase carcinogen exposure	PMID: 3726894; PMID: 28642381
Unidentified gut microbes	Methylmercury	Environmental Chemicals	Industrial Chemicals and Pollutants; Toxic Agents	n.a.	inorganic mercury	Decrease Toxicity	Rat	n.a.	n.a.	Lead to less toxicity,facilitate mercury excretion	PMID: 626001; PMID: 28642381
Unidentified gut microbes	Amygdalin	Herbal Substance; Dietary Substance	Medicinal Herbal Compounds; Dietary Compounds	n.a.	mandelonitrile	Increase Toxicity	n.a.	n.a.	Hydrolyze the glycosidic linkage	Produce benzaldehydy and toxic cyanide	PMID: 7362642; PMID: 28642381
Unidentified gut microbes	Loperamide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Reduce the N-oxide	n.a.	PMID: 7628301; PMID: 28642381
Eggerthella lenta	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	dihydrodigoxin	n.a.	Human; GF mice	n.a.	Flavin-dependent reductase(Cgr2)	n.a.	PMID: 28642381
Escherichia coli	Anticancer drugs	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Increase or decrease the efficacy of drug	PMID: 28642381
Listeria welshimeri	Anticancer drugs	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Increase or decrease the efficacy of drug	PMID: 28642381
Escherichia coli	CB954	Environmental Chemicals	Unclassified Substance	n.a.	n.a.	n.a.	n.a.	n.a.	Direct chemical modification	n.a.	PMID: 28642381
Escherichia coli	Fludarabine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Direct chemical modification	n.a.	PMID: 28642381
Escherichia coli	Gemcitabine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Direct chemical modification	n.a.	PMID: 28642381
Lactobacillus brevis	Levodopa	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	mtyramine	n.a.	n.a.	n.a.	Microbial decarboxylation and p-dehydroxylation(a tyrosine decarboxylase accepts L-dopa in vitro)	Contribute to the substantial variation	PMID: 28642381
Klebsiella	Phenoxyethanol	Therapeutic Substance	Approved Drug	n.a.	cyanuric acid	Increase Toxicity	Mouse	n.a.	Deaminate	Lead to renal toxicity	PMID: 28642381
Pseudomonas aeruginosa	Gluten	Dietary Substance	Dietary Compounds	n.a.	n.a.	n.a.	Mouse	n.a.	n.a.	Elicit an enhanced gluten-specific immune response(compare with peptieds produced by Lactobacillus spp.from healthy individuals)	PMID: 28642381
Unidentified gut microbes	Thiazolidinediones	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	Rat	Diet-induced obesity	n.a.	Indirectlyaffect gut bacteria(HFD leads to an increase in the relative abundance of Proteobacteria)	PMID: 27751827; PMID: 28973971
Unidentified gut microbes	Acarbose	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	Human	Patients with hyperlipidemia or T2D	Prevent starch processing and absorption;	Enhance starch-fermenting and butyrate-producing bacteria;inhibit starch use by propionate-producing bacteria;increase Lactobacillus,Bifidobacterium and other SCFA-producing bacteria;associated with a diminution of Enterobacteriaceae,Bacteroidaceae and lecithinase positive Clostridum in human feces	PMID: 28973971
Escherichia coli	Acarbose	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Affect nutrient sources of bacteria	Block the growth of E.coli	PMID: 28973971
SCFA-producing bacteria	Antidiabetic drugs	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Positively influence the bacteria	PMID: 28973971
SCFA-producing bacteria	High-fiber diets	Dietary Substance	Dietary Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Positively influence the bacteria	PMID: 28973971
Unidentified gut microbes	Incretin	Environmental Chemicals	Human Metabolite	n.a.	n.a.	n.a.	Primary murine colonic culture	n.a.	Microbiota fermentation products	Influence incretin secretion	PMID: 28973971
Unidentified gut microbes	Liraglutide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Mouse	High-fat diet(HFD),HF-fed,diabetes-induced	n.a.	Enrich Firmicutes;deplete Bacteroidetes,Proteobacteria and Actinobacteria phyla;enrich 13 phylotypes(Allobaculum,Turicibacter,Anaerostipes,Blautia,Lactobacillus,Butyricimonas,Desulfovibrio);decrease 20 phylotypes in the orders Clostridiales and Bacteroidales	PMID: 28973971
Escherichia	Metformin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	Human	n.a.	Inhibit the dihydrofolate reductase activity of bacteria	Influence the side-effects of drug	PMID: 28973971
Bacteroides	Metformin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	SCFA-producing bacteria	Enric the bacteria	PMID: 28973971
Lactobacillus	Metformin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Positive effects	PMID: 28973971
Phascolarctobacterium	Metformin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	SCFA-producing bacteria	Enric the bacteria	PMID: 28973971
Blautia	Metformin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	SCFA-producing bacteria	Enric the bacteria	PMID: 28973971
Butyricicoccus	Metformin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	SCFA-producing bacteria	Enric the bacteria	PMID: 28973971
Bacteroidetes	Metformin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	Mouse	High-fat diet(HFD)	n.a.	Decrease bacterial diversity	PMID: 28973971
Proteobacteria	Metformin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Positive effects	PMID: 28973971
Firmicutes	Metformin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	Mouse	High-fat diet(HFD)	n.a.	Decrease bacterial diversity	PMID: 28973971
Verrucomicrobia	Metformin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	Mouse	High-fat diet(HFD)	Genus Akkermansia	Increase the relative abundance of bacteria	PMID: 28973971
Bifidobacterium adolescentis	Metformin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Promote bacteria growth	Contribute to the glucose-lowering effect	PMID: 28973971
Allobaculum	Metformin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Positive effects	PMID: 28973971
Coriobacteriaceae	Miglitol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Mouse	A high fat and high glucose diet	Suppression of intestinal inflammation	Reverse the increase of bacteria	PMID: 28973971
Erysipelotrichaceae	Miglitol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Mouse	A high fat and high glucose diet	Suppression of intestinal inflammation	Reverse the increase of bacteria	PMID: 28973971
SCFA-producing bacteria	Physical activity	Environmental Chemicals	Unclassified Substance	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Positively influence the bacteria	PMID: 28973971
Proteobacteria	Pioglitazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	High-fat diet(HFD)	Correlate with the decrease of plasma endotoxin, TNF-α , IL-6 and MCP-1 levels	Reduce the abundance of bacteria	PMID: 28973971
Unidentified gut microbes	Saxagliptin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Mouse	HF-fed,diabetic-induced	n.a.	Enrich Firmicutes,mainly the genera Lactobacillus,Allobaculum and Turicibacter;contain less Bacteroides and Prevotella;decrease the phylum Bacteroidetes	PMID: 28973971
Unidentified gut microbes	Sitagliptin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	Diabetes-induced	n.a.	Increase in the relative abundance of Bacteroidetes and Proteobacteria;decrease Firmicute;influence SCFA-producing bacteria;Lactobacillus and Bifidobacterium are depleted in feces	PMID: 28973971
Unidentified gut microbes	Voglibose	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Decrease the Firmicutes to Bacteroidetes ratio and higher the abundance in Verrucomicrobia	PMID: 28973971
Unidentified gut microbes	Mesalazine	Therapeutic Substance	Approved Drug	n.a.	acetylated 5-aminosalicylic acid	Increase Efficacy	n.a.	n.a.	N-acetyltransferases from bacteria	Exert physiopathological effects,increase activity	PMID: 11344150; PMID: 30227749
Unidentified gut microbes	Ranitidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Lead to poor bioavailability of ranitidine	PMID: 11564550; PMID: 30227749
Unidentified gut microbes	Morphine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Hydrolysis of glucuronide	Increase drug toxicity	PMID: 1185599; PMID: 30227749
Unidentified gut microbes	Nizatidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	Decrease Efficacy	n.a.	n.a.	N-oxide bond cleavage	Decrease activity	PMID: 30227749; PMID: 11955801
Unidentified gut microbes	Lovastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	M1 (demethylbutyryl metabolite), M4 (hydroxylated metabolite), M8 (the active hydroxy acid metabolite), and M9 (hydroxylated M8)	n.a.	Human; Rat	n.a.	n.a.	Produce four metabolites	PMID: 30227749; PMID: 24947972
Unidentified gut microbes	Deleobuvir	Therapeutic Substance	Investigational Drug	n.a.	CD 6168	n.a.	n.a.	n.a.	An alkene reduction by the gut microbiota	n.a.	PMID: 30227749; PMID: 26068924
Unidentified gut microbes	Amlodipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Efficacy	n.a.	n.a.	n.a.	Increase activity	PMID: 30227749; PMID: 26630218
Unidentified gut microbes	Epacadostat	Therapeutic Substance	Investigational Drug	n.a.	Amidine metabolite	Decrease Efficacy	n.a.	n.a.	n.a.	Decrease activity	PMID: 30227749; PMID: 27457784
Unidentified gut microbes	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Amine formation	n.a.	PMID: 30227749; PMID: 4165044
Unidentified gut microbes	Sulfanilamide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Azoreductase enzymes,Activation of azo-bond containing prodrug to sulfanilamid	Increase toxicity	PMID: 5173017; PMID: 30227749
Unidentified gut microbes	Sulfonamide antibiotics	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	Microbial transformation	n.a.	PMID: 5173017; PMID: 30227749
Unidentified gut microbes	Clonazepam	Therapeutic Substance	Approved Drug	n.a.	7-aminoclonazepam	Increase Toxicity	n.a.	n.a.	Nitro reduction	n.a.	PMID: 6506755; PMID: 30227749
Unidentified gut microbes	Risperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	Decrease Efficacy	n.a.	n.a.	Isoxazole scission or hydroxylation	Decrease activity	PMID: 7512019; PMID: 30227749
Unidentified gut microbes	Loperamide oxide	Therapeutic Substance	Investigational Drug	n.a.	active drug loperamide	Increase Efficacy	Human; Dog; Rat	n.a.	n.a.	Make the metabolism and increase activity of loperamide oxide	PMID: 7628301; PMID: 30227749
Unidentified gut microbes	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	No alteration of pharmacokinetics	PMID: 7629748; PMID: 30227749
Unidentified gut microbes	Calcitonin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Susceptible to proteolysis,Protease	Increase large-intestinal absorption,decrease activity	PMID: 30227749; PMID: 9055189
Unidentified gut microbes	Insulin human	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Susceptible to proteolysis,Protease	Increase large-intestinal absorption,decrease activity	PMID: 30227749; PMID: 9055189
Unidentified gut microbes	Cimetidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Influence drug delivery and absorption	PMID: 30227749
Unidentified gut microbes	Famotidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Influence drug delivery and absorption	PMID: 30227749
Unidentified gut microbes	Nizatidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Influence drug delivery and absorption	PMID: 30227749
Bacteroides	Sorivudine	Therapeutic Substance	Investigational Drug	n.a.	(E)-5-(2-bromovinyl)uracil	Decrease Efficacy	n.a.	n.a.	n.a.	Reduce activity	PMID: 30227749
Clostridioides difficile	Acetaminophen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Decrease Efficacy; Increase Toxicity	n.a.	n.a.	P-cresol(microbial metabolite) reduces metabolic clearance	Reduce activity;delay the metabolism of drug in the human body and increase risk of hepatotoxicity	PMID: 30227749
Enterobacteriales	Acetylsalicylic acid	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Efficacy	n.a.	n.a.	n.a.	Modulate the metabolism and pharmacokinetics;Potentiate the therapeutic potency	PMID: 30227749
Enterococcus	Acetylsalicylic acid	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Efficacy	n.a.	n.a.	n.a.	Modulate the metabolism and pharmacokinetics;Potentiate the therapeutic potency	PMID: 30227749
Lactobacillus	Acetylsalicylic acid	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Efficacy	n.a.	n.a.	n.a.	Modulate the metabolism and pharmacokinetics;Potentiate the therapeutic potency	PMID: 30227749
Escherichia coli Nissle 1917	Amiodarone	Therapeutic Substance	Approved Drug	n.a.	DEA	Increase Efficacy; Increase Bioavailability	Animal model	n.a.	n.a.	Increase bioavailability of AMI,increase plasma levels of desethylamiodarone(DEA),promote the absorption of AMI and increase the activity of CYP2C	PMID: 30227749
Clostridium sp.	Balsalazide	Therapeutic Substance	Approved Drug	n.a.	5-aminosalicylic acid	Increase Toxicity	n.a.	n.a.	Reduction and Release of 5-aminosalicylic acid;Azoreductases	Increase toxicity	PMID: 30227749
Eggerthella lenta	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	digoxigenin,or dihydrodigoxin	Decrease Efficacy	human	n.a.	Reduction	Produce inactive metabolites;[interaction]:(gnotobiotic mice)dietary protein reduces microbial metabolism of digoxin(vivo) and changes drug concentration(in the serum and urine);[drug interaction]:antibiotics(tetracycline or erythromycin) increase plasma concentration of digoxin	PMID: 30227749
Bacteroides	Glucuronides	Environmental Chemicals	Unclassified Substance	n.a.	diclofenac,ketoprofen,indomethacin	Increase Toxicity	n.a.	n.a.	Hydrolysis of the glycosidicbon	Increase toxicity	PMID: 30227749
Clostridium	Glucuronides	Environmental Chemicals	Unclassified Substance	n.a.	diclofenac,ketoprofen,indomethacin	Increase Toxicity	n.a.	n.a.	Hydrolysis of the glycosidicbon	Increase toxicity	PMID: 30227749
Bifidobacterium sp.	Glucuronides	Environmental Chemicals	Unclassified Substance	n.a.	diclofenac,ketoprofen,indomethacin	Increase Toxicity	n.a.	n.a.	Hydrolysis of the glycosidicbon	Increase toxicity	PMID: 30227749
Escherichia coli	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	SN-38	Increase Toxicity	n.a.	n.a.	Hydrolysis of the glycosidicbon,bacterial b-glucuronidases	Increase toxicity	PMID: 30227749
Bacteroides vulgatus	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	SN-38	Increase Toxicity	n.a.	n.a.	Hydrolysis of the glycosidicbon,bacterial b-glucuronidases	Increase toxicity	PMID: 30227749
Erysipelatoclostridium ramosum	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	SN-38	Increase Toxicity	n.a.	n.a.	Hydrolysis of the glycosidicbon,bacterial b-glucuronidases	Increase toxicity	PMID: 30227749
Bacteroides	Lactulose	Therapeutic Substance	Approved Drug	n.a.	lactic and acetic acidsactive metabolite	Decrease Efficacy	n.a.	n.a.	n.a.	Reduce activity	PMID: 30227749
Clostridium	Lactulose	Therapeutic Substance	Approved Drug	n.a.	lactic and acetic acidsactive metabolite	Decrease Efficacy	n.a.	n.a.	n.a.	Reduce activity	PMID: 30227749
Lactobacillus	Lactulose	Therapeutic Substance	Approved Drug	n.a.	lactic and acetic acidsactive metabolite	Decrease Efficacy	n.a.	n.a.	n.a.	Reduce activity	PMID: 30227749
Bacteroides	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Increase Efficacy	n.a.	n.a.	Thiazole ring opening	Increase activity	PMID: 30227749
Clostridium sp.	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Increase Efficacy	n.a.	n.a.	Thiazole ring opening	Increase activity	PMID: 30227749
Unidentified gut microbes	Levodopa	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Catalyze p-dehydroxylation of L-dopa to mhydroxyphenylacetic acid	n.a.	PMID: 30227749
Helicobacter pylori	Levodopa	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Decrease Bioavailability	Human	Patients with Parkinson’s disease (PD)	Dehydroxylation	Reduce acute L-dopa absorption;reduce L-dopa onset time, ON duration, motor severity, and quality of life parameters	PMID: 30227749
Clostridium perfringens	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	N-(2-hydroxyethyl)-oxamic acid and acetamide	Decrease Efficacy	n.a.	n.a.	Reduction	Reduce activity	PMID: 30227749
[Clostridium] leptum	Nitrazepam	Therapeutic Substance	Approved Drug	n.a.	7-acetylaminonitrazepam	Decrease Toxicity	n.a.	n.a.	Nitroreductase	Produce teratogenic activity metabolites,Induce teratogenicity	PMID: 30227749
Clostridium sp.	Olsalazine	Therapeutic Substance	Approved Drug	n.a.	5-aminosalicylic acid	Increase Toxicity	n.a.	n.a.	Reduction and Release of 5-aminosalicylic acid;Azoreductases	Increase toxicity	PMID: 30227749
Lactobacillus	Simvastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Affect the pharmacokinetics and pharmacodynamics;increase the risk of myopathy	PMID: 30227749
Clostridium sp.	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	5-aminosalicylic acid	Increase Toxicity	n.a.	n.a.	Reduction and Release of 5-aminosalicylic acid;Azoreductases	Increase toxicity	PMID: 30227749
Clostridium sporogenes	Zonisamide	Therapeutic Substance	Approved Drug	n.a.	2-sulphamoylacetylphenol	Increase Efficacy	n.a.	n.a.	Zonisamide reductase	Increase activity	PMID: 30227749
Pseudomonas fluorescens	Zonisamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Reductive metabolism	n.a.	PMID: 30227749
Escherichia coli	Zonisamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Reductive metabolism	n.a.	PMID: 30227749
Bacteroides vulgatus	Zonisamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Reductive metabolism	n.a.	PMID: 30227749
Enterococcus faecalis	Zonisamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Reductive metabolism	n.a.	PMID: 30227749
Clostridium sporogenes	Zonisamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Reductive metabolism	n.a.	PMID: 30227749
Bifidobacterium bifidum	Zonisamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Reductive metabolism	n.a.	PMID: 30227749
Lactobacillus rhamnosus	Zonisamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Reductive metabolism	n.a.	PMID: 30227749
Salmonella enterica subsp. enterica serovar Typhimurium	Zonisamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Reductive metabolism	n.a.	PMID: 30227749
Eubacterium sp.	Balsalazide	Therapeutic Substance	Approved Drug	n.a.	5-aminosalicylic acid	Increase Toxicity	n.a.	n.a.	Reduction and Release of 5-aminosalicylic acid;Azoreductases	Increase toxicity	PMID: 30227749
Unidentified gut microbes	Diclofenac	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Bacterial b-glucuronidases	Reduce intestinal tract toxicity	PMID: 30227749
Unidentified gut microbes	Indomethacin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Bacterial b-glucuronidases	Reduce intestinal tract toxicity	PMID: 30227749
Unidentified gut microbes	Ketoprofen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Bacterial b-glucuronidases	Reduce intestinal tract toxicity	PMID: 30227749
Eubacterium sp.	Olsalazine	Therapeutic Substance	Approved Drug	n.a.	5-aminosalicylic acid	Increase Toxicity	n.a.	n.a.	Reduction and Release of 5-aminosalicylic acid;Azoreductases	Increase toxicity	PMID: 30227749
Eubacterium sp.	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	5-aminosalicylic acid	Increase Toxicity	n.a.	n.a.	Reduction and Release of 5-aminosalicylic acid;Azoreductases	Increase toxicity	PMID: 30227749
Unidentified gut microbes	Mesalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	N-acetyltransferase	Acetylating to acid	PMID: 11344150; PMID: 30338735
Unidentified gut microbes	Nizatidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Metabolized by bacteria	n.a.	PMID: 30338735; PMID: 11955801
Unidentified gut microbes	Sulfonamide antibiotics	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	Azoreductase enzymes	Activation of prodrug to 5-aminosalicylic acid	PMID: 30338735; PMID: 1711964
Clostridium perfringens	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Reduction to acetamide	PMID: 30338735; PMID: 231450
Bacterium DZY-HS11	Arsenic	Environmental Chemicals	Toxic Agents	n.a.	n.a.	n.a.	Mouse	n.a.	Reduce the abundance of bacteria	n.a.	PMID: 30338735; PMID: 24413286
Unidentified gut microbes	Lovastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Β-D-glucosidase, α-L-rhamnosidase,α-D-glucosidase enzyme	Drug interaction:antibiotics can reduce the biotransformation	PMID: 30338735; PMID: 24947972
Unidentified gut microbes	Digitoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Β-glucuronidase	Hydrolysis of glucuronide	PMID: 28922; PMID: 30338735
Unidentified gut microbes	Nifedipine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	Rat	n.a.	n.a.	n.a.	PMID: 30338735; PMID: 29790376
Unidentified gut microbes	Nifedipine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	Hypoxic conditions at high altitudes	Changes of intestinal microflora caused by high plateau hypoxia	Increase the bioavailability of drug	PMID: 30338735; PMID: 29790376
Unidentified gut microbes	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	n.a.	Result in increased toxicity	PMID: 30338735; PMID: 430360
Unidentified gut microbes	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	sulfapyridine and 5-ASA	Decrease Efficacy	n.a.	n.a.	n.a.	Lose activity	PMID: 30338735; PMID: 4402374
Unidentified gut microbes	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Active 5-aminosalicyclic acid by intestinal azoreductase enzymes	Increase the drug	PMID: 30338735; PMID: 4402374
Unidentified gut microbes	Dihydroxyphenylalanine (DOPA)	Therapeutic Substance	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Direct dopa to alternative metabolic pathways	PMID: 4723308; PMID: 30338735
Unidentified gut microbes	Artificial sweetener cyclamate	Dietary Substance	Dietary Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Hydrolysis	n.a.	PMID: 7362642; PMID: 30338735
Unidentified gut microbes	Plant-derived glycosides(amygdalin)	Herbal Substance	Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Hydrolysis	n.a.	PMID: 7362642; PMID: 30338735
Unidentified gut microbes	Loperamide oxide	Therapeutic Substance	Investigational Drug	n.a.	loperamide	n.a.	Human; Dog; Rat	n.a.	Bacteria affect activation of prodrugs and drug inactivation	n.a.	PMID: 30338735; PMID: 7628301
Unidentified gut microbes	Nitrazepam	Therapeutic Substance	Approved Drug	n.a.	7-acetylaminonitrazepam	n.a.	n.a.	n.a.	Nitroreductase	n.a.	PMID: 30338735; PMID: 9310649
Clostridium	Acetaminophen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	p-cresol	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 30338735
Enterobacteriales	Acetylsalicylic acid	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Drug interaction:antibiotics can potentiate the therapeutic potency	PMID: 30338735
Enterococcus	Acetylsalicylic acid	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Drug interaction:antibiotics can potentiate the therapeutic potency	PMID: 30338735
Lactobacillus	Acetylsalicylic acid	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Drug interaction:antibiotics can potentiate the therapeutic potency	PMID: 30338735
Unidentified gut microbes	Daidzein	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	calycosin	n.a.	n.a.	n.a.	Bacteria produces O-methyltransferase and aromatic hydroxylase	n.a.	PMID: 30338735
Eggerthella lenta	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	dihydrodigoxigenin,dihydrodigoxin	Decrease Efficacy	n.a.	n.a.	Reduction to inactive metabolites	n.a.	PMID: 30338735
Escherichia	Diosmin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Generated to glycosidic bond, followed by diosmetin	n.a.	PMID: 30338735
Enterococcus	Diosmin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Generated to glycosidic bond, followed by diosmetin	n.a.	PMID: 30338735
Clostridium	Diosmin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Generated to glycosidic bond, followed by diosmetin	n.a.	PMID: 30338735
Lactobacillus	Diosmin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Generated to glycosidic bond, followed by diosmetin	n.a.	PMID: 30338735
Bifidobacterium	Diosmin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Generated to glycosidic bond, followed by diosmetin	n.a.	PMID: 30338735
Bacteroides	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	SN-38	n.a.	n.a.	n.a.	Hydrolysis and release of SN-38	Leads to GI toxicity	PMID: 30338735
Clostridium	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	SN-38	n.a.	n.a.	n.a.	Hydrolysis and release of SN-38	Leads to GI toxicity	PMID: 30338735
Escherichia coli	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Β-glucuronidases	Enhance the irinotecan toxicity	PMID: 30338735
Bacteroides vulgatus	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Β-glucuronidases	Enhance the irinotecan toxicity	PMID: 30338735
Erysipelatoclostridium ramosum	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Β-glucuronidases	Enhance the irinotecan toxicity	PMID: 30338735
Bifidobacterium sp.	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	SN-38	n.a.	n.a.	n.a.	Hydrolysis and release of SN-38	Leads to GI toxicity	PMID: 30338735
Bacteroides	Lactulose	Therapeutic Substance	Approved Drug	n.a.	acetic lactic,acids active	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 30338735
Clostridium	Lactulose	Therapeutic Substance	Approved Drug	n.a.	acetic lactic,acids active	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 30338735
Lactobacillus	Lactulose	Therapeutic Substance	Approved Drug	n.a.	acetic lactic,acids active	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 30338735
Bacteroides	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	levametabol-I,levametabol-III	Increase Efficacy	n.a.	n.a.	n.a.	Generate active metabolites	PMID: 30338735
Clostridium sp.	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	levametabol-I,levametabol-III	Increase Efficacy	n.a.	n.a.	n.a.	Generate active metabolites	PMID: 30338735
[Eubacterium] rectale	Puerarin	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	daidzein	n.a.	n.a.	n.a.	Convert by bacteria	n.a.	PMID: 30338735
Bacteroides	Rutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Generated to glycosidic bond, followed by quercetin	n.a.	PMID: 30338735
Clostridium	Rutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Generated to glycosidic bond, followed by quercetin	n.a.	PMID: 30338735
Lactobacillus	Rutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Generated to glycosidic bond, followed by quercetin	n.a.	PMID: 30338735
Eubacterium	Rutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Generated to glycosidic bond, followed by quercetin	n.a.	PMID: 30338735
Bifidobacterium sp.	Rutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Generated to glycosidic bond, followed by quercetin	n.a.	PMID: 30338735
Escherichia	Scutellaria baicalensis root	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Generated to glycosidic bond,followed by baicalein.	n.a.	PMID: 30338735
Streptococcus	Scutellaria baicalensis root	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Generated to glycosidic bond,followed by baicalein.	n.a.	PMID: 30338735
Lactobacillus	Scutellaria baicalensis root	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Generated to glycosidic bond,followed by baicalein.	n.a.	PMID: 30338735
Eubacterium	Scutellaria baicalensis root	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Generated to glycosidic bond,followed by baicalein.	n.a.	PMID: 30338735
Bifidobacterium sp.	Scutellaria baicalensis root	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Generated to glycosidic bond,followed by baicalein.	n.a.	PMID: 30338735
Lactobacillus	Simvastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	n.a.	Increase the risk of myopathy	PMID: 30338735
Bacteroides	Sorivudine	Therapeutic Substance	Investigational Drug	n.a.	(E)-5-(2-bromovinyl) uracil	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 30338735
Gardnerella	Tenofovir	Therapeutic Substance	Investigational Drug	n.a.	n.a.	Decrease Efficacy	n.a.	n.a.	Catabolized tenofovir into an inactive compound	n.a.	PMID: 30338735
Clostridium	Zonisamide	Therapeutic Substance	Approved Drug	n.a.	2-sulphamoylacetylphenol	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 30338735
Unidentified gut microbes	Daidzein	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	Calycosin	n.a.	n.a.	n.a.	Aromatic hydroxylase,O-methyltransferase	n.a.	PMID: 30338735
Faecalibacterium prausnitzii	Anti‑PD‑1 therapy	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	Human	Patients with metastatic melanoma	n.a.	Higher relative abundance of bacteria in responding (R) patients;therapy is defined by eight species driven by Bifidobacterium longum	PMID: 30530851
Bifidobacterium longum	Anti‑PD‑1 therapy	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	Human	Patients with metastatic melanoma	n.a.	Higher relative abundance of bacteria in responding (R) patients;therapy is defined by eight species driven by Bifidobacterium longum	PMID: 30530851
Akkermansia muciniphila	Anti‑PD‑1 therapy	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	Human	Patients with non-small cell lung cancer	n.a.	Increased relative abundance of bacteria in PD-1 R	PMID: 30530851
Unidentified gut microbes	Simvastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Increase Efficacy	Human	n.a.	n.a.	221% increase in simvastatin AUC for homozygotes	PMID: 19833260; PMID: 18650507; PMID: 24918167; PMID: 22380001; PMID: 31171383
Eggerthella lenta	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Lactone ring reduction	n.a.	Increase Toxicity	Human	n.a.	n.a.	Decreased AUC; narrow therapeutic window	PMID: 24637603; PMID: 18334914; PMID: 31171383
Unidentified gut microbes	Warfarin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	Human	n.a.	Vitamin K production	Altered activity of drug	PMID: 22380001; PMID: 17042764; PMID: 26962786; PMID: 31171383
Unidentified gut microbes	Bromazepam	Therapeutic Substance	Approved Drug	Nitroreduction	n.a.	Increase Toxicity	Human	n.a.	n.a.	Amino-metabolite generation, Inactivation	PMID: 27591027; PMID: 30227749; PMID: 31171383
Unidentified gut microbes	Bromazepam	Therapeutic Substance	Approved Drug	Nitroreduction	n.a.	Decrease Efficacy	Human	n.a.	n.a.	Change to inactive metabolite	PMID: 27591027; PMID: 30227749; PMID: 31171383
Unidentified gut microbes	Clonazepam	Therapeutic Substance	Approved Drug	Nitroreduction	n.a.	Increase Toxicity	Human	n.a.	n.a.	Amino-metabolite generation, Inactivation	PMID: 27591027; PMID: 30227749; PMID: 31171383
Unidentified gut microbes	Clonazepam	Therapeutic Substance	Approved Drug	Nitroreduction	n.a.	Decrease Efficacy	Human	n.a.	n.a.	Change to inactive metabolite	PMID: 27591027; PMID: 30227749; PMID: 31171383
Unidentified gut microbes	Diclofenac	Therapeutic Substance	Approved Drug	Deglucuronidation	n.a.	Increase Toxicity	Human	n.a.	n.a.	Reformation of cytotoxic drug;Diarrhea, bowel distress, GI lesions	PMID: 27591027; PMID: 30227749; PMID: 31171383
Unidentified gut microbes	Indomethacin	Therapeutic Substance	Approved Drug	Deglucuronidation	n.a.	Increase Toxicity	Human	n.a.	n.a.	Reformation of cytotoxic drug;Diarrhea, bowel distress, GI lesions	PMID: 27591027; PMID: 30227749; PMID: 31171383
Unidentified gut microbes	Irinotecan	Therapeutic Substance	Approved Drug	Deglucuronidation	n.a.	Increase Toxicity	Human	n.a.	n.a.	Reformation of cytotoxic drug;Diarrhea, bowel distress, GI lesions	PMID: 27591027; PMID: 30227749; PMID: 31171383
Unidentified gut microbes	Ketoprofen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Deglucuronidation	n.a.	Increase Toxicity	Human	n.a.	n.a.	Reformation of cytotoxic drug;Diarrhea, bowel distress, GI lesions	PMID: 27591027; PMID: 30227749; PMID: 31171383
Unidentified gut microbes	Nitrazepam	Therapeutic Substance	Approved Drug	Nitroreduction	n.a.	Increase Toxicity	Human	n.a.	n.a.	Amino-metabolite generation, Inactivation	PMID: 27591027; PMID: 30227749; PMID: 31171383
Unidentified gut microbes	Nitrazepam	Therapeutic Substance	Approved Drug	Nitroreduction	n.a.	Decrease Efficacy	Human	n.a.	n.a.	Change to inactive metabolite	PMID: 27591027; PMID: 30227749; PMID: 31171383
Unidentified gut microbes	Irinotecan	Therapeutic Substance	Approved Drug	Deglucuronidation	SN-38G metabolite	Increase Toxicity	Human	n.a.	n.a.	Defect in glucuronidation; increased toxicity	PMID: 29104759; PMID: 18349289; PMID: 31171383
Unidentified gut microbes	Acetaminophen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Sulfonation	n.a.	Decrease Toxicity	Human	n.a.	n.a.	Increased rate of glucuronidation; decreased risk of liver failure	PMID: 23408116; PMID: 19667173; PMID: 29705271; PMID: 31171383
Unidentified gut microbes	Brivudine	Therapeutic Substance	Approved Drug	n.a.	additional bromovinyluracil	Increase Toxicity	Human	n.a.	n.a.	Hepatotoxicity; bromovinyluracil prevents clearance of 5-FU	PMID: 9690942; PMID: 30733391; PMID: 31171383
Unidentified gut microbes	Sorivudine	Therapeutic Substance	Investigational Drug	n.a.	additional bromovinyluracil	Increase Toxicity	Human	n.a.	n.a.	Hepatotoxicity; bromovinyluracil prevents clearance of 5-FU	PMID: 9690942; PMID: 30733391; PMID: 31171383
Unidentified gut microbes	Balsalazide	Therapeutic Substance	Approved Drug	Azoreduction	local 5-ASA	Increase Efficacy	Human	n.a.	n.a.	Prodrug activation: local 5-ASA release	PMID: 27591027; PMID: 31171383
Unidentified gut microbes	Calcitonin	Therapeutic Substance	Approved Drug	Proteolysis	n.a.	Decrease Efficacy	Human	n.a.	n.a.	Breakdown of therapeutic protein	PMID: 27591027; PMID: 31171383
Unidentified gut microbes	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Nitroreduction	p-aminophenyl-2-amino-1,3-propanediol	Increase Toxicity	Human	n.a.	n.a.	Bone marrow toxicity	PMID: 27591027; PMID: 31171383
Unidentified gut microbes	Insulin human	Therapeutic Substance	Approved Drug	Proteolysis	n.a.	Decrease Efficacy	Human	n.a.	n.a.	Breakdown of therapeutic protein	PMID: 27591027; PMID: 31171383
Unidentified gut microbes	Ipsalazide	Therapeutic Substance	Approved Drug	Azoreduction	local 5-ASA	Increase Efficacy	Human	n.a.	n.a.	Prodrug activation: local 5-ASA release	PMID: 27591027; PMID: 31171383
Unidentified gut microbes	Neoprontosil	Therapeutic Substance	Approved Drug	Azoreduction	n.a.	Increase Efficacy	Human	n.a.	n.a.	Antibiotic activation	PMID: 27591027; PMID: 31171383
Unidentified gut microbes	Olsalazine	Therapeutic Substance	Approved Drug	Azoreduction	local 5-ASA	Increase Efficacy	Human	n.a.	n.a.	Prodrug activation: local 5-ASA release	PMID: 27591027; PMID: 31171383
Unidentified gut microbes	Picosulfuric acid	Therapeutic Substance	Approved Drug	Desulfation	n.a.	Increase Efficacy	Human	n.a.	n.a.	Solubility increase	PMID: 27591027; PMID: 31171383
Unidentified gut microbes	Prontosil	Therapeutic Substance	Approved Drug	Azoreduction	n.a.	Increase Efficacy	Human	n.a.	n.a.	Antibiotic activation	PMID: 27591027; PMID: 31171383
Unidentified gut microbes	Sulfadiazine	Therapeutic Substance	Approved Drug	Azoreduction	local 5-ASA	Increase Efficacy	Human	n.a.	n.a.	Prodrug activation: local 5-ASA release	PMID: 27591027; PMID: 31171383
Unidentified gut microbes	Mesalazine	Therapeutic Substance	Approved Drug	N-Acetylation	n.a.	Decrease Efficacy	Human	n.a.	n.a.	Less efficacy; possible pancreatic toxicity	PMID: 30227749; PMID: 31171383
Unidentified gut microbes	Amiodarone	Therapeutic Substance	Approved Drug	N-dealkylation	n.a.	Increase Efficacy	Human	n.a.	n.a.	Increased bioavailability of active metabolite	PMID: 30227749; PMID: 31171383
Unidentified gut microbes	Codeine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Deglucuronidation	n.a.	Increase Efficacy	Human	n.a.	n.a.	Reformation of active metabolite	PMID: 30227749; PMID: 31171383
Unidentified gut microbes	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Lactone ring reduction	n.a.	Decrease Efficacy	Human	n.a.	n.a.	Change to inactive metabolite	PMID: 30227749; PMID: 31171383
Unidentified gut microbes	Metamfetamine	Therapeutic Substance	Approved Drug	N-Demethylation	n.a.	Decrease Efficacy	Human	n.a.	n.a.	Change to inactive metabolite	PMID: 30227749; PMID: 31171383
Unidentified gut microbes	Morphine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Deglucuronidation	n.a.	Increase Efficacy	Human	n.a.	n.a.	Reformation of active metabolite	PMID: 30227749; PMID: 31171383
Unidentified gut microbes	Brivudine	Therapeutic Substance	Approved Drug	N-Dealkylation	n.a.	Increase Toxicity	Human	n.a.	n.a.	Bacteroides-mediated hepatotoxicity; potentially fatal 5-FU accumulation	PMID: 30733391; PMID: 31171383
Unidentified gut microbes	Sorivudine	Therapeutic Substance	Investigational Drug	N-Dealkylation	n.a.	Increase Toxicity	Human	n.a.	n.a.	Bacteroides-mediated hepatotoxicity; potentially fatal 5-FU accumulation	PMID: 30733391; PMID: 31171383
Helicobacter pylori	Levodopa	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	P-Dehydroxylation	n.a.	Decrease Efficacy	Human	n.a.	n.a.	Decrease in L-dopa absorption	PMID: 31171383
Pseudomonas aeruginosa	Morphine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Deglucuronidation	morphine-glucuronide metabolite	n.a.	Human	n.a.	n.a.	Decreased clearance of morphine; Induces virulence in some strains of Pseudomonas aeruginosa	PMID: 31171383
Unidentified gut microbes	Estradiol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Increase Bioavailability	human	n.a.	Β-glucuronidase mediate deconjugation and enterohepatic circulation of estrogen	Greater absroption of estrogens;develop estrogen-driven cancer	PMID: 27107051; PMID: 31184303; PMID: 24187630
Unidentified gut microbes	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Toxicity	Human; Mouse	n.a.	Microbial β-glucuronidases mediate the reactivation of metabolite（deconjugation and reactivation of SN-38）	Cause toxicity(epithelial damage;severe diarrhea);analog:plant-based compound scutellarin(inadvertently modulating the effect of cancer therapy)	PMID: 29104759; PMID: 21051639; PMID: 31184303
Unidentified gut microbes	Taurine conjugated bile acid	Environmental Chemicals	Human Metabolite	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Meidate de-conjugation of taurineconjugates;generate hydrogen sulfid	Contribute to the etiology of cancer	PMID: 27003186; PMID: 31184303
Eggerthella lenta	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Decrease Efficacy	human	n.a.	Be linked to cgr operon expression levels;human microbiome reductase inactivates the drug	Lead to inactivation and decreased bioavailability;drug substructure similarity:cardenolides(great),progesterone、cortisone(bad);	PMID: 31184303
Unidentified gut microbes	Altretamine	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Toxicity	Human	n.a.	Alter the drug structure	Cause diarrhea and kidney damage;interaction:tamoxifen、diphenhydramine、theobromine	PMID: 31184303
Pseudomonas putida	Altretamine	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Microbial N-demethylase enzymes	Lead to similar toxic effects as seen with melamine;Substrate similar(no evidence)	PMID: 31184303
Styrax aureus	Hypochlorite	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Human	Patients with cutaneous T cell lymphoma	n.a.	Reduce the amount of bacteria	PMID: 18835065; PMID: 31186074
Unidentified probiotic	Common azole treatment	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Reduce the amount of azoleresistant fungal strains	PMID: 25362524; PMID: 31186074
Unidentified gut microbes	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Reactivate drug by the β-glucuronidase enzyme	Result in side effects( stage 4 diarrhea and gastrointestinal damage)	PMID: 31186074; PMID: 26364932
Unidentified gut microbes	Levodopa	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	m-tyramine, m-hydroxyphenylacetic acid (m-HPAA)	Decrease Efficacy	Rat	n.a.	n.a.	Decrease L-DOPA half-life and efficacy	PMID: 4723308; PMID: 31186074
Unidentified gut microbes	Lactulose	Therapeutic Substance	Approved Drug	n.a.	acetic,lactic acid	Increase Efficacy	n.a.	n.a.	n.a.	Product therapeutic metabolites	PMID: 6804597; PMID: 31186074
Unidentified gut microbes	Antibiotic (extensive treatment)	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	Eliminate the majority of the intestinal microbiome and improve harmful bacteria(Clostridium difficile)	Lead to intestinal complications(antibiotic-associated diarrhea and colitis);drug interaction: C. difficile can be treated with vancomycin and metronidazole	PMID: 31186074
Unidentified gut microbes	Bromazepam	Therapeutic Substance	Approved Drug	n.a.	7-aminoclonazepam,2-(2-amino-5-bromobenzoyl) pyridine	n.a.	n.a.	n.a.	Gut microbial nitroreductase activity	n.a.	PMID: 2893665; PMID: 6506755
Unidentified gut microbes	Clonazepam	Therapeutic Substance	Approved Drug	n.a.	7-aminoclonazepam,2-(2-amino-5-bromobenzoyl) pyridine	n.a.	n.a.	n.a.	Gut microbial nitroreductase activity	n.a.	PMID: 2893665; PMID: 6506755
Unidentified gut microbes	Potassium oxonate	Environmental Chemicals	Unclassified Substance	n.a.	cyanuric acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 10997934
Unidentified gut microbes	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	N-acetyl sulfapyridine,N-acetyl-5-aminosalicylic acid	n.a.	Human; Rat; Guinea pig; Dog	n.a.	Bacterial N-acetylation	n.a.	PMID: 1425876
Unidentified gut microbes	Picosulfuric acid	Therapeutic Substance	Approved Drug	n.a.	4,40-dihydroxydiphenyl-(2 pyridyl)-methane	n.a.	n.a.	n.a.	Conversion by gut bacteria	n.a.	PMID: 1507649
Unidentified gut microbes	Phosphate or sulfate ester prodrugs	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	The drug act on hydrolytic enzymes of bacteria	n.a.	PMID: 1507649
Unidentified gut microbes	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	5-amino 5-salicylic acid	Increase Efficacy	n.a.	n.a.	Microbial azoreductases	Convert to its pharmacologically active form;enhance drug distribution：olsalazine、balsalazide（inflammatory bowel disease）——introduction of azo bonds	PMID: 18305431
Unidentified gut microbes	Antibiotic	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	Eliminate vitamin K-producing bacteria	Lead to alteration in coagulation status	PMID: 18841274
Unidentified gut microbes	Nitrazepam	Therapeutic Substance	Approved Drug	n.a.	7-aminonitrazepam,7-acetylaminonitrazepam	Increase Toxicity	Rat	Pregnant	Gut microbial nitroreductase activity	Lead to nitrazepam-related teratogenicity;drug interaction:antibiotic reduced metabolites	PMID: 1925980
Unidentified gut microbes	Acetaminophen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	N-acetyl p-benzoquuinone imine	Increase Toxicity	Human	n.a.	A microbial-derived metabolite p-cresol compete with acetaminophen	Impede the ability for the liver to detoxify	PMID: 19667173; PMID: 31462078
Unidentified anaerobic bacterium	Fostamatinib	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Microbial O-dealkylation	n.a.	PMID: 20371637
Unidentified gut microbes	Rosuvastatin	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Compete with TMA for metabolism by FMO3	Cause side effect on fish odor syndrom	PMID: 21422137
Unidentified gut microbes	Indomethacin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Mouse	n.a.	n.a.	Alterations in bacteria(expansion of proinflammatory bacteria)	PMID: 22328575
Unidentified gut microbes	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	1-(2-aminoimidazol-1-yl)-3 methoxypropanol-2-ol and acetamide	n.a.	Rat	n.a.	Gut microbiome–derived nitroreduction	Lead to rat carcinogen	PMID: 231450
Unidentified gut microbes	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Decrease Efficacy	n.a.	n.a.	n.a.	Microbial inactivation	PMID: 23869020
Unidentified gut microbes	CpG-oligonucleotide immunotherapy	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	Prime murine immune cells to secrete tumor necrosis factor(TNF)	Stimulate the immune system to attack cancer cells	PMID: 24264989
Unidentified gut microbes	Lovastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Drug interaction:long-term antibiotic treatment might lead to a failure to control serum cholesterol levels	PMID: 24947972
Unidentified gut microbes	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Efficacy	n.a.	n.a.	n.a.	Lead to activation of drug	PMID: 25091594
Unidentified gut microbes	Eltrombopag	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Human; Dog	n.a.	Reductive cleavag	n.a.	PMID: 25581726
Unidentified gut microbes	Levosimendan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Human; Dog	n.a.	Reductive cleavag	n.a.	PMID: 25581726
Unidentified gut microbes	Indole	Therapeutic Substance; Herbal Substance	Investigational Drug	n.a.	indole-3-propionic acid	n.a.	n.a.	n.a.	n.a.	Provide ligands for the aryl hydrocarbon receptor	PMID: 26041783
Unidentified gut microbes	Tryptophan	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	indole-3-propionic acid	n.a.	n.a.	n.a.	n.a.	Provide ligands for the aryl hydrocarbon receptor	PMID: 26041783
Unidentified gut microbes	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	B-glucuronidase activity	Lead to severe diarrhea;drug interaction:antibiotic mixtures(streptomycin,penicillin or neomycin and bacitracin)eliminated fecal b-glucuronidase activity; TJ-14 administration moderate weight loss and delay the drug-associated diarrhea; the P-glycoprotein and (cMOA T/MRP2) inhibitor of cyclosporin A or (UDP)-glucuronosyltransferase inhibitor valproic acid increased intestinal toxicity	PMID: 26518357
Unidentified gut microbes	Indomethacin	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Efficacy	Mouse	n.a.	Β-glucuronidases	Enhance pharmacological effect	PMID: 26701907
Unidentified oral microbes	PPIs	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	Associated with changes toward a less healthy gut microbiome and in line with changes predisposing users to infection with C. difficile	Species of bacteria were seen to be over-represented in the fecal microbiome	PMID: 26719299
Unidentified gut microbes	PPIs	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	Changes in bacterial populations(decrease Bacteroidetes and increase Firmicutes)	Predispose PPI-treated subjects to C. difficile infection;[drug interaction]:frequent use of PPIs can exacerbate NSAID-induced small intestinal injury;[probiotics]prevent NSAID-induced damage in patients receiving PPI and NSAIDs	PMID: 26923470
Unidentified gut microbes	Rosuvastatin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Mouse	With rosuvastatin	Reduce hepatic expression of the CYP27a1,alter the concentrations of bile acids	Contribute to the composition of gut microbiota	PMID: 28209601
Unidentified gut microbes	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	Decrease Toxicity	n.a.	n.a.	n.a.	Causes toxic side effects	PMID: 29104759
Unidentified gut microbes	Levodopa	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	dopamine	n.a.	n.a.	n.a.	Tyrosine decarboxylase	n.a.	PMID: 30659181
Escherichia coli	Flucytosine	Therapeutic Substance	Approved Drug	n.a.	5-FU	n.a.	n.a.	n.a.	Deamination by bacteria	n.a.	PMID: 3729334
Unidentified gut microbes	2-amino-3,6-dihydro-3H-imidazo[4,5-f]quinoline	Environmental Chemicals	Unclassified Substance	n.a.	7-hydroxy metabolite	n.a.	n.a.	n.a.	Gut microbiotal oxidation/dehydrogenation	n.a.	PMID: 3821779
Unidentified gut microbes	Acetaminophen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Drug is deacetylated	n.a.	PMID: 4418213
Unidentified gut microbes	Phenacetin	Therapeutic Substance	Approved Drug (Withdrawn)	n.a.	n.a.	n.a.	n.a.	n.a.	Drug is deacetylated	n.a.	PMID: 4418213
Unidentified gut microbes	Levodopa	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	m-hydroxyphenylacetic acid	n.a.	Rat	n.a.	Some microbial dehydroxylation	Reduce the exposure of the drug in the brain	PMID: 5343357
Unidentified gut microbes	Methotrexate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Mouse	Normal	n.a.	n.a.	PMID: 5345205
Unidentified gut microbes	Radiation sensitizer misonidazole	Therapeutic Substance	n.a.	n.a.	l-(2-l-(2-aminoimidazol-l-yl)-3-methoxypropan-2-ol	n.a.	Rat	Normal,germ-free(GF)	Nitroreduction	Drug interaction:penicillin increased drug exposure and decreased neurotoxicity	PMID: 6260109
Unidentified gut microbes	Risperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat; Dog	n.a.	Reductive metabolism	n.a.	PMID: 7512019
Unidentified gut microbes	Calcitonin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	n.a.	n.a.	Drug is rapidly degraded;more prone to proteolysis;drug interaction:protease inhibitors(camostat/aprotinin) improve the stability and bioavailability of these peptides	PMID: 7550138
Unidentified gut microbes	Loperamide oxide	Therapeutic Substance	Investigational Drug	n.a.	loperamide,the ranitidine,nitazidine	n.a.	Dog	n.a.	n.a.	n.a.	PMID: 7628301
Unidentified gut microbes	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	sulfide metabolite	n.a.	n.a.	n.a.	Reduction	n.a.	PMID: 7629748
Unidentified anaerobic bacterium	Azetirelin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	n.a.	n.a.	Drug interaction:concentrations of the drug were maintained after the administration of antibiotic	PMID: 9279880
Bacteroides	1-b-D-arabinofuranosyl-5-(E)-(2-bromovinyl)uracil	Environmental Chemicals	Unclassified Substance	n.a.	BVU	n.a.	Rat	n.a.	The result of hydrolysis by anaerobic bacteria	Drug interaction: the drug with the anticancer drug 5-FU or prodrugs tegafur,5-FU accumulate(increase toxicity, including death)	PMID: 9808711
Unidentified gut microbes	Sulfanilamide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	molecule sulfanilamide	Increase Efficacy	n.a.	n.a.	n.a.	Generate the active form of the drug	PMID: 31235939
Bacteroides thetaiotaomicron	Diltiazem	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Mouse	Germ-free(GF)	Bt4096 encodes an enzyme that metabolizes diltiazem	n.a.	PMID: 31235939
Faecalibacterium	Anti‑PD‑1 therapy	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	Human	Patients with melanoma	n.a.	Prolong progession-free survival	PMID: 31462078
Bacteroidetes	Checkpoint inhibitor therapy	Therapeutic Substance	Drug Class	n.a.	n.a.	Decrease Toxicity	n.a.	n.a.	Overabundance of the bacteroidetes phylum	Decrease occrrence of side effect	PMID: 31462078
Eggerthella lenta	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	dihydrodigoxin	Decrease Bioavailability	Human	n.a.	A cytochrome-encoding operon (termed the cardiac glycoside reductase)	Convert to the inactive microbial metabolite;limit absorbtion;drug interaction:antibiotics,arginine-rich diet(impair this reaction)	PMID: 31462078
Unidentified gut microbes	Rosuvastatin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Human	Patients with with hyperlipidemia	Activity of bacteria containing bile salt hydrolases	Phyla Firmicutes、Fusobacteria（negatively associated with LDL-C levels）;Cyanobacteria、Lentisphaerae(positively)	PMID: 31462078
Firmicutes	Rosuvastatin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Human	n.a.	Bile salt hydrolase activity	Reduce LDL-C levels	PMID: 31462078
Lactobacillus reuteri	Rosuvastatin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Human	n.a.	Bile salt hydrolase activity	Reduce LDL-C levels	PMID: 31462078
Unidentified gut microbes	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	SN-38	Increase Toxicity	n.a.	n.a.	Β-glucuronidases remove the glucuronide group;reactive the drug	Sever diarrhea;drug interaction(mice:oral administration of a specific inhibitor of the β-glucuronidase enzyme,reduce irinotecan-induced toxicity)	PMID: 31462078
Unidentified gut microbes	Dietary choline	Dietary Substance	Dietary Compounds	n.a.	trimethylamine-N-oxide(TMAO)	Increase Toxicity	n.a.	n.a.	Microbiome-derived metabolites	Interfer with drug pharmacokinetics and pharmacodynamics	PMID: 31462078
Unidentified gut microbes	Levocarnitine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	trimethylamine-N-oxide(TMAO)	Increase Toxicity	n.a.	n.a.	Microbiome-derived metabolites	Interfer with drug pharmacokinetics and pharmacodynamics	PMID: 31462078
Unidentified gut microbes	Acetylsalicylic acid	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Damage the mucosa of the upper GI tract;be able to distinguish aspirin users:(Prevotella species, Bacteroides species, a member of the Ruminococaceae family, and Barnesiella species	PMID: 31462078
Unidentified gut microbes	Amlodipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Human; Rat	n.a.	Presystemic metabolism by dehydrogenation	Decreased amount of active drug reaching target tissues;its major metabolite increased;drug interaction:rat(pretreated with ampicillin),enhance amlodipine's absorption;	PMID: 31462078
Unidentified gut microbes	Atorvastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	Human; Rat	Rat(high-fat diet);hypercholesterolemia patients	Decreased amount of secondary bile acids	Increase abundance of putative anti-inflammatory species	PMID: 31462078
Unidentified gut microbes	Captopril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	Hypertensive	Decreased intestinal permeability and fibrosis; and improved villi length	Reverse the dysbiotic state	PMID: 31462078
Unidentified gut microbes	Clonazepam	Therapeutic Substance	Approved Drug	n.a.	7-aminoclonazapam	n.a.	n.a.	n.a.	Reduction reactions	Drug interaction:antibiotics(inhibit)	PMID: 31462078
Unidentified gut microbes	Simvastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Decrease Efficacy	n.a.	n.a.	Microbial-derived bile acids competing for host uptake transporters	Decreased amount of drug reaching target tissues	PMID: 31462078
Unidentified gut microbes	Simvastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	Human	n.a.	Bacterial-derived bile acids(lithocholic acid,taurolithocholic acid,glycolithocholic acid)	Predict the magnitude of LDL-C lowering	PMID: 31462078
Unidentified gut microbes	Nitrazepam	Therapeutic Substance	Approved Drug	n.a.	7-amino-nitrazepam	Increase Toxicity	n.a.	n.a.	Nitro reduction by microbiota	Produce a teratogenic metabolite;drug interaction:antibiotics(inhibit)	PMID: 31462078
Bacteroides dorei DSM17855	Alfuzosin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.339 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bifidobacterium ruminatum	Alprenolol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.339 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bifidobacterium breve DSM20213	Benzbromarone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.828 [FDR-adjusted p-Value=0.049]	PMID: 31158845
Clostridium difficile 120	Camylofine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.425 [FDR-adjusted p-Value=0.05]	PMID: 31158845
Salmonella typhimurium LT2	Capecitabine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.688 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Blautia hansenii DSM20583	Clemizole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.408 [FDR-adjusted p-Value=0.047]	PMID: 31158845
Bifidobacterium ruminatum	Diphenylpyraline	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.329 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Eubacterium rectale ATCC33656	Ethoxzolamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.557 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bifidobacterium ruminatum	Irsogladine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.45 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides fragilis ATCC43859	Lofexidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.341 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Bacteroides uniformis ATCC8492	Metitepine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.765 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Blautia hansenii DSM20583	Orphenadrine citrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.408 [FDR-adjusted p-Value=0.026]	PMID: 31158845
Bacteroides dorei DSM17855	Oxcarbazepine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.441 [FDR-adjusted p-Value=0.048]	PMID: 31158845
Bacteroides dorei DSM17855	Papaverine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.394 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Clostridium sp.	Paroxetine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.378 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Bacteroides coprophilus DSM18228	Rizatriptan benzoate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.54 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Bacteroides fragilis HMW610	Sulpiride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.399 [FDR-adjusted p-Value=0.04]	PMID: 31158845
Bacteroides fragilis 3397 T10	Trimetazidine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.72 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Verapamil	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.372 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Anaerococcus hydrogenalis DSM7454	Zidovudine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.952 [FDR-adjusted p-Value=0.047]	PMID: 31158845
Bacteroides uniformis ATCC8492	Acecainide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.376 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides fragilis ATCC43859	Acecainide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.345 [FDR-adjusted p-Value=0.031]	PMID: 31158845
Blautia hansenii DSM20583	Anastrozole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.381 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Clostridium sp.	Anastrozole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.443 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Blautia hansenii DSM20583	Benzthiazide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.459 [FDR-adjusted p-Value=0.045]	PMID: 31158845
Clostridium sp.	Benzthiazide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.459 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides fragilis HMW610	Bicalutamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.612 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides fragilis HMW615	Bicalutamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.493 [FDR-adjusted p-Value=0.038]	PMID: 31158845
Escherichia coli BW25113	Bupropion	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.598 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bifidobacterium ruminatum	Bupropion	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.682 [FDR-adjusted p-Value=0.035]	PMID: 31158845
Clostridium sporogenes ATCC15579	Celecoxib	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.809 [FDR-adjusted p-Value=0.031]	PMID: 31158845
Eubacterium biforme DSM3989	Celecoxib	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.898 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Blautia hansenii DSM20583	Cyclobenzaprine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.482 [FDR-adjusted p-Value=0.035]	PMID: 31158845
Clostridium sp.	Cyclobenzaprine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.449 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Imatinib	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.453 [FDR-adjusted p-Value=0.028]	PMID: 31158845
Anaerostipes sp.	Imatinib	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.405 [FDR-adjusted p-Value=0.037]	PMID: 31158845
Bifidobacterium ruminatum	Memantine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.419 [FDR-adjusted p-Value=0.047]	PMID: 31158845
Eubacterium biforme DSM3989	Memantine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.329 [FDR-adjusted p-Value=0.046]	PMID: 31158845
Clostridium sp.	Methsuximide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.51 [FDR-adjusted p-Value=0.035]	PMID: 31158845
Bacteroides dorei DSM17855	Methsuximide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Dorea formicigenerans ATCC27755	Methysergide maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.374 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Victivallis vadensis ATCC BAA-548	Methysergide maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Bifidobacterium ruminatum	Metoprolol tartrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.347 [FDR-adjusted p-Value=0.023]	PMID: 31158845
Bacteroides fragilis ATCC43859	Metoprolol tartrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.328 [FDR-adjusted p-Value=0.039]	PMID: 31158845
Akkermansia muciniphila ATCC BAA-835	Naftopidil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.325 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Bacteroides fragilis HMW610	Naftopidil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.006 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Blautia hansenii DSM20583	Nevirapine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.441 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Clostridium sp.	Nevirapine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.474 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Blautia hansenii DSM20583	Thiothixene	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.577 [FDR-adjusted p-Value=0.043]	PMID: 31158845
Clostridium sp.	Thiothixene	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.594 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Tranilast	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.45 [FDR-adjusted p-Value=0.023]	PMID: 31158845
Bacteroides fragilis HMW610	Tranilast	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.033]	PMID: 31158845
Blautia hansenii DSM20583	Vinpocetine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Clostridium sp.	Vinpocetine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.49 [FDR-adjusted p-Value=0.027]	PMID: 31158845
Blautia hansenii DSM20583	Dipyridamole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.58 [FDR-adjusted p-Value=0.028]	PMID: 31158845
Clostridium sp.	Dipyridamole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.512 [FDR-adjusted p-Value=0.032]	PMID: 31158845
Bacteroides dorei DSM17855	Dipyridamole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.805 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Blautia hansenii DSM20583	Doxazosin mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.493 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Clostridium sp.	Doxazosin mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.544 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Bacteroides dorei DSM17855	Doxazosin mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.461 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Blautia hansenii DSM20583	Enalapril maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.439 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Enalapril maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.335 [FDR-adjusted p-Value=0.049]	PMID: 31158845
Eubacterium biforme DSM3989	Enalapril maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.329 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Blautia hansenii DSM20583	Fluvoxamine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.537 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Clostridium sp.	Fluvoxamine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.541 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bifidobacterium ruminatum	Fluvoxamine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.04]	PMID: 31158845
Blautia hansenii DSM20583	Sildenafil citrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.494 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Clostridium sp.	Sildenafil citrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.524 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Clostridium difficile 120	Sildenafil citrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.424 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Sumatriptan succinate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.413 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Bacteroides fragilis DS-208	Sumatriptan succinate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.623 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides fragilis HMW610	Sumatriptan succinate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.502 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Warfarin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.453 [FDR-adjusted p-Value=0.049]	PMID: 31158845
Bacteroides fragilis HMW615	Warfarin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.408 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Bacteroides fragilis ATCC43859	Warfarin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.58 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Escherichia coli BW25113	Ziprasidone mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.54 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Ziprasidone mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.632 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Alistipes indistinctus DSM 22520	Ziprasidone mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.689 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Bacteroides uniformis ATCC8492	Amantadine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.378 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Bifidobacterium ruminatum	Amantadine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.422 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Amantadine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.347 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Bacteroides fragilis DS-208	Amantadine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.325 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Blautia hansenii DSM20583	Cyclophosphamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.325 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Alistipes indistinctus DSM 22520	Cyclophosphamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.327 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Eubacterium biforme DSM3989	Cyclophosphamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.34 [FDR-adjusted p-Value=0.032]	PMID: 31158845
Bacteroides fragilis HMW615	Cyclophosphamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.335 [FDR-adjusted p-Value=0.046]	PMID: 31158845
Bacteroides coprophilus DSM18228	Ergotamine tartrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.956 [FDR-adjusted p-Value=0.033]	PMID: 31158845
Bacteroides WH2 WH2	Ergotamine tartrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.774 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Ergotamine tartrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.23 [FDR-adjusted p-Value=0.024]	PMID: 31158845
Bacteroides fragilis DS-208	Ergotamine tartrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.969 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Escherichia coli BW25113	Mefloquine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.977 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Providencia alcalifaciens DSM30120	Mefloquine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.464 [FDR-adjusted p-Value=0.035]	PMID: 31158845
Roseburia intestinalis L1-82	Mefloquine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.658 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Eggerthella lenta ATCC25559	Mefloquine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.995 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Clostridium sp.	Penbutolol sulfate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.44 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Penbutolol sulfate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.48 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Bacteroides uniformis ATCC8492	Penbutolol sulfate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Eubacterium biforme DSM3989	Penbutolol sulfate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.356 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Clostridium sp.	Pimozide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.774 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Anaerotruncus colihominis DSM17241	Pimozide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.725 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Clostridium bolteae ATCCBAA-613	Pimozide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.558 [FDR-adjusted p-Value=0.028]	PMID: 31158845
Akkermansia muciniphila ATCC BAA-835	Pimozide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.128 [FDR-adjusted p-Value=0.04]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Tadalafil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.448 [FDR-adjusted p-Value=0.023]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Tadalafil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.547 [FDR-adjusted p-Value=0.048]	PMID: 31158845
Bacteroides fragilis HMW610	Tadalafil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.523 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides fragilis HMW615	Tadalafil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.434 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Blautia hansenii DSM20583	Biperiden	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.385 [FDR-adjusted p-Value=0.045]	PMID: 31158845
Clostridium sp.	Biperiden	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.361 [FDR-adjusted p-Value=0.047]	PMID: 31158845
Bacteroides dorei DSM17855	Biperiden	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.488 [FDR-adjusted p-Value=0.047]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Biperiden	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.583 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Blautia hansenii DSM20583	Methylphenidate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.451 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Clostridium sp.	Methylphenidate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.538 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bifidobacterium ruminatum	Methylphenidate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.373 [FDR-adjusted p-Value=0.042]	PMID: 31158845
Eggerthella lenta ATCC25559	Methylphenidate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.433 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Blautia hansenii DSM20583	Ethopropazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.517 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Clostridium sp.	Ethopropazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.555 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Bacteroides dorei DSM17855	Ethopropazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.536 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Ethopropazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.447 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Odoribacter splanchnius	Ethopropazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.384 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides dorei DSM17855	Phenytoin sodium	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.618 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Phenytoin sodium	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.555 [FDR-adjusted p-Value=0.027]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Phenytoin sodium	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.364 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Phenytoin sodium	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.326 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides uniformis ATCC8492	Phenytoin sodium	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.48 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Blautia hansenii DSM20583	Trihexyphenidyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Clostridium sp.	Trihexyphenidyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.526 [FDR-adjusted p-Value=0.031]	PMID: 31158845
Bacteroides dorei DSM17855	Trihexyphenidyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.386 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Bacteroides uniformis ATCC8492	Trihexyphenidyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.331 [FDR-adjusted p-Value=0.045]	PMID: 31158845
Bifidobacterium ruminatum	Trihexyphenidyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.402 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Bacteroides dorei DSM17855	Cimetidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.506 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides uniformis ATCC8492	Cimetidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.404 [FDR-adjusted p-Value=0.026]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Cimetidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.512 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Cimetidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.4 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Bacteroides fragilis 3397 T10	Cimetidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.546 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Bacteroides fragilis T(B)9	Cimetidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.556 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Blautia hansenii DSM20583	Dasatinib	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.38 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Clostridium sp.	Dasatinib	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.485 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Clostridium bolteae ATCCBAA-613	Dasatinib	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.327 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Lactobacillus reuteri CF48-3A BEI HM-102	Dasatinib	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.961 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bifidobacterium ruminatum	Dasatinib	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.533 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides fragilis HMW610	Dasatinib	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.482 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Blautia hansenii DSM20583	Nafronyl oxalate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.409 [FDR-adjusted p-Value=0.049]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Nafronyl oxalate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.581 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Nafronyl oxalate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.364 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Bacteroides uniformis ATCC8492	Nafronyl oxalate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.474 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bifidobacterium ruminatum	Nafronyl oxalate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.338 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Odoribacter splanchnius	Nafronyl oxalate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.39 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Odoribacter splanchnius	Olanzapine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.708 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Bacteroides coprophilus DSM18228	Olanzapine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.538 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides fragilis 3397 T10	Olanzapine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.057 [FDR-adjusted p-Value=0.032]	PMID: 31158845
Bacteroides fragilis T(B)9	Olanzapine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.46 [FDR-adjusted p-Value=0.033]	PMID: 31158845
Bacteroides fragilis HMW610	Olanzapine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.653 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Bacteroides fragilis HMW615	Olanzapine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.653 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Blautia hansenii DSM20583	Anagrelide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.398 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Clostridium sp.	Anagrelide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.387 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Bacteroides dorei DSM17855	Anagrelide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.426 [FDR-adjusted p-Value=0.031]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Anagrelide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.329 [FDR-adjusted p-Value=0.028]	PMID: 31158845
Odoribacter splanchnius	Anagrelide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.431 [FDR-adjusted p-Value=0.032]	PMID: 31158845
Eubacterium biforme DSM3989	Anagrelide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.332 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Bacteroides fragilis T(B)9	Anagrelide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.346 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Bacteroides dorei DSM17855	Bezafibrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.382 [FDR-adjusted p-Value=0.031]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Bezafibrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.486 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Bezafibrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.554 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Odoribacter splanchnius	Bezafibrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.437 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Parabacteroides merdae ATCC43184	Bezafibrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.362 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides fragilis HMW610	Bezafibrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.634 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Bacteroides fragilis ATCC43859	Bezafibrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.709 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Blautia hansenii DSM20583	Carbetapentane citrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.451 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Clostridium sp.	Carbetapentane citrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.444 [FDR-adjusted p-Value=0.027]	PMID: 31158845
Bacteroides dorei DSM17855	Carbetapentane citrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.344 [FDR-adjusted p-Value=0.031]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Carbetapentane citrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.335 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Bacteroides uniformis ATCC8492	Carbetapentane citrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.43 [FDR-adjusted p-Value=0.023]	PMID: 31158845
Odoribacter splanchnius	Carbetapentane citrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.342 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Victivallis vadensis ATCC BAA-548	Carbetapentane citrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.649 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Blautia hansenii DSM20583	Chlormezanone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.365 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Clostridium sp.	Chlormezanone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.405 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Chlormezanone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.349 [FDR-adjusted p-Value=0.047]	PMID: 31158845
Clostridium asparagiforme DSM15981	Chlormezanone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.331 [FDR-adjusted p-Value=0.039]	PMID: 31158845
Bifidobacterium ruminatum	Chlormezanone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.49 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Alistipes indistinctus DSM 22520	Chlormezanone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.349 [FDR-adjusted p-Value=0.026]	PMID: 31158845
Eubacterium biforme DSM3989	Chlormezanone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.412 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Bacteroides dorei DSM17855	Dicyclomine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.817 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Dicyclomine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.585 [FDR-adjusted p-Value=0.033]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Dicyclomine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.394 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Pretovella copri DSM18205	Dicyclomine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.373 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Ruminococcus torques ATCC27756	Dicyclomine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.695 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Dicyclomine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.461 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Eggerthella lenta ATCC25559	Dicyclomine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.546 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides eggerthii DSM20697	Fenofibrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.545 [FDR-adjusted p-Value=0.035]	PMID: 31158845
Proteus penneri ATCC35198	Fenofibrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.417 [FDR-adjusted p-Value=0.036]	PMID: 31158845
Pretovella copri DSM18205	Fenofibrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.516 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Clostridium asparagiforme DSM15981	Fenofibrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.559 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Fenofibrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.05 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Clostridium difficile 120	Fenofibrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.308 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides fragilis T(B)9	Fenofibrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.855 [FDR-adjusted p-Value=0.038]	PMID: 31158845
Blautia hansenii DSM20583	Itraconazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.527 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Clostridium sp.	Itraconazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.649 [FDR-adjusted p-Value=0.049]	PMID: 31158845
Bacteroides uniformis ATCC8492	Itraconazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.82 [FDR-adjusted p-Value=0.043]	PMID: 31158845
Akkermansia muciniphila ATCC BAA-835	Itraconazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.067 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Blautia luti DSM14534	Itraconazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.827 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Odoribacter splanchnius	Itraconazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.136 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Clostridium sporogenes ATCC15579	Itraconazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.204 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Escherichia coli BW25113	Nicergoline	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.477 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Blautia hansenii DSM20583	Nicergoline	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.433 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Clostridium sp.	Nicergoline	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.482 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Nicergoline	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.69 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Bacteroides uniformis ATCC8492	Nicergoline	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.698 [FDR-adjusted p-Value=0.036]	PMID: 31158845
Clostridium difficile 120	Nicergoline	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.744 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Salmonella typhimurium LT2	Nicergoline	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.567 [FDR-adjusted p-Value=0.042]	PMID: 31158845
Bacteroides cellulosilyticus DSM14838	Ramipril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.41 [FDR-adjusted p-Value=0.043]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Ramipril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.65 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Ramipril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.506 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Bacteroides uniformis ATCC8492	Ramipril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.76 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Eubacterium biforme DSM3989	Ramipril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.377 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides fragilis T(B)9	Ramipril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.441 [FDR-adjusted p-Value=0.045]	PMID: 31158845
Bacteroides fragilis ATCC43859	Ramipril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.692 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Bacteroides dorei DSM17855	Ooscapine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.405 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Ruminococcus torques ATCC27756	Ooscapine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.338 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Lactobacillus reuteri CF48-3A BEI HM-102	Ooscapine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.343 [FDR-adjusted p-Value=0.035]	PMID: 31158845
Providencia alcalifaciens DSM30120	Ooscapine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.322 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bryantia formatexigens DSM 14469	Ooscapine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.457 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Alistipes indistinctus DSM 22520	Ooscapine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.378 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Eubacterium biforme DSM3989	Ooscapine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.458 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Escherichia coli BW25113	Oorgestimate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.713 [FDR-adjusted p-Value=0.031]	PMID: 31158845
Blautia hansenii DSM20583	Oorgestimate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.162 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Clostridium sp.	Oorgestimate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.328 [FDR-adjusted p-Value=0.042]	PMID: 31158845
Coprococcus comes ATCC27758	Oorgestimate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.324 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Oorgestimate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.486 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Bifidobacterium ruminatum	Oorgestimate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.704 [FDR-adjusted p-Value=0.046]	PMID: 31158845
Eubacterium biforme DSM3989	Oorgestimate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.47 [FDR-adjusted p-Value=0.035]	PMID: 31158845
Eggerthella lenta ATCC25559	Oorgestimate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.287 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Clostridium hathewayi DSM13479	Ranitidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.443 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Ranitidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.419 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Bifidobacterium breve DSM20213	Ranitidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.878 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Enterococcus faecalis V583	Ranitidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.498 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides fragilis T(B)9	Ranitidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.349 [FDR-adjusted p-Value=0.023]	PMID: 31158845
Bacteroides fragilis DS-208	Ranitidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.452 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Bacteroides fragilis HMW610	Ranitidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Bacteroides fragilis HMW615	Ranitidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.493 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Escherichia coli BW25113	Duloxetine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.576 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Blautia hansenii DSM20583	Duloxetine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.632 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Clostridium sp.	Duloxetine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.573 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides dorei DSM17855	Duloxetine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.455 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Enterobacter cancerogenus ATCC35316	Duloxetine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.343 [FDR-adjusted p-Value=0.043]	PMID: 31158845
Bacteroides uniformis ATCC8492	Duloxetine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.345 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Bacteroides ovatus ATCC8483	Duloxetine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.478 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Bacteroides coprophilus DSM18228	Duloxetine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.843 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides dorei DSM17855	Dexamethasone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.511 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Clostridium scindens ATCC35704	Dexamethasone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.605 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Dexamethasone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.362 [FDR-adjusted p-Value=0.039]	PMID: 31158845
Bacteroides uniformis ATCC8492	Dexamethasone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.613 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Bacteroides stercoris ATCC43183	Dexamethasone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.336 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Dexamethasone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.363 [FDR-adjusted p-Value=0.031]	PMID: 31158845
Bacteroides fragilis DS-208	Dexamethasone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.475 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides fragilis HMW610	Dexamethasone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.551 [FDR-adjusted p-Value=0.023]	PMID: 31158845
Bacteroides fragilis ATCC43859	Dexamethasone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.632 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides dorei DSM17855	Glipizide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.778 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Glipizide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.751 [FDR-adjusted p-Value=0.035]	PMID: 31158845
Odoribacter splanchnius	Glipizide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.555 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Bacteroides coprophilus DSM18228	Glipizide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.335 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Eubacterium biforme DSM3989	Glipizide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.461 [FDR-adjusted p-Value=0.027]	PMID: 31158845
Bacteroides fragilis 3397 T10	Glipizide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.62 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Bacteroides fragilis T(B)9	Glipizide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.693 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Bacteroides fragilis HMW610	Glipizide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.77 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides fragilis ATCC43859	Glipizide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.801 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Blautia hansenii DSM20583	Mifepristone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.492 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Clostridium sp.	Mifepristone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.476 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides dorei DSM17855	Mifepristone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.778 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Mifepristone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.713 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Mifepristone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.504 [FDR-adjusted p-Value=0.045]	PMID: 31158845
Odoribacter splanchnius	Mifepristone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides fragilis DS-208	Mifepristone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.355 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Bacteroides fragilis HMW610	Mifepristone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.554 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides fragilis ATCC43859	Mifepristone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.458 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Bacteroides caccae ATCC43185	Pericyazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.937 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Bacteroides dorei DSM17855	Pericyazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.453 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Pericyazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.656 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Pericyazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.701 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Pericyazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.587 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Alistipes indistinctus DSM 22520	Pericyazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.857 [FDR-adjusted p-Value=0.05]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Pericyazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.623 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Pericyazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.46 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Bacteroides fragilis HMW610	Pericyazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.923 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Escherichia coli BW25113	Primaquine phosphate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.364 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Anaerococcus hydrogenalis DSM7454	Primaquine phosphate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.531 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Clostridium bolteae ATCCBAA-613	Primaquine phosphate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.817 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Clostridium symbiosum ATCC14940	Primaquine phosphate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.613 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Clostridium spiroforme DSM1552	Primaquine phosphate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.549 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Primaquine phosphate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.808 [FDR-adjusted p-Value=0.04]	PMID: 31158845
Bacteroides pectinophilus ATCC43243	Primaquine phosphate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.673 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bifidobacterium breve DSM20213	Primaquine phosphate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.605 [FDR-adjusted p-Value=0.043]	PMID: 31158845
Clostridium difficile 120	Primaquine phosphate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.474 [FDR-adjusted p-Value=0.048]	PMID: 31158845
Bacteroides dorei DSM17855	Drospirenone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.706 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Drospirenone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.72 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Drospirenone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.521 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Drospirenone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.561 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Drospirenone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.355 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Bacteroides uniformis ATCC8492	Drospirenone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.521 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Odoribacter splanchnius	Drospirenone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.505 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Eubacterium biforme DSM3989	Drospirenone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.868 [FDR-adjusted p-Value=0.035]	PMID: 31158845
Bacteroides fragilis HMW610	Drospirenone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.68 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides fragilis HMW615	Drospirenone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.546 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Clostridium sp.	Eszopiclone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.19 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Collinsella aerofaciens ATCC25986	Eszopiclone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.339 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Anaerococcus hydrogenalis DSM7454	Eszopiclone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.372 [FDR-adjusted p-Value=0.028]	PMID: 31158845
Clostridium symbiosum ATCC14940	Eszopiclone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.324 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Ruminococcus lactaris ATCC29176	Eszopiclone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.039]	PMID: 31158845
Eubacterium hallii DSM3353	Eszopiclone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.736 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides coprophilus DSM18228	Eszopiclone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.44 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Eubacterium rectale ATCC33656	Eszopiclone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.599 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bryantia formatexigens DSM 14469	Eszopiclone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.429 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Eggerthella lenta ATCC25559	Eszopiclone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.458 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Escherichia coli BW25113	Fluphenazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.081 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Blautia hansenii DSM20583	Fluphenazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.555 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Bacteroides dorei DSM17855	Fluphenazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.188 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Fluphenazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.906 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Anaerostipes sp.	Fluphenazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.751 [FDR-adjusted p-Value=0.039]	PMID: 31158845
Eubacterium ventriosum ATCC27560	Fluphenazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.029 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Fluphenazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.37 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Pretovella copri DSM18205	Fluphenazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.809 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Bacteroides uniformis ATCC8492	Fluphenazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.767 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Roseburia intestinalis L1-82	Fluphenazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.81 [FDR-adjusted p-Value=0.042]	PMID: 31158845
Clostridium sp.	Ketorolac tromethamine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.513 [FDR-adjusted p-Value=0.028]	PMID: 31158845
Bacteroides dorei DSM17855	Ketorolac tromethamine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.76 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Ketorolac tromethamine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.636 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Ketorolac tromethamine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.651 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Ketorolac tromethamine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.731 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Bacteroides uniformis ATCC8492	Ketorolac tromethamine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.798 [FDR-adjusted p-Value=0.043]	PMID: 31158845
Bacteroides fragilis T(B)9	Ketorolac tromethamine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.71 [FDR-adjusted p-Value=0.024]	PMID: 31158845
Bacteroides fragilis DS-208	Ketorolac tromethamine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.737 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Bacteroides fragilis HMW610	Ketorolac tromethamine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.74 [FDR-adjusted p-Value=0.042]	PMID: 31158845
Bacteroides fragilis ATCC43859	Ketorolac tromethamine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.764 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Blautia hansenii DSM20583	Oxybutynin chloride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.539 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Clostridium sp.	Oxybutynin chloride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.614 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides dorei DSM17855	Oxybutynin chloride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.518 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Oxybutynin chloride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.469 [FDR-adjusted p-Value=0.042]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Oxybutynin chloride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.459 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides uniformis ATCC8492	Oxybutynin chloride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.545 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bifidobacterium ruminatum	Oxybutynin chloride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.377 [FDR-adjusted p-Value=0.039]	PMID: 31158845
Odoribacter splanchnius	Oxybutynin chloride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.362 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Eubacterium biforme DSM3989	Oxybutynin chloride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.336 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides fragilis HMW610	Oxybutynin chloride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.593 [FDR-adjusted p-Value=0.023]	PMID: 31158845
Escherichia coli BW25113	Paclitaxel	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.507 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Paclitaxel	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.617 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Bacteroides uniformis ATCC8492	Paclitaxel	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.572 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Odoribacter splanchnius	Paclitaxel	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.661 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Paclitaxel	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.509 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Paclitaxel	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.411 [FDR-adjusted p-Value=0.049]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Paclitaxel	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.47 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Eggerthella lenta ATCC25559	Paclitaxel	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.36 [FDR-adjusted p-Value=0.044]	PMID: 31158845
Bacteroides fragilis DS-208	Paclitaxel	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.559 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Bacteroides fragilis HMW615	Paclitaxel	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.367 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides dorei DSM17855	Repaglinide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.384 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Repaglinide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.325 [FDR-adjusted p-Value=0.036]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Repaglinide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.504 [FDR-adjusted p-Value=0.045]	PMID: 31158845
Bacteroides uniformis ATCC8492	Repaglinide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.748 [FDR-adjusted p-Value=0.024]	PMID: 31158845
Odoribacter splanchnius	Repaglinide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.38 [FDR-adjusted p-Value=0.023]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Repaglinide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.357 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Repaglinide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.435 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides fragilis HMW610	Repaglinide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.508 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides fragilis HMW615	Repaglinide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.508 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides fragilis ATCC43859	Repaglinide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.517 [FDR-adjusted p-Value=0.04]	PMID: 31158845
Pretovella copri DSM18205	Sotalol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.371 [FDR-adjusted p-Value=0.042]	PMID: 31158845
Bacteroides uniformis ATCC8492	Sotalol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.529 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Bacteroides ovatus ATCC8483	Sotalol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.629 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Sotalol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.545 [FDR-adjusted p-Value=0.044]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Sotalol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.681 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides fragilis 3397 T10	Sotalol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.701 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides fragilis DS-208	Sotalol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.629 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Bacteroides fragilis HMW610	Sotalol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.896 [FDR-adjusted p-Value=0.039]	PMID: 31158845
Bacteroides fragilis HMW615	Sotalol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.826 [FDR-adjusted p-Value=0.033]	PMID: 31158845
Bacteroides fragilis ATCC43859	Sotalol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.907 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Blautia hansenii DSM20583	Zaleplon	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.448 [FDR-adjusted p-Value=0.032]	PMID: 31158845
Clostridium sp.	Zaleplon	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.438 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides dorei DSM17855	Zaleplon	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.807 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Zaleplon	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.668 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Zaleplon	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Zaleplon	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.466 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides uniformis ATCC8492	Zaleplon	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.394 [FDR-adjusted p-Value=0.045]	PMID: 31158845
Bacteroides fragilis HMW610	Zaleplon	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.519 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Bacteroides fragilis HMW615	Zaleplon	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.407 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides fragilis ATCC43859	Zaleplon	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.568 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Clostridium sp.	Ezetimibe	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.402 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Ezetimibe	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.511 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Bacteroides uniformis ATCC8492	Ezetimibe	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.865 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides stercoris ATCC43183	Ezetimibe	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.541 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Odoribacter splanchnius	Ezetimibe	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.644 [FDR-adjusted p-Value=0.035]	PMID: 31158845
Clostridium sporogenes ATCC15579	Ezetimibe	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.872 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Ezetimibe	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.417 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Bacteroides fragilis 3397 T10	Ezetimibe	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.613 [FDR-adjusted p-Value=0.038]	PMID: 31158845
Bacteroides fragilis T(B)9	Ezetimibe	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.742 [FDR-adjusted p-Value=0.036]	PMID: 31158845
Bacteroides fragilis DS-208	Ezetimibe	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.531 [FDR-adjusted p-Value=0.04]	PMID: 31158845
Bacteroides fragilis HMW615	Ezetimibe	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.513 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Bacteroides dorei DSM17855	Gliclazide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.491 [FDR-adjusted p-Value=0.026]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Gliclazide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.578 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Gliclazide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.375 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Odoribacter splanchnius	Gliclazide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.411 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Gliclazide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.45 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Gliclazide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.441 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides fragilis 3397 T10	Gliclazide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.473 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Bacteroides fragilis DS-208	Gliclazide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.423 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides fragilis HMW610	Gliclazide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.498 [FDR-adjusted p-Value=0.045]	PMID: 31158845
Bacteroides fragilis HMW615	Gliclazide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.438 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Bacteroides fragilis ATCC43859	Gliclazide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.582 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides dorei DSM17855	Rebamipide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.852 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Rebamipide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.426 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Rebamipide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.737 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides uniformis ATCC8492	Rebamipide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.069 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides stercoris ATCC43183	Rebamipide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.455 [FDR-adjusted p-Value=0.031]	PMID: 31158845
Bifidobacterium ruminatum	Rebamipide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.52 [FDR-adjusted p-Value=0.031]	PMID: 31158845
Bacteroides ovatus ATCC8483	Rebamipide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.444 [FDR-adjusted p-Value=0.047]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Rebamipide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.72 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides fragilis 3397 T10	Rebamipide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.529 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Bacteroides fragilis HMW610	Rebamipide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.759 [FDR-adjusted p-Value=0.037]	PMID: 31158845
Bacteroides fragilis HMW615	Rebamipide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.767 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Escherichia coli BW25113	Sulfinpyrazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.511 [FDR-adjusted p-Value=0.035]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Sulfinpyrazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.402 [FDR-adjusted p-Value=0.039]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Sulfinpyrazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.582 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Sulfinpyrazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.544 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Odoribacter splanchnius	Sulfinpyrazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.638 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Sulfinpyrazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.443 [FDR-adjusted p-Value=0.048]	PMID: 31158845
Eggerthella lenta ATCC25559	Sulfinpyrazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.912 [FDR-adjusted p-Value=0.043]	PMID: 31158845
Bacteroides fragilis DS-208	Sulfinpyrazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.546 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Bacteroides fragilis HMW610	Sulfinpyrazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.681 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Bacteroides fragilis HMW615	Sulfinpyrazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Bacteroides fragilis ATCC43859	Sulfinpyrazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.724 [FDR-adjusted p-Value=0.044]	PMID: 31158845
Blautia hansenii DSM20583	Etodolac	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.406 [FDR-adjusted p-Value=0.044]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Etodolac	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.579 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Bacteroides uniformis ATCC8492	Etodolac	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.791 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Odoribacter splanchnius	Etodolac	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.51 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Etodolac	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.473 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Etodolac	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.4 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Etodolac	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.474 [FDR-adjusted p-Value=0.031]	PMID: 31158845
Bacteroides fragilis 3397 T10	Etodolac	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.374 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Bacteroides fragilis T(B)9	Etodolac	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.596 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides fragilis DS-208	Etodolac	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.614 [FDR-adjusted p-Value=0.023]	PMID: 31158845
Bacteroides fragilis HMW615	Etodolac	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.783 [FDR-adjusted p-Value=0.042]	PMID: 31158845
Bacteroides fragilis ATCC43859	Etodolac	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.814 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Bacteroides dorei DSM17855	Finasteride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.723 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Finasteride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.735 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Finasteride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.392 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Finasteride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.592 [FDR-adjusted p-Value=0.031]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Finasteride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.587 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides uniformis ATCC8492	Finasteride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.589 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Akkermansia muciniphila ATCC BAA-835	Finasteride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.039 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Odoribacter splanchnius	Finasteride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.496 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Bacteroides fragilis DS-208	Finasteride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.54 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Bacteroides fragilis HMW610	Finasteride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.668 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides fragilis HMW615	Finasteride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.564 [FDR-adjusted p-Value=0.024]	PMID: 31158845
Bacteroides fragilis ATCC43859	Finasteride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.706 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides uniformis ATCC8492	Galantamine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.495 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides ovatus ATCC8483	Galantamine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.494 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides coprophilus DSM18228	Galantamine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.578 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Galantamine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.627 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Galantamine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.453 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Galantamine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.589 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Bacteroides fragilis 3397 T10	Galantamine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.519 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides fragilis T(B)9	Galantamine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.457 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides fragilis DS-208	Galantamine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.563 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides fragilis HMW610	Galantamine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.67 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides fragilis HMW615	Galantamine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.594 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides fragilis ATCC43859	Galantamine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.71 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides dorei DSM17855	Griseofulvin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.69 [FDR-adjusted p-Value=0.039]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Griseofulvin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.782 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Griseofulvin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.503 [FDR-adjusted p-Value=0.024]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Griseofulvin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.721 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Griseofulvin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.54 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides uniformis ATCC8492	Griseofulvin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.76 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Griseofulvin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.419 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Bacteroides fragilis 3397 T10	Griseofulvin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.588 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Bacteroides fragilis T(B)9	Griseofulvin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.609 [FDR-adjusted p-Value=0.038]	PMID: 31158845
Bacteroides fragilis DS-208	Griseofulvin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.666 [FDR-adjusted p-Value=0.037]	PMID: 31158845
Bacteroides fragilis HMW615	Griseofulvin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.585 [FDR-adjusted p-Value=0.028]	PMID: 31158845
Bacteroides fragilis ATCC43859	Griseofulvin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.778 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Blautia hansenii DSM20583	Metaxalone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.579 [FDR-adjusted p-Value=0.048]	PMID: 31158845
Clostridium sp.	Metaxalone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.53 [FDR-adjusted p-Value=0.032]	PMID: 31158845
Bacteroides dorei DSM17855	Metaxalone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.828 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Metaxalone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.764 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Metaxalone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.483 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Bacteroides pectinophilus ATCC43243	Metaxalone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.525 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Metaxalone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.632 [FDR-adjusted p-Value=0.047]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Metaxalone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.633 [FDR-adjusted p-Value=0.039]	PMID: 31158845
Bacteroides uniformis ATCC8492	Metaxalone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.694 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Bacteroides fragilis HMW610	Metaxalone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.654 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides fragilis HMW615	Metaxalone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.654 [FDR-adjusted p-Value=0.044]	PMID: 31158845
Bacteroides fragilis ATCC43859	Metaxalone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.76 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Pretovella copri DSM18205	Naloxone	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.366 [FDR-adjusted p-Value=0.04]	PMID: 31158845
Bacteroides uniformis ATCC8492	Naloxone	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.694 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides ovatus ATCC8483	Naloxone	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.722 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides coprophilus DSM18228	Naloxone	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.98 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Naloxone	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.663 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Naloxone	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.548 [FDR-adjusted p-Value=0.045]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Naloxone	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.723 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides fragilis 3397 T10	Naloxone	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.924 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides fragilis T(B)9	Naloxone	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.839 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Bacteroides fragilis DS-208	Naloxone	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.898 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides fragilis HMW610	Naloxone	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.708 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bacteroides fragilis ATCC43859	Naloxone	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.155 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Naproxen(+)	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.455 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Naproxen(+)	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.337 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Naproxen(+)	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.376 [FDR-adjusted p-Value=0.039]	PMID: 31158845
Bacteroides uniformis ATCC8492	Naproxen(+)	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.454 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Odoribacter splanchnius	Naproxen(+)	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.453 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Naproxen(+)	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.364 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Naproxen(+)	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.362 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides fragilis 3397 T10	Naproxen(+)	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.447 [FDR-adjusted p-Value=0.032]	PMID: 31158845
Bacteroides fragilis T(B)9	Naproxen(+)	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.387 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides fragilis HMW610	Naproxen(+)	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.654 [FDR-adjusted p-Value=0.024]	PMID: 31158845
Bacteroides fragilis HMW615	Naproxen(+)	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.569 [FDR-adjusted p-Value=0.039]	PMID: 31158845
Bacteroides fragilis ATCC43859	Naproxen(+)	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.765 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides dorei DSM17855	Neostigmine bromide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.528 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Neostigmine bromide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.611 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides uniformis ATCC8492	Neostigmine bromide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.568 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides ovatus ATCC8483	Neostigmine bromide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.62 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Parabacteroides merdae ATCC43184	Neostigmine bromide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.342 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides coprophilus DSM18228	Neostigmine bromide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.533 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Neostigmine bromide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.515 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Neostigmine bromide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.352 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Neostigmine bromide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.598 [FDR-adjusted p-Value=0.035]	PMID: 31158845
Bacteroides fragilis 3397 T10	Neostigmine bromide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.693 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides fragilis T(B)9	Neostigmine bromide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.535 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides fragilis DS-208	Neostigmine bromide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.584 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Bacteroides dorei DSM17855	Telmisartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.999 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides cellulosilyticus DSM14838	Telmisartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.567 [FDR-adjusted p-Value=0.035]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Telmisartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.856 [FDR-adjusted p-Value=0.026]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Telmisartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.73 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Telmisartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.886 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Telmisartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.784 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Bacteroides uniformis ATCC8492	Telmisartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.005 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides stercoris ATCC43183	Telmisartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.599 [FDR-adjusted p-Value=0.04]	PMID: 31158845
Odoribacter splanchnius	Telmisartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.402 [FDR-adjusted p-Value=0.035]	PMID: 31158845
Bacteroides ovatus ATCC8483	Telmisartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.349 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Telmisartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.619 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Bacteroides fragilis HMW610	Telmisartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.615 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Blautia hansenii DSM20583	Colchicine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.371 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Clostridium sp.	Colchicine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.408 [FDR-adjusted p-Value=0.033]	PMID: 31158845
Bacteroides dorei DSM17855	Colchicine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.647 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Colchicine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.559 [FDR-adjusted p-Value=0.028]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Colchicine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.365 [FDR-adjusted p-Value=0.048]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Colchicine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.53 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Bacteroides uniformis ATCC8492	Colchicine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Odoribacter splanchnius	Colchicine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.359 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Bacteroides fragilis 3397 T10	Colchicine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.533 [FDR-adjusted p-Value=0.024]	PMID: 31158845
Bacteroides fragilis T(B)9	Colchicine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.495 [FDR-adjusted p-Value=0.033]	PMID: 31158845
Bacteroides fragilis DS-208	Colchicine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.459 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides fragilis HMW610	Colchicine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.502 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides fragilis ATCC43859	Colchicine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.574 [FDR-adjusted p-Value=0.026]	PMID: 31158845
Blautia hansenii DSM20583	Diltiazem	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.448 [FDR-adjusted p-Value=0.043]	PMID: 31158845
Clostridium sp.	Diltiazem	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.396 [FDR-adjusted p-Value=0.044]	PMID: 31158845
Bacteroides dorei DSM17855	Diltiazem	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.478 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Diltiazem	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.599 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Diltiazem	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.828 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Diltiazem	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.781 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides uniformis ATCC8492	Diltiazem	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.469 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Bacteroides ovatus ATCC8483	Diltiazem	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.207 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Alistipes indistinctus DSM 22520	Diltiazem	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.401 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Diltiazem	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.677 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Diltiazem	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.654 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Diltiazem	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.964 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Victivallis vadensis ATCC BAA-548	Diltiazem	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.453 [FDR-adjusted p-Value=0.036]	PMID: 31158845
Bacteroides dorei DSM17855	Ergonovine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.409 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Bacteroides cellulosilyticus DSM14838	Ergonovine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.493 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Bacteroides pectinophilus ATCC43243	Ergonovine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.337 [FDR-adjusted p-Value=0.044]	PMID: 31158845
Clostridium asparagiforme DSM15981	Ergonovine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.42 [FDR-adjusted p-Value=0.049]	PMID: 31158845
Coprococcus comes ATCC27758	Ergonovine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.402 [FDR-adjusted p-Value=0.045]	PMID: 31158845
Lactobacillus reuteri CF48-3A BEI HM-102	Ergonovine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.505 [FDR-adjusted p-Value=0.047]	PMID: 31158845
Bacteroides coprophilus DSM18228	Ergonovine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.785 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Clostridium difficile 120	Ergonovine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.375 [FDR-adjusted p-Value=0.042]	PMID: 31158845
Bacteroides fragilis T(B)9	Ergonovine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.653 [FDR-adjusted p-Value=0.036]	PMID: 31158845
Bacteroides fragilis DS-208	Ergonovine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.601 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides fragilis HMW610	Ergonovine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.636 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides fragilis HMW615	Ergonovine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.634 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides fragilis ATCC43859	Ergonovine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.655 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Bacteroides dorei DSM17855	Losartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.533 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Losartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.59 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Losartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.357 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Losartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.405 [FDR-adjusted p-Value=0.031]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Losartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.384 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Losartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.489 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides uniformis ATCC8492	Losartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.599 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bifidobacterium ruminatum	Losartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.338 [FDR-adjusted p-Value=0.033]	PMID: 31158845
Odoribacter splanchnius	Losartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.485 [FDR-adjusted p-Value=0.027]	PMID: 31158845
Parabacteroides merdae ATCC43184	Losartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.354 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides fragilis HMW610	Losartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.63 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides fragilis HMW615	Losartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.602 [FDR-adjusted p-Value=0.023]	PMID: 31158845
Bacteroides fragilis ATCC43859	Losartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.753 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides dorei DSM17855	Voriconazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.552 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Voriconazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.451 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Voriconazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.373 [FDR-adjusted p-Value=0.042]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Voriconazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.477 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides uniformis ATCC8492	Voriconazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.618 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Odoribacter splanchnius	Voriconazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.396 [FDR-adjusted p-Value=0.044]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Voriconazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.505 [FDR-adjusted p-Value=0.047]	PMID: 31158845
Bacteroides fragilis 3397 T10	Voriconazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.523 [FDR-adjusted p-Value=0.038]	PMID: 31158845
Bacteroides fragilis T(B)9	Voriconazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.526 [FDR-adjusted p-Value=0.048]	PMID: 31158845
Bacteroides fragilis DS-208	Voriconazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.588 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Bacteroides fragilis HMW610	Voriconazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.635 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Bacteroides fragilis HMW615	Voriconazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.605 [FDR-adjusted p-Value=0.045]	PMID: 31158845
Bacteroides fragilis ATCC43859	Voriconazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.727 [FDR-adjusted p-Value=0.032]	PMID: 31158845
Bacteroides dorei DSM17855	Nizatidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.623 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Nizatidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.426 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bifidobacterium breve DSM20213	Nizatidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.952 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides uniformis ATCC8492	Nizatidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.551 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Parabacteroides merdae ATCC43184	Nizatidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.422 [FDR-adjusted p-Value=0.033]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Nizatidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.505 [FDR-adjusted p-Value=0.032]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Nizatidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.514 [FDR-adjusted p-Value=0.04]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Nizatidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.623 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Bacteroides fragilis T(B)9	Nizatidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.451 [FDR-adjusted p-Value=0.045]	PMID: 31158845
Bacteroides fragilis DS-208	Nizatidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.609 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides fragilis HMW610	Nizatidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.574 [FDR-adjusted p-Value=0.036]	PMID: 31158845
Bacteroides fragilis HMW615	Nizatidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.573 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides fragilis ATCC43859	Nizatidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.506 [FDR-adjusted p-Value=0.039]	PMID: 31158845
Bacteroides dorei DSM17855	Clonidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.485 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Clonidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.476 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides uniformis ATCC8492	Clonidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.694 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides stercoris ATCC43183	Clonidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.414 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Odoribacter splanchnius	Clonidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.352 [FDR-adjusted p-Value=0.031]	PMID: 31158845
Bacteroides ovatus ATCC8483	Clonidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.427 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Bacteroides coprophilus DSM18228	Clonidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.354 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Clonidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.422 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Clonidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.358 [FDR-adjusted p-Value=0.044]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Clonidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.452 [FDR-adjusted p-Value=0.044]	PMID: 31158845
Bacteroides fragilis 3397 T10	Clonidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.663 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides fragilis T(B)9	Clonidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Bacteroides fragilis DS-208	Clonidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.501 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Bacteroides fragilis HMW615	Clonidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.376 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Blautia hansenii DSM20583	Fluconazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.385 [FDR-adjusted p-Value=0.044]	PMID: 31158845
Clostridium sp.	Fluconazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.429 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides dorei DSM17855	Fluconazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.58 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Fluconazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.342 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Fluconazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.489 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides uniformis ATCC8492	Fluconazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.672 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides stercoris ATCC43183	Fluconazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.432 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Odoribacter splanchnius	Fluconazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.528 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides ovatus ATCC8483	Fluconazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.384 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Fluconazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.484 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Fluconazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.356 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides fragilis 3397 T10	Fluconazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.605 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides fragilis T(B)9	Fluconazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.61 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides fragilis HMW610	Fluconazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.685 [FDR-adjusted p-Value=0.027]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Indomethacin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.688 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Bacteroides uniformis ATCC8492	Indomethacin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.716 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides stercoris ATCC43183	Indomethacin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.446 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Odoribacter splanchnius	Indomethacin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.658 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Parabacteroides merdae ATCC43184	Indomethacin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.357 [FDR-adjusted p-Value=0.044]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Indomethacin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.39 [FDR-adjusted p-Value=0.033]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Indomethacin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.493 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Indomethacin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.498 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides fragilis 3397 T10	Indomethacin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.569 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides fragilis T(B)9	Indomethacin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.677 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides fragilis DS-208	Indomethacin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.565 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Bacteroides fragilis HMW610	Indomethacin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.645 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides fragilis HMW615	Indomethacin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.614 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides fragilis ATCC43859	Indomethacin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.78 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Blautia hansenii DSM20583	Betamethasone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.423 [FDR-adjusted p-Value=0.036]	PMID: 31158845
Clostridium sp.	Betamethasone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.369 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides dorei DSM17855	Betamethasone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.614 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Betamethasone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.668 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Betamethasone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.333 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides stercoris ATCC43183	Betamethasone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.467 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Odoribacter splanchnius	Betamethasone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.553 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides coprophilus DSM18228	Betamethasone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.325 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Betamethasone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.43 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Betamethasone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.356 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides fragilis 3397 T10	Betamethasone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.582 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides fragilis T(B)9	Betamethasone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.623 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides fragilis DS-208	Betamethasone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.576 [FDR-adjusted p-Value=0.047]	PMID: 31158845
Bacteroides fragilis HMW615	Betamethasone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.821 [FDR-adjusted p-Value=0.04]	PMID: 31158845
Bacteroides fragilis ATCC43859	Betamethasone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.012 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides eggerthii DSM20697	Budesonide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.394 [FDR-adjusted p-Value=0.045]	PMID: 31158845
Blautia hansenii DSM20583	Budesonide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.429 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Clostridium sp.	Budesonide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.408 [FDR-adjusted p-Value=0.026]	PMID: 31158845
Bacteroides dorei DSM17855	Budesonide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.716 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Budesonide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.666 [FDR-adjusted p-Value=0.039]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Budesonide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.372 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Budesonide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.334 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Odoribacter splanchnius	Budesonide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.512 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Parabacteroides merdae ATCC43184	Budesonide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.349 [FDR-adjusted p-Value=0.024]	PMID: 31158845
Eubacterium biforme DSM3989	Budesonide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.997 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Bacteroides fragilis 3397 T10	Budesonide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.425 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides fragilis T(B)9	Budesonide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides fragilis HMW610	Budesonide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.652 [FDR-adjusted p-Value=0.028]	PMID: 31158845
Bacteroides fragilis HMW615	Budesonide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.606 [FDR-adjusted p-Value=0.033]	PMID: 31158845
Bacteroides fragilis ATCC43859	Budesonide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.669 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Blautia hansenii DSM20583	Carvedilol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.922 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides dorei DSM17855	Carvedilol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.225 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Carvedilol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.632 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Carvedilol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.426 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Bacteroides uniformis ATCC8492	Carvedilol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.691 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Roseburia intestinalis L1-82	Carvedilol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.975 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Bacteroides ovatus ATCC8483	Carvedilol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.243 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Bacteroides coprophilus DSM18228	Carvedilol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.653 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Clostridium sporogenes ATCC15579	Carvedilol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.566 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Eubacterium biforme DSM3989	Carvedilol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.604 [FDR-adjusted p-Value=0.046]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Carvedilol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.683 [FDR-adjusted p-Value=0.037]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Carvedilol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.092 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides fragilis T(B)9	Carvedilol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.46 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Bacteroides fragilis DS-208	Carvedilol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.656 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides fragilis HMW615	Carvedilol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.322 [FDR-adjusted p-Value=0.027]	PMID: 31158845
Blautia hansenii DSM20583	Irbesartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.341 [FDR-adjusted p-Value=0.033]	PMID: 31158845
Bacteroides dorei DSM17855	Irbesartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.724 [FDR-adjusted p-Value=0.035]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Irbesartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.494 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Irbesartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.428 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Irbesartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.515 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides uniformis ATCC8492	Irbesartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.599 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bifidobacterium ruminatum	Irbesartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.365 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Odoribacter splanchnius	Irbesartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.478 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Parabacteroides merdae ATCC43184	Irbesartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.391 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Irbesartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.452 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Irbesartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.404 [FDR-adjusted p-Value=0.032]	PMID: 31158845
Bacteroides fragilis DS-208	Irbesartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.513 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides fragilis HMW610	Irbesartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.658 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Bacteroides fragilis HMW615	Irbesartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.606 [FDR-adjusted p-Value=0.032]	PMID: 31158845
Bacteroides fragilis ATCC43859	Irbesartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.706 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Bacteroides caccae ATCC43185	Linagliptin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.043 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Bacteroides dorei DSM17855	Linagliptin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.6 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Bacteroides finegoldii DSM17565	Linagliptin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.968 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Linagliptin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.215 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides intestinalis DSM17393	Linagliptin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.387 [FDR-adjusted p-Value=0.05]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Linagliptin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.342 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Pretovella copri DSM18205	Linagliptin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.623 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Linagliptin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.764 [FDR-adjusted p-Value=0.036]	PMID: 31158845
Bacteroides uniformis ATCC8492	Linagliptin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.722 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Bacteroides stercoris ATCC43183	Linagliptin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.787 [FDR-adjusted p-Value=0.031]	PMID: 31158845
Odoribacter splanchnius	Linagliptin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.253 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides coprophilus DSM18228	Linagliptin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.544 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Linagliptin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.018 [FDR-adjusted p-Value=0.048]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Linagliptin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.902 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides fragilis 3397 T10	Linagliptin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.569 [FDR-adjusted p-Value=0.04]	PMID: 31158845
Escherichia coli BW25113	Ritonavir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.482 [FDR-adjusted p-Value=0.031]	PMID: 31158845
Bacteroides eggerthii DSM20697	Ritonavir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.627 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Blautia hansenii DSM20583	Ritonavir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.636 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Clostridium sp.	Ritonavir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.518 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides dorei DSM17855	Ritonavir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.719 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Ritonavir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.679 [FDR-adjusted p-Value=0.031]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Ritonavir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.387 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Ritonavir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.768 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Ritonavir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.603 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides uniformis ATCC8492	Ritonavir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.641 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Odoribacter splanchnius	Ritonavir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.592 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Ritonavir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Ritonavir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.398 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Bacteroides fragilis 3397 T10	Ritonavir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.414 [FDR-adjusted p-Value=0.048]	PMID: 31158845
Bacteroides fragilis DS-208	Ritonavir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.652 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides dorei DSM17855	Mevastatin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.013 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Bacteroides cellulosilyticus DSM14838	Mevastatin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.989 [FDR-adjusted p-Value=0.044]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Mevastatin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.126 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides intestinalis DSM17393	Mevastatin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.787 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Mevastatin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.806 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides pectinophilus ATCC43243	Mevastatin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.479 [FDR-adjusted p-Value=0.05]	PMID: 31158845
Bifidobacterium breve DSM20213	Mevastatin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.545 [FDR-adjusted p-Value=0.032]	PMID: 31158845
Lactobacillus reuteri CF48-3A BEI HM-102	Mevastatin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.516 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides uniformis ATCC8492	Mevastatin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.052 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Odoribacter splanchnius	Mevastatin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.534 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Parabacteroides merdae ATCC43184	Mevastatin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.684 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Mevastatin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.833 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Mevastatin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.934 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides fragilis DS-208	Mevastatin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.596 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Bacteroides fragilis HMW610	Mevastatin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.414 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Fenspiride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.392 [FDR-adjusted p-Value=0.039]	PMID: 31158845
Pretovella copri DSM18205	Fenspiride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.511 [FDR-adjusted p-Value=0.023]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Fenspiride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.528 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides uniformis ATCC8492	Fenspiride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.747 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides stercoris ATCC43183	Fenspiride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.493 [FDR-adjusted p-Value=0.044]	PMID: 31158845
Bacteroides ovatus ATCC8483	Fenspiride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.064 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides coprophilus DSM18228	Fenspiride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.816 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Fenspiride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.812 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Fenspiride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.53 [FDR-adjusted p-Value=0.032]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Fenspiride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.847 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Bacteroides fragilis 3397 T10	Fenspiride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.909 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides fragilis T(B)9	Fenspiride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.738 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides fragilis DS-208	Fenspiride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.022 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides fragilis HMW610	Fenspiride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.932 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Bacteroides fragilis HMW615	Fenspiride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.922 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Bacteroides fragilis ATCC43859	Fenspiride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.153 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Clostridium sp.	Procarbazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.425 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Bacteroides dorei DSM17855	Procarbazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.577 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Procarbazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.654 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Procarbazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.34 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Procarbazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.497 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides uniformis ATCC8492	Procarbazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.634 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Bacteroides stercoris ATCC43183	Procarbazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.47 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Odoribacter splanchnius	Procarbazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.542 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Bacteroides ovatus ATCC8483	Procarbazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.356 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Bacteroides coprophilus DSM18228	Procarbazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.341 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Procarbazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.42 [FDR-adjusted p-Value=0.044]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Procarbazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.332 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides fragilis T(B)9	Procarbazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.598 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Bacteroides fragilis HMW610	Procarbazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.829 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Bacteroides fragilis HMW615	Procarbazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.761 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides fragilis ATCC43859	Procarbazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.969 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Bacteroides eggerthii DSM20697	Trandolapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.479 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Bacteroides dorei DSM17855	Trandolapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.908 [FDR-adjusted p-Value=0.037]	PMID: 31158845
Bacteroides cellulosilyticus DSM14838	Trandolapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.452 [FDR-adjusted p-Value=0.037]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Trandolapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.867 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Trandolapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.66 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Pretovella copri DSM18205	Trandolapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.503 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Trandolapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.619 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Trandolapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.678 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Bacteroides uniformis ATCC8492	Trandolapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.065 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Odoribacter splanchnius	Trandolapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.559 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Eubacterium biforme DSM3989	Trandolapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.502 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Bacteroides fragilis 3397 T10	Trandolapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.676 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides fragilis T(B)9	Trandolapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.772 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Bacteroides fragilis DS-208	Trandolapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.637 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Bacteroides fragilis HMW615	Trandolapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.628 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Bacteroides fragilis ATCC43859	Trandolapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.825 [FDR-adjusted p-Value=0.028]	PMID: 31158845
Bacteroides dorei DSM17855	Valsartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.464 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Valsartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.513 [FDR-adjusted p-Value=0.024]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Valsartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.536 [FDR-adjusted p-Value=0.049]	PMID: 31158845
Pretovella copri DSM18205	Valsartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.337 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Valsartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.449 [FDR-adjusted p-Value=0.031]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Valsartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.689 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Bacteroides uniformis ATCC8492	Valsartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.651 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Odoribacter splanchnius	Valsartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.613 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides ovatus ATCC8483	Valsartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.409 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Valsartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.532 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Valsartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.663 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Bacteroides fragilis T(B)9	Valsartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.503 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Bacteroides fragilis DS-208	Valsartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.625 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Bacteroides fragilis HMW610	Valsartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.737 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides fragilis HMW615	Valsartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.547 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Bacteroides fragilis ATCC43859	Valsartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.742 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Escherichia coli BW25113	Betamethasone valerate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.502 [FDR-adjusted p-Value=0.027]	PMID: 31158845
Bacteroides eggerthii DSM20697	Betamethasone valerate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.701 [FDR-adjusted p-Value=0.05]	PMID: 31158845
Blautia hansenii DSM20583	Betamethasone valerate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.748 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Clostridium sp.	Betamethasone valerate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.795 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Betamethasone valerate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.734 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Betamethasone valerate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.483 [FDR-adjusted p-Value=0.039]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Betamethasone valerate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.588 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Bacteroides uniformis ATCC8492	Betamethasone valerate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.83 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Odoribacter splanchnius	Betamethasone valerate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.799 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Subdoligranulum variabile DSM15176	Betamethasone valerate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.448 [FDR-adjusted p-Value=0.037]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Betamethasone valerate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.329 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Betamethasone valerate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.491 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Eggerthella lenta ATCC25559	Betamethasone valerate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.709 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Victivallis vadensis ATCC BAA-548	Betamethasone valerate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.535 [FDR-adjusted p-Value=0.027]	PMID: 31158845
Bacteroides fragilis DS-208	Betamethasone valerate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.548 [FDR-adjusted p-Value=0.023]	PMID: 31158845
Bacteroides fragilis HMW610	Betamethasone valerate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.629 [FDR-adjusted p-Value=0.028]	PMID: 31158845
Bacteroides fragilis HMW615	Betamethasone valerate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.573 [FDR-adjusted p-Value=0.039]	PMID: 31158845
Bacteroides eggerthii DSM20697	Cyproterone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.461 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Blautia hansenii DSM20583	Cyproterone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.544 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Clostridium sp.	Cyproterone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.61 [FDR-adjusted p-Value=0.024]	PMID: 31158845
Bacteroides dorei DSM17855	Cyproterone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.659 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Cyproterone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.685 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Cyproterone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.426 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Cyproterone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.708 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Cyproterone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.474 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides uniformis ATCC8492	Cyproterone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.628 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Odoribacter splanchnius	Cyproterone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.515 [FDR-adjusted p-Value=0.026]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Cyproterone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.344 [FDR-adjusted p-Value=0.043]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Cyproterone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.439 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides fragilis T(B)9	Cyproterone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.48 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Bacteroides fragilis DS-208	Cyproterone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.611 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides fragilis HMW610	Cyproterone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.668 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Bacteroides fragilis HMW615	Cyproterone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.516 [FDR-adjusted p-Value=0.037]	PMID: 31158845
Bacteroides fragilis ATCC43859	Cyproterone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.466 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides caccae ATCC43185	Methoxsalen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.506 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Clostridium ramosum DSM1402	Methoxsalen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.146 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides eggerthii DSM20697	Methoxsalen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.458 [FDR-adjusted p-Value=0.036]	PMID: 31158845
Blautia hansenii DSM20583	Methoxsalen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.664 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides dorei DSM17855	Methoxsalen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.011 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides finegoldii DSM17565	Methoxsalen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.089 [FDR-adjusted p-Value=0.038]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Methoxsalen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.492 [FDR-adjusted p-Value=0.026]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Methoxsalen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.483 [FDR-adjusted p-Value=0.039]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Methoxsalen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.711 [FDR-adjusted p-Value=0.045]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Methoxsalen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.709 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides uniformis ATCC8492	Methoxsalen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.918 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Odoribacter splanchnius	Methoxsalen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.565 [FDR-adjusted p-Value=0.05]	PMID: 31158845
Clostridium sporogenes ATCC15579	Methoxsalen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.613 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Bacteroides fragilis T(B)9	Methoxsalen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.47 [FDR-adjusted p-Value=0.037]	PMID: 31158845
Bacteroides fragilis HMW610	Methoxsalen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.774 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Bacteroides fragilis HMW615	Methoxsalen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.588 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Bacteroides fragilis ATCC43859	Methoxsalen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.93 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides eggerthii DSM20697	Nateglinide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.385 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Blautia hansenii DSM20583	Nateglinide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.489 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Clostridium sp.	Nateglinide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.354 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Nateglinide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.656 [FDR-adjusted p-Value=0.05]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Nateglinide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.487 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Nateglinide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.536 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides uniformis ATCC8492	Nateglinide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.706 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Odoribacter splanchnius	Nateglinide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.58 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Parabacteroides merdae ATCC43184	Nateglinide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.406 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Nateglinide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.434 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Nateglinide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.42 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Nateglinide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.543 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides fragilis T(B)9	Nateglinide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.551 [FDR-adjusted p-Value=0.044]	PMID: 31158845
Bacteroides fragilis DS-208	Nateglinide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.643 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides fragilis HMW610	Nateglinide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.756 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Bacteroides fragilis HMW615	Nateglinide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.594 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Bacteroides fragilis ATCC43859	Nateglinide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.776 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides eggerthii DSM20697	Febuxostat	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.371 [FDR-adjusted p-Value=0.023]	PMID: 31158845
Blautia hansenii DSM20583	Febuxostat	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.611 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Clostridium sp.	Febuxostat	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.618 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides dorei DSM17855	Febuxostat	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.642 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Febuxostat	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.128 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Febuxostat	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.417 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Febuxostat	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.412 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Febuxostat	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.488 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides uniformis ATCC8492	Febuxostat	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.703 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bifidobacterium ruminatum	Febuxostat	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.35 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Odoribacter splanchnius	Febuxostat	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.723 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Parabacteroides merdae ATCC43184	Febuxostat	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.39 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Febuxostat	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.429 [FDR-adjusted p-Value=0.035]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Febuxostat	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.513 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides fragilis 3397 T10	Febuxostat	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.678 [FDR-adjusted p-Value=0.024]	PMID: 31158845
Bacteroides fragilis T(B)9	Febuxostat	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.75 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Bacteroides fragilis HMW615	Febuxostat	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.61 [FDR-adjusted p-Value=0.031]	PMID: 31158845
Bacteroides fragilis ATCC43859	Febuxostat	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.856 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides eggerthii DSM20697	Ramelteon	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.481 [FDR-adjusted p-Value=0.033]	PMID: 31158845
Blautia hansenii DSM20583	Ramelteon	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.466 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides dorei DSM17855	Ramelteon	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.604 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Ramelteon	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.57 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Ramelteon	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.577 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Pretovella copri DSM18205	Ramelteon	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.394 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Ramelteon	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.507 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Ramelteon	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.573 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Bacteroides uniformis ATCC8492	Ramelteon	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.769 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides stercoris ATCC43183	Ramelteon	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.394 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Bifidobacterium ruminatum	Ramelteon	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.34 [FDR-adjusted p-Value=0.049]	PMID: 31158845
Odoribacter splanchnius	Ramelteon	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.51 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Parabacteroides merdae ATCC43184	Ramelteon	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.383 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Ramelteon	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.472 [FDR-adjusted p-Value=0.038]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Ramelteon	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.367 [FDR-adjusted p-Value=0.038]	PMID: 31158845
Bacteroides fragilis DS-208	Ramelteon	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.72 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides fragilis HMW610	Ramelteon	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.587 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides fragilis ATCC43859	Ramelteon	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.652 [FDR-adjusted p-Value=0.039]	PMID: 31158845
Bacteroides eggerthii DSM20697	Mebendazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.71 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Blautia hansenii DSM20583	Mebendazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.59 [FDR-adjusted p-Value=0.049]	PMID: 31158845
Clostridium sp.	Mebendazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.623 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Bacteroides dorei DSM17855	Mebendazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.807 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides cellulosilyticus DSM14838	Mebendazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.415 [FDR-adjusted p-Value=0.039]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Mebendazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.837 [FDR-adjusted p-Value=0.038]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Mebendazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.674 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Bacteroides pectinophilus ATCC43243	Mebendazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.435 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Mebendazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.621 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Mebendazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.69 [FDR-adjusted p-Value=0.038]	PMID: 31158845
Bacteroides uniformis ATCC8492	Mebendazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.864 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides stercoris ATCC43183	Mebendazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.53 [FDR-adjusted p-Value=0.023]	PMID: 31158845
Bifidobacterium ruminatum	Mebendazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.498 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Odoribacter splanchnius	Mebendazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Mebendazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.528 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Mebendazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.426 [FDR-adjusted p-Value=0.033]	PMID: 31158845
Bacteroides fragilis T(B)9	Mebendazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.752 [FDR-adjusted p-Value=0.028]	PMID: 31158845
Bacteroides fragilis DS-208	Mebendazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.802 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides fragilis HMW610	Mebendazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.799 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Bacteroides caccae ATCC43185	Paliperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.679 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Anaerococcus hydrogenalis DSM7454	Paliperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.405 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Clostridium scindens ATCC35704	Paliperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.757 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Anaerotruncus colihominis DSM17241	Paliperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.104 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Clostridium symbiosum ATCC14940	Paliperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.732 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Ruminococcus lactaris ATCC29176	Paliperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.59 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Enterobacter cancerogenus ATCC35316	Paliperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.658 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Clostridium asparagiforme DSM15981	Paliperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.963 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Bifidobacterium breve DSM20213	Paliperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.656 [FDR-adjusted p-Value=0.045]	PMID: 31158845
Coprococcus comes ATCC27758	Paliperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.777 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Eubacterium hallii DSM3353	Paliperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.94 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Collinsella intestinalis DSM13280	Paliperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.519 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Blautia luti DSM14534	Paliperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.545 [FDR-adjusted p-Value=0.037]	PMID: 31158845
Roseburia intestinalis L1-82	Paliperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.231 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Eubacterium rectale ATCC33656	Paliperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.171 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Subdoligranulum variabile DSM15176	Paliperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.133 [FDR-adjusted p-Value=0.023]	PMID: 31158845
Clostridium sporogenes ATCC15579	Paliperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.821 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Alistipes indistinctus DSM 22520	Paliperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.837 [FDR-adjusted p-Value=0.027]	PMID: 31158845
Bacteroides fragilis DS-208	Paliperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.653 [FDR-adjusted p-Value=0.024]	PMID: 31158845
Blautia hansenii DSM20583	Pidotimod	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.3 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Clostridium sp.	Pidotimod	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.178 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides dorei DSM17855	Pidotimod	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.392 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Pidotimod	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.432 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Pidotimod	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.375 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Pretovella copri DSM18205	Pidotimod	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.557 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Pidotimod	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.564 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Bacteroides uniformis ATCC8492	Pidotimod	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.872 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides stercoris ATCC43183	Pidotimod	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.591 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides ovatus ATCC8483	Pidotimod	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.896 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides coprophilus DSM18228	Pidotimod	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.84 [FDR-adjusted p-Value=0.026]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Pidotimod	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.812 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Pidotimod	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.828 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Bacteroides fragilis 3397 T10	Pidotimod	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.965 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides fragilis T(B)9	Pidotimod	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.757 [FDR-adjusted p-Value=0.033]	PMID: 31158845
Bacteroides fragilis DS-208	Pidotimod	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.05 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides fragilis HMW610	Pidotimod	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.974 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides fragilis HMW615	Pidotimod	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.01 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides fragilis ATCC43859	Pidotimod	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.072 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Blautia hansenii DSM20583	Benazepril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.489 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides dorei DSM17855	Benazepril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.838 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Benazepril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.587 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides intestinalis DSM17393	Benazepril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.411 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Benazepril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.771 [FDR-adjusted p-Value=0.048]	PMID: 31158845
Pretovella copri DSM18205	Benazepril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.549 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Benazepril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.652 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Bacteroides stercoris ATCC43183	Benazepril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.467 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Odoribacter splanchnius	Benazepril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.413 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Bacteroides ovatus ATCC8483	Benazepril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.425 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Parabacteroides merdae ATCC43184	Benazepril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.322 [FDR-adjusted p-Value=0.036]	PMID: 31158845
Bacteroides coprophilus DSM18228	Benazepril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.415 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Benazepril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.625 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Benazepril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.457 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Benazepril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.565 [FDR-adjusted p-Value=0.033]	PMID: 31158845
Bacteroides fragilis 3397 T10	Benazepril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.552 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides fragilis T(B)9	Benazepril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.566 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Bacteroides fragilis DS-208	Benazepril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.799 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bacteroides fragilis HMW610	Benazepril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.664 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides fragilis HMW615	Benazepril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.648 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Bacteroides fragilis ATCC43859	Benazepril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.694 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Blautia hansenii DSM20583	Carisoprodol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.49 [FDR-adjusted p-Value=0.035]	PMID: 31158845
Clostridium sp.	Carisoprodol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.501 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Bacteroides dorei DSM17855	Carisoprodol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.971 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides cellulosilyticus DSM14838	Carisoprodol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.59 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Carisoprodol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.977 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Carisoprodol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.706 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Bacteroides pectinophilus ATCC43243	Carisoprodol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.437 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Pretovella copri DSM18205	Carisoprodol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.517 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Carisoprodol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.719 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Carisoprodol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.598 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides uniformis ATCC8492	Carisoprodol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.857 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides stercoris ATCC43183	Carisoprodol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.558 [FDR-adjusted p-Value=0.045]	PMID: 31158845
Bacteroides coprophilus DSM18228	Carisoprodol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.566 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Carisoprodol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.037]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Carisoprodol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.618 [FDR-adjusted p-Value=0.033]	PMID: 31158845
Bacteroides fragilis 3397 T10	Carisoprodol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.772 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Bacteroides fragilis T(B)9	Carisoprodol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.694 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Bacteroides fragilis DS-208	Carisoprodol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.785 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Bacteroides fragilis HMW610	Carisoprodol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.663 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Bacteroides fragilis HMW615	Carisoprodol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.58 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides fragilis ATCC43859	Carisoprodol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.86 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Bacteroides eggerthii DSM20697	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.43 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Blautia hansenii DSM20583	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.383 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Clostridium sp.	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.396 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides dorei DSM17855	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.594 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.663 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.488 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.468 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides uniformis ATCC8492	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.607 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides stercoris ATCC43183	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.369 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Odoribacter splanchnius	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.472 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bacteroides ovatus ATCC8483	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.339 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Parabacteroides merdae ATCC43184	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.367 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides coprophilus DSM18228	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.333 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.448 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.393 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides fragilis 3397 T10	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.593 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides fragilis T(B)9	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.605 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides fragilis DS-208	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.631 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides fragilis HMW610	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.783 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides fragilis HMW615	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.68 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides fragilis ATCC43859	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.907 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Blautia hansenii DSM20583	Famprofazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.538 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Bacteroides dorei DSM17855	Famprofazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.715 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides cellulosilyticus DSM14838	Famprofazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.349 [FDR-adjusted p-Value=0.026]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Famprofazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.724 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Famprofazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.608 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Pretovella copri DSM18205	Famprofazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.429 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Famprofazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.585 [FDR-adjusted p-Value=0.023]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Famprofazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.507 [FDR-adjusted p-Value=0.031]	PMID: 31158845
Bacteroides stercoris ATCC43183	Famprofazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.501 [FDR-adjusted p-Value=0.027]	PMID: 31158845
Odoribacter splanchnius	Famprofazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.537 [FDR-adjusted p-Value=0.023]	PMID: 31158845
Bacteroides ovatus ATCC8483	Famprofazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.436 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides coprophilus DSM18228	Famprofazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.44 [FDR-adjusted p-Value=0.027]	PMID: 31158845
Subdoligranulum variabile DSM15176	Famprofazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.359 [FDR-adjusted p-Value=0.024]	PMID: 31158845
Eubacterium biforme DSM3989	Famprofazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.469 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Famprofazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.445 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Famprofazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.367 [FDR-adjusted p-Value=0.026]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Famprofazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.563 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides fragilis 3397 T10	Famprofazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.621 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides fragilis T(B)9	Famprofazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.562 [FDR-adjusted p-Value=0.024]	PMID: 31158845
Bacteroides fragilis DS-208	Famprofazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.725 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides fragilis HMW610	Famprofazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.584 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Clostridium sp.	Idebenone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.563 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Idebenone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.708 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Clostridium bolteae ATCCBAA-613	Idebenone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.96 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Ruminococcus lactaris ATCC29176	Idebenone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.906 [FDR-adjusted p-Value=0.044]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Idebenone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.399 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Bacteroides pectinophilus ATCC43243	Idebenone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.332 [FDR-adjusted p-Value=0.026]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Idebenone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.876 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Idebenone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.782 [FDR-adjusted p-Value=0.026]	PMID: 31158845
Bacteroides uniformis ATCC8492	Idebenone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.839 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Blautia luti DSM14534	Idebenone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.089 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Roseburia intestinalis L1-82	Idebenone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.364 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Odoribacter splanchnius	Idebenone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.772 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides ovatus ATCC8483	Idebenone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.357 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Subdoligranulum variabile DSM15176	Idebenone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.7 [FDR-adjusted p-Value=0.023]	PMID: 31158845
Alistipes indistinctus DSM 22520	Idebenone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.622 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Idebenone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.464 [FDR-adjusted p-Value=0.05]	PMID: 31158845
Bacteroides fragilis 3397 T10	Idebenone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.636 [FDR-adjusted p-Value=0.05]	PMID: 31158845
Bacteroides fragilis T(B)9	Idebenone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.765 [FDR-adjusted p-Value=0.027]	PMID: 31158845
Bacteroides fragilis DS-208	Idebenone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.706 [FDR-adjusted p-Value=0.038]	PMID: 31158845
Bacteroides fragilis HMW610	Idebenone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.988 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides fragilis ATCC43859	Idebenone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.799 [FDR-adjusted p-Value=0.05]	PMID: 31158845
Escherichia coli BW25113	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.179 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bacteroides dorei DSM17855	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.565 [FDR-adjusted p-Value=0.028]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.43 [FDR-adjusted p-Value=0.023]	PMID: 31158845
Anaerococcus hydrogenalis DSM7454	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.096 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Anaerotruncus colihominis DSM17241	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.183 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.467 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Edwardsiella tarda ATCC23685	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.764 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.351 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.384 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides uniformis ATCC8492	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.819 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bacteroides stercoris ATCC43183	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.53 [FDR-adjusted p-Value=0.039]	PMID: 31158845
Odoribacter splanchnius	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.402 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Clostridium sporogenes ATCC15579	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.624 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Clostridium difficile 120	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.34 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.396 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.438 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides fragilis 3397 T10	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.544 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides fragilis T(B)9	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.541 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bacteroides fragilis DS-208	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.466 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides fragilis HMW610	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.522 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides fragilis ATCC43859	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.697 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Escherichia coli BW25113	Loperamide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.594 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides eggerthii DSM20697	Loperamide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.584 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Blautia hansenii DSM20583	Loperamide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.761 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Clostridium sp.	Loperamide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.731 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides dorei DSM17855	Loperamide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.761 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Loperamide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.76 [FDR-adjusted p-Value=0.024]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Loperamide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.613 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Loperamide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.551 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Loperamide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides uniformis ATCC8492	Loperamide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.777 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides stercoris ATCC43183	Loperamide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.439 [FDR-adjusted p-Value=0.024]	PMID: 31158845
Providencia rettgeri DSM1131	Loperamide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.399 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Roseburia intestinalis L1-82	Loperamide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.492 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Odoribacter splanchnius	Loperamide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.651 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides coprophilus DSM18228	Loperamide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.467 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Clostridium sporogenes ATCC15579	Loperamide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.447 [FDR-adjusted p-Value=0.047]	PMID: 31158845
Alistipes indistinctus DSM 22520	Loperamide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.373 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Eubacterium biforme DSM3989	Loperamide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.478 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides fragilis 3397 T10	Loperamide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.436 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Bacteroides fragilis T(B)9	Loperamide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.536 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Bacteroides fragilis HMW610	Loperamide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.559 [FDR-adjusted p-Value=0.024]	PMID: 31158845
Escherichia coli BW25113	Megestrol acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.332 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Blautia hansenii DSM20583	Megestrol acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.622 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Clostridium sp.	Megestrol acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.59 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides dorei DSM17855	Megestrol acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.712 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Megestrol acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.756 [FDR-adjusted p-Value=0.032]	PMID: 31158845
Clostridium hathewayi DSM13479	Megestrol acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.024 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Megestrol acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.43 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Megestrol acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.707 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Megestrol acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.49 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Bacteroides uniformis ATCC8492	Megestrol acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.679 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bifidobacterium ruminatum	Megestrol acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.375 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Odoribacter splanchnius	Megestrol acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.566 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Parabacteroides merdae ATCC43184	Megestrol acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.401 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Megestrol acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.386 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Megestrol acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.469 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides fragilis 3397 T10	Megestrol acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.461 [FDR-adjusted p-Value=0.05]	PMID: 31158845
Bacteroides fragilis T(B)9	Megestrol acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.553 [FDR-adjusted p-Value=0.023]	PMID: 31158845
Bacteroides fragilis DS-208	Megestrol acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.616 [FDR-adjusted p-Value=0.048]	PMID: 31158845
Bacteroides fragilis HMW610	Megestrol acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.689 [FDR-adjusted p-Value=0.023]	PMID: 31158845
Bacteroides fragilis HMW615	Megestrol acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.537 [FDR-adjusted p-Value=0.035]	PMID: 31158845
Bacteroides fragilis ATCC43859	Megestrol acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.507 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides caccae ATCC43185	Levonorgestrel	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.556 [FDR-adjusted p-Value=0.026]	PMID: 31158845
Clostridium sp.	Levonorgestrel	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.485 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Ruminococcus gnavus ATCC29149	Levonorgestrel	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.579 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides dorei DSM17855	Levonorgestrel	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.565 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides cellulosilyticus DSM14838	Levonorgestrel	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.571 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Levonorgestrel	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.148 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Levonorgestrel	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.847 [FDR-adjusted p-Value=0.032]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Levonorgestrel	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.952 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Levonorgestrel	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.823 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides uniformis ATCC8492	Levonorgestrel	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.69 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Odoribacter splanchnius	Levonorgestrel	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.53 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Parabacteroides merdae ATCC43184	Levonorgestrel	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.814 [FDR-adjusted p-Value=0.047]	PMID: 31158845
Bacteroides WH2 WH2	Levonorgestrel	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.477 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Eubacterium biforme DSM3989	Levonorgestrel	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.605 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Levonorgestrel	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.684 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Levonorgestrel	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.648 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Bacteroides fragilis 3397 T10	Levonorgestrel	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.674 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Bacteroides fragilis T(B)9	Levonorgestrel	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.682 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides fragilis DS-208	Levonorgestrel	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.645 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides fragilis HMW610	Levonorgestrel	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.846 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Bacteroides fragilis HMW615	Levonorgestrel	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.658 [FDR-adjusted p-Value=0.046]	PMID: 31158845
Bacteroides fragilis ATCC43859	Levonorgestrel	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.769 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Blautia hansenii DSM20583	Oxaprozin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.458 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Clostridium sp.	Oxaprozin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.408 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Bacteroides dorei DSM17855	Oxaprozin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.616 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Oxaprozin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.536 [FDR-adjusted p-Value=0.028]	PMID: 31158845
Bacteroides intestinalis DSM17393	Oxaprozin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.323 [FDR-adjusted p-Value=0.047]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Oxaprozin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.432 [FDR-adjusted p-Value=0.047]	PMID: 31158845
Pretovella copri DSM18205	Oxaprozin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.322 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Oxaprozin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.496 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Oxaprozin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.686 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides uniformis ATCC8492	Oxaprozin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.794 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides stercoris ATCC43183	Oxaprozin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.386 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bifidobacterium ruminatum	Oxaprozin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.469 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Odoribacter splanchnius	Oxaprozin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.6 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides ovatus ATCC8483	Oxaprozin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.395 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Oxaprozin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.617 [FDR-adjusted p-Value=0.045]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Oxaprozin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.556 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Oxaprozin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.565 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bacteroides fragilis T(B)9	Oxaprozin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.594 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides fragilis DS-208	Oxaprozin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.621 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Bacteroides fragilis HMW610	Oxaprozin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.694 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides fragilis HMW615	Oxaprozin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.663 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides fragilis ATCC43859	Oxaprozin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.759 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Escherichia coli BW25113	Clemastine fumarate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.613 [FDR-adjusted p-Value=0.04]	PMID: 31158845
Bacteroides eggerthii DSM20697	Clemastine fumarate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.666 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Blautia hansenii DSM20583	Clemastine fumarate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.644 [FDR-adjusted p-Value=0.047]	PMID: 31158845
Clostridium sp.	Clemastine fumarate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.638 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides dorei DSM17855	Clemastine fumarate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.819 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides cellulosilyticus DSM14838	Clemastine fumarate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.419 [FDR-adjusted p-Value=0.037]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Clemastine fumarate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.79 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Clemastine fumarate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.77 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides pectinophilus ATCC43243	Clemastine fumarate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.341 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Pretovella copri DSM18205	Clemastine fumarate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.575 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Clemastine fumarate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.711 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Clemastine fumarate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.449 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides uniformis ATCC8492	Clemastine fumarate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.963 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides stercoris ATCC43183	Clemastine fumarate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.506 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Providencia rettgeri DSM1131	Clemastine fumarate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.404 [FDR-adjusted p-Value=0.044]	PMID: 31158845
Roseburia intestinalis L1-82	Clemastine fumarate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.46 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Odoribacter splanchnius	Clemastine fumarate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.664 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides coprophilus DSM18228	Clemastine fumarate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.661 [FDR-adjusted p-Value=0.035]	PMID: 31158845
Eubacterium biforme DSM3989	Clemastine fumarate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.455 [FDR-adjusted p-Value=0.039]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Clemastine fumarate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.391 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Bacteroides fragilis 3397 T10	Clemastine fumarate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.489 [FDR-adjusted p-Value=0.044]	PMID: 31158845
Bacteroides fragilis DS-208	Clemastine fumarate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.664 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides fragilis HMW610	Clemastine fumarate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.526 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Blautia hansenii DSM20583	Diflorasone diacetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.55 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Clostridium sp.	Diflorasone diacetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.511 [FDR-adjusted p-Value=0.032]	PMID: 31158845
Bacteroides dorei DSM17855	Diflorasone diacetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.44 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides cellulosilyticus DSM14838	Diflorasone diacetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.475 [FDR-adjusted p-Value=0.04]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Diflorasone diacetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.837 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Diflorasone diacetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.987 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Diflorasone diacetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.839 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Pretovella copri DSM18205	Diflorasone diacetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.55 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Diflorasone diacetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.252 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Bacteroides uniformis ATCC8492	Diflorasone diacetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.86 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Odoribacter splanchnius	Diflorasone diacetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.558 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides ovatus ATCC8483	Diflorasone diacetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.05 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Parabacteroides merdae ATCC43184	Diflorasone diacetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.676 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Alistipes indistinctus DSM 22520	Diflorasone diacetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.474 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Diflorasone diacetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.045 [FDR-adjusted p-Value=0.027]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Diflorasone diacetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.677 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Diflorasone diacetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.149 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides fragilis 3397 T10	Diflorasone diacetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Victivallis vadensis ATCC BAA-548	Diflorasone diacetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.351 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides fragilis T(B)9	Diflorasone diacetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.469 [FDR-adjusted p-Value=0.028]	PMID: 31158845
Bacteroides fragilis HMW610	Diflorasone diacetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.689 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides fragilis HMW615	Diflorasone diacetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.636 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides fragilis ATCC43859	Diflorasone diacetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.636 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides eggerthii DSM20697	Digitoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.421 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Blautia hansenii DSM20583	Digitoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.433 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Clostridium sp.	Digitoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.382 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides dorei DSM17855	Digitoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.557 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Digitoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.557 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Digitoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.659 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Digitoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.35 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Digitoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.475 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides uniformis ATCC8492	Digitoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.611 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bacteroides stercoris ATCC43183	Digitoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.423 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Odoribacter splanchnius	Digitoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.524 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bacteroides ovatus ATCC8483	Digitoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.394 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Parabacteroides merdae ATCC43184	Digitoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.396 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides coprophilus DSM18228	Digitoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.355 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Clostridium sporogenes ATCC15579	Digitoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.342 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Digitoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.433 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Digitoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.338 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides fragilis 3397 T10	Digitoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.54 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bacteroides fragilis T(B)9	Digitoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.553 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides fragilis DS-208	Digitoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.672 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides fragilis HMW610	Digitoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.826 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides fragilis HMW615	Digitoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.74 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides fragilis ATCC43859	Digitoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.903 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Blautia hansenii DSM20583	Trimebutine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.678 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Clostridium sp.	Trimebutine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.787 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides dorei DSM17855	Trimebutine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.46 [FDR-adjusted p-Value=0.023]	PMID: 31158845
Clostridium hathewayi DSM13479	Trimebutine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.443 [FDR-adjusted p-Value=0.04]	PMID: 31158845
Anaerococcus hydrogenalis DSM7454	Trimebutine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.407 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Ruminococcus lactaris ATCC29176	Trimebutine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.469 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Enterobacter cancerogenus ATCC35316	Trimebutine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.414 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Clostridium spiroforme DSM1552	Trimebutine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.374 [FDR-adjusted p-Value=0.044]	PMID: 31158845
Bacteroides pectinophilus ATCC43243	Trimebutine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.337 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Clostridium asparagiforme DSM15981	Trimebutine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.691 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Eubacterium hallii DSM3353	Trimebutine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.496 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Ruminococcus torques ATCC27756	Trimebutine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.581 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Lactobacillus reuteri CF48-3A BEI HM-102	Trimebutine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.436 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bifidobacterium ruminatum	Trimebutine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.466 [FDR-adjusted p-Value=0.027]	PMID: 31158845
Akkermansia muciniphila ATCC BAA-835	Trimebutine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.354 [FDR-adjusted p-Value=0.033]	PMID: 31158845
Odoribacter splanchnius	Trimebutine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.691 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Bacteroides coprophilus DSM18228	Trimebutine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.624 [FDR-adjusted p-Value=0.026]	PMID: 31158845
Bryantia formatexigens DSM 14469	Trimebutine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.726 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Alistipes indistinctus DSM 22520	Trimebutine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.537 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Eubacterium biforme DSM3989	Trimebutine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.712 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Salmonella typhimurium LT2	Trimebutine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.458 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Eggerthella lenta ATCC25559	Trimebutine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.979 [FDR-adjusted p-Value=0.024]	PMID: 31158845
Victivallis vadensis ATCC BAA-548	Trimebutine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.808 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Bacteroides eggerthii DSM20697	Clopidogrel sulfate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.407 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Blautia hansenii DSM20583	Clopidogrel sulfate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.419 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Clostridium sp.	Clopidogrel sulfate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.42 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides dorei DSM17855	Clopidogrel sulfate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.638 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Clopidogrel sulfate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.624 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Clopidogrel sulfate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.561 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Clopidogrel sulfate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.341 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Clopidogrel sulfate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.368 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Clopidogrel sulfate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.46 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides uniformis ATCC8492	Clopidogrel sulfate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.597 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bacteroides stercoris ATCC43183	Clopidogrel sulfate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.433 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Odoribacter splanchnius	Clopidogrel sulfate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.522 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides ovatus ATCC8483	Clopidogrel sulfate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.366 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Parabacteroides merdae ATCC43184	Clopidogrel sulfate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.361 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides coprophilus DSM18228	Clopidogrel sulfate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.324 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Clostridium sporogenes ATCC15579	Clopidogrel sulfate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.327 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Clopidogrel sulfate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.464 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Clopidogrel sulfate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.416 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides fragilis 3397 T10	Clopidogrel sulfate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.605 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides fragilis T(B)9	Clopidogrel sulfate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.654 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bacteroides fragilis DS-208	Clopidogrel sulfate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.69 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides fragilis HMW610	Clopidogrel sulfate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.818 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides fragilis HMW615	Clopidogrel sulfate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.791 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Bacteroides fragilis ATCC43859	Clopidogrel sulfate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.972 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Escherichia coli BW25113	Tacrolimus	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.971 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Clostridium ramosum DSM1402	Tacrolimus	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.822 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides eggerthii DSM20697	Tacrolimus	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.841 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Blautia hansenii DSM20583	Tacrolimus	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.928 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Clostridium sp.	Tacrolimus	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.801 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Ruminococcus gnavus ATCC29149	Tacrolimus	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.504 [FDR-adjusted p-Value=0.038]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Tacrolimus	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.372 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Tacrolimus	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.82 [FDR-adjusted p-Value=0.046]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Tacrolimus	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.463 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides uniformis ATCC8492	Tacrolimus	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.765 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Akkermansia muciniphila ATCC BAA-835	Tacrolimus	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.672 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Providencia alcalifaciens DSM30120	Tacrolimus	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.051 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Blautia luti DSM14534	Tacrolimus	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.643 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Roseburia intestinalis L1-82	Tacrolimus	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.211 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Odoribacter splanchnius	Tacrolimus	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.774 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Parabacteroides merdae ATCC43184	Tacrolimus	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.357 [FDR-adjusted p-Value=0.039]	PMID: 31158845
Clostridium sporogenes ATCC15579	Tacrolimus	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.451 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Alistipes indistinctus DSM 22520	Tacrolimus	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.808 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Eubacterium biforme DSM3989	Tacrolimus	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.964 [FDR-adjusted p-Value=0.045]	PMID: 31158845
Clostridium difficile 120	Tacrolimus	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.901 [FDR-adjusted p-Value=0.033]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Tacrolimus	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.398 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Eggerthella lenta ATCC25559	Tacrolimus	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.827 [FDR-adjusted p-Value=0.026]	PMID: 31158845
Victivallis vadensis ATCC BAA-548	Tacrolimus	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.019 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides fragilis T(B)9	Tacrolimus	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.753 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Bifidobacterium adolescentis ATCC 15703	Lovastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.11 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Clostridium sp.	Lovastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.856 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Bacteroides dorei DSM17855	Lovastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.076 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Bacteroides cellulosilyticus DSM14838	Lovastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.041 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Lovastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.244 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Lovastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.931 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides intestinalis DSM17393	Lovastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.444 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Lovastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.716 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Pretovella copri DSM18205	Lovastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.365 [FDR-adjusted p-Value=0.035]	PMID: 31158845
Clostridium asparagiforme DSM15981	Lovastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.642 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bifidobacterium breve DSM20213	Lovastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.685 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Lovastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.884 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Lovastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.5 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides uniformis ATCC8492	Lovastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.94 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Odoribacter splanchnius	Lovastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.782 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Parabacteroides merdae ATCC43184	Lovastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.633 [FDR-adjusted p-Value=0.048]	PMID: 31158845
Bacteroides WH2 WH2	Lovastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.486 [FDR-adjusted p-Value=0.024]	PMID: 31158845
Eubacterium biforme DSM3989	Lovastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.61 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Lovastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.419 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Lovastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.632 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides fragilis 3397 T10	Lovastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.666 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Eggerthella lenta ATCC25559	Lovastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.4 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Victivallis vadensis ATCC BAA-548	Lovastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.462 [FDR-adjusted p-Value=0.027]	PMID: 31158845
Bacteroides fragilis T(B)9	Lovastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.71 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides fragilis HMW610	Lovastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.679 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides fragilis HMW615	Lovastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.789 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides eggerthii DSM20697	Pranoprofen	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.592 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Blautia hansenii DSM20583	Pranoprofen	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.436 [FDR-adjusted p-Value=0.033]	PMID: 31158845
Clostridium sp.	Pranoprofen	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.456 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Bacteroides dorei DSM17855	Pranoprofen	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.923 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Pranoprofen	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.974 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Pranoprofen	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.707 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides pectinophilus ATCC43243	Pranoprofen	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.472 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Pretovella copri DSM18205	Pranoprofen	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.42 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Pranoprofen	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.778 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Pranoprofen	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.648 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides uniformis ATCC8492	Pranoprofen	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.898 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides stercoris ATCC43183	Pranoprofen	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.677 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Bifidobacterium ruminatum	Pranoprofen	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.376 [FDR-adjusted p-Value=0.04]	PMID: 31158845
Odoribacter splanchnius	Pranoprofen	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.633 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides ovatus ATCC8483	Pranoprofen	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.445 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides coprophilus DSM18228	Pranoprofen	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.478 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides WH2 WH2	Pranoprofen	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.39 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Alistipes indistinctus DSM 22520	Pranoprofen	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.426 [FDR-adjusted p-Value=0.043]	PMID: 31158845
Eubacterium biforme DSM3989	Pranoprofen	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.535 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Pranoprofen	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.618 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Pranoprofen	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.529 [FDR-adjusted p-Value=0.044]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Pranoprofen	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.62 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides fragilis 3397 T10	Pranoprofen	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.79 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides fragilis T(B)9	Pranoprofen	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.826 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bacteroides fragilis DS-208	Pranoprofen	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.704 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides fragilis HMW610	Pranoprofen	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.809 [FDR-adjusted p-Value=0.042]	PMID: 31158845
Bacteroides fragilis HMW615	Pranoprofen	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.597 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides fragilis ATCC43859	Pranoprofen	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.934 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides eggerthii DSM20697	Tolazamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.643 [FDR-adjusted p-Value=0.032]	PMID: 31158845
Blautia hansenii DSM20583	Tolazamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.497 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Clostridium sp.	Tolazamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.513 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides dorei DSM17855	Tolazamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.834 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides cellulosilyticus DSM14838	Tolazamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.375 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Tolazamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.809 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Tolazamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.459 [FDR-adjusted p-Value=0.027]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Tolazamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.582 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bacteroides pectinophilus ATCC43243	Tolazamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.322 [FDR-adjusted p-Value=0.037]	PMID: 31158845
Pretovella copri DSM18205	Tolazamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.485 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Tolazamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.627 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Tolazamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.679 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides uniformis ATCC8492	Tolazamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.909 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides stercoris ATCC43183	Tolazamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.608 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bifidobacterium ruminatum	Tolazamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.344 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Odoribacter splanchnius	Tolazamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.596 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides ovatus ATCC8483	Tolazamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.54 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides coprophilus DSM18228	Tolazamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.558 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Eubacterium biforme DSM3989	Tolazamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.457 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Tolazamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.628 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Tolazamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.469 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Tolazamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.642 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides fragilis 3397 T10	Tolazamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.731 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides fragilis T(B)9	Tolazamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.749 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides fragilis DS-208	Tolazamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.77 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides fragilis HMW610	Tolazamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.734 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Bacteroides fragilis HMW615	Tolazamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.766 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Bacteroides fragilis ATCC43859	Tolazamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.905 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides eggerthii DSM20697	Cetirizine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.539 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Blautia hansenii DSM20583	Cetirizine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.504 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Bacteroides dorei DSM17855	Cetirizine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.957 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides cellulosilyticus DSM14838	Cetirizine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.57 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Cetirizine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.895 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides finegoldii DSM17565	Cetirizine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.404 [FDR-adjusted p-Value=0.023]	PMID: 31158845
Bacteroides intestinalis DSM17393	Cetirizine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.349 [FDR-adjusted p-Value=0.04]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Cetirizine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.811 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides pectinophilus ATCC43243	Cetirizine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.434 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Pretovella copri DSM18205	Cetirizine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.552 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Cetirizine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.593 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Cetirizine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.57 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides uniformis ATCC8492	Cetirizine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.823 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Bacteroides stercoris ATCC43183	Cetirizine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.641 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides coprophilus DSM18228	Cetirizine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.415 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Subdoligranulum variabile DSM15176	Cetirizine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.431 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Bryantia formatexigens DSM 14469	Cetirizine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.333 [FDR-adjusted p-Value=0.039]	PMID: 31158845
Alistipes indistinctus DSM 22520	Cetirizine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.387 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Eubacterium biforme DSM3989	Cetirizine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.474 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Cetirizine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.704 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Cetirizine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.493 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Cetirizine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.688 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides fragilis 3397 T10	Cetirizine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.716 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Salmonella typhimurium LT2	Cetirizine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.34 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides fragilis T(B)9	Cetirizine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.687 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Bacteroides fragilis DS-208	Cetirizine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.759 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides fragilis HMW610	Cetirizine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.773 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides fragilis HMW615	Cetirizine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.633 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Bacteroides fragilis ATCC43859	Cetirizine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.877 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides eggerthii DSM20697	Vilazodone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.737 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides dorei DSM17855	Vilazodone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.699 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides cellulosilyticus DSM14838	Vilazodone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.23 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Vilazodone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.9 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Vilazodone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.742 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Clostridium spiroforme DSM1552	Vilazodone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.675 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides intestinalis DSM17393	Vilazodone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.287 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Vilazodone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.602 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Pretovella copri DSM18205	Vilazodone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.634 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Vilazodone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.304 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Vilazodone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.4 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bacteroides uniformis ATCC8492	Vilazodone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.075 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides stercoris ATCC43183	Vilazodone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.163 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Odoribacter splanchnius	Vilazodone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.091 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides ovatus ATCC8483	Vilazodone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.049 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Parabacteroides merdae ATCC43184	Vilazodone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.485 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides coprophilus DSM18228	Vilazodone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.018 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides WH2 WH2	Vilazodone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.449 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Clostridium sporogenes ATCC15579	Vilazodone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.025 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Alistipes indistinctus DSM 22520	Vilazodone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.377 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Vilazodone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.714 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Vilazodone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.772 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Vilazodone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.525 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bacteroides fragilis 3397 T10	Vilazodone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.985 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides fragilis T(B)9	Vilazodone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.379 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides fragilis DS-208	Vilazodone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.232 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides fragilis HMW610	Vilazodone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.198 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides fragilis HMW615	Vilazodone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.726 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides fragilis ATCC43859	Vilazodone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.194 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides caccae ATCC43185	Deflazacort	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.863 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides eggerthii DSM20697	Deflazacort	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.667 [FDR-adjusted p-Value=0.039]	PMID: 31158845
Blautia hansenii DSM20583	Deflazacort	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.519 [FDR-adjusted p-Value=0.026]	PMID: 31158845
Clostridium sp.	Deflazacort	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.458 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides dorei DSM17855	Deflazacort	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.773 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides cellulosilyticus DSM14838	Deflazacort	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.084 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Deflazacort	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.485 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Deflazacort	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.916 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides intestinalis DSM17393	Deflazacort	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.495 [FDR-adjusted p-Value=0.026]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Deflazacort	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.475 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Pretovella copri DSM18205	Deflazacort	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.073 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Deflazacort	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.272 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides uniformis ATCC8492	Deflazacort	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.27 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bifidobacterium ruminatum	Deflazacort	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.392 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Odoribacter splanchnius	Deflazacort	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.776 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bacteroides ovatus ATCC8483	Deflazacort	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.231 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Parabacteroides merdae ATCC43184	Deflazacort	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.643 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides WH2 WH2	Deflazacort	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.913 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Eubacterium rectale ATCC33656	Deflazacort	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.389 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Alistipes indistinctus DSM 22520	Deflazacort	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.878 [FDR-adjusted p-Value=0.026]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Deflazacort	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.315 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Deflazacort	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.262 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Deflazacort	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.321 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides fragilis 3397 T10	Deflazacort	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.516 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Victivallis vadensis ATCC BAA-548	Deflazacort	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.852 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides fragilis T(B)9	Deflazacort	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.786 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Bacteroides fragilis DS-208	Deflazacort	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.815 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides fragilis HMW610	Deflazacort	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.797 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides fragilis HMW615	Deflazacort	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.785 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides fragilis ATCC43859	Deflazacort	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.926 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Bacteroides caccae ATCC43185	Famciclovir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.603 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides eggerthii DSM20697	Famciclovir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.022 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bacteroides dorei DSM17855	Famciclovir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.84 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides cellulosilyticus DSM14838	Famciclovir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.405 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Famciclovir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.199 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides finegoldii DSM17565	Famciclovir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.744 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Famciclovir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.635 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides intestinalis DSM17393	Famciclovir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.919 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Famciclovir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.957 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Pretovella copri DSM18205	Famciclovir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.857 [FDR-adjusted p-Value=0.049]	PMID: 31158845
Bifidobacterium longum subsp. Infantis CCUG52486	Famciclovir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.998 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Famciclovir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.783 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Famciclovir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.331 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides uniformis ATCC8492	Famciclovir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.225 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides stercoris ATCC43183	Famciclovir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.153 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Odoribacter splanchnius	Famciclovir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.791 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides ovatus ATCC8483	Famciclovir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.893 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Parabacteroides merdae ATCC43184	Famciclovir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.383 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides coprophilus DSM18228	Famciclovir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.409 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides WH2 WH2	Famciclovir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.95 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Alistipes indistinctus DSM 22520	Famciclovir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.474 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Famciclovir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.096 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Famciclovir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.639 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Famciclovir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.397 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bacteroides fragilis 3397 T10	Famciclovir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.783 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Victivallis vadensis ATCC BAA-548	Famciclovir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.554 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides fragilis T(B)9	Famciclovir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.872 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides fragilis DS-208	Famciclovir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.353 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides fragilis HMW610	Famciclovir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.818 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides fragilis HMW615	Famciclovir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.942 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides fragilis ATCC43859	Famciclovir	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.097 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides caccae ATCC43185	Quinapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.435 [FDR-adjusted p-Value=0.031]	PMID: 31158845
Bacteroides eggerthii DSM20697	Quinapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.608 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Blautia hansenii DSM20583	Quinapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.541 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Clostridium sp.	Quinapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.576 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides dorei DSM17855	Quinapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.061 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides cellulosilyticus DSM14838	Quinapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.639 [FDR-adjusted p-Value=0.038]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Quinapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.924 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides intestinalis DSM17393	Quinapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.487 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Quinapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.841 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides pectinophilus ATCC43243	Quinapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.447 [FDR-adjusted p-Value=0.026]	PMID: 31158845
Pretovella copri DSM18205	Quinapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.717 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bifidobacterium breve DSM20213	Quinapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.384 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Quinapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.559 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Quinapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.8 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides uniformis ATCC8492	Quinapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.062 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides stercoris ATCC43183	Quinapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.698 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bifidobacterium ruminatum	Quinapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Odoribacter splanchnius	Quinapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.588 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Bacteroides coprophilus DSM18228	Quinapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.366 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Subdoligranulum variabile DSM15176	Quinapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.479 [FDR-adjusted p-Value=0.032]	PMID: 31158845
Bryantia formatexigens DSM 14469	Quinapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.035]	PMID: 31158845
Eubacterium biforme DSM3989	Quinapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.573 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Quinapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.669 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Quinapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.514 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Quinapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.642 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides fragilis 3397 T10	Quinapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.746 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Salmonella typhimurium LT2	Quinapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.391 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Bacteroides fragilis T(B)9	Quinapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.817 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Bacteroides fragilis DS-208	Quinapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.859 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides fragilis HMW615	Quinapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.753 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides fragilis ATCC43859	Quinapril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.948 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Bacteroides caccae ATCC43185	Riluzole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.476 [FDR-adjusted p-Value=0.039]	PMID: 31158845
Clostridium ramosum DSM1402	Riluzole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.464 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides eggerthii DSM20697	Riluzole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.621 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Blautia hansenii DSM20583	Riluzole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.632 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Clostridium sp.	Riluzole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.616 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides dorei DSM17855	Riluzole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.661 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Riluzole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.532 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Riluzole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.561 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Pretovella copri DSM18205	Riluzole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.536 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Riluzole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.335 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Riluzole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.751 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Lactobacillus reuteri CF48-3A BEI HM-102	Riluzole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.394 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides uniformis ATCC8492	Riluzole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.002 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides stercoris ATCC43183	Riluzole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.636 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bifidobacterium ruminatum	Riluzole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.581 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Akkermansia muciniphila ATCC BAA-835	Riluzole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.461 [FDR-adjusted p-Value=0.037]	PMID: 31158845
Roseburia intestinalis L1-82	Riluzole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.35 [FDR-adjusted p-Value=0.033]	PMID: 31158845
Odoribacter splanchnius	Riluzole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.511 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Bacteroides ovatus ATCC8483	Riluzole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.326 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Subdoligranulum variabile DSM15176	Riluzole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.362 [FDR-adjusted p-Value=0.045]	PMID: 31158845
Clostridium sporogenes ATCC15579	Riluzole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.45 [FDR-adjusted p-Value=0.043]	PMID: 31158845
Alistipes indistinctus DSM 22520	Riluzole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.381 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Riluzole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.543 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Riluzole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.418 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Riluzole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.552 [FDR-adjusted p-Value=0.028]	PMID: 31158845
Bacteroides fragilis 3397 T10	Riluzole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.452 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Bacteroides fragilis T(B)9	Riluzole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.677 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides fragilis DS-208	Riluzole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.849 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides fragilis HMW610	Riluzole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.71 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides fragilis HMW615	Riluzole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.578 [FDR-adjusted p-Value=0.039]	PMID: 31158845
Bacteroides fragilis ATCC43859	Riluzole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.682 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Bacteroides caccae ATCC43185	Risperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.03 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Blautia hansenii DSM20583	Risperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.342 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Clostridium sp.	Risperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.806 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Ruminococcus gnavus ATCC29149	Risperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.707 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Clostridium hathewayi DSM13479	Risperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.923 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Anaerococcus hydrogenalis DSM7454	Risperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.949 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Clostridium scindens ATCC35704	Risperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.962 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Anaerotruncus colihominis DSM17241	Risperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.505 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Clostridium bolteae ATCCBAA-613	Risperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.381 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Clostridium symbiosum ATCC14940	Risperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.892 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Ruminococcus lactaris ATCC29176	Risperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.838 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Enterobacter cancerogenus ATCC35316	Risperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.598 [FDR-adjusted p-Value=0.026]	PMID: 31158845
Clostridium asparagiforme DSM15981	Risperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.178 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bifidobacterium breve DSM20213	Risperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.073 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Coprococcus comes ATCC27758	Risperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.515 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Eubacterium hallii DSM3353	Risperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.735 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Ruminococcus torques ATCC27756	Risperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.381 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Collinsella intestinalis DSM13280	Risperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.801 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Blautia luti DSM14534	Risperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.054 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Roseburia intestinalis L1-82	Risperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.949 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Odoribacter splanchnius	Risperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.897 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Eubacterium rectale ATCC33656	Risperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.898 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Subdoligranulum variabile DSM15176	Risperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.549 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Clostridium sporogenes ATCC15579	Risperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.476 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Enterococcus faecalis V583	Risperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.901 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bryantia formatexigens DSM 14469	Risperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.863 [FDR-adjusted p-Value=0.033]	PMID: 31158845
Alistipes indistinctus DSM 22520	Risperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.134 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Eubacterium biforme DSM3989	Risperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.974 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Clostridium difficile 120	Risperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.19 [FDR-adjusted p-Value=0.023]	PMID: 31158845
Bacteroides fragilis T(B)9	Risperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.756 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides fragilis DS-208	Risperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.091 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides fragilis HMW610	Risperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.015 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides fragilis ATCC43859	Risperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.674 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Bacteroides caccae ATCC43185	Oorethindrone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.202 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Escherichia coli BW25113	Oorethindrone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.358 [FDR-adjusted p-Value=0.028]	PMID: 31158845
Bacteroides eggerthii DSM20697	Oorethindrone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.39 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Blautia hansenii DSM20583	Oorethindrone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Clostridium sp.	Oorethindrone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.573 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Ruminococcus gnavus ATCC29149	Oorethindrone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.132 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides dorei DSM17855	Oorethindrone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.995 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides cellulosilyticus DSM14838	Oorethindrone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.233 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Oorethindrone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.173 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Clostridium hathewayi DSM13479	Oorethindrone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.672 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides finegoldii DSM17565	Oorethindrone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.38 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Oorethindrone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.826 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Bacteroides intestinalis DSM17393	Oorethindrone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.316 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Pretovella copri DSM18205	Oorethindrone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.429 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Ruminococcus torques ATCC27756	Oorethindrone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.901 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Oorethindrone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.305 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Oorethindrone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.537 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides uniformis ATCC8492	Oorethindrone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.273 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides stercoris ATCC43183	Oorethindrone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.14 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Odoribacter splanchnius	Oorethindrone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.74 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides ovatus ATCC8483	Oorethindrone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.875 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Parabacteroides merdae ATCC43184	Oorethindrone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.369 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides coprophilus DSM18228	Oorethindrone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.404 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides WH2 WH2	Oorethindrone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.04 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Alistipes indistinctus DSM 22520	Oorethindrone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.159 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Eubacterium biforme DSM3989	Oorethindrone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.066 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Oorethindrone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.859 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Oorethindrone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.981 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Oorethindrone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.76 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides fragilis 3397 T10	Oorethindrone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.89 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides fragilis T(B)9	Oorethindrone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.799 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides fragilis DS-208	Oorethindrone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.489 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides fragilis HMW610	Oorethindrone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.161 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides fragilis HMW615	Oorethindrone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.91 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bacteroides fragilis ATCC43859	Oorethindrone acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.97 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides caccae ATCC43185	Roxatidine acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.794 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Escherichia coli BW25113	Roxatidine acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.772 [FDR-adjusted p-Value=0.04]	PMID: 31158845
Bacteroides eggerthii DSM20697	Roxatidine acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.298 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides dorei DSM17855	Roxatidine acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.488 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Bacteroides cellulosilyticus DSM14838	Roxatidine acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.93 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Roxatidine acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.33 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides finegoldii DSM17565	Roxatidine acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.418 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Roxatidine acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.144 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Providencia stuartii ATCC25827	Roxatidine acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.766 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides intestinalis DSM17393	Roxatidine acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.133 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Roxatidine acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.491 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides pectinophilus ATCC43243	Roxatidine acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.834 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Pretovella copri DSM18205	Roxatidine acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.607 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bifidobacterium longum subsp. Infantis CCUG52486	Roxatidine acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Roxatidine acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.379 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Roxatidine acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.133 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides uniformis ATCC8492	Roxatidine acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.876 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides stercoris ATCC43183	Roxatidine acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.742 [FDR-adjusted p-Value=0.028]	PMID: 31158845
Bifidobacterium ruminatum	Roxatidine acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.379 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Providencia alcalifaciens DSM30120	Roxatidine acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.033 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Odoribacter splanchnius	Roxatidine acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.37 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides ovatus ATCC8483	Roxatidine acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.251 [FDR-adjusted p-Value=0.033]	PMID: 31158845
Parabacteroides merdae ATCC43184	Roxatidine acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.435 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides WH2 WH2	Roxatidine acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.493 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Subdoligranulum variabile DSM15176	Roxatidine acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.444 [FDR-adjusted p-Value=0.042]	PMID: 31158845
Alistipes indistinctus DSM 22520	Roxatidine acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.025 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Roxatidine acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.586 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Roxatidine acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.811 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Roxatidine acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.766 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides fragilis 3397 T10	Roxatidine acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.382 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Salmonella typhimurium LT2	Roxatidine acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.362 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Victivallis vadensis ATCC BAA-548	Roxatidine acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.313 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides fragilis T(B)9	Roxatidine acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.428 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides fragilis DS-208	Roxatidine acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.922 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides fragilis HMW610	Roxatidine acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.831 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides fragilis HMW615	Roxatidine acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.629 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides fragilis ATCC43859	Roxatidine acetate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.419 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bifidobacterium adolescentis ATCC 15703	Racecadotril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.071 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Blautia hansenii DSM20583	Racecadotril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.164 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Clostridium sp.	Racecadotril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.959 [FDR-adjusted p-Value=0.026]	PMID: 31158845
Bacteroides dorei DSM17855	Racecadotril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.427 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides cellulosilyticus DSM14838	Racecadotril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.801 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Racecadotril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.567 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Clostridium hathewayi DSM13479	Racecadotril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.715 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Bacteroides finegoldii DSM17565	Racecadotril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.715 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Racecadotril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.804 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Eubacterium ventriosum ATCC27560	Racecadotril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.483 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Ruminococcus lactaris ATCC29176	Racecadotril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.837 [FDR-adjusted p-Value=0.037]	PMID: 31158845
Bacteroides intestinalis DSM17393	Racecadotril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.556 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Racecadotril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.672 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Bacteroides pectinophilus ATCC43243	Racecadotril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.664 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Pretovella copri DSM18205	Racecadotril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.684 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bifidobacterium breve DSM20213	Racecadotril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.679 [FDR-adjusted p-Value=0.047]	PMID: 31158845
Bifidobacterium longum subsp. Infantis CCUG52486	Racecadotril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.066 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Racecadotril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.333 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Racecadotril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.515 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Bacteroides uniformis ATCC8492	Racecadotril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.066 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Bacteroides stercoris ATCC43183	Racecadotril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.664 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Akkermansia muciniphila ATCC BAA-835	Racecadotril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.527 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Roseburia intestinalis L1-82	Racecadotril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.443 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Odoribacter splanchnius	Racecadotril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.612 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Bacteroides ovatus ATCC8483	Racecadotril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.289 [FDR-adjusted p-Value=0.033]	PMID: 31158845
Parabacteroides merdae ATCC43184	Racecadotril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.55 [FDR-adjusted p-Value=0.033]	PMID: 31158845
Bacteroides coprophilus DSM18228	Racecadotril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.027 [FDR-adjusted p-Value=0.05]	PMID: 31158845
Bacteroides WH2 WH2	Racecadotril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.566 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Clostridium sporogenes ATCC15579	Racecadotril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.885 [FDR-adjusted p-Value=0.039]	PMID: 31158845
Bryantia formatexigens DSM 14469	Racecadotril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.815 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Alistipes indistinctus DSM 22520	Racecadotril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.039 [FDR-adjusted p-Value=0.033]	PMID: 31158845
Clostridium difficile 120	Racecadotril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.853 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Racecadotril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.933 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Racecadotril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.728 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Racecadotril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.386 [FDR-adjusted p-Value=0.027]	PMID: 31158845
Victivallis vadensis ATCC BAA-548	Racecadotril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.23 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Bacteroides fragilis T(B)9	Racecadotril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.706 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Bacteroides fragilis DS-208	Racecadotril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.426 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides fragilis HMW610	Racecadotril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.312 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides fragilis HMW615	Racecadotril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.694 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Bacteroides caccae ATCC43185	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.254 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Escherichia coli BW25113	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.717 [FDR-adjusted p-Value=0.033]	PMID: 31158845
Bacteroides dorei DSM17855	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.057 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides cellulosilyticus DSM14838	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.932 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.366 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Collinsella aerofaciens ATCC25986	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.244 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Clostridium hathewayi DSM13479	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.772 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Anaerococcus hydrogenalis DSM7454	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.939 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Anaerotruncus colihominis DSM17241	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.431 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Clostridium bolteae ATCCBAA-613	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.026 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Clostridium symbiosum ATCC14940	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.799 [FDR-adjusted p-Value=0.023]	PMID: 31158845
Bacteroides finegoldii DSM17565	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.139 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.106 [FDR-adjusted p-Value=0.032]	PMID: 31158845
Anaerostipes sp.	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.652 [FDR-adjusted p-Value=0.046]	PMID: 31158845
Eubacterium ventriosum ATCC27560	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.671 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Ruminococcus lactaris ATCC29176	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.798 [FDR-adjusted p-Value=0.049]	PMID: 31158845
Proteus penneri ATCC35198	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.556 [FDR-adjusted p-Value=0.031]	PMID: 31158845
Edwardsiella tarda ATCC23685	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.522 [FDR-adjusted p-Value=0.036]	PMID: 31158845
Dorea formicigenerans ATCC27755	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.593 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Enterobacter cancerogenus ATCC35316	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.923 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Providencia stuartii ATCC25827	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.75 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides intestinalis DSM17393	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.818 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.556 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides pectinophilus ATCC43243	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.06 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Pretovella copri DSM18205	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.205 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Clostridium asparagiforme DSM15981	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.869 [FDR-adjusted p-Value=0.023]	PMID: 31158845
Bifidobacterium breve DSM20213	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.016 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Eubacterium hallii DSM3353	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.877 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bifidobacterium longum subsp. Infantis CCUG52486	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.038]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.613 [FDR-adjusted p-Value=0.047]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.21 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Lactobacillus reuteri CF48-3A BEI HM-102	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.515 [FDR-adjusted p-Value=0.039]	PMID: 31158845
Bacteroides uniformis ATCC8492	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.262 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides stercoris ATCC43183	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.105 [FDR-adjusted p-Value=0.036]	PMID: 31158845
Odoribacter splanchnius	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.674 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Bacteroides coprophilus DSM18228	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.003 [FDR-adjusted p-Value=0.046]	PMID: 31158845
Eubacterium rectale ATCC33656	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.905 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Subdoligranulum variabile DSM15176	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.878 [FDR-adjusted p-Value=0.038]	PMID: 31158845
Bryantia formatexigens DSM 14469	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.903 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Eubacterium biforme DSM3989	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.253 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Clostridium difficile 120	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.293 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides fragilis 3397 T10	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.344 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Salmonella typhimurium LT2	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.166 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Eggerthella lenta ATCC25559	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.92 [FDR-adjusted p-Value=0.023]	PMID: 31158845
Victivallis vadensis ATCC BAA-548	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.968 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Bacteroides fragilis T(B)9	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.756 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides fragilis DS-208	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.657 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Bacteroides fragilis HMW610	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.917 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides fragilis ATCC43859	Olmesartan medoxomil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.731 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides caccae ATCC43185	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.875 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Escherichia coli BW25113	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.65 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Clostridium ramosum DSM1402	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.707 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bifidobacterium adolescentis ATCC 15703	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.535 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides eggerthii DSM20697	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.821 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Blautia hansenii DSM20583	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.695 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Clostridium sp.	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.789 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Ruminococcus gnavus ATCC29149	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.032]	PMID: 31158845
Bacteroides dorei DSM17855	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.559 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.566 [FDR-adjusted p-Value=0.035]	PMID: 31158845
Collinsella aerofaciens ATCC25986	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.445 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Clostridium bolteae ATCCBAA-613	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.567 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.413 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Eubacterium ventriosum ATCC27560	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.46 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Ruminococcus lactaris ATCC29176	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.514 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Proteus penneri ATCC35198	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.539 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Dorea formicigenerans ATCC27755	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.43 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Enterobacter cancerogenus ATCC35316	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.364 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Providencia stuartii ATCC25827	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.479 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides intestinalis DSM17393	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.689 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.726 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides pectinophilus ATCC43243	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.528 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Pretovella copri DSM18205	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.795 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Clostridium asparagiforme DSM15981	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.634 [FDR-adjusted p-Value=0.04]	PMID: 31158845
Bifidobacterium breve DSM20213	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.587 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Eubacterium hallii DSM3353	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.47 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bifidobacterium longum subsp. Infantis CCUG52486	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.536 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.984 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.602 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Lactobacillus reuteri CF48-3A BEI HM-102	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.635 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides uniformis ATCC8492	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.155 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides stercoris ATCC43183	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.662 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bifidobacterium ruminatum	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Roseburia intestinalis L1-82	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.429 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Odoribacter splanchnius	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.003 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides ovatus ATCC8483	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.932 [FDR-adjusted p-Value=0.031]	PMID: 31158845
Parabacteroides merdae ATCC43184	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.669 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides WH2 WH2	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.517 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Eubacterium rectale ATCC33656	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.614 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Subdoligranulum variabile DSM15176	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.718 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Clostridium sporogenes ATCC15579	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.824 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Enterococcus faecalis V583	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.383 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Alistipes indistinctus DSM 22520	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.517 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Eubacterium biforme DSM3989	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.448 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Clostridium difficile 120	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.48 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.123 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.932 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.017 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides fragilis 3397 T10	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.064 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Salmonella typhimurium LT2	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.606 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bacteroides fragilis T(B)9	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.215 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides fragilis DS-208	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.37 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bacteroides fragilis HMW610	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.479 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides fragilis HMW615	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.38 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides fragilis ATCC43859	Fluoxetine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.666 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Clostridium ramosum DSM1402	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.764 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Blautia hansenii DSM20583	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.178 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Clostridium sp.	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.136 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Ruminococcus gnavus ATCC29149	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.872 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides dorei DSM17855	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.888 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Bacteroides cellulosilyticus DSM14838	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.961 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.886 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Collinsella aerofaciens ATCC25986	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.983 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Clostridium hathewayi DSM13479	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.213 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Anaerococcus hydrogenalis DSM7454	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.094 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Anaerotruncus colihominis DSM17241	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.006 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Clostridium bolteae ATCCBAA-613	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.715 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Clostridium symbiosum ATCC14940	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.719 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides finegoldii DSM17565	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.59 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.471 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Anaerostipes sp.	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.21 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Eubacterium ventriosum ATCC27560	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.719 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Ruminococcus lactaris ATCC29176	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.711 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Proteus penneri ATCC35198	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.4 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Dorea formicigenerans ATCC27755	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.977 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Clostridium spiroforme DSM1552	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.813 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides intestinalis DSM17393	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.98 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.047 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Pretovella copri DSM18205	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.105 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Clostridium asparagiforme DSM15981	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.241 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bifidobacterium breve DSM20213	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.52 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Coprococcus comes ATCC27758	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.531 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Eubacterium hallii DSM3353	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.243 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Ruminococcus torques ATCC27756	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.089 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.536 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.164 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides uniformis ATCC8492	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.581 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bifidobacterium ruminatum	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.589 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Collinsella intestinalis DSM13280	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.825 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Blautia luti DSM14534	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.806 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Roseburia intestinalis L1-82	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.878 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Odoribacter splanchnius	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.017 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Bacteroides ovatus ATCC8483	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.08 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Parabacteroides merdae ATCC43184	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.877 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides WH2 WH2	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.086 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Eubacterium rectale ATCC33656	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.323 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Subdoligranulum variabile DSM15176	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.613 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Clostridium sporogenes ATCC15579	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.071 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Enterococcus faecalis V583	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.578 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bryantia formatexigens DSM 14469	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.856 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Alistipes indistinctus DSM 22520	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.69 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Eubacterium biforme DSM3989	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.729 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Clostridium difficile 120	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.323 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.792 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.153 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.479 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Bacteroides fragilis 3397 T10	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.225 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Eggerthella lenta ATCC25559	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.878 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Victivallis vadensis ATCC BAA-548	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.966 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Bacteroides fragilis T(B)9	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.11 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides fragilis DS-208	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.19 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides fragilis HMW610	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.103 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides fragilis HMW615	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.037 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Bacteroides fragilis ATCC43859	Phenazopyridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.173 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides caccae ATCC43185	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.479 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Clostridium ramosum DSM1402	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.222 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bifidobacterium adolescentis ATCC 15703	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.514 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bacteroides eggerthii DSM20697	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.516 [FDR-adjusted p-Value=0.044]	PMID: 31158845
Blautia hansenii DSM20583	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.868 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Clostridium sp.	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.937 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Ruminococcus gnavus ATCC29149	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.569 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides dorei DSM17855	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.556 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides cellulosilyticus DSM14838	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.907 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.631 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Collinsella aerofaciens ATCC25986	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.588 [FDR-adjusted p-Value=0.036]	PMID: 31158845
Clostridium hathewayi DSM13479	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.073 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Anaerococcus hydrogenalis DSM7454	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.508 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Clostridium scindens ATCC35704	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.095 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Anaerotruncus colihominis DSM17241	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.385 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Clostridium bolteae ATCCBAA-613	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.858 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Clostridium symbiosum ATCC14940	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.938 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides finegoldii DSM17565	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.443 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.168 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Anaerostipes sp.	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.237 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Eubacterium ventriosum ATCC27560	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.484 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Ruminococcus lactaris ATCC29176	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.786 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Dorea formicigenerans ATCC27755	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.982 [FDR-adjusted p-Value=0.033]	PMID: 31158845
Clostridium spiroforme DSM1552	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.999 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides intestinalis DSM17393	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.666 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.08 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Pretovella copri DSM18205	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.639 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Clostridium asparagiforme DSM15981	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.384 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Coprococcus comes ATCC27758	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.432 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Eubacterium hallii DSM3353	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.272 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bifidobacterium longum subsp. Infantis CCUG52486	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.037 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.551 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.975 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides uniformis ATCC8492	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.045 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides stercoris ATCC43183	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.736 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bifidobacterium ruminatum	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.463 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Collinsella intestinalis DSM13280	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.258 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Blautia luti DSM14534	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.846 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Roseburia intestinalis L1-82	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.876 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Odoribacter splanchnius	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.669 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Parabacteroides merdae ATCC43184	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.286 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides WH2 WH2	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.928 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Eubacterium rectale ATCC33656	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.836 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Subdoligranulum variabile DSM15176	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.663 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Clostridium sporogenes ATCC15579	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.509 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bryantia formatexigens DSM 14469	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.279 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Alistipes indistinctus DSM 22520	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.725 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Eubacterium biforme DSM3989	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.586 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Clostridium difficile 120	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.322 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.234 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.631 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.224 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides fragilis 3397 T10	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.648 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Eggerthella lenta ATCC25559	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.056 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Victivallis vadensis ATCC BAA-548	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.351 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides fragilis T(B)9	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.911 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides fragilis DS-208	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.167 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides fragilis HMW610	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.405 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides fragilis HMW615	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.389 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Bacteroides fragilis ATCC43859	Nitrendipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.722 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides caccae ATCC43185	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.247 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Escherichia coli BW25113	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.714 [FDR-adjusted p-Value=0.038]	PMID: 31158845
Clostridium ramosum DSM1402	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.046 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bifidobacterium adolescentis ATCC 15703	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.7 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Bacteroides eggerthii DSM20697	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.59 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Blautia hansenii DSM20583	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.234 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Clostridium sp.	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.08 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Ruminococcus gnavus ATCC29149	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.639 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bacteroides dorei DSM17855	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.631 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Bacteroides cellulosilyticus DSM14838	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.502 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.242 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Collinsella aerofaciens ATCC25986	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.629 [FDR-adjusted p-Value=0.046]	PMID: 31158845
Clostridium hathewayi DSM13479	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.679 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Anaerococcus hydrogenalis DSM7454	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.826 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Clostridium scindens ATCC35704	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.064 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Anaerotruncus colihominis DSM17241	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.088 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Clostridium bolteae ATCCBAA-613	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.113 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Clostridium symbiosum ATCC14940	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.256 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides finegoldii DSM17565	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.79 [FDR-adjusted p-Value=0.042]	PMID: 31158845
Anaerostipes sp.	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.337 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Ruminococcus lactaris ATCC29176	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.522 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Proteus penneri ATCC35198	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.657 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Dorea formicigenerans ATCC27755	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.071 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Clostridium spiroforme DSM1552	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.478 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides intestinalis DSM17393	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.296 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.007 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Pretovella copri DSM18205	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.693 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Clostridium asparagiforme DSM15981	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.184 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bifidobacterium breve DSM20213	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.241 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Coprococcus comes ATCC27758	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.182 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Eubacterium hallii DSM3353	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.031 [FDR-adjusted p-Value=0.028]	PMID: 31158845
Bifidobacterium longum subsp. Infantis CCUG52486	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.585 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Ruminococcus torques ATCC27756	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.384 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.184 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.663 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Lactobacillus reuteri CF48-3A BEI HM-102	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.888 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Bacteroides uniformis ATCC8492	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.605 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bifidobacterium ruminatum	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.08 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Collinsella intestinalis DSM13280	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.916 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Blautia luti DSM14534	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.857 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Roseburia intestinalis L1-82	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.876 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Odoribacter splanchnius	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.892 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Parabacteroides merdae ATCC43184	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.749 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides WH2 WH2	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.751 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Eubacterium rectale ATCC33656	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.002 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Subdoligranulum variabile DSM15176	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.854 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Clostridium sporogenes ATCC15579	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.072 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Enterococcus faecalis V583	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.61 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Alistipes indistinctus DSM 22520	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.01 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Eubacterium biforme DSM3989	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.927 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Clostridium difficile 120	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.039 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.252 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.303 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.032 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides fragilis 3397 T10	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.974 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Eggerthella lenta ATCC25559	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.435 [FDR-adjusted p-Value=0.038]	PMID: 31158845
Victivallis vadensis ATCC BAA-548	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.844 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides fragilis T(B)9	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.252 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides fragilis DS-208	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.327 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides fragilis HMW610	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.522 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides fragilis HMW615	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.398 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Bacteroides fragilis ATCC43859	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.576 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides caccae ATCC43185	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.641 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Clostridium ramosum DSM1402	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.756 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bifidobacterium adolescentis ATCC 15703	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.211 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides eggerthii DSM20697	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.21 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Blautia hansenii DSM20583	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.326 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Clostridium sp.	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.625 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Ruminococcus gnavus ATCC29149	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.355 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides dorei DSM17855	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.221 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides cellulosilyticus DSM14838	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.879 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.405 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Collinsella aerofaciens ATCC25986	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.161 [FDR-adjusted p-Value=0.036]	PMID: 31158845
Clostridium hathewayi DSM13479	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.51 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Anaerococcus hydrogenalis DSM7454	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.402 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Clostridium scindens ATCC35704	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.773 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Anaerotruncus colihominis DSM17241	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.078 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Clostridium bolteae ATCCBAA-613	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.639 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Clostridium symbiosum ATCC14940	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.163 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides finegoldii DSM17565	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.325 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.75 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Anaerostipes sp.	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.885 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Eubacterium ventriosum ATCC27560	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.333 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Ruminococcus lactaris ATCC29176	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.636 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Dorea formicigenerans ATCC27755	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.896 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Clostridium spiroforme DSM1552	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.977 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides intestinalis DSM17393	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.401 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.688 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Pretovella copri DSM18205	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.251 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Clostridium asparagiforme DSM15981	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.946 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bifidobacterium breve DSM20213	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.152 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Coprococcus comes ATCC27758	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.03 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Eubacterium hallii DSM3353	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.863 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bifidobacterium longum subsp. Infantis CCUG52486	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.098 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Ruminococcus torques ATCC27756	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.082 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.527 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.682 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides uniformis ATCC8492	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.753 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides stercoris ATCC43183	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.781 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bifidobacterium ruminatum	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.021 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Akkermansia muciniphila ATCC BAA-835	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.284 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Collinsella intestinalis DSM13280	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.676 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Blautia luti DSM14534	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.668 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Roseburia intestinalis L1-82	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.134 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Odoribacter splanchnius	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.536 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides ovatus ATCC8483	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.592 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Parabacteroides merdae ATCC43184	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.624 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides WH2 WH2	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.053 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Eubacterium rectale ATCC33656	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.387 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Subdoligranulum variabile DSM15176	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.609 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Clostridium sporogenes ATCC15579	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.995 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Enterococcus faecalis V583	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.603 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bryantia formatexigens DSM 14469	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.448 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Alistipes indistinctus DSM 22520	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.943 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Eubacterium biforme DSM3989	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.845 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Clostridium difficile 120	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.338 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.026 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.933 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.026 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides fragilis 3397 T10	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.31 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Eggerthella lenta ATCC25559	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.418 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Victivallis vadensis ATCC BAA-548	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.685 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides fragilis T(B)9	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.839 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bacteroides fragilis DS-208	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.07 [FDR-adjusted p-Value=0.04]	PMID: 31158845
Bacteroides fragilis HMW610	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.71 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides fragilis HMW615	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.543 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides fragilis ATCC43859	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.994 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Escherichia coli BW25113	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.593 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Clostridium ramosum DSM1402	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.098 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bifidobacterium adolescentis ATCC 15703	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.438 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides eggerthii DSM20697	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.525 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Blautia hansenii DSM20583	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.89 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Clostridium sp.	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.897 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides dorei DSM17855	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.917 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.806 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Clostridium hathewayi DSM13479	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.455 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Anaerococcus hydrogenalis DSM7454	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.668 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Clostridium scindens ATCC35704	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.736 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Clostridium bolteae ATCCBAA-613	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.436 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.657 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Anaerostipes sp.	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.553 [FDR-adjusted p-Value=0.043]	PMID: 31158845
Proteus penneri ATCC35198	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.366 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Edwardsiella tarda ATCC23685	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.364 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Dorea formicigenerans ATCC27755	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.382 [FDR-adjusted p-Value=0.035]	PMID: 31158845
Enterobacter cancerogenus ATCC35316	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.528 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Providencia stuartii ATCC25827	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.408 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Clostridium spiroforme DSM1552	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.623 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides intestinalis DSM17393	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.413 [FDR-adjusted p-Value=0.023]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.462 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bacteroides pectinophilus ATCC43243	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.353 [FDR-adjusted p-Value=0.035]	PMID: 31158845
Pretovella copri DSM18205	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.799 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Clostridium asparagiforme DSM15981	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.044 [FDR-adjusted p-Value=0.027]	PMID: 31158845
Bifidobacterium breve DSM20213	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.3 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Coprococcus comes ATCC27758	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.446 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Eubacterium hallii DSM3353	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.374 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bifidobacterium longum subsp. Infantis CCUG52486	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.503 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Ruminococcus torques ATCC27756	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.456 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.48 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.579 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Lactobacillus reuteri CF48-3A BEI HM-102	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.534 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides uniformis ATCC8492	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.877 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bacteroides stercoris ATCC43183	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.507 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bifidobacterium ruminatum	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.781 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Akkermansia muciniphila ATCC BAA-835	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.517 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Providencia alcalifaciens DSM30120	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.493 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Providencia rettgeri DSM1131	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.49 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Collinsella intestinalis DSM13280	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.454 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Blautia luti DSM14534	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.223 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Roseburia intestinalis L1-82	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.579 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Odoribacter splanchnius	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.917 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides ovatus ATCC8483	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.462 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Parabacteroides merdae ATCC43184	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.731 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bacteroides coprophilus DSM18228	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.643 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides WH2 WH2	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.079 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Eubacterium rectale ATCC33656	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.617 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Subdoligranulum variabile DSM15176	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.675 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Enterococcus faecalis V583	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.289 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bryantia formatexigens DSM 14469	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.609 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Alistipes indistinctus DSM 22520	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.065 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Eubacterium biforme DSM3989	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.818 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Clostridium difficile 120	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.175 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.693 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.665 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.712 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides fragilis 3397 T10	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.707 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Salmonella typhimurium LT2	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.584 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Eggerthella lenta ATCC25559	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.831 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Victivallis vadensis ATCC BAA-548	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.742 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides fragilis T(B)9	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.79 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides fragilis DS-208	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.578 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides fragilis HMW610	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.758 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides fragilis HMW615	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.654 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Bacteroides fragilis ATCC43859	Mycophenolate mofetil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.662 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Escherichia coli BW25113	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.242 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Clostridium ramosum DSM1402	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.889 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bifidobacterium adolescentis ATCC 15703	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.012 [FDR-adjusted p-Value=0.031]	PMID: 31158845
Bacteroides eggerthii DSM20697	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.164 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Blautia hansenii DSM20583	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.789 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Clostridium sp.	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.977 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Ruminococcus gnavus ATCC29149	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.865 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Bacteroides dorei DSM17855	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.348 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides cellulosilyticus DSM14838	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.02 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.211 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Collinsella aerofaciens ATCC25986	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.826 [FDR-adjusted p-Value=0.038]	PMID: 31158845
Clostridium hathewayi DSM13479	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.958 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Anaerococcus hydrogenalis DSM7454	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.617 [FDR-adjusted p-Value=0.031]	PMID: 31158845
Anaerotruncus colihominis DSM17241	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.327 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Clostridium bolteae ATCCBAA-613	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.321 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Clostridium symbiosum ATCC14940	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.717 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Bacteroides finegoldii DSM17565	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.993 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.841 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Anaerostipes sp.	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.574 [FDR-adjusted p-Value=0.05]	PMID: 31158845
Eubacterium ventriosum ATCC27560	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.64 [FDR-adjusted p-Value=0.05]	PMID: 31158845
Ruminococcus lactaris ATCC29176	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.73 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Proteus penneri ATCC35198	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.714 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Edwardsiella tarda ATCC23685	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.622 [FDR-adjusted p-Value=0.031]	PMID: 31158845
Dorea formicigenerans ATCC27755	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.641 [FDR-adjusted p-Value=0.046]	PMID: 31158845
Enterobacter cancerogenus ATCC35316	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.963 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Providencia stuartii ATCC25827	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.784 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Clostridium spiroforme DSM1552	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.699 [FDR-adjusted p-Value=0.031]	PMID: 31158845
Bacteroides intestinalis DSM17393	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.016 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.364 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides pectinophilus ATCC43243	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.13 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Pretovella copri DSM18205	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.272 [FDR-adjusted p-Value=0.024]	PMID: 31158845
Clostridium asparagiforme DSM15981	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.081 [FDR-adjusted p-Value=0.028]	PMID: 31158845
Bifidobacterium breve DSM20213	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.023 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Eubacterium hallii DSM3353	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.773 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Bifidobacterium longum subsp. Infantis CCUG52486	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.897 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Ruminococcus torques ATCC27756	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.911 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.097 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.343 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Lactobacillus reuteri CF48-3A BEI HM-102	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.933 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides uniformis ATCC8492	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.361 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Bifidobacterium ruminatum	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.887 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Akkermansia muciniphila ATCC BAA-835	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.127 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Providencia rettgeri DSM1131	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.731 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Collinsella intestinalis DSM13280	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.789 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Blautia luti DSM14534	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.647 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Roseburia intestinalis L1-82	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.022 [FDR-adjusted p-Value=0.028]	PMID: 31158845
Odoribacter splanchnius	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.976 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Bacteroides ovatus ATCC8483	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.519 [FDR-adjusted p-Value=0.05]	PMID: 31158845
Parabacteroides merdae ATCC43184	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.569 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides coprophilus DSM18228	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.921 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Eubacterium rectale ATCC33656	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.925 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Subdoligranulum variabile DSM15176	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.718 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Clostridium sporogenes ATCC15579	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.102 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Alistipes indistinctus DSM 22520	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.548 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Clostridium difficile 120	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.563 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.576 [FDR-adjusted p-Value=0.045]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.512 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.707 [FDR-adjusted p-Value=0.05]	PMID: 31158845
Bacteroides fragilis 3397 T10	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.699 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Salmonella typhimurium LT2	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.622 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Eggerthella lenta ATCC25559	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.157 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Victivallis vadensis ATCC BAA-548	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.198 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Bacteroides fragilis T(B)9	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.895 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides fragilis DS-208	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.066 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides fragilis HMW610	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.099 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Bacteroides fragilis HMW615	Bromocriptine mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.795 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides caccae ATCC43185	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.539 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Clostridium ramosum DSM1402	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.594 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bifidobacterium adolescentis ATCC 15703	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.053 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides eggerthii DSM20697	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.579 [FDR-adjusted p-Value=0.023]	PMID: 31158845
Blautia hansenii DSM20583	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.15 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Clostridium sp.	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.246 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Ruminococcus gnavus ATCC29149	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.121 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides dorei DSM17855	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.363 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides cellulosilyticus DSM14838	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.878 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.194 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Collinsella aerofaciens ATCC25986	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.106 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Clostridium hathewayi DSM13479	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.731 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Anaerococcus hydrogenalis DSM7454	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.636 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Clostridium scindens ATCC35704	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.508 [FDR-adjusted p-Value=0.032]	PMID: 31158845
Anaerotruncus colihominis DSM17241	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.532 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Clostridium bolteae ATCCBAA-613	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.365 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Clostridium symbiosum ATCC14940	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.445 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides finegoldii DSM17565	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.004 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.445 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Anaerostipes sp.	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.862 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Eubacterium ventriosum ATCC27560	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.171 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Ruminococcus lactaris ATCC29176	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.7 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Proteus penneri ATCC35198	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.543 [FDR-adjusted p-Value=0.032]	PMID: 31158845
Edwardsiella tarda ATCC23685	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.38 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Dorea formicigenerans ATCC27755	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.008 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Clostridium spiroforme DSM1552	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.066 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides intestinalis DSM17393	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.342 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.631 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides pectinophilus ATCC43243	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.282 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Pretovella copri DSM18205	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.099 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Clostridium asparagiforme DSM15981	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.865 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Bifidobacterium breve DSM20213	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.995 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Coprococcus comes ATCC27758	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.119 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Eubacterium hallii DSM3353	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.964 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bifidobacterium longum subsp. Infantis CCUG52486	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.665 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Ruminococcus torques ATCC27756	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.65 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.393 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.315 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides uniformis ATCC8492	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.548 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides stercoris ATCC43183	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.281 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bifidobacterium ruminatum	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.8 [FDR-adjusted p-Value=0.027]	PMID: 31158845
Akkermansia muciniphila ATCC BAA-835	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.034 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Collinsella intestinalis DSM13280	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.254 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Blautia luti DSM14534	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.375 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Roseburia intestinalis L1-82	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.213 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Odoribacter splanchnius	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.255 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Bacteroides ovatus ATCC8483	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.258 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Parabacteroides merdae ATCC43184	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.892 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Bacteroides WH2 WH2	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.842 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Eubacterium rectale ATCC33656	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.076 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Subdoligranulum variabile DSM15176	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.066 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Clostridium sporogenes ATCC15579	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.762 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Enterococcus faecalis V583	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.481 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Bryantia formatexigens DSM 14469	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.063 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Alistipes indistinctus DSM 22520	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.104 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Eubacterium biforme DSM3989	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.135 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Clostridium difficile 120	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.006 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.42 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.588 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.58 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides fragilis 3397 T10	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.77 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Eggerthella lenta ATCC25559	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.83 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Victivallis vadensis ATCC BAA-548	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.775 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides fragilis T(B)9	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.56 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides fragilis DS-208	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.334 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides fragilis HMW610	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.788 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides fragilis HMW615	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.839 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides fragilis ATCC43859	Entacapone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.877 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides caccae ATCC43185	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.094 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Escherichia coli BW25113	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.667 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Clostridium ramosum DSM1402	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.29 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bifidobacterium adolescentis ATCC 15703	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.686 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Bacteroides eggerthii DSM20697	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.012 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Blautia hansenii DSM20583	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.172 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Clostridium sp.	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.539 [FDR-adjusted p-Value=0.036]	PMID: 31158845
Ruminococcus gnavus ATCC29149	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.805 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides dorei DSM17855	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.544 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bacteroides cellulosilyticus DSM14838	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.099 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.901 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Collinsella aerofaciens ATCC25986	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.527 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Clostridium hathewayi DSM13479	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.834 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Anaerococcus hydrogenalis DSM7454	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.318 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Clostridium scindens ATCC35704	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.742 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Anaerotruncus colihominis DSM17241	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.254 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Clostridium bolteae ATCCBAA-613	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.623 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Clostridium symbiosum ATCC14940	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.624 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides finegoldii DSM17565	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.772 [FDR-adjusted p-Value=0.028]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.139 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Anaerostipes sp.	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.848 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Eubacterium ventriosum ATCC27560	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.913 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Ruminococcus lactaris ATCC29176	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.237 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Proteus penneri ATCC35198	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.912 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Edwardsiella tarda ATCC23685	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.35 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Dorea formicigenerans ATCC27755	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.388 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Enterobacter cancerogenus ATCC35316	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.995 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Providencia stuartii ATCC25827	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.165 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Clostridium spiroforme DSM1552	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.416 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides intestinalis DSM17393	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.826 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.035 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides pectinophilus ATCC43243	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.009 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Pretovella copri DSM18205	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.493 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bifidobacterium breve DSM20213	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.68 [FDR-adjusted p-Value=0.026]	PMID: 31158845
Coprococcus comes ATCC27758	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.212 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bifidobacterium longum subsp. Infantis CCUG52486	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.48 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Ruminococcus torques ATCC27756	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.371 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.315 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.112 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides uniformis ATCC8492	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.335 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides stercoris ATCC43183	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.81 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Bifidobacterium ruminatum	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.617 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Akkermansia muciniphila ATCC BAA-835	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.506 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Providencia alcalifaciens DSM30120	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.442 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Providencia rettgeri DSM1131	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.285 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Blautia luti DSM14534	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.181 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Roseburia intestinalis L1-82	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.454 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Odoribacter splanchnius	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.857 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Parabacteroides merdae ATCC43184	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.594 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Bacteroides WH2 WH2	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.994 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Eubacterium rectale ATCC33656	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.247 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Subdoligranulum variabile DSM15176	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.019 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Clostridium sporogenes ATCC15579	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.43 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Enterococcus faecalis V583	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.818 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bryantia formatexigens DSM 14469	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.465 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Alistipes indistinctus DSM 22520	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.732 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Eubacterium biforme DSM3989	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.232 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Clostridium difficile 120	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.789 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.758 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.135 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.834 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Bacteroides fragilis 3397 T10	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.187 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Salmonella typhimurium LT2	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.772 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Eggerthella lenta ATCC25559	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.917 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Victivallis vadensis ATCC BAA-548	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.995 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides fragilis T(B)9	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.67 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides fragilis DS-208	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.352 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides fragilis HMW610	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.019 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides fragilis HMW615	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.655 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides fragilis ATCC43859	Danazol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.937 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides caccae ATCC43185	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.126 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Escherichia coli BW25113	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.763 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Clostridium ramosum DSM1402	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.59 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bifidobacterium adolescentis ATCC 15703	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.097 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides eggerthii DSM20697	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.675 [FDR-adjusted p-Value=0.037]	PMID: 31158845
Blautia hansenii DSM20583	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.823 [FDR-adjusted p-Value=0.036]	PMID: 31158845
Clostridium sp.	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.724 [FDR-adjusted p-Value=0.026]	PMID: 31158845
Ruminococcus gnavus ATCC29149	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.867 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Bacteroides dorei DSM17855	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.32 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides cellulosilyticus DSM14838	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.068 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.1 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Collinsella aerofaciens ATCC25986	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.523 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Clostridium hathewayi DSM13479	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.841 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Anaerococcus hydrogenalis DSM7454	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.955 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Clostridium scindens ATCC35704	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.708 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Bacteroides finegoldii DSM17565	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.407 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Eubacterium ventriosum ATCC27560	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.364 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Proteus penneri ATCC35198	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.848 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Edwardsiella tarda ATCC23685	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.248 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Dorea formicigenerans ATCC27755	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.84 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Enterobacter cancerogenus ATCC35316	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.892 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Providencia stuartii ATCC25827	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.048 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Clostridium spiroforme DSM1552	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.744 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides intestinalis DSM17393	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.042 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.687 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides pectinophilus ATCC43243	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.783 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Pretovella copri DSM18205	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.833 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Clostridium asparagiforme DSM15981	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.968 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bifidobacterium breve DSM20213	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.611 [FDR-adjusted p-Value=0.04]	PMID: 31158845
Coprococcus comes ATCC27758	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.32 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Eubacterium hallii DSM3353	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.227 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Bifidobacterium longum subsp. Infantis CCUG52486	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.44 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Ruminococcus torques ATCC27756	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.429 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.804 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.024 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Lactobacillus reuteri CF48-3A BEI HM-102	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.912 [FDR-adjusted p-Value=0.026]	PMID: 31158845
Bacteroides uniformis ATCC8492	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.086 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Bacteroides stercoris ATCC43183	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.877 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Bifidobacterium ruminatum	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.491 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Akkermansia muciniphila ATCC BAA-835	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.817 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Providencia alcalifaciens DSM30120	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.831 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Providencia rettgeri DSM1131	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.717 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Collinsella intestinalis DSM13280	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.158 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Blautia luti DSM14534	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.367 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Roseburia intestinalis L1-82	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.126 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Odoribacter splanchnius	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.638 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides ovatus ATCC8483	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.433 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Parabacteroides merdae ATCC43184	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.12 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides coprophilus DSM18228	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.345 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides WH2 WH2	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.595 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Eubacterium rectale ATCC33656	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.46 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Subdoligranulum variabile DSM15176	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.636 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Clostridium sporogenes ATCC15579	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.291 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Enterococcus faecalis V583	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.178 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bryantia formatexigens DSM 14469	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.41 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Alistipes indistinctus DSM 22520	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.888 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Eubacterium biforme DSM3989	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.138 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Clostridium difficile 120	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.314 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.67 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.406 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.404 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides fragilis 3397 T10	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.57 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Salmonella typhimurium LT2	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.716 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Eggerthella lenta ATCC25559	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.131 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Victivallis vadensis ATCC BAA-548	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.916 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides fragilis T(B)9	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.244 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides fragilis DS-208	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.117 [FDR-adjusted p-Value=0.048]	PMID: 31158845
Bacteroides fragilis HMW610	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.334 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides fragilis HMW615	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.709 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides fragilis ATCC43859	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.928 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides caccae ATCC43185	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.363 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Clostridium ramosum DSM1402	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.109 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bifidobacterium adolescentis ATCC 15703	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.531 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides eggerthii DSM20697	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.103 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Ruminococcus gnavus ATCC29149	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.76 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides dorei DSM17855	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.572 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides cellulosilyticus DSM14838	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.686 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.301 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Collinsella aerofaciens ATCC25986	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.649 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Clostridium hathewayi DSM13479	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.671 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Anaerococcus hydrogenalis DSM7454	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.8 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Clostridium scindens ATCC35704	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.733 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Anaerotruncus colihominis DSM17241	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.947 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Clostridium bolteae ATCCBAA-613	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.983 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Clostridium symbiosum ATCC14940	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.5 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides finegoldii DSM17565	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.028 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.156 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Anaerostipes sp.	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.414 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Eubacterium ventriosum ATCC27560	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.609 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Ruminococcus lactaris ATCC29176	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.062 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Proteus penneri ATCC35198	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.408 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Edwardsiella tarda ATCC23685	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.032 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Dorea formicigenerans ATCC27755	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.373 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Providencia stuartii ATCC25827	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.668 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Clostridium spiroforme DSM1552	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.97 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides intestinalis DSM17393	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.147 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.801 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides pectinophilus ATCC43243	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.683 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Pretovella copri DSM18205	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.671 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Clostridium asparagiforme DSM15981	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.378 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Bifidobacterium breve DSM20213	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.635 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Coprococcus comes ATCC27758	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.59 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Eubacterium hallii DSM3353	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.38 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bifidobacterium longum subsp. Infantis CCUG52486	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.096 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Ruminococcus torques ATCC27756	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.521 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.22 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.556 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Lactobacillus reuteri CF48-3A BEI HM-102	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.53 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides uniformis ATCC8492	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.423 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides stercoris ATCC43183	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.089 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bifidobacterium ruminatum	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.893 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Akkermansia muciniphila ATCC BAA-835	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.92 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Providencia alcalifaciens DSM30120	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.898 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Providencia rettgeri DSM1131	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.645 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Collinsella intestinalis DSM13280	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.407 [FDR-adjusted p-Value=0.042]	PMID: 31158845
Blautia luti DSM14534	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.183 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Roseburia intestinalis L1-82	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.762 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Odoribacter splanchnius	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.166 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides ovatus ATCC8483	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.863 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Parabacteroides merdae ATCC43184	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.529 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides coprophilus DSM18228	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.676 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides WH2 WH2	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.927 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Eubacterium rectale ATCC33656	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.609 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Subdoligranulum variabile DSM15176	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.216 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Clostridium sporogenes ATCC15579	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.259 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Enterococcus faecalis V583	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.117 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bryantia formatexigens DSM 14469	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.366 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Alistipes indistinctus DSM 22520	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.709 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Eubacterium biforme DSM3989	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.738 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Clostridium difficile 120	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.065 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.642 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.583 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.576 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides fragilis 3397 T10	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.617 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Salmonella typhimurium LT2	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.831 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Eggerthella lenta ATCC25559	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.52 [FDR-adjusted p-Value=0.031]	PMID: 31158845
Victivallis vadensis ATCC BAA-548	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.595 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides fragilis T(B)9	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.215 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides fragilis DS-208	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.392 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides fragilis HMW610	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.268 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides fragilis HMW615	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.246 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides fragilis ATCC43859	Diacetamate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.28 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides caccae ATCC43185	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.156 [FDR-adjusted p-Value=0.038]	PMID: 31158845
Escherichia coli BW25113	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.966 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Clostridium ramosum DSM1402	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.873 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bifidobacterium adolescentis ATCC 15703	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.453 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides eggerthii DSM20697	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.013 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Blautia hansenii DSM20583	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.812 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Clostridium sp.	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.563 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Ruminococcus gnavus ATCC29149	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.397 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides dorei DSM17855	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.517 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides cellulosilyticus DSM14838	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.289 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.345 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Collinsella aerofaciens ATCC25986	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.876 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Clostridium hathewayi DSM13479	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.183 [FDR-adjusted p-Value=0.027]	PMID: 31158845
Anaerococcus hydrogenalis DSM7454	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.458 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Clostridium scindens ATCC35704	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.355 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Anaerotruncus colihominis DSM17241	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.371 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Clostridium bolteae ATCCBAA-613	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.558 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Clostridium symbiosum ATCC14940	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.065 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides finegoldii DSM17565	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.334 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.464 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Anaerostipes sp.	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.374 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Eubacterium ventriosum ATCC27560	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.584 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Ruminococcus lactaris ATCC29176	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.429 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Proteus penneri ATCC35198	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.412 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Edwardsiella tarda ATCC23685	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.3 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Dorea formicigenerans ATCC27755	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.363 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Enterobacter cancerogenus ATCC35316	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.442 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Providencia stuartii ATCC25827	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.385 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Clostridium spiroforme DSM1552	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.391 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides intestinalis DSM17393	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.379 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.379 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides pectinophilus ATCC43243	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.844 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Pretovella copri DSM18205	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.526 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Clostridium asparagiforme DSM15981	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.546 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bifidobacterium breve DSM20213	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.901 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Coprococcus comes ATCC27758	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.173 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Eubacterium hallii DSM3353	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.316 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bifidobacterium longum subsp. Infantis CCUG52486	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.874 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Ruminococcus torques ATCC27756	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.784 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.195 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.467 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Lactobacillus reuteri CF48-3A BEI HM-102	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.27 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Bacteroides uniformis ATCC8492	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.311 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides stercoris ATCC43183	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.146 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Bifidobacterium ruminatum	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.006 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Akkermansia muciniphila ATCC BAA-835	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.571 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Providencia alcalifaciens DSM30120	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.505 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Providencia rettgeri DSM1131	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.849 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Collinsella intestinalis DSM13280	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.314 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Blautia luti DSM14534	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.645 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Roseburia intestinalis L1-82	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.733 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Odoribacter splanchnius	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.445 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Bacteroides ovatus ATCC8483	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.543 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Parabacteroides merdae ATCC43184	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.405 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides WH2 WH2	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.966 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Eubacterium rectale ATCC33656	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.581 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Subdoligranulum variabile DSM15176	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.699 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Clostridium sporogenes ATCC15579	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.776 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Enterococcus faecalis V583	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.296 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bryantia formatexigens DSM 14469	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.344 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Alistipes indistinctus DSM 22520	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.443 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Eubacterium biforme DSM3989	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.416 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Clostridium difficile 120	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.173 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.615 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.786 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.363 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides fragilis 3397 T10	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.249 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Salmonella typhimurium LT2	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.861 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Eggerthella lenta ATCC25559	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.686 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Victivallis vadensis ATCC BAA-548	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.893 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides fragilis T(B)9	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.546 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides fragilis DS-208	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.601 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Bacteroides fragilis HMW610	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.731 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides fragilis HMW615	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.281 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides fragilis ATCC43859	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.742 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Bacteroides caccae ATCC43185	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.148 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Escherichia coli BW25113	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.706 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Clostridium ramosum DSM1402	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.802 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bifidobacterium adolescentis ATCC 15703	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.855 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides eggerthii DSM20697	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.448 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Blautia hansenii DSM20583	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.162 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Clostridium sp.	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.005 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Ruminococcus gnavus ATCC29149	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.718 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides dorei DSM17855	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.153 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides cellulosilyticus DSM14838	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.851 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.201 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Collinsella aerofaciens ATCC25986	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.659 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Clostridium hathewayi DSM13479	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.61 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Anaerococcus hydrogenalis DSM7454	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.892 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Clostridium scindens ATCC35704	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.492 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Anaerotruncus colihominis DSM17241	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.986 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Clostridium bolteae ATCCBAA-613	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.578 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Clostridium symbiosum ATCC14940	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.773 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides finegoldii DSM17565	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.513 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.681 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Anaerostipes sp.	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.667 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Eubacterium ventriosum ATCC27560	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.467 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Ruminococcus lactaris ATCC29176	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.362 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Proteus penneri ATCC35198	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.316 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Edwardsiella tarda ATCC23685	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.65 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Dorea formicigenerans ATCC27755	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.463 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Enterobacter cancerogenus ATCC35316	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.2 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Providencia stuartii ATCC25827	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.427 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Clostridium spiroforme DSM1552	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.436 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides intestinalis DSM17393	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.415 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Bacteroides pectinophilus ATCC43243	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.481 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Pretovella copri DSM18205	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.097 [FDR-adjusted p-Value=0.039]	PMID: 31158845
Clostridium asparagiforme DSM15981	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.775 [FDR-adjusted p-Value=0.036]	PMID: 31158845
Bifidobacterium breve DSM20213	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.071 [FDR-adjusted p-Value=0.023]	PMID: 31158845
Coprococcus comes ATCC27758	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.503 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Eubacterium hallii DSM3353	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.67 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bifidobacterium longum subsp. Infantis CCUG52486	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.396 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Ruminococcus torques ATCC27756	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.764 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.628 [FDR-adjusted p-Value=0.035]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.499 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Lactobacillus reuteri CF48-3A BEI HM-102	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.014 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides uniformis ATCC8492	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.563 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides stercoris ATCC43183	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.246 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Bifidobacterium ruminatum	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.067 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Akkermansia muciniphila ATCC BAA-835	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.917 [FDR-adjusted p-Value=0.027]	PMID: 31158845
Providencia alcalifaciens DSM30120	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.804 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Providencia rettgeri DSM1131	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.496 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Collinsella intestinalis DSM13280	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.786 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Blautia luti DSM14534	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.449 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Roseburia intestinalis L1-82	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.045 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Odoribacter splanchnius	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.212 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides ovatus ATCC8483	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.419 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Parabacteroides merdae ATCC43184	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.364 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides coprophilus DSM18228	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.679 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides WH2 WH2	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.287 [FDR-adjusted p-Value=0.045]	PMID: 31158845
Eubacterium rectale ATCC33656	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.319 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Subdoligranulum variabile DSM15176	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.391 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Clostridium sporogenes ATCC15579	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.987 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Enterococcus faecalis V583	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.875 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bryantia formatexigens DSM 14469	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.814 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Alistipes indistinctus DSM 22520	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.65 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Eubacterium biforme DSM3989	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.944 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Clostridium difficile 120	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.527 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.421 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.418 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.794 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides fragilis 3397 T10	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.716 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Salmonella typhimurium LT2	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.222 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Eggerthella lenta ATCC25559	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.207 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Victivallis vadensis ATCC BAA-548	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.66 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides fragilis T(B)9	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.531 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides fragilis DS-208	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.252 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides fragilis HMW610	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.654 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides fragilis HMW615	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.87 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides fragilis ATCC43859	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.612 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides caccae ATCC43185	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.102 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Escherichia coli BW25113	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.027 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Clostridium ramosum DSM1402	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.233 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bifidobacterium adolescentis ATCC 15703	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.813 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides eggerthii DSM20697	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.878 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Blautia hansenii DSM20583	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.22 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Clostridium sp.	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.378 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Ruminococcus gnavus ATCC29149	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.752 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides dorei DSM17855	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.091 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides cellulosilyticus DSM14838	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.989 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-12.105 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Collinsella aerofaciens ATCC25986	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.313 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Clostridium hathewayi DSM13479	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.466 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Anaerococcus hydrogenalis DSM7454	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.173 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Clostridium scindens ATCC35704	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.918 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Anaerotruncus colihominis DSM17241	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.431 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Clostridium bolteae ATCCBAA-613	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.122 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Clostridium symbiosum ATCC14940	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.718 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides finegoldii DSM17565	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.5 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.186 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Anaerostipes sp.	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.204 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Eubacterium ventriosum ATCC27560	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.255 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Ruminococcus lactaris ATCC29176	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.885 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Proteus penneri ATCC35198	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.918 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Edwardsiella tarda ATCC23685	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.422 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Dorea formicigenerans ATCC27755	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.311 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Enterobacter cancerogenus ATCC35316	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.728 [FDR-adjusted p-Value=0.031]	PMID: 31158845
Providencia stuartii ATCC25827	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.452 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Clostridium spiroforme DSM1552	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.686 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides intestinalis DSM17393	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.712 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.324 [FDR-adjusted p-Value=0.032]	PMID: 31158845
Bacteroides pectinophilus ATCC43243	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.654 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Pretovella copri DSM18205	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.456 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Clostridium asparagiforme DSM15981	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.716 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bifidobacterium breve DSM20213	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.49 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Coprococcus comes ATCC27758	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.584 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Eubacterium hallii DSM3353	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.081 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bifidobacterium longum subsp. Infantis CCUG52486	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.328 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Ruminococcus torques ATCC27756	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.122 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.549 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.863 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Lactobacillus reuteri CF48-3A BEI HM-102	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.547 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides uniformis ATCC8492	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.23 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides stercoris ATCC43183	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.41 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bifidobacterium ruminatum	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.369 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Akkermansia muciniphila ATCC BAA-835	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.192 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Providencia alcalifaciens DSM30120	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.472 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Providencia rettgeri DSM1131	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.201 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Collinsella intestinalis DSM13280	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.266 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Blautia luti DSM14534	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.587 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Roseburia intestinalis L1-82	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.506 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Odoribacter splanchnius	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.678 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides ovatus ATCC8483	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.639 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Parabacteroides merdae ATCC43184	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.854 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides coprophilus DSM18228	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.863 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides WH2 WH2	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.33 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Eubacterium rectale ATCC33656	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.0 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Subdoligranulum variabile DSM15176	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.708 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Clostridium sporogenes ATCC15579	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.324 [FDR-adjusted p-Value=0.027]	PMID: 31158845
Enterococcus faecalis V583	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.482 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bryantia formatexigens DSM 14469	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.339 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Alistipes indistinctus DSM 22520	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.438 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Eubacterium biforme DSM3989	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.176 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Clostridium difficile 120	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.146 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.462 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.412 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.394 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides fragilis 3397 T10	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.531 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Salmonella typhimurium LT2	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.5 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Eggerthella lenta ATCC25559	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.735 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Victivallis vadensis ATCC BAA-548	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.213 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides fragilis T(B)9	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.349 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides fragilis DS-208	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.329 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides fragilis HMW610	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.467 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides fragilis HMW615	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.69 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides fragilis ATCC43859	Bisacodyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.127 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides caccae ATCC43185	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.295 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Escherichia coli BW25113	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.788 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Clostridium ramosum DSM1402	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.796 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bifidobacterium adolescentis ATCC 15703	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.658 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides eggerthii DSM20697	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.571 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Blautia hansenii DSM20583	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.068 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Clostridium sp.	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.955 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Ruminococcus gnavus ATCC29149	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.441 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides dorei DSM17855	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.52 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides cellulosilyticus DSM14838	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.869 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.412 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Collinsella aerofaciens ATCC25986	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.969 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Clostridium hathewayi DSM13479	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.142 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Anaerococcus hydrogenalis DSM7454	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.785 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Clostridium scindens ATCC35704	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.529 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Anaerotruncus colihominis DSM17241	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.376 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Clostridium bolteae ATCCBAA-613	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.657 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Clostridium symbiosum ATCC14940	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.488 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides finegoldii DSM17565	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.949 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.2 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Anaerostipes sp.	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.127 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Eubacterium ventriosum ATCC27560	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.673 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Ruminococcus lactaris ATCC29176	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.432 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Proteus penneri ATCC35198	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.41 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Edwardsiella tarda ATCC23685	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.326 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Dorea formicigenerans ATCC27755	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.147 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Enterobacter cancerogenus ATCC35316	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.965 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Providencia stuartii ATCC25827	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.968 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Clostridium spiroforme DSM1552	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.823 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides intestinalis DSM17393	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.304 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.47 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides pectinophilus ATCC43243	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.907 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Pretovella copri DSM18205	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.297 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Clostridium asparagiforme DSM15981	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.973 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bifidobacterium breve DSM20213	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.704 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Coprococcus comes ATCC27758	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.711 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Eubacterium hallii DSM3353	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.726 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bifidobacterium longum subsp. Infantis CCUG52486	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.622 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Ruminococcus torques ATCC27756	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.618 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.254 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.301 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Lactobacillus reuteri CF48-3A BEI HM-102	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.758 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides uniformis ATCC8492	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.454 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides stercoris ATCC43183	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.289 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bifidobacterium ruminatum	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.754 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Akkermansia muciniphila ATCC BAA-835	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.645 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Providencia alcalifaciens DSM30120	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.417 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Providencia rettgeri DSM1131	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.376 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Collinsella intestinalis DSM13280	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.877 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Blautia luti DSM14534	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.918 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Roseburia intestinalis L1-82	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.905 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Odoribacter splanchnius	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.588 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides ovatus ATCC8483	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.235 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Parabacteroides merdae ATCC43184	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.155 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides coprophilus DSM18228	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.954 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides WH2 WH2	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.768 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Eubacterium rectale ATCC33656	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.734 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Subdoligranulum variabile DSM15176	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.71 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Clostridium sporogenes ATCC15579	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.074 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Enterococcus faecalis V583	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.528 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bryantia formatexigens DSM 14469	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.385 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Alistipes indistinctus DSM 22520	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.445 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Eubacterium biforme DSM3989	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.393 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Clostridium difficile 120	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.216 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.383 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.233 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.234 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides fragilis 3397 T10	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.345 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Salmonella typhimurium LT2	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.025 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Eggerthella lenta ATCC25559	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.014 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Victivallis vadensis ATCC BAA-548	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.95 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides fragilis T(B)9	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.492 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides fragilis DS-208	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.196 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides fragilis HMW610	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.862 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides fragilis HMW615	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.808 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Bacteroides fragilis ATCC43859	Melphalan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.753 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides caccae ATCC43185	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.773 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Escherichia coli BW25113	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.945 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Clostridium ramosum DSM1402	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.55 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bifidobacterium adolescentis ATCC 15703	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.373 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides eggerthii DSM20697	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.959 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Blautia hansenii DSM20583	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.119 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Clostridium sp.	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.079 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Ruminococcus gnavus ATCC29149	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.484 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides dorei DSM17855	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.711 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides cellulosilyticus DSM14838	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.503 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.705 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Collinsella aerofaciens ATCC25986	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.12 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Clostridium hathewayi DSM13479	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.579 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Anaerococcus hydrogenalis DSM7454	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.747 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Clostridium scindens ATCC35704	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.42 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Anaerotruncus colihominis DSM17241	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.17 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Clostridium bolteae ATCCBAA-613	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.643 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Clostridium symbiosum ATCC14940	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.399 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides finegoldii DSM17565	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.707 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.462 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Anaerostipes sp.	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.543 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Eubacterium ventriosum ATCC27560	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.097 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Ruminococcus lactaris ATCC29176	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.181 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Proteus penneri ATCC35198	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.443 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Edwardsiella tarda ATCC23685	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.542 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Dorea formicigenerans ATCC27755	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.027 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Enterobacter cancerogenus ATCC35316	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.617 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Providencia stuartii ATCC25827	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.09 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Clostridium spiroforme DSM1552	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.853 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides intestinalis DSM17393	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.116 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.99 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides pectinophilus ATCC43243	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.76 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Pretovella copri DSM18205	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.312 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Clostridium asparagiforme DSM15981	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.948 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Bifidobacterium breve DSM20213	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.484 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Coprococcus comes ATCC27758	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.892 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Eubacterium hallii DSM3353	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.732 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bifidobacterium longum subsp. Infantis CCUG52486	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.468 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Ruminococcus torques ATCC27756	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.958 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.307 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.779 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Lactobacillus reuteri CF48-3A BEI HM-102	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.879 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides uniformis ATCC8492	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.232 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bacteroides stercoris ATCC43183	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.417 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bifidobacterium ruminatum	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.706 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Akkermansia muciniphila ATCC BAA-835	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.859 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Providencia alcalifaciens DSM30120	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.112 [FDR-adjusted p-Value=0.04]	PMID: 31158845
Providencia rettgeri DSM1131	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.788 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Collinsella intestinalis DSM13280	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.406 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Blautia luti DSM14534	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.642 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Roseburia intestinalis L1-82	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.147 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Odoribacter splanchnius	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.449 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides ovatus ATCC8483	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.952 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Parabacteroides merdae ATCC43184	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.709 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bacteroides coprophilus DSM18228	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.73 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides WH2 WH2	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.928 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Eubacterium rectale ATCC33656	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.421 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Subdoligranulum variabile DSM15176	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.337 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Clostridium sporogenes ATCC15579	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.252 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Enterococcus faecalis V583	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.065 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bryantia formatexigens DSM 14469	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.043 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Alistipes indistinctus DSM 22520	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.689 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Eubacterium biforme DSM3989	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.387 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Clostridium difficile 120	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.87 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.729 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.835 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.624 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides fragilis 3397 T10	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.695 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Salmonella typhimurium LT2	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.086 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Eggerthella lenta ATCC25559	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.188 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Victivallis vadensis ATCC BAA-548	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.887 [FDR-adjusted p-Value=0.024]	PMID: 31158845
Bacteroides fragilis T(B)9	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.069 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides fragilis DS-208	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.966 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bacteroides fragilis HMW610	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.267 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides fragilis HMW615	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.621 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides fragilis ATCC43859	Pantoprazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.158 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Gordonibacter urolithinfaciens sp. nov	Pedunculagin	Herbal Substance	Medicinal Herbal Compounds	n.a.	Ellagic acid; urolithin A, B, C and D	n.a.	n.a.	n.a.	n.a.	n.a.	DOI: 10.1016/j.foodres.2011.04.027; PMID: 24744017
Chaetomium spp.	Baicalin	Herbal Substance	Medicinal Herbal Compounds	n.a.	4’,5,6,7-tetrahydroxyflavone; 5,7-dihydroxy-6-methoxxyflavone	n.a.	n.a.	n.a.	n.a.	n.a.	; DOI: 10.1016/j.molcatb.2007.08.009
Bacteroides fragilis subspp. Thetaotus	Shikonin	Herbal Substance	Medicinal Herbal Compounds	n.a.	Anhydroalkannin; deoxyshikonin; cycloshikonin; metaboshikonin I; metaboshikonin II; shikometabolins A; B, C, D and E	n.a.	n.a.	n.a.	n.a.	n.a.	; DOI: 10.1016/S0040-4020(01)81108-X
Bacteroides thetaiotaomicron	Pectin	Herbal Substance	Medicinal Herbal Compounds	n.a.	Nogalacturonic acid; SCFAs	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 10742206
Eubacterium spp. SDG-2	Secoisolariciresinol diglucoside	Herbal Substance	Medicinal Herbal Compounds	n.a.	(-)-secoisolariciresinol; 3-demethyl-(-)-secoisolariciresinol; 2-(3-hydroxybenzyl)-3-(4-hydroxy-3-methoxybenzyl)butane-1; 4-diol; didemethylsecoisolariciresinol	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 11086885
Peptostreptococcus spp. SDG-1	Secoisolariciresinol diglucoside	Herbal Substance	Medicinal Herbal Compounds	n.a.	(-)-secoisolariciresinol; 3-demethyl-(-)-secoisolariciresinol; 2-(3-hydroxybenzyl)-3-(4-hydroxy-3-methoxybenzyl)butane-1; 4-diol; didemethylsecoisolariciresinol	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 11086885
Eubacterium spp. SDG-2	Caffeic acid	Herbal Substance	Medicinal Herbal Compounds	n.a.	Dihydrocaffeic acid; m-hydroxyphenylpropionic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 11767089
Bacteroides spp.	Ginsenoside Rg3	Herbal Substance	Medicinal Herbal Compounds	n.a.	20(S)-ginsenoside Rh2; 20(S)-protopanaxadiol; 20(R)-ginsenoside Rh2; 20(R)-protopanaxadiol	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 11824558
Bifidobacterium spp.	Ginsenoside Rg3	Herbal Substance	Medicinal Herbal Compounds	n.a.	20(S)-ginsenoside Rh2; 20(S)-protopanaxadiol; 20(R)-ginsenoside Rh2; 20(R)-protopanaxadiol	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 11824558
Eubacterium spp.	Ginsenoside Rg3	Herbal Substance	Medicinal Herbal Compounds	n.a.	20(S)-ginsenoside Rh2; 20(S)-protopanaxadiol; 20(R)-ginsenoside Rh2; 20(R)-protopanaxadiol	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 11824558
Clostridium butyricum	Phorbol	Herbal Substance	Medicinal Herbal Compounds	n.a.	Isophorbol; deoxyphorbol; 4β,9α,20-trihydroxy-13,15-seco-1,6,15-tigliatriene-3,13-dione; 4β,9a,20-trihydroxy-15,16,17-trinor-1,6-tigliadiene-3,13-dione; 4β,9a,20-trihydroxy-14(13→12)-abeo12aH-1,6-tigliadiene-3,13-dione	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 11848202
Bifidobacterium adolescentis	Phorbol	Herbal Substance	Medicinal Herbal Compounds	n.a.	Isophorbol; deoxyphorbol; 4β,9α,20-trihydroxy-13,15-seco-1,6,15-tigliatriene-3,13-dione; 4β,9a,20-trihydroxy-15,16,17-trinor-1,6-tigliadiene-3,13-dione; 4β,9a,20-trihydroxy-14(13→12)-abeo12aH-1,6-tigliadiene-3,13-dione	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 11848202
Bacteroides fragilis subspp. Thetaotus	Phorbol	Herbal Substance	Medicinal Herbal Compounds	n.a.	Isophorbol; deoxyphorbol; 4β,9α,20-trihydroxy-13,15-seco-1,6,15-tigliatriene-3,13-dione; 4β,9a,20-trihydroxy-15,16,17-trinor-1,6-tigliadiene-3,13-dione; 4β,9a,20-trihydroxy-14(13→12)-abeo12aH-1,6-tigliadiene-3,13-dione	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 11848202
Clostridium innocuum ES 24-06	Phorbol	Herbal Substance	Medicinal Herbal Compounds	n.a.	Isophorbol; deoxyphorbol; 4β,9α,20-trihydroxy-13,15-seco-1,6,15-tigliatriene-3,13-dione; 4β,9a,20-trihydroxy-15,16,17-trinor-1,6-tigliadiene-3,13-dione; 4β,9a,20-trihydroxy-14(13→12)-abeo12aH-1,6-tigliadiene-3,13-dione	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 11848202
Fusobacterium nucleatum G-470	Phorbol	Herbal Substance	Medicinal Herbal Compounds	n.a.	Isophorbol; deoxyphorbol; 4β,9α,20-trihydroxy-13,15-seco-1,6,15-tigliatriene-3,13-dione; 4β,9a,20-trihydroxy-15,16,17-trinor-1,6-tigliadiene-3,13-dione; 4β,9a,20-trihydroxy-14(13→12)-abeo12aH-1,6-tigliadiene-3,13-dione	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 11848202
Peptostreptococcus anaerobius 0240	Phorbol	Herbal Substance	Medicinal Herbal Compounds	n.a.	Isophorbol; deoxyphorbol; 4β,9α,20-trihydroxy-13,15-seco-1,6,15-tigliatriene-3,13-dione; 4β,9a,20-trihydroxy-15,16,17-trinor-1,6-tigliadiene-3,13-dione; 4β,9a,20-trihydroxy-14(13→12)-abeo12aH-1,6-tigliadiene-3,13-dione	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 11848202
Peptostreptococcus intermedius EBF 77/25	Phorbol	Herbal Substance	Medicinal Herbal Compounds	n.a.	Isophorbol; deoxyphorbol; 4β,9α,20-trihydroxy-13,15-seco-1,6,15-tigliatriene-3,13-dione; 4β,9a,20-trihydroxy-15,16,17-trinor-1,6-tigliadiene-3,13-dione; 4β,9a,20-trihydroxy-14(13→12)-abeo12aH-1,6-tigliadiene-3,13-dione	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 11848202
Proteus mirabillis S2	Phorbol	Herbal Substance	Medicinal Herbal Compounds	n.a.	Isophorbol; deoxyphorbol; 4β,9α,20-trihydroxy-13,15-seco-1,6,15-tigliatriene-3,13-dione; 4β,9a,20-trihydroxy-15,16,17-trinor-1,6-tigliadiene-3,13-dione; 4β,9a,20-trihydroxy-14(13→12)-abeo12aH-1,6-tigliadiene-3,13-dione	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 11848202
Ruminococcus spp. P01-3	Phorbol	Herbal Substance	Medicinal Herbal Compounds	n.a.	Isophorbol; deoxyphorbol; 4β,9α,20-trihydroxy-13,15-seco-1,6,15-tigliatriene-3,13-dione; 4β,9a,20-trihydroxy-15,16,17-trinor-1,6-tigliadiene-3,13-dione; 4β,9a,20-trihydroxy-14(13→12)-abeo12aH-1,6-tigliadiene-3,13-dione	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 11848202
Butyrivibrio fibrisolvens	Linoleic acid	Herbal Substance	Medicinal Herbal Compounds	n.a.	Rumenic acid (RA; cis-9, trans-11-18:2), trans-9, trans-11-18:2, and trans-10, cis-12-18:2	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 17644775
Butyrivibrio proteoclasticus	Linoleic acid	Herbal Substance	Medicinal Herbal Compounds	n.a.	Rumenic acid (RA; cis-9, trans-11-18:2), trans-9, trans-11-18:2, and trans-10, cis-12-18:2	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 17644775
Bacteroides intestinalis AM-1	Chenodeoxycholic acid	Herbal Substance	Medicinal Herbal Compounds	n.a.	7-oxo-lithocholic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 19243441
Bacteroides intestinalis AM-1	Cholic acid	Herbal Substance	Medicinal Herbal Compounds	n.a.	7-oxo-deoxycholic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 19243441
Eggerthella sp. Julong732	Dihydrodaidzein	Herbal Substance	Medicinal Herbal Compounds	n.a.	(3S)-equol	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 19304836
Bacteroides fragilis	Geniposide	Herbal Substance	Medicinal Herbal Compounds	n.a.	Genipin	Increase Toxicity	n.a.	n.a.	n.a.	n.a.	PMID: 22553067
Bifidobacterium longum HY8001	Geniposide	Herbal Substance	Medicinal Herbal Compounds	n.a.	Genipin	Increase Toxicity	n.a.	n.a.	n.a.	n.a.	PMID: 22553067
Enterobacter cloacae	Berberine	Herbal Substance	Medicinal Herbal Compounds	n.a.	Dihydroberberine	Increase Bioavailability	n.a.	n.a.	n.a.	n.a.	PMID: 26174047
Escherichia coli	Berberine	Herbal Substance	Medicinal Herbal Compounds	n.a.	Dihydroberberine	Increase Bioavailability	n.a.	n.a.	n.a.	n.a.	PMID: 26174047
Staphylococcus aureus	Berberine	Herbal Substance	Medicinal Herbal Compounds	n.a.	Dihydroberberine	Increase Bioavailability	n.a.	n.a.	n.a.	n.a.	PMID: 26174047
Enterococcus faecalis	Berberine	Herbal Substance	Medicinal Herbal Compounds	n.a.	Dihydroberberine	Increase Bioavailability	n.a.	n.a.	n.a.	n.a.	PMID: 26174047
Enterococcus faecium	Berberine	Herbal Substance	Medicinal Herbal Compounds	n.a.	Dihydroberberine	Increase Bioavailability	n.a.	n.a.	n.a.	n.a.	PMID: 26174047
Bacteroides JY-6	Ginsenoside Rb1	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	ginsenoside compound K	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Bifidobacterium longum H-1	Ginsenoside Rb1	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	ginsenoside compound K	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Bifidobacterium breve K-110	Ginsenoside Rb1	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	ginsenoside compound K	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Bifidobacterium K-506	Ginsenoside Rb1	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	ginsenoside compound K	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Eubacterium A-44	Ginsenoside Rb1	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	ginsenoside compound K	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Fusobacterium K-60	Ginsenoside Rb1	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	ginsenoside compound K	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Prevotella oris	Ginsenoside Rb1	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	ginsenoside compound K	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Bacteroides JY-6	Ginsenoside Rb2	Herbal Substance	Medicinal Herbal Compounds	n.a.	ginsenoside compound K	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Bifidobacterium longum H-1	Ginsenoside Rb2	Herbal Substance	Medicinal Herbal Compounds	n.a.	ginsenoside compound K	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Bifidobacterium breve K-110	Ginsenoside Rb2	Herbal Substance	Medicinal Herbal Compounds	n.a.	ginsenoside compound K	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Bifidobacterium K-506	Ginsenoside Rb2	Herbal Substance	Medicinal Herbal Compounds	n.a.	ginsenoside compound K	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Eubacterium A-44	Ginsenoside Rb2	Herbal Substance	Medicinal Herbal Compounds	n.a.	ginsenoside compound K	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Fusobacterium K-60	Ginsenoside Rb2	Herbal Substance	Medicinal Herbal Compounds	n.a.	ginsenoside compound K	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Prevotella oris	Ginsenoside Rb2	Herbal Substance	Medicinal Herbal Compounds	n.a.	ginsenoside compound K	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Bacteroides JY-6	Ginsenoside Rc	Herbal Substance	Medicinal Herbal Compounds	n.a.	ginsenoside compound K	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Bifidobacterium longum H-1	Ginsenoside Rc	Herbal Substance	Medicinal Herbal Compounds	n.a.	ginsenoside compound K	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Bifidobacterium breve K-110	Ginsenoside Rc	Herbal Substance	Medicinal Herbal Compounds	n.a.	ginsenoside compound K	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Bifidobacterium K-506	Ginsenoside Rc	Herbal Substance	Medicinal Herbal Compounds	n.a.	ginsenoside compound K	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Eubacterium A-44	Ginsenoside Rc	Herbal Substance	Medicinal Herbal Compounds	n.a.	ginsenoside compound K	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Fusobacterium K-60	Ginsenoside Rc	Herbal Substance	Medicinal Herbal Compounds	n.a.	ginsenoside compound K	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Prevotella oris	Ginsenoside Rc	Herbal Substance	Medicinal Herbal Compounds	n.a.	ginsenoside compound K	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Bacteroides JY-6	Ginsenoside Re	Herbal Substance	Medicinal Herbal Compounds	n.a.	protopanaxatriol; ginsenoside F1; ginsenoside Rh1	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Bacteroides stercoris HJ-15	Ginsenoside Re	Herbal Substance	Medicinal Herbal Compounds	n.a.	protopanaxatriol; ginsenoside F1; ginsenoside Rh1	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Eubacterium A-44	Ginsenoside Re	Herbal Substance	Medicinal Herbal Compounds	n.a.	protopanaxatriol; ginsenoside F1; ginsenoside Rh1	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Fusobacterium K-60	Ginsenoside Re	Herbal Substance	Medicinal Herbal Compounds	n.a.	protopanaxatriol; ginsenoside F1; ginsenoside Rh1	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Bacteroides JY-6	Ginsenoside Rf	Herbal Substance	Medicinal Herbal Compounds	n.a.	protopanaxatriol; ginsenoside F1; ginsenoside Rh1	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Bacteroides stercoris HJ-15	Ginsenoside Rf	Herbal Substance	Medicinal Herbal Compounds	n.a.	protopanaxatriol; ginsenoside F1; ginsenoside Rh1	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Eubacterium A-44	Ginsenoside Rf	Herbal Substance	Medicinal Herbal Compounds	n.a.	protopanaxatriol; ginsenoside F1; ginsenoside Rh1	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Fusobacterium K-60	Ginsenoside Rf	Herbal Substance	Medicinal Herbal Compounds	n.a.	protopanaxatriol; ginsenoside F1; ginsenoside Rh1	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Bacteroides JY-6	Ginsenoside Rg1	Herbal Substance	Medicinal Herbal Compounds	n.a.	protopanaxatriol; ginsenoside F1; ginsenoside Rh1	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Bacteroides stercoris HJ-15	Ginsenoside Rg1	Herbal Substance	Medicinal Herbal Compounds	n.a.	protopanaxatriol; ginsenoside F1; ginsenoside Rh1	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Eubacterium A-44	Ginsenoside Rg1	Herbal Substance	Medicinal Herbal Compounds	n.a.	protopanaxatriol; ginsenoside F1; ginsenoside Rh1	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Fusobacterium K-60	Ginsenoside Rg1	Herbal Substance	Medicinal Herbal Compounds	n.a.	protopanaxatriol; ginsenoside F1; ginsenoside Rh1	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Bacteroides JY-6	Ginsenoside Rg3	Herbal Substance	Medicinal Herbal Compounds	n.a.	ginsenoside Rh2	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Bifidobacterium longum H-1	Ginsenoside Rg3	Herbal Substance	Medicinal Herbal Compounds	n.a.	ginsenoside Rh2	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Bifidobacterium breve K-110	Ginsenoside Rg3	Herbal Substance	Medicinal Herbal Compounds	n.a.	ginsenoside Rh2	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Bifidobacterium K-506	Ginsenoside Rg3	Herbal Substance	Medicinal Herbal Compounds	n.a.	ginsenoside Rh2	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Eubacterium A-44	Ginsenoside Rg3	Herbal Substance	Medicinal Herbal Compounds	n.a.	ginsenoside Rh2	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Fusobacterium K-60	Ginsenoside Rg3	Herbal Substance	Medicinal Herbal Compounds	n.a.	ginsenoside Rh2	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Prevotella oris	Ginsenoside Rg3	Herbal Substance	Medicinal Herbal Compounds	n.a.	ginsenoside Rh2	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Bacteroides JY-6	Ginsenoside Rg5	Herbal Substance	Medicinal Herbal Compounds	n.a.	ginsenoside Rh3	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Bifidobacterium longum H-1	Ginsenoside Rg5	Herbal Substance	Medicinal Herbal Compounds	n.a.	ginsenoside Rh3	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Bifidobacterium breve K-110	Ginsenoside Rg5	Herbal Substance	Medicinal Herbal Compounds	n.a.	ginsenoside Rh3	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Bifidobacterium K-506	Ginsenoside Rg5	Herbal Substance	Medicinal Herbal Compounds	n.a.	ginsenoside Rh3	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Eubacterium A-44	Ginsenoside Rg5	Herbal Substance	Medicinal Herbal Compounds	n.a.	ginsenoside Rh3	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Fusobacterium K-60	Ginsenoside Rg5	Herbal Substance	Medicinal Herbal Compounds	n.a.	ginsenoside Rh3	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Prevotella oris	Ginsenoside Rg5	Herbal Substance	Medicinal Herbal Compounds	n.a.	ginsenoside Rh3	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Bacteroides spp.	Ginsenosides	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Lactobacillus spp.	Ginsenosides	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 29983606
Lacrimispora sphenoides	Sennoside A	Herbal Substance	Medicinal Herbal Compounds	n.a.	8-glucosylrheinanthrone; rheinanthrone; sennidin	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 3368516
[Eubacterium] rectale	Sennoside A	Herbal Substance	Medicinal Herbal Compounds	n.a.	8-glucosylrheinanthrone; rheinanthrone; sennidin	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 3368516
Eubacterium spp.	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Dihydrodigoxin	Decrease Toxicity	n.a.	n.a.	n.a.	n.a.	PMID: 7266632
Streptococcus S-2	Rutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Quercetin; 4-hydroxybenzoic acid; 3,4-dDihydroxybenzoic acid; 3,4-dihydroxyphenylacetic acid	Increase Bioavailability	n.a.	n.a.	n.a.	n.a.	PMID: 9875509
Bacteroides J-37	Daidzin	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	Daidzein; 2,4-dihydroxyacetophenone; 4-hydroxybenzoic acid; resorcinol; 4-hydroxyphenylacetic acid; 2,4-dihydroxybenzoic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 9875509
Eubacterium A-44	Daidzin	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	Daidzein; 2,4-dihydroxyacetophenone; 4-hydroxybenzoic acid; resorcinol; 4-hydroxyphenylacetic acid; 2,4-dihydroxybenzoic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 9875509
Fusobacterium K-60	Daidzin	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	Daidzein; 2,4-dihydroxyacetophenone; 4-hydroxybenzoic acid; resorcinol; 4-hydroxyphenylacetic acid; 2,4-dihydroxybenzoic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 9875509
Bacteroides JY-6	Naringin	Herbal Substance	Medicinal Herbal Compounds	n.a.	Naringenin; 4-hydroxybenzoic acid; phloroglucinol; 2,4,6-trihydroxybenzoic acid; 4-hydroxyphenylacetic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 9875509
Eubacterium YK-4	Naringin	Herbal Substance	Medicinal Herbal Compounds	n.a.	Naringenin; 4-hydroxybenzoic acid; phloroglucinol; 2,4,6-trihydroxybenzoic acid; 4-hydroxyphenylacetic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 9875509
Feptostreptoccous YK-10	Naringin	Herbal Substance	Medicinal Herbal Compounds	n.a.	Naringenin; 4-hydroxybenzoic acid; phloroglucinol; 2,4,6-trihydroxybenzoic acid; 4-hydroxyphenylacetic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 9875509
Fusobacterium K-60	Naringin	Herbal Substance	Medicinal Herbal Compounds	n.a.	Naringenin; 4-hydroxybenzoic acid; phloroglucinol; 2,4,6-trihydroxybenzoic acid; 4-hydroxyphenylacetic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 9875509
Lactobacillus L-2	Naringin	Herbal Substance	Medicinal Herbal Compounds	n.a.	Naringenin; 4-hydroxybenzoic acid; phloroglucinol; 2,4,6-trihydroxybenzoic acid; 4-hydroxyphenylacetic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 9875509
Streptococcus S-2	Naringin	Herbal Substance	Medicinal Herbal Compounds	n.a.	Naringenin; 4-hydroxybenzoic acid; phloroglucinol; 2,4,6-trihydroxybenzoic acid; 4-hydroxyphenylacetic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 9875509
Bacteroides JY-6	Rutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Quercetin; 4-hydroxybenzoic acid; 3,4-dDihydroxybenzoic acid; 3,4-dihydroxyphenylacetic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 9875509
Bifidobacterium B-9	Rutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Quercetin; 4-hydroxybenzoic acid; 3,4-dDihydroxybenzoic acid; 3,4-dihydroxyphenylacetic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 9875509
Eubacterium YK-4	Rutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Quercetin; 4-hydroxybenzoic acid; 3,4-dDihydroxybenzoic acid; 3,4-dihydroxyphenylacetic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 9875509
Fusobacterium K-60	Rutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Quercetin; 4-hydroxybenzoic acid; 3,4-dDihydroxybenzoic acid; 3,4-dihydroxyphenylacetic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 9875509
Lactobacillus L-2	Rutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Quercetin; 4-hydroxybenzoic acid; 3,4-dDihydroxybenzoic acid; 3,4-dihydroxyphenylacetic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 9875509

Active Substances Alteration of Microbes

✅ Active substances (drugs, traditional medicines/herbs, bioactive compounds, environmental chemicals) that affect microbes

Microbe Name	Substance Name	Substance Category	Substance Subcategory	Substance Details	Effects on Microbe	Effect Strength	Experimental Organism	Experimental Disease Condition	References
Escherichia coli	Acacia catechu	Herbal Substance	Medicinal Herb	epicatechin- and catechins-rich extract	Decrease	n.a.	n.a.	n.a.	PMID: 28422543
Salmonella spp.	Acacia catechu	Herbal Substance	Medicinal Herb	epicatechin- and catechins-rich extract	Decrease	n.a.	n.a.	n.a.	PMID: 28422543
Bifidobacterium	Aloe vera	Herbal Substance	Medicinal Herb	Aloe vera mucilage	n.a.	n.a.	n.a.	n.a.	PMID: 25504136
Atopobium spp.	Aloe vera	Herbal Substance	Medicinal Herb	Aloe vera mucilage	n.a.	n.a.	n.a.	n.a.	PMID: 25504136
Blautia spp.	AMC formula	Herbal Substance	TCM Formula	n.a.	Increase	n.a.	Human clinical trial	T2DM with hyperlipidemia	PMID: 29789365
Faecalibacterium spp.	AMC formula	Herbal Substance	TCM Formula	n.a.	Increase	n.a.	Human clinical trial	T2DM with hyperlipidemia	PMID: 29789365
Akkermansia muciniphila	Antrodia cinnamomea	Herbal Substance	Medicinal Herb	water extract	Increase	n.a.	C57BL/6J mice	Obesity	PMID: 28630461
Bacteroidetes	Bawei Xileisan	Herbal Substance	TCM Formula	n.a.	Increase	n.a.	n.a.	Ulcerative colitis	DOI: 10.1016/j.eng.2018.11.013
Lactobacillus	Bawei Xileisan	Herbal Substance	TCM Formula	n.a.	Increase	n.a.	n.a.	Ulcerative colitis	DOI: 10.1016/j.eng.2018.11.013
Akkermansia	Camellia sinensis	Herbal Substance	Medicinal Herb	catechin-rich extract	Increase	n.a.	Mice	n.a.	PMID: 30856467
Bifidobacterium	Camellia sinensis	Herbal Substance	Medicinal Herb	catechin-rich extract	Increase	n.a.	Mice	n.a.	PMID: 30856467
Dorea	Camellia sinensis	Herbal Substance	Medicinal Herb	catechin-rich extract	Increase	n.a.	Mice	n.a.	PMID: 30856467
Lactobacillus	Camellia sinensis	Herbal Substance	Medicinal Herb	catechin-rich extract	Increase	n.a.	Mice	n.a.	PMID: 30856467
Oscillospira	Camellia sinensis	Herbal Substance	Medicinal Herb	catechin-rich extract	Increase	n.a.	Mice	n.a.	PMID: 30856467
Alistipes	Cichorium intybus	Herbal Substance	Medicinal Herb	Roots	Decrease	Significantly	In vivo	n.a.	PMID: 31408679
Alloprevotella	Cichorium intybus	Herbal Substance	Medicinal Herb	Roots	Increase	Significantly	In vivo	n.a.	PMID: 31408679
Bacteroidetes	Cichorium intybus	Herbal Substance	Medicinal Herb	Roots	Increase	Significantly	In vivo	n.a.	PMID: 31408679
Blautia	Cichorium intybus	Herbal Substance	Medicinal Herb	Roots	Decrease	Significantly	In vivo	n.a.	PMID: 31408679
Firmicutes	Cichorium intybus	Herbal Substance	Medicinal Herb	Roots	Decrease	Significantly	In vivo	n.a.	PMID: 31408679
Oscillibacter	Cichorium intybus	Herbal Substance	Medicinal Herb	Roots	Decrease	Significantly	In vivo	n.a.	PMID: 31408679
Bacteroidales unclassified	Cichorium intybus	Herbal Substance	Medicinal Herb	Roots	Increase	Significantly	In vivo	n.a.	PMID: 31408679
Clostridiales unclassified	Cichorium intybus	Herbal Substance	Medicinal Herb	Roots	Decrease	Significantly	In vivo	n.a.	PMID: 31408679
Lachnospiraceae unclassified	Cichorium intybus	Herbal Substance	Medicinal Herb	Roots	Decrease	Significantly	In vivo	n.a.	PMID: 31408679
Ruminococcaceae unclassified	Cichorium intybus	Herbal Substance	Medicinal Herb	Roots	Decrease	Significantly	In vivo	n.a.	PMID: 31408679
Collinsella	Cichorium intybus	Herbal Substance	Medicinal Herb	Roots	Increase	Significantly	In vitro	n.a.	PMID: 31408679
Alistipes putredinis	Curcuma longa	Herbal Substance	Medicinal Herb	Roots	Increase	n.a.	Human	n.a.	PMID: 31408679
Eisenbergiella tayi	Curcuma longa	Herbal Substance	Medicinal Herb	Roots	Decrease	n.a.	Human	n.a.	PMID: 31408679
Anaerotruncus colihominis	Ganoderma lucidum	Herbal Substance	Medicinal Herb	n.a.	Increase	n.a.	n.a.	Obesity	DOI: 10.1016/j.eng.2018.11.013
Bacteroides spp.	Ganoderma lucidum	Herbal Substance	Medicinal Herb	n.a.	Increase	n.a.	n.a.	Obesity	DOI: 10.1016/j.eng.2018.11.013
Clostridium	Ganoderma lucidum	Herbal Substance	Medicinal Herb	n.a.	Increase	n.a.	n.a.	Obesity	DOI: 10.1016/j.eng.2018.11.013
Parabacteroides goldsteinii	Ganoderma lucidum	Herbal Substance	Medicinal Herb	n.a.	Increase	n.a.	n.a.	Obesity	DOI: 10.1016/j.eng.2018.11.013
Proteobacteria	Ganoderma lucidum	Herbal Substance	Medicinal Herb	n.a.	Decrease	n.a.	n.a.	Obesity	DOI: 10.1016/j.eng.2018.11.013
Roseburia hominis	Ganoderma lucidum	Herbal Substance	Medicinal Herb	n.a.	Increase	n.a.	n.a.	Obesity	DOI: 10.1016/j.eng.2018.11.013
Akkermansia	Gegen Qilian decoction	Herbal Substance	TCM Formula	n.a.	Increase	n.a.	Pig	Diarrhea	PMID: 31057525
Alistipes	Gegen Qilian decoction	Herbal Substance	TCM Formula	n.a.	Decrease	n.a.	Human (clinical trial)	T2DM	PMID: 25279787
Bacteroides	Gegen Qilian decoction	Herbal Substance	TCM Formula	n.a.	Decrease	n.a.	Human (clinical trial)	T2DM	PMID: 25279787
Bacteroides	Gegen Qilian decoction	Herbal Substance	TCM Formula	n.a.	Increase	n.a.	Pig	Diarrhea	PMID: 31057525
Bifidobacterium	Gegen Qilian decoction	Herbal Substance	TCM Formula	n.a.	Increase	n.a.	Human (clinical trial)	T2DM	PMID: 25279787
Clostridium	Gegen Qilian decoction	Herbal Substance	TCM Formula	n.a.	Increase	n.a.	Pig	Diarrhea	PMID: 31057525
Escherichia	Gegen Qilian decoction	Herbal Substance	TCM Formula	n.a.	Increase	n.a.	Human (clinical trial)	T2DM	PMID: 25279787
Faecalibacterium	Gegen Qilian decoction	Herbal Substance	TCM Formula	n.a.	Increase	n.a.	Human (clinical trial)	T2DM	PMID: 25279787
Faecalibacterium prausnitzii	Gegen Qilian decoction	Herbal Substance	TCM Formula	n.a.	Increase	n.a.	Human (clinical trial)	T2DM	PMID: 25279787
Gemmiger	Gegen Qilian decoction	Herbal Substance	TCM Formula	n.a.	Increase	n.a.	Human (clinical trial)	T2DM	PMID: 25279787
Odoribacter	Gegen Qilian decoction	Herbal Substance	TCM Formula	n.a.	Decrease	n.a.	Human (clinical trial)	T2DM	PMID: 25279787
Parabacteroides	Gegen Qilian decoction	Herbal Substance	TCM Formula	n.a.	Decrease	n.a.	Human (clinical trial)	T2DM	PMID: 25279787
Phascolarctobacterium	Gegen Qilian decoction	Herbal Substance	TCM Formula	n.a.	Increase	n.a.	Pig	Diarrhea	PMID: 31057525
Pseudobutyrivibrio	Gegen Qilian decoction	Herbal Substance	TCM Formula	n.a.	Decrease	n.a.	Human (clinical trial)	T2DM	PMID: 25279787
Ruminococcus	Gegen Qilian decoction	Herbal Substance	TCM Formula	n.a.	Increase	n.a.	Pig	Diarrhea	PMID: 31057525
Lachnospiraceae incertae sedis	Gegen Qilian decoction	Herbal Substance	TCM Formula	n.a.	Increase	n.a.	Human (clinical trial)	T2DM	PMID: 25279787
Bacteroides	Glycyrrhiza glabra	Herbal Substance	Medicinal Herb	Roots	Increase	10-85 fold	In vitro	n.a.	PMID: 31408679
Bifidobacterium	Glycyrrhiza glabra	Herbal Substance	Medicinal Herb	Roots	Increase	10-85 fold	In vitro	n.a.	PMID: 31408679
Cloacibacillus	Glycyrrhiza glabra	Herbal Substance	Medicinal Herb	Roots	Increase	10-85 fold	In vitro	n.a.	PMID: 31408679
Desulfovibrio	Glycyrrhiza glabra	Herbal Substance	Medicinal Herb	Roots	Increase	10-85 fold	In vitro	n.a.	PMID: 31408679
Enterococcus faecalis	Glycyrrhiza glabra	Herbal Substance	Medicinal Herb	Roots	Decrease	n.a.	In vitro	n.a.	PMID: 31408679
Gemmiger	Glycyrrhiza glabra	Herbal Substance	Medicinal Herb	Roots	Increase	10-85 fold	In vitro	n.a.	PMID: 31408679
Klebsiella pneumoniae	Glycyrrhiza glabra	Herbal Substance	Medicinal Herb	Roots	Decrease	n.a.	In vitro	n.a.	PMID: 31408679
Parasutterella	Glycyrrhiza glabra	Herbal Substance	Medicinal Herb	Roots	Increase	10-85 fold	In vitro	n.a.	PMID: 31408679
Roseburia	Glycyrrhiza glabra	Herbal Substance	Medicinal Herb	Roots	Increase	10-85 fold	In vitro	n.a.	PMID: 31408679
Sutterella	Glycyrrhiza glabra	Herbal Substance	Medicinal Herb	Roots	Increase	> 150 fold	In vitro	n.a.	PMID: 31408679
Eubacterium spp.	Glycyrrhiza glabra	Herbal Substance	Medicinal Herb	Roots	Decrease	n.a.	In vitro	n.a.	PMID: 31408679
Phascolarctobacter	Glycyrrhiza glabra	Herbal Substance	Medicinal Herb	Roots	Increase	> 150 fold	In vitro	n.a.	PMID: 31408679
Mucispirillum	Glycyrrhiza uralensis	Herbal Substance	Medicinal Herb	Roots	Decrease	Significantly	In vivo	n.a.	PMID: 31408679
Roseburia	Glycyrrhiza uralensis	Herbal Substance	Medicinal Herb	Roots	Increase	Significantly	In vivo	n.a.	PMID: 31408679
Akkermansia muciniphila	Linum usitatissimum	Herbal Substance	Medicinal Herb	Seeds	Decrease	Significantly	In vivo	n.a.	PMID: 31408679
Bacteroides caccae	Linum usitatissimum	Herbal Substance	Medicinal Herb	Seeds	Increase	Significantly	In vivo	n.a.	PMID: 31408679
Bacteroides uniformis	Linum usitatissimum	Herbal Substance	Medicinal Herb	Seeds	Increase	Significantly	In vivo	n.a.	PMID: 31408679
Clostridiales	Linum usitatissimum	Herbal Substance	Medicinal Herb	Seeds	Increase	Significantly	In vivo	n.a.	PMID: 31408679
Firmicutes	Linum usitatissimum	Herbal Substance	Medicinal Herb	Seeds	Increase	Significantly	In vivo	n.a.	PMID: 31408679
Parabacteroides distasonis	Linum usitatissimum	Herbal Substance	Medicinal Herb	Seeds	Decrease	Significantly	In vivo	n.a.	PMID: 31408679
Peptostreptococcaceae	Linum usitatissimum	Herbal Substance	Medicinal Herb	Seeds	Decrease	Significantly	In vivo	n.a.	PMID: 31408679
Porphyromonadaceae	Linum usitatissimum	Herbal Substance	Medicinal Herb	Seeds	Decrease	Significantly	In vivo	n.a.	PMID: 31408679
Prevotellaceae	Linum usitatissimum	Herbal Substance	Medicinal Herb	Seeds	Increase	Significantly	In vivo	n.a.	PMID: 31408679
Rikenellaceae	Linum usitatissimum	Herbal Substance	Medicinal Herb	Seeds	Decrease	Significantly	In vivo	n.a.	PMID: 31408679
[Ruminococcus] gnavus	Linum usitatissimum	Herbal Substance	Medicinal Herb	Seeds	Decrease	Significantly	In vivo	n.a.	DOI: 10.1016/j.eng.2018.11.013
[Ruminococcus] lactaris	Linum usitatissimum	Herbal Substance	Medicinal Herb	Seeds	Increase	Significantly	Human	n.a.	PMID: 31408679
Streptococcaceae	Linum usitatissimum	Herbal Substance	Medicinal Herb	Seeds	Decrease	Significantly	In vivo	n.a.	PMID: 31408679
Sutterella	Linum usitatissimum	Herbal Substance	Medicinal Herb	Seeds	Increase	Significantly	In vivo	n.a.	PMID: 31408679
Clostridium perfringens	Linum usitatissimum	Herbal Substance	Medicinal Herb	Seeds	Decrease	Significantly	In vivo	n.a.	PMID: 31408679
Lachnospiracae	Linum usitatissimum	Herbal Substance	Medicinal Herb	Seeds	Increase	Significantly	In vivo	n.a.	PMID: 31408679
Rosburia ssp, S24-7	Linum usitatissimum	Herbal Substance	Medicinal Herb	Seeds	Increase	Significantly	In vivo	n.a.	PMID: 31408679
Akkermansia muciniphila	Nopal	Herbal Substance	Medicinal Herb	n.a.	Increase	n.a.	n.a.	Obesity	DOI: 10.1016/j.eng.2018.11.013
Bacteroides acidifaciens	Nopal	Herbal Substance	Medicinal Herb	n.a.	Decrease	n.a.	n.a.	Obesity	DOI: 10.1016/j.eng.2018.11.013
Bacteroides fragilis	Nopal	Herbal Substance	Medicinal Herb	n.a.	Increase	n.a.	n.a.	Obesity	DOI: 10.1016/j.eng.2018.11.013
Blautia producta	Nopal	Herbal Substance	Medicinal Herb	n.a.	Decrease	n.a.	n.a.	Obesity	DOI: 10.1016/j.eng.2018.11.013
Butyricicoccus pullicaecorum	Nopal	Herbal Substance	Medicinal Herb	n.a.	Decrease	n.a.	n.a.	Obesity	DOI: 10.1016/j.eng.2018.11.013
Enterocloster citroniae	Nopal	Herbal Substance	Medicinal Herb	n.a.	Decrease	n.a.	n.a.	Obesity	DOI: 10.1016/j.eng.2018.11.013
Faecalibacterium prausnitzii	Nopal	Herbal Substance	Medicinal Herb	n.a.	Decrease	n.a.	n.a.	Obesity	DOI: 10.1016/j.eng.2018.11.013
Lactobacillus reuteri	Nopal	Herbal Substance	Medicinal Herb	n.a.	Increase	n.a.	n.a.	Obesity	DOI: 10.1016/j.eng.2018.11.013
Ruminococcus bromii	Nopal	Herbal Substance	Medicinal Herb	n.a.	Increase	n.a.	n.a.	Obesity	DOI: 10.1016/j.eng.2018.11.013
Ruminococcus flavefaciens	Nopal	Herbal Substance	Medicinal Herb	n.a.	Increase	n.a.	n.a.	Obesity	DOI: 10.1016/j.eng.2018.11.013
Lachnospiraceae	Oil tea	Herbal Substance	Medicinal Herb	n.a.	Increase	n.a.	Mice	T2DM	PMID: 30122197
Bacteroides sp.	Plantago asiatica L.	Herbal Substance	Medicinal Herb	Seeds	Increase	n.a.	Mice	n.a.	PMID: 24341731
Bifidobacterium bifidum	Plantago asiatica L.	Herbal Substance	Medicinal Herb	Seeds	Increase	n.a.	Mice	n.a.	PMID: 24341731
Butyrivibrio sp.	Plantago asiatica L.	Herbal Substance	Medicinal Herb	Seeds	Increase	n.a.	Mice	n.a.	PMID: 24341731
Eubacterium sp.	Plantago asiatica L.	Herbal Substance	Medicinal Herb	Seeds	Increase	n.a.	Mice	n.a.	PMID: 24341731
Lactobacillus fermentum	Plantago asiatica L.	Herbal Substance	Medicinal Herb	Seeds	Increase	n.a.	Mice	n.a.	PMID: 24341731
Lactobacillus fermentum	Plantago asiatica L.	Herbal Substance	Medicinal Herb	n.a.	n.a.	n.a.	Rats	T2DM	DOI: 10.1016/j.foodhyd.2017.12.026
Lactobacillus reuteri	Plantago asiatica L.	Herbal Substance	Medicinal Herb	Seeds	Increase	n.a.	Mice	n.a.	PMID: 24341731
Bacteroides vulgatus	Plantago asiatica L.	Herbal Substance	Medicinal Herb	n.a.	n.a.	n.a.	Rats	T2DM	DOI: 10.1016/j.foodhyd.2017.12.026
Prevotella pneumophila	Plantago asiatica L.	Herbal Substance	Medicinal Herb	n.a.	n.a.	n.a.	Rats	T2DM	DOI: 10.1016/j.foodhyd.2017.12.026
Bifidobacterium	Pomegranate extract	Herbal Substance; Dietary Substance	Herbal Substance; Dietary Substance	n.a.	Increase	n.a.	n.a.	Ulcerative colitis	DOI: 10.1016/j.eng.2018.11.013
Lactobacillus	Pomegranate extract	Herbal Substance; Dietary Substance	Herbal Substance; Dietary Substance	n.a.	Increase	n.a.	n.a.	Ulcerative colitis	DOI: 10.1016/j.eng.2018.11.013
Proteobacteria	Potentilla discolor Bunge	Herbal Substance	Medicinal Herb	n.a.	Decrease	n.a.	Mice	T2DM	PMID: 30897784
Collinsella	Qushi Huayu Fang	Herbal Substance	TCM Formula	n.a.	Increase	n.a.	n.a.	Chronic liver disease	DOI: 10.1016/j.eng.2018.11.013
Collinsella	Qushi Huayu Fang	Herbal Substance	TCM Formula	n.a.	Increase	n.a.	Rats	Non-alcoholic fatty liver disease (NAFLD)	PMID: 23453736
Lactobacillus	Red Ginseng	Herbal Substance	Medicinal Herb	n.a.	Increase	n.a.	n.a.	Ulcerative colitis	DOI: 10.1016/j.eng.2018.11.013
Bifidobacterium	Red Ginseng	Herbal Substance	Medicinal Herb	n.a.	Increase	n.a.	n.a.	Ulcerative colitis	DOI: 10.1016/j.eng.2018.11.013
Bifidobacterium	Rosmarinus officinals	Herbal Substance	Medicinal Herb	Leaves	Increase	Significantly	In vivo	n.a.	PMID: 31408679
[Clostridium] leptum	Rosmarinus officinals	Herbal Substance	Medicinal Herb	Leaves	Decrease	Significantly	In vivo	n.a.	PMID: 31408679
Lactobacillus	Rosmarinus officinals	Herbal Substance	Medicinal Herb	Leaves	Decrease	Significantly	In vivo	n.a.	PMID: 31408679
Leuconostoc	Rosmarinus officinals	Herbal Substance	Medicinal Herb	Leaves	Decrease	Significantly	In vivo	n.a.	PMID: 31408679
Pediococcus	Rosmarinus officinals	Herbal Substance	Medicinal Herb	Leaves	Decrease	Significantly	In vivo	n.a.	PMID: 31408679
Blautia coccoides	Rosmarinus officinals	Herbal Substance	Medicinal Herb	Leaves	Increase	Significantly	In vivo	n.a.	PMID: 31408679
Bacteroidetes	Salvia officinalis	Herbal Substance	Medicinal Herb	Leaves	Increase	n.a.	In vitro	n.a.	PMID: 31408679
Roseburia hominis	Salvia officinalis	Herbal Substance	Medicinal Herb	Leaves	Decrease	n.a.	In vitro	n.a.	PMID: 31408679
Lactobacillus	Semen Coicis	Herbal Substance	Medicinal Herb	n.a.	Increase	n.a.	n.a.	Ulcerative colitis	DOI: 10.1016/j.eng.2018.11.013
Bifidobacterium	Semen Coicis	Herbal Substance	Medicinal Herb	n.a.	Increase	n.a.	n.a.	Ulcerative colitis	DOI: 10.1016/j.eng.2018.11.013
Akkermansia	Silybum marianum	Herbal Substance	Medicinal Herb	Fruits	Decrease	Significantly	In vitro	n.a.	PMID: 31408679
Bacteroidetes	Silybum marianum	Herbal Substance	Medicinal Herb	Fruits	Decrease	Significantly	In vitro	n.a.	PMID: 31408679
Enterobacteriaceae	Silybum marianum	Herbal Substance	Medicinal Herb	Fruits	Decrease	Significantly	In vitro	n.a.	PMID: 31408679
Clostridium	Terminalia arjuna	Herbal Substance	Medicinal Herb	hydro-ethanolic extract	Decrease	n.a.	n.a.	n.a.	PMID: 30367989
Bifidobacterium	Urolithin-A	Herbal Substance	Medicinal Herbal Compounds	n.a.	Increase	n.a.	n.a.	Ulcerative colitis	DOI: 10.1016/j.eng.2018.11.013
Lactobacillus	Urolithin-A	Herbal Substance	Medicinal Herbal Compounds	n.a.	Increase	n.a.	n.a.	Ulcerative colitis	DOI: 10.1016/j.eng.2018.11.013
Aspergillus oryzae	Vaccinium myrtillus	Herbal Substance	Medicinal Herb	Fruits	Increase	Significantly	In vivo	n.a.	PMID: 31408679
Bacteroides	Vaccinium myrtillus	Herbal Substance	Medicinal Herb	Fruits	Increase	Significantly	In vivo	n.a.	PMID: 31408679
Lactobacillus	Vaccinium myrtillus	Herbal Substance	Medicinal Herb	Fruits	Increase	Significantly	In vivo	n.a.	PMID: 31408679
Methanobrevibacter	Vaccinium myrtillus	Herbal Substance	Medicinal Herb	Fruits	Decrease	Significantly	In vivo	n.a.	PMID: 31408679
Verrucomicrobia	Vaccinium myrtillus	Herbal Substance	Medicinal Herb	Fruits	Decrease	Significantly	In vivo	n.a.	PMID: 31408679
Weissella confusa	Vaccinium myrtillus	Herbal Substance	Medicinal Herb	Fruits	Increase	Significantly	In vivo	n.a.	PMID: 31408679
Bacteroidetes	Xiao-Qing-Long Tang	Herbal Substance	TCM Formula	n.a.	Decrease	n.a.	Rats	n.a.	PMID: 31396536
Proteobacteria	Xiao-Qing-Long Tang	Herbal Substance	TCM Formula	n.a.	Decrease	n.a.	Rats	n.a.	PMID: 31396536
Actinobacteria	Zingiber officinale	Herbal Substance	Medicinal Herb	Roots	Increase	Significantly	In vivo	n.a.	PMID: 31408679
Actinobacteria	Zingiber officinale	Herbal Substance	Medicinal Herb	Roots	Increase	Significantly	In vivo	n.a.	PMID: 31408679
Allobaculum	Zingiber officinale	Herbal Substance	Medicinal Herb	Roots	Increase	Significantly	In vivo	n.a.	PMID: 31408679
Bifidobacteriaceae	Zingiber officinale	Herbal Substance	Medicinal Herb	Roots	Increase	Significantly	In vivo	n.a.	PMID: 31408679
Bifidobacteriales	Zingiber officinale	Herbal Substance	Medicinal Herb	Roots	Increase	Significantly	In vivo	n.a.	PMID: 31408679
Bifidobacterium	Zingiber officinale	Herbal Substance	Medicinal Herb	Roots	Increase	Significantly	In vivo	n.a.	PMID: 31408679
Clostridia	Zingiber officinale	Herbal Substance	Medicinal Herb	Roots	Decrease	Significantly	In vivo	n.a.	PMID: 31408679
Clostridiales	Zingiber officinale	Herbal Substance	Medicinal Herb	Roots	Decrease	Significantly	In vivo	n.a.	PMID: 31408679
Erysipelotrichales	Zingiber officinale	Herbal Substance	Medicinal Herb	Roots	Increase	Significantly	In vivo	n.a.	PMID: 31408679
Erysipelotrichia	Zingiber officinale	Herbal Substance	Medicinal Herb	Roots	Increase	Significantly	In vivo	n.a.	PMID: 31408679
Proteobacteria	Zingiber officinale	Herbal Substance	Medicinal Herb	Roots	Increase	Significantly	In vivo	n.a.	PMID: 31408679
Erysipelotrichacesae	Zingiber officinale	Herbal Substance	Medicinal Herb	Roots	Increase	Significantly	In vivo	n.a.	PMID: 31408679
Pseudomonas	Magnoloside A	Herbal Substance	Medicinal Herbal Compounds	n.a.	Increase	n.a.	Rat	Functional dyspepsia (FD)	PMID: 31412264
Escherichia coli	Gallic acid	Herbal Substance	Medicinal Herbal Compounds	n.a.	Decrease	n.a.	n.a.	n.a.	PMID: 31344423
Escherichia coli	Quercetin	Herbal Substance	Medicinal Herbal Compounds	n.a.	Decrease	n.a.	n.a.	n.a.	PMID: 31344423
Escherichia coli	Cinnamon essential oil	Environmental Chemicals	Unclassified Substance	n.a.	Decrease	n.a.	n.a.	n.a.	PMID: 17551716
Bacteroides	Resveratrol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Increase	n.a.	Mouse	T2DM	DOI: 10.1016/j.eng.2018.11.013
Bacteroides vulgatus	Polysaccharide	Herbal Substance	Medicinal Herbal Compounds	n.a.	Increase	n.a.	n.a.	T2DM	DOI: 10.1016/j.eng.2018.11.013
Prevotella loescheii	Polysaccharide	Herbal Substance	Medicinal Herbal Compounds	n.a.	Increase	n.a.	n.a.	T2DM	DOI: 10.1016/j.eng.2018.11.013
Roseburia	Zn(ii)-curcumin	Environmental Chemicals	Nutrient Supplement	n.a.	Increase	n.a.	Rat	Doxorubicin-induced cardiotoxicity	PMID: 31432062
Proteobacteria	Magnoloside A	Herbal Substance	Medicinal Herbal Compounds	n.a.	Decrease	n.a.	Rat	Functional dyspepsia (FD)	PMID: 31412264
Gammaproteobacteria	Magnoloside A	Herbal Substance	Medicinal Herbal Compounds	n.a.	Decrease	n.a.	Rat	Functional dyspepsia (FD)	PMID: 31412264
Firmicutes	Polysaccharide	Herbal Substance	Medicinal Herbal Compounds	n.a.	Increase	n.a.	Rat	Over-fatigue and acute cold stress (OACS)	PMID: 26932472
Firmicutes	Oligofructose	Herbal Substance	Medicinal Herbal Compounds	n.a.	Increase	n.a.	Rat	Over-fatigue and acute cold stress (OACS)	PMID: 26932472
Staphylococcus aureus	Cinnamon essential oil	Environmental Chemicals	Unclassified Substance	n.a.	Decrease	n.a.	n.a.	n.a.	PMID: 17551716
Lactobacillus	Gallic acid	Herbal Substance	Medicinal Herbal Compounds	n.a.	Increase	n.a.	n.a.	n.a.	PMID: 31344423
Lactobacillus	Quercetin	Herbal Substance	Medicinal Herbal Compounds	n.a.	Increase	n.a.	n.a.	n.a.	PMID: 31344423
Lactobacillus	Sodium butyrate	Environmental Chemicals	Microbiota metabolite	n.a.	Increase	n.a.	C57BL/6J Mouse	Non-alcoholic fatty liver disease (NAFLD)	PMID: 28104981
Lactobacillus fermentum	Polysaccharide	Herbal Substance	Medicinal Herbal Compounds	n.a.	Increase	n.a.	n.a.	T2DM	DOI: 10.1016/j.eng.2018.11.013
Bacteroides spp.	Polysaccharide	Herbal Substance	Medicinal Herbal Compounds	n.a.	Increase	n.a.	Rat	Over-fatigue and acute cold stress (OACS)	PMID: 26932472
Bacteroides spp.	Oligofructose	Herbal Substance	Medicinal Herbal Compounds	n.a.	Increase	n.a.	Rat	Over-fatigue and acute cold stress (OACS)	PMID: 26932472
Phascolarctobacterium	Stachyose	Dietary Substance	Dietary Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	DOI: 10.1016/j.eng.2018.11.013
Verrucomicrobia	Aloin	Herbal Substance	Medicinal Herbal Compounds	n.a.	Increase	n.a.	Rat	F344/N rats	PMID: 28525602
Coriobacteriales	Curcumin	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	Increase	n.a.	Mouse	Colon cancer	PMID: 26218141
Coriobacteriales	Curcumin	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	Decrease	n.a.	Mouse	Wild type	PMID: 26218141
Bifidobacteriales	Curcumin	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	Increase	n.a.	Mouse	Colon cancer	PMID: 26218141
Bifidobacteriales	Curcumin	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	Decrease	n.a.	Mouse	Wild type	PMID: 26218141
Alteromonadales	Magnoloside A	Herbal Substance	Medicinal Herbal Compounds	n.a.	Decrease	n.a.	Rat	Functional dyspepsia (FD)	PMID: 31412264
Clostridiales	Curcumin	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	Decrease	n.a.	Mouse	Colon cancer	PMID: 26218141
Lachnospiraceae	Resveratrol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	n.a.	Mouse	T2DM	DOI: 10.1016/j.eng.2018.11.013
Lactobacillales	Curcumin	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	Increase	n.a.	Mouse	Colon cancer	PMID: 26218141
Lactobacillales	Curcumin	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	Increase	n.a.	Mouse	Wild type	PMID: 26218141
Bacteroidetes	Polysaccharide	Herbal Substance	Medicinal Herbal Compounds	n.a.	Decrease	n.a.	Rat	Over-fatigue and acute cold stress (OACS)	PMID: 26932472
Bacteroidetes	Oligofructose	Herbal Substance	Medicinal Herbal Compounds	n.a.	Decrease	n.a.	Rat	Over-fatigue and acute cold stress (OACS)	PMID: 26932472
Bacteroidetes	Aloin	Herbal Substance	Medicinal Herbal Compounds	n.a.	Increase	n.a.	Rat	F344/N rats	PMID: 28525602
Akkermansia	Resveratrol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	n.a.	Mouse	T2DM	DOI: 10.1016/j.eng.2018.11.013
Akkermansia	Caffeic acid	Herbal Substance	Medicinal Herbal Compounds	n.a.	Increase	n.a.	n.a.	Ulcerative colitis	DOI: 10.1016/j.eng.2018.11.013
Akkermansia	Zn(ii)-curcumin	Environmental Chemicals	Nutrient Supplement	n.a.	Increase	n.a.	Rat	Doxorubicin-induced cardiotoxicity	PMID: 31432062
Akkermansia	Magnoloside A	Herbal Substance	Medicinal Herbal Compounds	n.a.	Increase	n.a.	Rat	Functional dyspepsia (FD)	PMID: 31412264
Subdoligranulum	Magnoloside A	Herbal Substance	Medicinal Herbal Compounds	n.a.	Increase	n.a.	Rat	Functional dyspepsia (FD)	PMID: 31412264
Parabacteroides	Resveratrol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Increase	n.a.	Mouse	T2DM	DOI: 10.1016/j.eng.2018.11.013
Moryella	Resveratrol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	n.a.	Mouse	T2DM	DOI: 10.1016/j.eng.2018.11.013
Blautia	Sodium butyrate	Environmental Chemicals	Microbiota metabolite	n.a.	Increase	n.a.	C57BL/6J Mouse	Non-alcoholic fatty liver disease (NAFLD)	PMID: 28104981
Butyricicoccus	Zn(ii)-curcumin	Environmental Chemicals	Nutrient Supplement	n.a.	Increase	n.a.	Rat	Doxorubicin-induced cardiotoxicity	PMID: 31432062
Christensenellaceae	Sodium butyrate	Environmental Chemicals	Microbiota metabolite	n.a.	Increase	n.a.	C57BL/6J Mouse	Non-alcoholic fatty liver disease (NAFLD)	PMID: 28104981
Blautia spp.	Metformin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Increase	n.a.	Human (Clinical trial)	T2DM with hyperlipidemia	PMID: 29789365
Firmicutes/Bacteroidetes ratio	Caffeic acid	Herbal Substance	Medicinal Herbal Compounds	n.a.	Decrease	n.a.	n.a.	Ulcerative colitis	DOI: 10.1016/j.eng.2018.11.013
Firmicutes/Bacteroidetes ratio	Zn(ii)-curcumin	Environmental Chemicals	Nutrient Supplement	n.a.	Increase	n.a.	Rat	Doxorubicin-induced cardiotoxicity	PMID: 31432062
Lactobacillus spp.	Polysaccharide	Herbal Substance	Medicinal Herbal Compounds	n.a.	Increase	n.a.	Rat	Over-fatigue and acute cold stress (OACS)	PMID: 26932472
Lactobacillus spp.	Oligofructose	Herbal Substance	Medicinal Herbal Compounds	n.a.	Increase	n.a.	Rat	Over-fatigue and acute cold stress (OACS)	PMID: 26932472
Prevotellaceae_NK3B31_group	Magnoloside A	Herbal Substance	Medicinal Herbal Compounds	n.a.	Decrease	n.a.	Rat	Functional dyspepsia (FD)	PMID: 31412264
Akkermansia muciniphila	Rifabutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.58E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Rifabutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Doxycycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.32E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Chlortetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.28E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Tosufloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000682966]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.99E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Minocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Meclocycline sulfosalicylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.72E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Demeclocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Methacycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.84E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Chlorhexidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.65E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Florfenicol	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Rifapentine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.03E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Azithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.54E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Clindamycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.04E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Clarithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Tetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.32E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Linezolid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.84E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Thiamphenicol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.08E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Oxytetracycline dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Rifampicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Furazolidone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.62E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Niridazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.49E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Carbadox	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.59E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Benzylpenicillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.41E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Rifaximin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Furaltadone hydrochloride	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000289729]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Meropenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.20E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Erythromycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.37E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Josamycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Lincomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Cefazolin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00597968]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Piperacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Roxithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.93E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Hexachlorophene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.20E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Alexidine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.77E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Tylosin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.07E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Novobiocin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Ticarcillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.32E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Dirithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002343758]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Spiramycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000176808]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Niclosamide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.76E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Benzathine benzylpenicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.84E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Ampicillin trihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.80E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Cefotaxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.47E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Cefoperazone dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.29E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Amoxicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0002712]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Thiostrepton	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.28E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Ronidazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Talampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000313055]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000651143]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Cefdinir	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000569297]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Ornidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001780397]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Ceforanide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.84E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Imipenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000507548]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Phenethicillin potassium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.59E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002065724]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Nifurtimox	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.06E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Secnidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006585507]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Cefuroxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00010915]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Cefepime hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.44E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Dicloxacillin sodium salt hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.08E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Azlocillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Triclosan	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.76E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Flucloxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000121136]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Cloxacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.70E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Nafcillin sodium salt monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Oxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Trimethoprim	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.36E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Colistin sulfate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.60E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Pyrimethamine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000864218]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Tazobactam	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00358652]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Promazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.57E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Astemizole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000539056]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Chlorprothixene hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.02E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Zotepine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0056596]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Zuclopenthixol dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000933639]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Chlorpromazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000323877]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Promethazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003400942]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Azelastine HCl	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.44E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Perphenazine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002509681]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Cyclobenzaprine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001347342]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Asenapine maleate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003502773]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Haloperidol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006623603]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Mebhydroline 1,5-naphtalenedisulfonate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.22E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Triflupromazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000685478]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Chlorpheniramine maleate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003216147]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Sumatriptan succinate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008307524]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Trazodone hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000277264]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Benzydamine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000584515]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Benfluorex hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007068035]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Bromperidol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009428028]	High-throughput incubation assays	n.a.	PMID: 29555994
Akkermansia muciniphila	Chlorcyclizine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000594816]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Doxycycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.21E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Chlortetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Tosufloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Minocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.82E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Meclocycline sulfosalicylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Demeclocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Methacycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.99E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Chlorhexidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Florfenicol	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Ciprofloxacin hydrochloride monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Rifapentine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Azithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.39E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Clindamycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Clarithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Clinafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.55E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Tetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Linezolid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Moxifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.27E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Thiamphenicol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Oxytetracycline dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.83E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Rifampicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.14E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Furazolidone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Niridazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Carbadox	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Benzylpenicillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.79E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Nadifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.23E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Gatifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.16E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Sarafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.70E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Rifaximin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Furaltadone hydrochloride	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Meropenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Erythromycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Josamycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Lincomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Nifuroxazide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000119893]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Cefazolin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.29E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Piperacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.43E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Roxithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Hexachlorophene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Alexidine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Tylosin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Novobiocin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.92E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Ticarcillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Dirithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.40E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Spiramycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Niclosamide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Thimerosal	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000275861]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Auranofin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.37E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Closantel	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Benzathine benzylpenicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.94E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Ampicillin trihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.40E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Cefotaxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.51E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Cefoperazone dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Amoxicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.41E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Fusidic acid sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Nitrofural	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.65E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Thiostrepton	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.17E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Ronidazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Talampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000172932]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Sparfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.63E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Cephalothin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.52E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Cefdinir	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.91E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Rufloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.67E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Ornidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Troleandomycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.08E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Ceforanide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.13E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Imipenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.77E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Phenethicillin potassium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.11E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Cefoxitin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.98E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Nifurtimox	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.97E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Secnidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Methyl benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Diacerein	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Monensin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003263891]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Chloroxine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.51E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Pentamidine isethionate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.94E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Merbromin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Ebselen	Therapeutic Substance	Investigational Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009959859]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Dicloxacillin sodium salt hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.45E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Vancomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.51E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Bacitracin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003138697]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Daunorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001045178]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Cefotiam hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.19E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Clioquinol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.51E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Triclosan	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.47E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Dequalinium dichloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.53E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Enoxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.25E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Isoconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001902308]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Clotrimazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001339048]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Cloxacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001689365]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Lomefloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.41E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Miconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002157434]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	5-fluorouracil	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.73E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Flumequine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.02E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Clofazimine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.89E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Ofloxacin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000559075]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Streptozotocin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.41E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Lymecycline	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.26E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Norfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001078837]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Trimethoprim	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000244787]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Colistin sulfate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.68E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Floxuridine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.64E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Pyrimethamine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.86E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Hexestrol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000422533]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Pefloxacine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000756371]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Mafenide hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000129582]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Dienestrol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001220011]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Felodipine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000112711]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Pyrvinium pamoate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000301738]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Diethylstilbestrol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003741022]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Tazobactam	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000249869]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Azaguanine-8	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005590073]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Zidovudine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.74E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Trifluridine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000223955]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Estradiol Valerate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00431781]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Promazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000488322]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Ethopropazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.62E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Aprepitant	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003977197]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Tolfenamic acid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005043812]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Metixene hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005682417]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Protriptyline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005259467]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Hycanthone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004412596]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Hydrocortisone base	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008623045]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides caccae	Eburnamonine (-)	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002903472]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Rifabutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.05E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Doxycycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Chlortetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.14E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Tosufloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.87E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Minocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.37E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Meclocycline sulfosalicylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Demeclocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Methacycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Chlorhexidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000104068]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Florfenicol	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.45E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Ciprofloxacin hydrochloride monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003986644]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Rifapentine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Azithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Clindamycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.23E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Clarithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Clinafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Tetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.12E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Linezolid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Moxifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Thiamphenicol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Oxytetracycline dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.39E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Rifampicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Furazolidone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Niridazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Carbadox	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.38E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Benzylpenicillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000489548]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Nadifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.10E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Gatifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Sarafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.06E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Rifaximin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Furaltadone hydrochloride	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Meropenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.23E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Erythromycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.91E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Josamycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.99E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Lincomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.57E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Nifuroxazide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.16E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Cefazolin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.96E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Piperacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000427754]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Roxithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.05E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Hexachlorophene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.91E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Alexidine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.91E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Tylosin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Novobiocin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000109768]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Ticarcillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000281647]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Dirithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002053979]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Spiramycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Niclosamide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.09E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Thimerosal	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Auranofin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Closantel	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Benzathine benzylpenicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000288831]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Cefoperazone dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001529607]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Fusidic acid sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.91E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Nitrofural	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000124525]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Thiostrepton	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Ronidazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.22E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Sparfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.43E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Cephalothin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.59E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.91E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Rufloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.38E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Ornidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.23E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Troleandomycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Ceforanide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00209371]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Imipenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000812744]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.24E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Cefoxitin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.07E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Nifurtimox	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.45E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Secnidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Methyl benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Diacerein	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.65E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Monensin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.38E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Chloroxine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000105033]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Merbromin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002594892]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Nitrofurantoin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.58E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Moxalactam disodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.18E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Ebselen	Therapeutic Substance	Investigational Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000269368]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Cefotetan	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Vancomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Cefmetazole sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.91E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Clioquinol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.23E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Triclosan	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000209667]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Enoxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005817323]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Clotrimazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Lomefloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.21E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Ceftazidime pentahydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.47E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Miconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00055263]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	5-fluorouracil	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000699998]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Benzbromarone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000160752]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Flumequine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001030079]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Clofazimine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001585698]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Oxethazaine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006143524]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Thonzonium bromide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000970824]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Ofloxacin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000518619]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Streptozotocin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.96E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Trimethoprim	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00065096]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Oxiconazole Nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000617244]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Floxuridine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.89E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Pyrimethamine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000159762]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Hexestrol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Pefloxacine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000560041]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Mafenide hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.54E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Dienestrol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.99E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Felodipine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000324943]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Pyrvinium pamoate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00165225]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Loratadine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002103888]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Diethylstilbestrol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000539738]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Tazobactam	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.01E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Azaguanine-8	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.94E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Thioridazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000278128]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Zidovudine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005331174]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Clomiphene citrate (Z,E)	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00888111]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Trifluridine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000160215]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Estradiol Valerate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006648497]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Promazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000208434]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Ethopropazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.49E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Efavirenz	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003048825]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Aprepitant	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000241869]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Tolfenamic acid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000680623]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Cephalosporanic acid, 7-amino	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000250272]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Metixene hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00665058]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Protriptyline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00893217]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Toltrazuril	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001700046]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Acarbose	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000422533]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Ethacrynic acid	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000869818]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Tolnaftate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009316771]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Cilnidipine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009528998]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Meclofenamic acid sodium salt monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000537636]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis enterotoxigenic	Prenylamine lactate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001316391]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Rifabutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.82E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Doxycycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.75E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Chlortetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Tosufloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.71E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.99E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Minocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.76E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Meclocycline sulfosalicylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.79E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Demeclocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.61E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Methacycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Chlorhexidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.99E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Florfenicol	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.15E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Ciprofloxacin hydrochloride monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Rifapentine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.71E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Azithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Clindamycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.93E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Clarithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.75E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Clinafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Tetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Linezolid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.69E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Moxifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000267555]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Thiamphenicol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.79E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Oxytetracycline dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.76E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Rifampicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.79E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Furazolidone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.73E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Niridazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.71E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Carbadox	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.95E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Benzylpenicillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.32E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Nadifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.03E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Gatifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.78E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Sarafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.76E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Rifaximin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.64E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Furaltadone hydrochloride	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.62E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Meropenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.05E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Erythromycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.02E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Josamycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Lincomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.76E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Nifuroxazide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.90E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Cefazolin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.59E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Piperacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.82E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Roxithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.84E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Hexachlorophene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.66E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Alexidine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.63E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Tylosin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Novobiocin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001677974]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Ticarcillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Dirithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.81E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Spiramycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.67E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Niclosamide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Thimerosal	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Auranofin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Closantel	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.09E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Benzathine benzylpenicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000906821]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Ampicillin trihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002477444]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Cefotaxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001321505]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Cefoperazone dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000170551]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Amoxicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00457977]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Fusidic acid sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.95E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Nitrofural	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001126779]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.27E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Thiostrepton	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.77E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Ronidazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.03E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Sparfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Cephalothin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001022261]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.61E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Cefdinir	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008610966]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Rufloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Ornidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.56E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Troleandomycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.91E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Ceforanide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000646302]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Imipenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.57E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Phenethicillin potassium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000125508]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.22E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Cefoxitin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.07E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Nifurtimox	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.56E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Secnidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.69E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Methyl benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.52E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Diacerein	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.62E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Monensin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.76E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Chloroxine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000187809]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Pentamidine isethionate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00759669]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Merbromin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.27E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Nitrofurantoin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000857592]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Cefuroxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003534694]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Moxalactam disodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001829832]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Ebselen	Therapeutic Substance	Investigational Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000416203]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Cefepime hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001836614]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Cefotetan	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.79E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Vancomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003903545]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Bacitracin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003217095]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Cefmetazole sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.49E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Clioquinol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.98E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Triclosan	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.07E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Enoxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Isoconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000385531]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Clotrimazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000187916]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Lomefloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.97E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Ceftazidime pentahydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004975989]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	5-fluorouracil	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.96E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Benzbromarone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00262628]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Flumequine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000504227]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Clofazimine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.78E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Cefixime	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003029048]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Tioconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001704304]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Econazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002511467]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Thonzonium bromide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.20E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Ofloxacin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.24E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Streptozotocin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.59E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Lymecycline	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.34E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Norfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017055]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Trimethoprim	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000135733]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Cefsulodin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005294977]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Floxuridine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.82E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Pyrimethamine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.36E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Hexestrol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.01E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Pefloxacine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.06E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Mafenide hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000612559]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Dienestrol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.62E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Zafirlukast	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0018713]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Felodipine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.68E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Tamoxifen citrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000859086]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Diethylstilbestrol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000671946]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Tazobactam	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.62E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Mefloquine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008623045]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Troglitazone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00406747]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Thioridazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001913202]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Zidovudine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000343393]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Trifluridine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001921381]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Anthralin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002112696]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Estradiol Valerate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.97E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Promazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003286927]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Ethopropazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000437689]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Fleroxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.38E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Efavirenz	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.27E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Aprepitant	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000276431]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Tolfenamic acid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003731208]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Dicumarol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00203836]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Cephalosporanic acid, 7-amino	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.03E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Toremifene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003573495]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Sertindole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000762503]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Diclazuril	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00184996]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Protriptyline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003451354]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Ethacrynic acid	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000683269]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Pimethixene maleate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003050721]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Promethazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00641235]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Idoxuridine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007141128]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Meclofenamic acid sodium salt monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008962491]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides fragilis nontoxigenic	Pipemidic acid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001002675]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Rifabutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Doxycycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Chlortetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Tosufloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Minocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Meclocycline sulfosalicylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Demeclocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Methacycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Chlorhexidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Florfenicol	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Ciprofloxacin hydrochloride monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Rifapentine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Azithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Clindamycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Clarithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Clinafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Tetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Linezolid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Moxifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Thiamphenicol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Oxytetracycline dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Rifampicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Furazolidone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Niridazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Carbadox	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Benzylpenicillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.30E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Nadifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Gatifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Sarafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Rifaximin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Furaltadone hydrochloride	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Meropenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Erythromycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Josamycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Lincomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Nifuroxazide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.00E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Cefazolin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000923016]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Piperacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Roxithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Hexachlorophene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Alexidine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Tylosin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Novobiocin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Ticarcillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.63E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Dirithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Spiramycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Niclosamide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Thimerosal	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.23E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Auranofin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Closantel	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Benzathine benzylpenicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001659558]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Ampicillin trihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004276717]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Cefotaxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001403982]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Cefoperazone dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00013257]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Amoxicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00921525]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Fusidic acid sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Nitrofural	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Thiostrepton	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Ronidazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Talampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00615579]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Sparfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Rufloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.91E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Ornidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Troleandomycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Imipenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Phenethicillin potassium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00811522]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Cefoxitin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.89E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Nifurtimox	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Secnidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Methyl benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.42E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Diacerein	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Monensin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002632027]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Chloroxine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Pentamidine isethionate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0001943]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Merbromin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Nitrofurantoin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004295111]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Dicloxacillin sodium salt hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000650497]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Azlocillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003295689]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Bacitracin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000945301]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Daunorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Clioquinol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Triclosan	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Dequalinium dichloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006747737]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Enoxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.50E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Clotrimazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007729025]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Lomefloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Nafcillin sodium salt monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003459073]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	5-fluorouracil	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Benzbromarone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001233291]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Oxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001691631]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Flumequine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.31E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Clofazimine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002099054]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Ofloxacin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.23E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Streptozotocin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Lymecycline	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Norfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007347466]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Trimethoprim	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Colistin sulfate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001083172]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Floxuridine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Pyrimethamine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Hexestrol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Pefloxacine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000991397]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Mafenide hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.28E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Dienestrol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Pyrvinium pamoate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Loratadine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000507497]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Diethylstilbestrol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Tazobactam	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000324146]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Tiratricol, 3,3',5-triiodothyroacetic acid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002723341]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Azaguanine-8	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.49E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Zidovudine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Trifluridine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Promazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.16E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Ethopropazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Tolfenamic acid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.13E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Dicumarol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002320022]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Metixene hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000109489]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Diclazuril	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009510718]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Chlorprothixene hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001963588]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Protriptyline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000469925]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Moricizine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.08E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Loxapine succinate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003157443]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Trimeprazine tartrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003354848]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Hycanthone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006642697]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Idoxuridine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000352557]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Meclofenamic acid sodium salt monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006173365]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Flufenamic acid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000601342]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Ribavirin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001080494]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Pioglitazone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000755608]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Etofenamate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000304871]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Flunixin meglumine	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001747188]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Fenbufen	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006136783]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Reserpine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001439963]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides ovatus	Sulfamonomethoxine	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000129611]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Rifabutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.34E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Doxycycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.55E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Chlortetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.00E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Tosufloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.10E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.66E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Minocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.55E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Meclocycline sulfosalicylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.11E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Demeclocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.48E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Methacycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.51E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Chlorhexidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.95E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Florfenicol	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.51E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Ciprofloxacin hydrochloride monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.01E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Rifapentine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.09E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Azithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.47E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Clindamycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.99E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Clarithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.57E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Clinafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.05E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Tetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.68E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Linezolid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.10E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Moxifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.10E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Thiamphenicol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.01E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Oxytetracycline dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.56E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Rifampicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.43E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Furazolidone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.93E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Niridazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.09E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Carbadox	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.41E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Nadifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.60E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Gatifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.10E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Sarafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.52E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Rifaximin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.08E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Furaltadone hydrochloride	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.42E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Meropenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.42E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Erythromycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.80E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Josamycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.94E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Lincomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.56E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Nifuroxazide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.43E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Roxithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.48E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Hexachlorophene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.44E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Alexidine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.38E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Tylosin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.66E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Dirithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.39E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Spiramycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Niclosamide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.64E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Thimerosal	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Auranofin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.41E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Closantel	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.09E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Fusidic acid sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000393088]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Nitrofural	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.43E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000750494]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Thiostrepton	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.91E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Ronidazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002379728]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Sparfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.43E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.43E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Rufloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.08E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Ornidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.00E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Troleandomycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.67E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Imipenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000174956]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.07E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Nifurtimox	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Secnidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.55E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Methyl benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000390662]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Diacerein	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.51E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Chloroxine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.97E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Pentamidine isethionate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.11E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Merbromin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.63E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Nitrofurantoin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.70E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Ebselen	Therapeutic Substance	Investigational Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001858081]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Vancomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001596639]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Daunorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00323688]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Clioquinol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.06E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Triclosan	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.96E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Dequalinium dichloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000478376]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Enoxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.71E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Isoconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001275288]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Clotrimazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000758779]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Lomefloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.17E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	5-fluorouracil	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002546255]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Benzbromarone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000322832]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Flumequine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.60E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Clofazimine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000958761]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Oxethazaine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001797486]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Ofloxacin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.31E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Streptozotocin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00040782]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Lymecycline	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.23E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Trimethoprim	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.02E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Colistin sulfate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006561372]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Floxuridine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.09E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Pyrimethamine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.74E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Hexestrol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.87E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Pefloxacine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.01E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Mafenide hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000244742]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Dienestrol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002834728]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Felodipine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008429051]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Pyrvinium pamoate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.08E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Diethylstilbestrol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.68E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Bepridil hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007469016]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Mefloquine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007503786]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Azaguanine-8	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.76E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Thioridazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000321751]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Zidovudine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.64E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Clomiphene citrate (Z,E)	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008333416]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Trifluridine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.80E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Promazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000835296]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Ethopropazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.27E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Tolfenamic acid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003263891]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Metixene hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.78E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Chlorprothixene hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000462902]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Protriptyline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001072952]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Moricizine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00019571]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Loxapine succinate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000612907]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Trimeprazine tartrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000324701]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Pimethixene maleate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005767488]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Saquinavir mesylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009785517]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Mesoridazine besylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001895632]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides thetaiotaomicron	Norcyclobenzaprine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007567399]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Rifabutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.64E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Doxycycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.82E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Chlortetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Tosufloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.03E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Minocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Meclocycline sulfosalicylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Demeclocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.32E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Methacycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.50E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Chlorhexidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Florfenicol	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Ciprofloxacin hydrochloride monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.53E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Rifapentine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Azithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Clindamycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.54E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Clarithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.90E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Clinafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Tetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.83E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Linezolid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Moxifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Thiamphenicol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.90E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Oxytetracycline dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Rifampicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Furazolidone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.44E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Niridazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Carbadox	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.46E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Benzylpenicillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Nadifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.72E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Gatifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Sarafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Rifaximin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.32E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Furaltadone hydrochloride	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.32E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Meropenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.20E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Erythromycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Josamycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Lincomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Nifuroxazide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.05E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Cefazolin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.33E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Piperacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.32E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Roxithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Hexachlorophene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.32E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Alexidine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.31E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Tylosin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.89E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Novobiocin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Ticarcillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Dirithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.76E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Spiramycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.32E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Niclosamide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.92E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Thimerosal	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.98E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Auranofin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.55E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Closantel	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Benzathine benzylpenicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.50E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Ampicillin trihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.10E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Cefotaxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.63E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Cefoperazone dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.71E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Amoxicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005211253]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Fusidic acid sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.65E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Nitrofural	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008278923]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.14E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Thiostrepton	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Ronidazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.28E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Talampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.85E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Sparfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Cephalothin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.94E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.32E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Cefdinir	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Rufloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.82E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Ornidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.23E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Troleandomycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.92E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Ceforanide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.14E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Imipenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Phenethicillin potassium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.33E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.54E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Cefoxitin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Nifurtimox	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.41E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Secnidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.03E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Methyl benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000191748]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Diacerein	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.54E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Monensin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000507497]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Chloroxine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.60E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Pentamidine isethionate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Merbromin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003325765]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Nitrofurantoin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000681488]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Cefuroxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.44E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Moxalactam disodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.60E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Ebselen	Therapeutic Substance	Investigational Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000180117]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Cefepime hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007728184]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Dicloxacillin sodium salt hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Cefotetan	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Vancomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004873795]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Azlocillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Bacitracin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001295533]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Cefotiam hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000358235]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Cefmetazole sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.20E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Clioquinol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Triclosan	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.16E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Dequalinium dichloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000108547]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Flucloxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.55E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Enoxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Loracarbef	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001729015]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Isoconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000103719]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Clotrimazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Cloxacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000146112]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Lomefloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.26E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Miconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005367666]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Benzbromarone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007823119]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Oxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004605859]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Flumequine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002015009]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Clofazimine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005268297]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Cefixime	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Tioconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.94E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Oxethazaine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000806109]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Econazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.00E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Thonzonium bromide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007399353]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Ofloxacin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003190057]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Streptozotocin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.32E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Lymecycline	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.53E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Norfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004551067]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Trimethoprim	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000251723]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Oxiconazole Nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001757589]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Floxuridine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.14E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Bifonazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00032003]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Pyrimethamine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000532567]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Terfenadine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001694919]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Hexestrol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002181305]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Pefloxacine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000201749]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Mafenide hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0035891]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Dienestrol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Butoconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00016844]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Felodipine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008277451]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Tamoxifen citrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003377072]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Pyrvinium pamoate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000131961]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Tazobactam	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001986996]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Mefloquine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007710688]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Thioridazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Methotrexate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.64E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Perhexiline maleate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004546858]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Amethopterin (R,S)	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.24E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Promazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.92E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Ethopropazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Fleroxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005217961]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Efavirenz	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002422736]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Dicumarol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001765715]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Cephalosporanic acid, 7-amino	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Toremifene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004974898]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Sertindole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002066042]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Metixene hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.34E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Fendiline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.81E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Protriptyline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.59E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Moricizine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000100831]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Loxapine succinate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.92E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Zotepine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.84E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Pimozide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002355867]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Trimeprazine tartrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000653747]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Acarbose	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001158548]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Ethacrynic acid	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.40E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Pimethixene maleate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.26E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Prochlorperazine dimaleate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00869897]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Chlorpromazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003157656]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Promethazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.56E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Haloprogin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000426281]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Cyclobenzaprine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004347253]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Proadifen hydrochloride	Environmental Chemicals	Unclassified Substance	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008016364]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Amodiaquin dihydrochloride dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003290192]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Mifepristone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002824993]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Mesoridazine besylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000861551]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Loperamide hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007377276]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Acetopromazine maleate salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003467683]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Pridinol methanesulfonate salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000103469]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Artemisinin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000890931]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Cyproheptadine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001175749]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Raloxifene hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003432585]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides uniformis	Pizotifen malate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000111644]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Rifabutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.58E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Doxycycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.98E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Chlortetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Tosufloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Minocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.63E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Meclocycline sulfosalicylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.96E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Demeclocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.29E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Methacycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000104443]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Chlorhexidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Florfenicol	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.94E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Ciprofloxacin hydrochloride monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00052783]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Rifapentine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Azithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Clindamycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.99E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Clarithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.86E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Clinafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.12E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Tetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.01E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Linezolid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.94E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Moxifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.94E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Thiamphenicol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Oxytetracycline dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.64E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Rifampicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Furazolidone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Niridazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Carbadox	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.19E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Benzylpenicillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.65E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Nadifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.65E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Gatifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Sarafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.66E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Rifaximin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.30E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Furaltadone hydrochloride	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.29E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Meropenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Erythromycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Josamycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Lincomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.64E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Nifuroxazide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Cefazolin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.31E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Piperacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.31E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Roxithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Hexachlorophene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.28E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Alexidine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.26E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Tylosin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.94E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Novobiocin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Ticarcillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.68E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Dirithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Spiramycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.30E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Niclosamide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Thimerosal	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.93E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Auranofin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.10E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Closantel	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Benzathine benzylpenicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.01E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Ampicillin trihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Cefotaxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.98E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Cefoperazone dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.73E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Amoxicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.84E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Fusidic acid sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.58E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Nitrofural	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000141464]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.61E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Thiostrepton	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.22E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Ronidazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.02E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Talampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Sparfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.21E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Cephalothin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.92E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.33E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Cefdinir	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.00E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Rufloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.05E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Ornidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.94E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Troleandomycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Ceforanide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.93E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Imipenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.78E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Phenethicillin potassium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.31E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.00E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Cefoxitin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Nifurtimox	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.01E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Secnidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.93E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Methyl benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.02E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Diacerein	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.39E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Monensin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.07E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Chloroxine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.21E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Pentamidine isethionate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.43E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Merbromin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000321397]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Nitrofurantoin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000288543]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Cefuroxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.05E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Moxalactam disodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.80E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Ebselen	Therapeutic Substance	Investigational Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.28E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Cefepime hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Dicloxacillin sodium salt hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.99E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Cefotetan	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Vancomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.05E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Azlocillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.25E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Bacitracin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Daunorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003081374]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Cefotiam hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.03E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Cefmetazole sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.01E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Clioquinol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.00E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Triclosan	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.30E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Dequalinium dichloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001280508]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Flucloxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000585698]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Enoxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.58E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Loracarbef	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.22E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Isoconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.39E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Clotrimazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.61E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Cloxacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000134609]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Lomefloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.26E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Ceftazidime pentahydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Miconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000197672]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	5-fluorouracil	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.39E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Benzbromarone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00226359]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Flumequine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000266312]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Clofazimine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006634684]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Bacampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Cefixime	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Tioconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000182756]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Oxethazaine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.21E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Econazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.41E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Thonzonium bromide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Ofloxacin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.86E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Streptozotocin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.38E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Lymecycline	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Trimethoprim	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017654]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Colistin sulfate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009344181]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Oxiconazole Nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000117632]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Floxuridine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000159192]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Bifonazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000280716]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Pyrimethamine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001127486]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Terfenadine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001563951]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Hexestrol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002638689]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Pefloxacine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000514387]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Mafenide hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000178054]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Dienestrol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.01E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Cefaclor hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.05E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Butoconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.87E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Felodipine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004419106]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Tamoxifen citrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00029395]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Diethylstilbestrol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002426018]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Tazobactam	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000325495]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Bepridil hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00811522]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Mefloquine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005806766]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Azaguanine-8	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000761829]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Thioridazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.31E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Methotrexate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.82E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Amethopterin (R,S)	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000394597]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Trifluridine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.76E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Anthralin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005675801]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Estradiol Valerate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.16E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Promazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.33E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Ethopropazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.37E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Fleroxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001913202]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Efavirenz	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009732678]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Entacapone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006752846]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Aprepitant	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.61E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Pinaverium bromide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.57E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Amiodarone hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00289599]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Cephalosporanic acid, 7-amino	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Toremifene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003326216]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Metixene hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.28E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Fendiline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.07E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Chlorprothixene hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000380382]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Meclozine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001419173]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Protriptyline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.15E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Moricizine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Loxapine succinate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.36E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Zotepine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.34E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Pimozide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001704304]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Trimeprazine tartrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Zuclopenthixol dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003428916]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Acarbose	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000656515]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Ethacrynic acid	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000372795]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Pimethixene maleate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.95E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Prochlorperazine dimaleate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007973156]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Chlorpromazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.26E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Promethazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.66E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Prenylamine lactate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000287651]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Haloprogin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002177626]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Cyclobenzaprine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00597968]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Proadifen hydrochloride	Environmental Chemicals	Unclassified Substance	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003489677]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Cinnarizine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004182486]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Mesoridazine besylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000191026]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Amoxapine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.46E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Acetopromazine maleate salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003784869]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Pridinol methanesulfonate salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.31E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Imiquimod	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005790619]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Quetiapine hemifumarate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000472811]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides vulgatus	Methotrimeprazine maleat salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006991298]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Rifabutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Doxycycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Chlortetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.66E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Tosufloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Minocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Meclocycline sulfosalicylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.06E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Demeclocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Methacycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.29E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Chlorhexidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002247276]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Florfenicol	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.79E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Ciprofloxacin hydrochloride monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.65E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Rifapentine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Azithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Clindamycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.65E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Clarithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Clinafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Tetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.65E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Linezolid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Moxifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Thiamphenicol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Oxytetracycline dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Rifampicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Furazolidone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Niridazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Carbadox	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Benzylpenicillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000349651]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Nadifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Gatifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Sarafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Rifaximin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Furaltadone hydrochloride	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Meropenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.06E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Erythromycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.06E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Josamycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.65E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Lincomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Nifuroxazide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.18E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Cefazolin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001081854]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Piperacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.22E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Roxithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Hexachlorophene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Alexidine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.97E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Tylosin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Novobiocin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.42E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Ticarcillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000495356]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Dirithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Spiramycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Niclosamide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Auranofin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008452406]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Closantel	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.38E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Fusidic acid sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Nitrofural	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000146181]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Thiostrepton	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Ronidazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Sparfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.06E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Rufloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.55E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Ornidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Troleandomycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.08E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Imipenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.72E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.65E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Cefoxitin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000133401]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Nifurtimox	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.31E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Secnidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Diacerein	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.17E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Monensin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009577361]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Chloroxine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Pentamidine isethionate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.56E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Merbromin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.26E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Nitrofurantoin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000677598]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Dicloxacillin sodium salt hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000376726]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Vancomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009237436]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Bacitracin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000135542]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Daunorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003770771]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Clioquinol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.60E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Enoxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.35E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Lomefloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	5-fluorouracil	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Flumequine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.60E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Oxethazaine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001467225]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Ofloxacin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.42E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Floxuridine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.32E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Pyrimethamine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Hexestrol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.01E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Pefloxacine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000878667]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Mafenide hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000631183]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Dienestrol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Zafirlukast	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001974927]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Diethylstilbestrol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001467284]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Tazobactam	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000165512]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Zidovudine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Trifluridine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Ethopropazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.14E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Tolfenamic acid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000524332]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Acarbose	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000404149]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Nalidixic acid sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002768125]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Oxolinic acid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003090159]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Ribavirin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007617779]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Pioglitazone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007046361]	High-throughput incubation assays	n.a.	PMID: 29555994
Bacteroides xylanisolvens	Cyclopenthiazide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002922821]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Rifabutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Doxycycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Chlortetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Tosufloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Minocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Meclocycline sulfosalicylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Demeclocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Methacycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Chlorhexidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Florfenicol	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Ciprofloxacin hydrochloride monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Rifapentine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Azithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Clindamycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Clarithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Clinafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Tetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Linezolid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Moxifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Thiamphenicol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Oxytetracycline dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Rifampicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Furazolidone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.17E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Niridazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Carbadox	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.06E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Benzylpenicillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Nadifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Gatifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Sarafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Rifaximin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.72E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Furaltadone hydrochloride	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.66E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Meropenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Erythromycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Josamycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Lincomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Nifuroxazide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.95E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Cefazolin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Piperacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Roxithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Hexachlorophene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.65E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Alexidine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.61E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Tylosin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Novobiocin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Ticarcillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Dirithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Spiramycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.70E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Niclosamide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Thimerosal	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Auranofin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Closantel	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Benzathine benzylpenicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Ampicillin trihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Cefotaxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Cefoperazone dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Amoxicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Fusidic acid sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Nitrofural	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000691798]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Thiostrepton	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Ronidazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.71E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Talampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Sparfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Cephalothin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Cefdinir	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Troleandomycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Ceforanide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Imipenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Phenethicillin potassium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.56E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Cefoxitin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Methyl benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Monensin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.58E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Pentamidine isethionate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Merbromin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000201053]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Nitrofurantoin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.19E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Cefuroxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Moxalactam disodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Ebselen	Therapeutic Substance	Investigational Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.68E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Cefepime hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Dicloxacillin sodium salt hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Cefotetan	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Vancomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Azlocillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Bacitracin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Daunorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Cefotiam hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Cefmetazole sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Triclosan	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000458844]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Dequalinium dichloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Flucloxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Loracarbef	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Isoconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004838051]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Clotrimazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.15E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Cloxacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Lomefloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.99E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Ceftazidime pentahydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Nafcillin sodium salt monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	5-fluorouracil	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Benzbromarone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004146819]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Oxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Bacampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Cefixime	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Thonzonium bromide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Ofloxacin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Norfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.50E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Trimethoprim	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Cefsulodin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Pivampicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Pyrimethamine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Doxorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Hexestrol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007296817]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Cefaclor hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Zafirlukast	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006721124]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Etoposide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000347105]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Loratadine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001480541]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Tazobactam	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Tiratricol, 3,3',5-triiodothyroacetic acid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.23E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Zidovudine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005860626]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Lacidipine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001704978]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium adolescentis	Propidium iodide	Environmental Chemicals	Unclassified Substance	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.55E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Rifabutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Doxycycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Chlortetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Tosufloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Minocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Meclocycline sulfosalicylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Demeclocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Methacycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.71E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Chlorhexidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Florfenicol	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Ciprofloxacin hydrochloride monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Rifapentine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Azithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Clindamycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Clarithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Clinafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.07E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Tetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Linezolid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Moxifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Thiamphenicol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Oxytetracycline dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Rifampicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Furazolidone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Niridazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Carbadox	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Benzylpenicillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Nadifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Gatifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Sarafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.96E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Rifaximin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Furaltadone hydrochloride	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Meropenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000153485]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Erythromycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Josamycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Lincomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Nifuroxazide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Cefazolin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Piperacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Roxithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Hexachlorophene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Alexidine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Tylosin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Novobiocin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Ticarcillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Dirithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Spiramycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Niclosamide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Closantel	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Benzathine benzylpenicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.40E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Ampicillin trihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Cefotaxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Cefoperazone dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Amoxicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Fusidic acid sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Nitrofural	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Thiostrepton	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Ronidazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Talampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.78E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Sparfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Cephalothin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Cefdinir	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.73E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Troleandomycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Imipenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Phenethicillin potassium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Nifurtimox	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.21E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Methyl benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Monensin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Pentamidine isethionate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Merbromin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.92E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Nitrofurantoin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Cefuroxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Moxalactam disodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Ebselen	Therapeutic Substance	Investigational Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Dicloxacillin sodium salt hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Vancomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Azlocillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Bacitracin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Daunorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Cefotiam hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Dequalinium dichloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Flucloxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.41E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Loracarbef	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Isoconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0065524]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Clotrimazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001890094]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Cloxacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.45E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Nafcillin sodium salt monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Oxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Bacampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Tioconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002922229]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Oxethazaine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.34E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Thonzonium bromide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Trimethoprim	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Pivampicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000779058]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Pyrimethamine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Terfenadine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.13E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Doxorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Zafirlukast	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Pyrvinium pamoate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.21E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Loratadine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00109898]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Amikacin hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007685758]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Avermectin B1a	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009131895]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Aprepitant	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008270317]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Pinaverium bromide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008178731]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Methiothepin maleate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000977939]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Amiodarone hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000413539]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Alfacalcidol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007674264]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Chlorotrianisene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003982696]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Propidium iodide	Environmental Chemicals	Unclassified Substance	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.48E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Spectinomycin dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Cyclosporin A	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003650878]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Dihydrostreptomycin sulfate	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Bifidobacterium longum	Naftopidil dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.67E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Rifabutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.50E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Doxycycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Chlortetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Tosufloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.02E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Minocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.56E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Meclocycline sulfosalicylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.14E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Demeclocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Methacycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Chlorhexidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Florfenicol	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Ciprofloxacin hydrochloride monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.35E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Rifapentine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.72E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Azithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Clindamycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Clarithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.50E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Clinafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.72E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Tetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Linezolid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.71E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Moxifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.12E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Thiamphenicol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.41E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Oxytetracycline dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.50E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Rifampicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Furazolidone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Niridazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Carbadox	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.53E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Benzylpenicillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.53E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Nadifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000310041]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Gatifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Sarafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.97E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Rifaximin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.28E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Furaltadone hydrochloride	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Meropenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.53E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Erythromycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Josamycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Lincomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.53E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Nifuroxazide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Cefazolin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.14E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Piperacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.50E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Roxithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Hexachlorophene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Alexidine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Tylosin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Novobiocin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Ticarcillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.56E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Dirithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Spiramycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.50E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Niclosamide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.05E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Thimerosal	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.88E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Auranofin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Closantel	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.72E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Benzathine benzylpenicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Ampicillin trihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.50E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Cefotaxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Cefoperazone dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.60E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Amoxicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.60E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Fusidic acid sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.77E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Nitrofural	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.50E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Thiostrepton	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.50E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Ronidazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.47E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Talampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Sparfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.71E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Cephalothin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.13E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Cefdinir	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Rufloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000338291]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Ornidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.41E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Troleandomycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.24E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Ceforanide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Imipenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Phenethicillin potassium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.50E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Cefoxitin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.77E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Nifurtimox	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Secnidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Methyl benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Diacerein	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Monensin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.52E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Chloroxine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.10E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Pentamidine isethionate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Merbromin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.59E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Nitrofurantoin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.52E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Cefuroxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.12E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Moxalactam disodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Ebselen	Therapeutic Substance	Investigational Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Cefepime hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.50E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Dicloxacillin sodium salt hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.79E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Cefotetan	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Vancomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Azlocillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Bacitracin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Daunorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.64E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Cefotiam hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Cefmetazole sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Clioquinol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.62E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Dequalinium dichloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.55E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Flucloxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.64E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Loracarbef	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Isoconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Clotrimazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.56E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Cloxacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.28E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Ceftazidime pentahydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.88E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Nafcillin sodium salt monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.50E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Miconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.03E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Benzbromarone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Oxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.04E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Flumequine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007130854]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Clofazimine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.15E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Bacampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.14E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Cefixime	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.62E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Tioconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.53E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Oxethazaine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.07E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Econazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.52E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Thonzonium bromide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Trimethoprim	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000181568]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Colistin sulfate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.67E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Cefsulodin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.81E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Oxiconazole Nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.14E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Pivampicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.43E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Bifonazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Doxorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000106944]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Hexestrol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.35E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Dienestrol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Cefaclor hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.20E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Butoconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.75E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Zafirlukast	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.23E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Etoposide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00016296]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Sertaconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.43E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Loratadine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.02E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Clemizole hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.46E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Diethylstilbestrol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000470942]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Sulconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Tiratricol, 3,3',5-triiodothyroacetic acid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.49E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Bepridil hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.81E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Azaguanine-8	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.84E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Troglitazone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.43E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Enilconazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Perhexiline maleate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000345879]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Clomiphene citrate (Z,E)	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003454674]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Avermectin B1a	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00063536]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Anthralin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Ketoconazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Astemizole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.39E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Entacapone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.71E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Aprepitant	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001204364]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Pinaverium bromide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.97E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Tolfenamic acid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001470956]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Methiothepin maleate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00025014]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Amiodarone hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.58E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Cephalosporanic acid, 7-amino	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.96E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Stanozolol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.95E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Gefitinib	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.45E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Suloctidil	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008448038]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Meclozine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00037081]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Lansoprazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.90E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Azathioprine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.94E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Hexetidine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.86E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Anethole-trithione	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.26E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Rabeprazole Sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.53E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Chlorotrianisene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004929581]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Propidium iodide	Environmental Chemicals	Unclassified Substance	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000452093]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Cyclosporin A	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004008817]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Ethaverine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.86E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Parbendazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.40E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Etomidate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009471157]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Vardenafil	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001064221]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Vecuronium bromide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000140478]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.49E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Cinnarizine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001296087]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Epirizole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.00E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Cefadroxil	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000723187]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Fenbendazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002022672]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Atovaquone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005811135]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Acenocoumarol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.21E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Bosentan	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.36E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Blautia obeum	Oxibendazol	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00615387]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Rifabutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Doxycycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Chlortetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.21E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Tosufloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.41E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.03E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Minocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Meclocycline sulfosalicylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.57E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Demeclocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Methacycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Chlorhexidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.09E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Florfenicol	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Ciprofloxacin hydrochloride monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.54E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Rifapentine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.46E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Azithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.63E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Clindamycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.27E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Clarithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Clinafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Tetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.19E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Linezolid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.54E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Moxifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.56E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Thiamphenicol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.02E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Oxytetracycline dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Rifampicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Furazolidone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Niridazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.45E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Carbadox	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Nadifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Gatifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.76E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Sarafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Rifaximin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Furaltadone hydrochloride	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Meropenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.79E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Erythromycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.46E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Josamycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.14E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Lincomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Nifuroxazide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.57E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Roxithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.26E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Hexachlorophene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Tylosin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Novobiocin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Dirithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.39E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Spiramycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Niclosamide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00243064]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Thimerosal	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Auranofin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Closantel	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.64E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Cefotaxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000524699]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Cefoperazone dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.28E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Amoxicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004980222]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Fusidic acid sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Nitrofural	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001738587]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Ronidazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001096791]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Sparfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.54E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.23E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Rufloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.67E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Ornidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Troleandomycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.17E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Imipenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00012308]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.15E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Cefoxitin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.32E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Nifurtimox	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Secnidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Methyl benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000196949]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Diacerein	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Monensin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Chloroxine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.70E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Merbromin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.43E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Nitrofurantoin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Moxalactam disodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Ebselen	Therapeutic Substance	Investigational Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004717236]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Cefepime hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.48E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Dicloxacillin sodium salt hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.26E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Cefotetan	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.60E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Vancomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Bacitracin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Daunorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.71E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Cefmetazole sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.44E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Clioquinol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.36E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Triclosan	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00282779]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Flucloxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.47E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Enoxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.10E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Isoconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.45E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Clotrimazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.83E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Cloxacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.08E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Lomefloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0001362]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Ceftazidime pentahydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.40E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Miconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001159592]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	5-fluorouracil	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000661825]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Benzbromarone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.20E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Oxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001031773]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Flumequine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00027409]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Tioconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.75E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Econazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.33E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Streptozotocin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Norfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.58E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Trimethoprim	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Cefsulodin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003531295]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Oxiconazole Nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000530647]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Bifonazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002100295]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Pyrimethamine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004374242]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Doxorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.15E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Pefloxacine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001863675]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Mafenide hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009606166]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Butoconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000926063]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Etoposide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.30E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Sertaconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000327625]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Sulconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00575307]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Bepridil hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00132593]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Azaguanine-8	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000516951]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Methotrexate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000117098]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Amethopterin (R,S)	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.99E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Anthralin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006857437]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Entacapone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.10E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Hycanthone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000289776]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Ethacrynic acid	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005559527]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Quinacrine dihydrochloride dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008674811]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Haloprogin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005736582]	High-throughput incubation assays	n.a.	PMID: 29555994
Enterocloster bolteae	Aripiprazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002537439]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Rifabutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.61E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Doxycycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.17E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Chlortetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.77E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Tosufloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.07E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.06E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Minocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Meclocycline sulfosalicylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.19E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Demeclocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00021134]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Methacycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.86E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Chlorhexidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.18E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Florfenicol	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Ciprofloxacin hydrochloride monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Rifapentine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Clindamycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000619008]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Clinafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.06E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Tetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001313179]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Linezolid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Moxifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Thiamphenicol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.12E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Oxytetracycline dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00061907]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Rifampicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.06E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Furazolidone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Niridazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Carbadox	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.84E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Benzylpenicillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Nadifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.76E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Gatifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.16E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Sarafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.15E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Rifaximin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001835278]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Furaltadone hydrochloride	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004692789]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Nifuroxazide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.68E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Piperacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001117861]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Hexachlorophene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.32E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Alexidine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00079853]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Tylosin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.25E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Novobiocin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.28E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Ticarcillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Niclosamide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.08E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Thimerosal	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000234995]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Auranofin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.39E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Closantel	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Benzathine benzylpenicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.16E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Ampicillin trihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.46E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Amoxicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Fusidic acid sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.64E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Nitrofural	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000103471]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000171892]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Thiostrepton	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.16E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Ronidazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.13E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Talampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.71E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Sparfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000638361]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.06E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Rufloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000100702]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Ornidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.10E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Ceforanide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.34E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Phenethicillin potassium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.30E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.20E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Nifurtimox	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.07E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Secnidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.29E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Methyl benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000185668]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Diacerein	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.37E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Monensin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.37E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Chloroxine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Merbromin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.55E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Moxalactam disodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.66E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Vancomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.05E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Azlocillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001584198]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Bacitracin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000254074]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Daunorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001440752]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Clioquinol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000247101]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Triclosan	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000562878]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Enoxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003421461]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Isoconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004646157]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Lomefloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001423006]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Nafcillin sodium salt monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003996211]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	5-fluorouracil	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.71E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Benzbromarone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.08E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Flumequine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000380382]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Clofazimine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.19E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Tioconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00469744]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Streptozotocin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000328272]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Norfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002546255]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Terfenadine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00739182]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Doxorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001734051]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Zafirlukast	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.21E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Felodipine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000202694]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Tiratricol, 3,3',5-triiodothyroacetic acid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000126633]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Azaguanine-8	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004646898]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Troglitazone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.47E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Perhexiline maleate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005306086]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Tobramycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005212897]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Avermectin B1a	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009795205]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Anthralin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009586015]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Dicumarol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006726948]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Diclazuril	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007631742]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Montelukast	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000869382]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Fendiline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006460559]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Meclozine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001293302]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Azathioprine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.13E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Lacidipine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001391325]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Cilnidipine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001096233]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Telmisartan	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.63E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Mercaptopurine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.08E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Mifepristone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000404149]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Amlodipine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008944477]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Carbenoxolone disodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002796885]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Tribenoside	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004733857]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Fentiazac	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000634437]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridioides difficile	Gliquidone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006069732]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Rifabutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.96E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Doxycycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.11E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Chlortetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Tosufloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.57E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Minocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Meclocycline sulfosalicylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Demeclocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Methacycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Chlorhexidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Florfenicol	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Ciprofloxacin hydrochloride monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Rifapentine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Azithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.40E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Clindamycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Clarithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Clinafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.28E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Tetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Linezolid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Moxifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Thiamphenicol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.57E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Oxytetracycline dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Rifampicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.33E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Furazolidone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.33E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Niridazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Carbadox	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.64E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Benzylpenicillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.52E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Nadifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Gatifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.53E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Sarafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.52E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Rifaximin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Furaltadone hydrochloride	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.10E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Meropenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Erythromycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Josamycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Lincomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Nifuroxazide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.46E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Cefazolin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Piperacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Roxithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.27E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Hexachlorophene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Alexidine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Tylosin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Novobiocin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.56E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Ticarcillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Dirithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.33E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Spiramycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Niclosamide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Thimerosal	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.08E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Auranofin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.33E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Closantel	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Benzathine benzylpenicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Ampicillin trihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Cefotaxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Cefoperazone dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.52E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Amoxicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Fusidic acid sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Nitrofural	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.90E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Thiostrepton	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.36E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Ronidazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Talampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Sparfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.77E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Cephalothin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Cefdinir	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.78E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Rufloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.07E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Ornidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Troleandomycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.33E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Ceforanide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Imipenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.36E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Phenethicillin potassium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Cefoxitin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.28E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Nifurtimox	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Secnidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Methyl benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.12E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Diacerein	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Monensin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Chloroxine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Pentamidine isethionate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.37E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Merbromin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005474974]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Nitrofurantoin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.87E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Cefuroxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Moxalactam disodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.33E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Ebselen	Therapeutic Substance	Investigational Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.32E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Cefepime hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Dicloxacillin sodium salt hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.52E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Cefotetan	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Vancomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.36E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Azlocillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.28E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Bacitracin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Daunorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000283455]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Cefotiam hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.35E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Cefmetazole sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.54E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Clioquinol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Triclosan	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.10E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Dequalinium dichloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Flucloxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.59E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Enoxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.05E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Loracarbef	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.77E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Isoconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.58E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Clotrimazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.16E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Cloxacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.77E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Lomefloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Ceftazidime pentahydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.41E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Nafcillin sodium salt monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.29E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Miconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.43E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	5-fluorouracil	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000100844]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Benzbromarone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Oxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Flumequine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Clofazimine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Bacampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Cefixime	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Tioconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.98E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Oxethazaine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.47E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Econazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.23E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Thonzonium bromide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001820012]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Ofloxacin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Streptozotocin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.21E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Lymecycline	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Norfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Trimethoprim	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004419677]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Cefsulodin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.70E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Oxiconazole Nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.73E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Floxuridine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.43E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Pivampicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.80E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Bifonazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.35E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Terfenadine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008990004]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Doxorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00294464]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Hexestrol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001729015]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Pefloxacine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Cefaclor hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.40E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Butoconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.59E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Zafirlukast	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.77E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Felodipine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.46E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Etoposide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000185636]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Sertaconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.73E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Pyrvinium pamoate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000981233]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Loratadine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000221323]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Clemizole hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Diethylstilbestrol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006417648]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Sulconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.08E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Tiratricol, 3,3',5-triiodothyroacetic acid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.06E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Bepridil hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004788164]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Troglitazone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.87E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Thioridazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.83E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Enilconazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000451654]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Zidovudine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000568494]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Methotrexate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000253827]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Amethopterin (R,S)	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Avermectin B1a	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000468584]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Anthralin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000893552]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Estradiol Valerate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00147683]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Fleroxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.88E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Ketoconazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004209638]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Dicumarol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009617755]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Diclazuril	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005776539]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Montelukast	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.55E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Alfacalcidol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.63E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Toltrazuril	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007164988]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Acarbose	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000436959]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Lacidipine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00390871]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Ethacrynic acid	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001641042]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Chlorpromazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000926722]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Tolnaftate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007289477]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Cyclosporin A	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.26E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Nalidixic acid sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008240679]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Oxolinic acid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.67E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Cinoxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Telmisartan	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007239027]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Idebenone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004608193]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Thioguanosine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00037355]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Indatraline hydrochloride	Environmental Chemicals	Unclassified Substance	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00684289]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Gemcitabine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.50E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Carbenoxolone disodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.87E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Etretinate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000341198]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Paclitaxel	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.59E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Phenindione	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00940513]	High-throughput incubation assays	n.a.	PMID: 29555994
Clostridium perfringens	Azacytidine-5	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.19E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Rifabutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Doxycycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Chlortetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.80E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Tosufloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.56E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Minocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Meclocycline sulfosalicylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Demeclocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.84E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Methacycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.26E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Chlorhexidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.61E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Florfenicol	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.87E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Ciprofloxacin hydrochloride monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.42E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Azithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Clindamycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.88E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Clarithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Clinafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Tetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.05E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Linezolid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.10E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Moxifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.28E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Thiamphenicol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000176723]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Oxytetracycline dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Furazolidone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Niridazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.22E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Carbadox	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Benzylpenicillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Nadifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Gatifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.73E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Sarafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Furaltadone hydrochloride	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Erythromycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.73E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Josamycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.03E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Lincomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Nifuroxazide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Cefazolin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.06E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Piperacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Roxithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.94E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Hexachlorophene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.87E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Alexidine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.86E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Tylosin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Novobiocin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.57E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Ticarcillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.43E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Dirithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000158672]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Spiramycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.90E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Niclosamide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Thimerosal	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.13E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Auranofin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.91E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Closantel	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.91E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Benzathine benzylpenicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.53E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Ampicillin trihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.36E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Cefotaxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.25E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Cefoperazone dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Amoxicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Fusidic acid sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Nitrofural	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000215531]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Thiostrepton	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Ronidazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.63E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Talampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.53E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Sparfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000217474]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Cephalothin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.01E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.89E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Cefdinir	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003441605]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Ornidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.47E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Troleandomycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.15E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Ceforanide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002743209]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Imipenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000469876]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Phenethicillin potassium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.82E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Nifurtimox	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.25E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Secnidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.30E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Diacerein	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.84E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Monensin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.87E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Chloroxine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.61E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Nitrofurantoin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Cefuroxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Moxalactam disodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Ebselen	Therapeutic Substance	Investigational Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.83E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Cefepime hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Cefotetan	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009455871]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Vancomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Azlocillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Daunorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Cefotiam hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Clioquinol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000213422]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Triclosan	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001307245]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Dequalinium dichloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005301499]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Flucloxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000964707]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Isoconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.53E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Clotrimazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.21E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Ceftazidime pentahydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.93E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Nafcillin sodium salt monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007815455]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Miconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.98E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	5-fluorouracil	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000491757]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Benzbromarone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.51E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Oxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0078121]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Flumequine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002583972]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Clofazimine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.58E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Bacampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.62E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Tioconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Oxethazaine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.99E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Econazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.34E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Thonzonium bromide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001779948]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Streptozotocin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.86E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Lymecycline	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.66E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Trimethoprim	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.34E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Oxiconazole Nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.90E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Floxuridine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.74E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Pivampicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001023755]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Bifonazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000102773]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Pyrimethamine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.87E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Doxorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.70E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Butoconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.75E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Zafirlukast	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.73E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Sertaconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000770567]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Clemizole hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00034551]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Sulconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00080865]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Tiratricol, 3,3',5-triiodothyroacetic acid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000533178]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Troglitazone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000283823]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Enilconazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001027896]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Methotrexate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.34E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Amethopterin (R,S)	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.37E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Trifluridine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.41E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Idebenone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000661483]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Folic acid	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017316]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Disulfiram	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001296427]	High-throughput incubation assays	n.a.	PMID: 29555994
Erysipelatoclostridium ramosum	Dacarbazine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000695859]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Rifabutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Doxycycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.76E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Chlortetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.47E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Tosufloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.02E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Minocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Meclocycline sulfosalicylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Demeclocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.22E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Methacycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Chlorhexidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Florfenicol	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Ciprofloxacin hydrochloride monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00030367]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Rifapentine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.33E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Azithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Clindamycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Clarithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.02E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Clinafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.64E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Tetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.82E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Linezolid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Moxifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.13E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Thiamphenicol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.32E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Oxytetracycline dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Rifampicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Furazolidone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Niridazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.39E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Carbadox	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Benzylpenicillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Nadifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.31E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Gatifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.01E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Sarafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.35E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Rifaximin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.60E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Furaltadone hydrochloride	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.52E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Meropenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.53E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Erythromycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.47E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Josamycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.77E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Lincomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Nifuroxazide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.23E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Cefazolin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Piperacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.22E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Roxithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Hexachlorophene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Alexidine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.40E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Tylosin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.77E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Novobiocin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005906099]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Ticarcillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.49E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Dirithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000601093]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Spiramycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.25E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Niclosamide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00181158]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Thimerosal	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.31E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Auranofin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.17E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Closantel	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.14E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Benzathine benzylpenicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Ampicillin trihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.14E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Cefotaxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Cefoperazone dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Amoxicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Fusidic acid sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Nitrofural	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.06E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Thiostrepton	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Ronidazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.16E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Talampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Cephalothin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.02E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Cefdinir	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Rufloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000138652]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Ornidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Troleandomycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Ceforanide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003205469]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Phenethicillin potassium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.77E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Cefoxitin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.06E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Nifurtimox	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Secnidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.79E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Methyl benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.11E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Diacerein	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.78E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Monensin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Chloroxine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.94E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Pentamidine isethionate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.53E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Merbromin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.42E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Cefuroxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.87E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Moxalactam disodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.15E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Ebselen	Therapeutic Substance	Investigational Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00013664]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Cefepime hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Dicloxacillin sodium salt hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Cefotetan	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.79E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Vancomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Azlocillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Bacitracin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.80E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Daunorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002397008]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Cefmetazole sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Clioquinol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Triclosan	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007296105]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Dequalinium dichloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000117411]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Flucloxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.78E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Isoconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.02E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Clotrimazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000100937]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Cloxacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Ceftazidime pentahydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.02E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Nafcillin sodium salt monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.79E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Miconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Benzbromarone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000263951]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Oxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Flumequine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007412673]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Bacampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.58E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Cefixime	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.66E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Tioconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.46E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Oxethazaine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.41E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Econazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.98E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Streptozotocin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Lymecycline	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Cefsulodin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.14E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Oxiconazole Nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.84E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Bifonazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002742893]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Hexestrol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000130388]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Mafenide hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003535641]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Butoconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001497309]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Tamoxifen citrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000631234]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Etoposide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.41E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Clemizole hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000110855]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Diethylstilbestrol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008553647]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Tiratricol, 3,3',5-triiodothyroacetic acid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000314737]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Azaguanine-8	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Tobramycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000202747]	High-throughput incubation assays	n.a.	PMID: 29555994
Lacrimispora saccharolytica	Thyroxine (L)	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001274877]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Rifabutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Doxycycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.79E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Chlortetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Tosufloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Minocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.92E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Meclocycline sulfosalicylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Demeclocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Methacycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.25E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Chlorhexidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Florfenicol	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Ciprofloxacin hydrochloride monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Rifapentine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Azithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Clindamycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Clarithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Clinafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Tetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Linezolid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Moxifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Thiamphenicol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Oxytetracycline dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.79E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Rifampicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.80E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Furazolidone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Niridazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Carbadox	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Benzylpenicillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.85E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Nadifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Gatifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Sarafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.80E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Rifaximin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Furaltadone hydrochloride	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Meropenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Erythromycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Josamycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Lincomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.78E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Nifuroxazide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.63E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Cefazolin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Piperacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Roxithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Hexachlorophene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Alexidine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Tylosin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Novobiocin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Ticarcillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.71E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Dirithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.82E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Spiramycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Niclosamide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Thimerosal	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.95E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Auranofin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Closantel	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Benzathine benzylpenicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.25E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Ampicillin trihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Cefotaxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Cefoperazone dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Amoxicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Fusidic acid sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Nitrofural	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.80E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Thiostrepton	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.80E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Ronidazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Talampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.37E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Sparfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Cephalothin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.86E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Cefdinir	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.81E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Rufloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00692846]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Ornidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Troleandomycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Ceforanide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Imipenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Phenethicillin potassium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Cefoxitin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Nifurtimox	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Secnidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Methyl benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.37E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Diacerein	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Monensin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Chloroxine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000164863]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Pentamidine isethionate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000138066]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Merbromin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.79E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Nitrofurantoin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Cefuroxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Moxalactam disodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Ebselen	Therapeutic Substance	Investigational Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Cefepime hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.72E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Dicloxacillin sodium salt hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Cefotetan	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000977135]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Vancomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Azlocillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Bacitracin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Daunorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Cefotiam hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.78E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Cefmetazole sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Dequalinium dichloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.05E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Flucloxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.44E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Enoxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000426771]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Loracarbef	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Isoconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Clotrimazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Cloxacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Lomefloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Ceftazidime pentahydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0001689]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Nafcillin sodium salt monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Miconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Benzbromarone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004132065]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Oxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Clofazimine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.32E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Bacampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Cefixime	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Tioconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Oxethazaine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.14E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Econazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Thonzonium bromide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Ofloxacin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Streptozotocin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.49E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Lymecycline	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.52E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Norfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Cefsulodin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Oxiconazole Nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Pivampicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.27E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Bifonazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Terfenadine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001404915]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Doxorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Pefloxacine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.31E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Cefaclor hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.80E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Butoconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Tamoxifen citrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003379116]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Etoposide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Sertaconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Pyrvinium pamoate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000275271]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Loratadine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000295286]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Clemizole hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Sulconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Bepridil hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001027457]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Enilconazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.98E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Perhexiline maleate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001915979]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Clomiphene citrate (Z,E)	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002315632]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Amikacin hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002376626]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Tobramycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Fleroxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Ketoconazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002306283]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Entacapone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009152734]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Methiothepin maleate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003241472]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Amiodarone hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001134983]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Cephalosporanic acid, 7-amino	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.43E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Stanozolol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008783433]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Chlorprothixene hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006089512]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Meclozine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.51E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Azathioprine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00322275]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Zuclopenthixol dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004949573]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Apramycin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.84E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Butenafine Hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.15E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Chlorotrianisene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000149994]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Propidium iodide	Environmental Chemicals	Unclassified Substance	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001348701]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Mercaptopurine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002094487]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Proadifen hydrochloride	Environmental Chemicals	Unclassified Substance	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004225595]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Asenapine maleate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006518934]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Cladribine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.80E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Cinnarizine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001760582]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Nilutamide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001197623]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Ribostamycin sulfate salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002052349]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Ibutilide fumarate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005740186]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Prilocaine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000109489]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006949505]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Estropipate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009514871]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Guanadrel sulfate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008720694]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Nimodipine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009606651]	High-throughput incubation assays	n.a.	PMID: 29555994
Collinsella aerofaciens	Amiprilose hydrochloride	Environmental Chemicals	Unclassified Substance	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004929581]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Rifabutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Doxycycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.11E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Chlortetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.80E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Tosufloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Minocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Meclocycline sulfosalicylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.69E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Demeclocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Methacycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Chlorhexidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.88E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Florfenicol	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Ciprofloxacin hydrochloride monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.04E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Rifapentine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Azithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.11E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Clindamycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.78E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Clarithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Clinafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Tetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.76E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Linezolid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Moxifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Thiamphenicol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Oxytetracycline dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Rifampicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.12E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Furazolidone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Niridazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Carbadox	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Benzylpenicillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Nadifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Gatifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.16E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Sarafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.28E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Rifaximin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Furaltadone hydrochloride	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Meropenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Erythromycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.73E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Josamycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.77E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Lincomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Nifuroxazide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.11E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Cefazolin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.76E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Piperacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Roxithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Hexachlorophene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Alexidine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Tylosin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Novobiocin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.13E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Ticarcillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Dirithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.13E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Spiramycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Niclosamide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.18E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Thimerosal	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.56E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Auranofin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Closantel	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Benzathine benzylpenicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Ampicillin trihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.88E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Cefotaxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.95E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Cefoperazone dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Amoxicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Fusidic acid sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Nitrofural	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.10E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Ronidazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Talampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Sparfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.84E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Cephalothin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.66E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Cefdinir	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.12E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Rufloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.66E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Ornidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Troleandomycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.73E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Ceforanide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Imipenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.12E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Phenethicillin potassium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.67E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Cefoxitin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Nifurtimox	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Secnidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Methyl benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Diacerein	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Monensin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Chloroxine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.73E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Pentamidine isethionate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.13E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Merbromin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Nitrofurantoin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Cefuroxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Moxalactam disodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Ebselen	Therapeutic Substance	Investigational Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Cefepime hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Dicloxacillin sodium salt hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Cefotetan	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Vancomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.12E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Azlocillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Bacitracin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Daunorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.10E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Cefotiam hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.12E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Cefmetazole sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Clioquinol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Triclosan	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004056104]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Dequalinium dichloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000849895]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Flucloxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Enoxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.56E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Loracarbef	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Isoconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.76E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Clotrimazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Cloxacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.73E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Lomefloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005069808]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Ceftazidime pentahydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.12E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Nafcillin sodium salt monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Miconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	5-fluorouracil	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007454688]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Benzbromarone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000759868]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Oxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Clofazimine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002866397]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Bacampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.73E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Tioconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.77E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Oxethazaine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Econazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Thonzonium bromide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Streptozotocin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.74E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Norfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000417653]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Colistin sulfate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00343082]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Cefsulodin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Oxiconazole Nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.66E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Pivampicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Bifonazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Terfenadine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00052388]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Doxorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000769478]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Pefloxacine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002624633]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Mafenide hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.19E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Dienestrol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Cefaclor hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004828422]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Butoconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Zafirlukast	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000165081]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Felodipine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001136075]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Tamoxifen citrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000283328]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Etoposide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.25E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Sertaconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Loratadine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000241584]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Clemizole hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Sulconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Tiratricol, 3,3',5-triiodothyroacetic acid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008944881]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Mefloquine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000296205]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Azaguanine-8	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Troglitazone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003892562]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Enilconazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Perhexiline maleate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00112447]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Clomiphene citrate (Z,E)	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003489629]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Amikacin hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000110866]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Avermectin B1a	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006347589]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Anthralin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000493545]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Estradiol Valerate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000199681]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Ketoconazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004739732]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Astemizole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005017795]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Entacapone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000207101]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Amiodarone hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.04E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Stanozolol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.70E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Diclazuril	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009519216]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Montelukast	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000234948]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Gefitinib	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000233009]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Fendiline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003648773]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Suloctidil	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000432177]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Lansoprazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.66E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Alfacalcidol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000508931]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Azathioprine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000735586]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Hycanthone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005921662]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Anethole-trithione	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003428591]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Lacidipine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009136971]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Spectinomycin dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.96E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Quinacrine dihydrochloride dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002051243]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Thiethylperazine dimalate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004408996]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Vardenafil	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006625292]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Mercaptopurine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000355458]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Iohexol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.15E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Indatraline hydrochloride	Environmental Chemicals	Unclassified Substance	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008151822]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Famotidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.96E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Oxaprozin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005356222]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Methantheline bromide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008706801]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Ziprasidone Hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003648773]	High-throughput incubation assays	n.a.	PMID: 29555994
Coprococcus comes	Alverine citrate salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006749194]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Rifabutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Doxycycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Chlortetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.03E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Tosufloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.08E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.96E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Minocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Meclocycline sulfosalicylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.40E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Demeclocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Methacycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Chlorhexidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.15E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Florfenicol	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Ciprofloxacin hydrochloride monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.31E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Rifapentine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Azithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Clindamycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Clarithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Clinafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.23E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Tetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Linezolid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Moxifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000150075]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Thiamphenicol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.96E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Oxytetracycline dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Rifampicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.13E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Furazolidone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Niridazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Carbadox	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.97E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Benzylpenicillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Gatifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000227146]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Sarafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.68E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Rifaximin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Furaltadone hydrochloride	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Meropenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Erythromycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Josamycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Lincomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Nifuroxazide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.42E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Cefazolin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.43E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Piperacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Roxithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Hexachlorophene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Alexidine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Tylosin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Novobiocin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.05E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Ticarcillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Dirithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Spiramycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Niclosamide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00821249]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Thimerosal	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.63E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Auranofin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Closantel	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Benzathine benzylpenicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Ampicillin trihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00023782]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Cefotaxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.35E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Cefoperazone dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Amoxicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Fusidic acid sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Nitrofural	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Thiostrepton	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Ronidazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Talampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Cephalothin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.27E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Cefdinir	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.07E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Rufloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002419759]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Ornidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Troleandomycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.11E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Ceforanide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Imipenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.07E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Phenethicillin potassium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Cefoxitin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Nifurtimox	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Secnidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Methyl benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Diacerein	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Monensin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Chloroxine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.30E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Pentamidine isethionate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.32E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Merbromin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Nitrofurantoin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.43E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Cefuroxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Moxalactam disodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Ebselen	Therapeutic Substance	Investigational Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.61E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Cefepime hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Dicloxacillin sodium salt hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Cefotetan	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Vancomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.09E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Azlocillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Bacitracin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Daunorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.92E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Cefotiam hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Cefmetazole sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Clioquinol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Flucloxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Enoxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006943422]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Loracarbef	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.71E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Isoconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Clotrimazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Cloxacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.46E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Ceftazidime pentahydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Nafcillin sodium salt monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Miconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.06E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Oxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Clofazimine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.46E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Bacampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.38E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Cefixime	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Tioconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.17E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Oxethazaine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.98E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Econazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Thonzonium bromide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Colistin sulfate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004285355]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Cefsulodin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Oxiconazole Nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.71E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Pivampicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Bifonazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Terfenadine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004498]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Doxorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003450843]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Mafenide hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0084923]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Dienestrol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000842546]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Cefaclor hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000121143]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Butoconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Etoposide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000387379]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Sertaconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Loratadine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Clemizole hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Sulconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Bepridil hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009131912]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Mefloquine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000361304]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Azaguanine-8	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00112447]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Enilconazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Perhexiline maleate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001634087]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Ketoconazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Astemizole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0003577]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Entacapone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.06E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Pinaverium bromide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005395687]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Stanozolol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.27E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Gefitinib	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.68E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Aztreonam	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Lansoprazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.31E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.32E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Hexetidine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003042737]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Anethole-trithione	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.39E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Rabeprazole Sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.06E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Chlorotrianisene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008706801]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Ethaverine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.84E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Parbendazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003381699]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Vecuronium bromide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000745054]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000758779]	High-throughput incubation assays	n.a.	PMID: 29555994
Dorea formicigenerans	Leflunomide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002219157]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Rifabutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.87E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Doxycycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.76E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Chlortetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.24E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Tosufloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.91E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.56E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Minocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.00E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Meclocycline sulfosalicylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.51E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Demeclocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.27E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Methacycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.26E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Chlorhexidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.16E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Florfenicol	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.21E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Ciprofloxacin hydrochloride monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.69E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Rifapentine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.67E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Azithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.76E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Clindamycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.22E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Clarithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.24E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Clinafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.58E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Tetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.26E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Linezolid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.52E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Moxifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.24E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Thiamphenicol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.58E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Oxytetracycline dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.00E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Rifampicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.77E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Furazolidone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.37E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Niridazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.87E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Carbadox	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.22E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Benzylpenicillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.05E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Nadifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.76E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Gatifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.18E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Sarafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.23E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Rifaximin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.28E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Furaltadone hydrochloride	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.80E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Meropenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.39E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Erythromycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.50E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Josamycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.28E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Lincomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.00E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Nifuroxazide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001029457]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Cefazolin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003422085]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Piperacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.77E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Roxithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.74E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Hexachlorophene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.48E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Alexidine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.37E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Tylosin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.07E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Novobiocin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.91E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Ticarcillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.01E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Dirithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.70E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Spiramycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.16E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Niclosamide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.67E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Auranofin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Closantel	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.07E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Benzathine benzylpenicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Ampicillin trihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.30E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Cefotaxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001552307]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Cefoperazone dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000290109]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Amoxicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.10E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Fusidic acid sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.58E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Nitrofural	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.39E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.17E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Thiostrepton	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.19E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Ronidazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001088287]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Talampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.36E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Sparfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.51E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Cephalothin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006144696]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.10E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Cefdinir	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.07E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Rufloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000779058]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Ornidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.00E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Troleandomycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002482895]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Imipenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001496762]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Phenethicillin potassium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.64E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.55E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Cefoxitin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.77E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Nifurtimox	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.14E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Secnidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.89E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Methyl benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.70E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Diacerein	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.68E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Monensin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.72E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Chloroxine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00019363]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Pentamidine isethionate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009392496]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Nitrofurantoin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000110867]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Moxalactam disodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.56E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Ebselen	Therapeutic Substance	Investigational Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000166937]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Dicloxacillin sodium salt hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000963399]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Cefotetan	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001088834]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Vancomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.02E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Azlocillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.87E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Bacitracin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000281578]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Daunorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.30E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Cefotiam hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006630414]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Cefmetazole sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.64E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Clioquinol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006477672]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Triclosan	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.62E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Dequalinium dichloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.03E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Flucloxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000136718]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Enoxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.32E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Loracarbef	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.96E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Isoconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000206272]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Lomefloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.27E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Nafcillin sodium salt monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.32E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Miconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001003844]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	5-fluorouracil	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002535612]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Flumequine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.06E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Clofazimine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000207238]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Bacampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.73E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Tioconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000445674]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Econazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001653916]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Thonzonium bromide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000320991]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Ofloxacin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.23E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Lymecycline	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Norfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.25E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Trimethoprim	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000105176]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Colistin sulfate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000483527]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Floxuridine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001923619]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Pivampicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002615896]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Pyrimethamine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004328366]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Doxorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.47E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Pefloxacine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.32E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Cefaclor hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.19E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Pyrvinium pamoate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.47E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Tiratricol, 3,3',5-triiodothyroacetic acid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006216034]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Tobramycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.06E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Anthralin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000150815]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Fleroxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Azathioprine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007574365]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Haloperidol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00721154]	High-throughput incubation assays	n.a.	PMID: 29555994
Eggerthella lenta	Bufexamac	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00773707]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Rifabutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.18E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Doxycycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.13E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Chlortetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.17E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Tosufloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.20E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.88E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Minocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.15E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Meclocycline sulfosalicylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.18E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Demeclocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.16E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Methacycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.15E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Chlorhexidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.15E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Florfenicol	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.16E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Ciprofloxacin hydrochloride monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.16E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Rifapentine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.57E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Azithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.00E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Clarithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.94E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Clinafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.20E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Tetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.15E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Moxifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.17E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Thiamphenicol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002697598]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Oxytetracycline dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.15E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Rifampicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.24E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Furazolidone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.15E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Niridazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.24E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Carbadox	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.16E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Benzylpenicillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00405416]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Nadifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.24E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Gatifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.18E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Sarafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.19E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Rifaximin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.88E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Furaltadone hydrochloride	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.39E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Meropenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.87E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Nifuroxazide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Cefazolin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.20E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Piperacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Hexachlorophene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006329494]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Alexidine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.47E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Novobiocin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.02E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Thimerosal	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000154779]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Ampicillin trihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.27E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Cefotaxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.19E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Cefoperazone dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.22E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Amoxicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.58E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Nitrofural	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.28E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Talampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000384468]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Sparfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.22E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Cephalothin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.53E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Cefdinir	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.24E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Rufloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.34E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Ceforanide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.39E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Cefoxitin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.40E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Nitrofurantoin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.02E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Cefuroxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.75E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Moxalactam disodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.39E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Cefepime hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.17E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Cefotetan	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.24E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Cefotiam hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.20E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Cefmetazole sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.31E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Triclosan	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.20E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Enoxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.26E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Loracarbef	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.53E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Lomefloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.88E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Ceftazidime pentahydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.26E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	5-fluorouracil	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.41E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Flumequine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.95E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Cefixime	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.27E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Ofloxacin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.88E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Streptozotocin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.26E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Norfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.85E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Trimethoprim	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.05E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Colistin sulfate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.15E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Floxuridine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.38E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Pefloxacine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.20E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Zidovudine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.54E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Fleroxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.16E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Aztreonam	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.99E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Idoxuridine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000843474]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Nalidixic acid sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001295934]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Oxolinic acid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.91E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Cinoxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.41E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Pipemidic acid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.77E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Thioguanosine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.97E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli ED1a	Pivmecillinam hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.05E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Rifabutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.22E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Doxycycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.72E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Chlortetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Tosufloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Minocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Meclocycline sulfosalicylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Demeclocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Methacycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Chlorhexidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Florfenicol	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Ciprofloxacin hydrochloride monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Rifapentine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.13E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Azithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.20E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Clindamycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000619485]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Clarithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.19E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Clinafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Tetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Linezolid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007723953]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Moxifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Thiamphenicol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Oxytetracycline dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Rifampicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.62E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Furazolidone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Niridazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Carbadox	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Benzylpenicillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00126153]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Nadifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Gatifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Sarafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Rifaximin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000751721]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Furaltadone hydrochloride	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Meropenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Nifuroxazide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.90E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Cefazolin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Piperacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Alexidine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005361641]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Novobiocin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.67E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Thimerosal	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Ampicillin trihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Cefotaxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Cefoperazone dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Amoxicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.05E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Nitrofural	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.41E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Talampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Sparfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Cephalothin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Cefdinir	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.00E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Rufloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Ceforanide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Imipenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.99E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Cefoxitin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Nitrofurantoin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.78E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Cefuroxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Moxalactam disodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Cefepime hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Cefotetan	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Cefotiam hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Cefmetazole sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Triclosan	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Enoxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Loracarbef	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Lomefloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Ceftazidime pentahydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.03E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	5-fluorouracil	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002511467]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Flumequine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Cefixime	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Ofloxacin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Norfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Trimethoprim	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Colistin sulfate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Floxuridine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.17E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Pefloxacine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Zidovudine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Fleroxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Aztreonam	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.72E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Nalidixic acid sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000480935]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Oxolinic acid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Cinoxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Pipemidic acid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Cladribine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.73E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Thioguanosine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.33E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Pivmecillinam hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Fexofenadine HCl	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008281463]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Fludarabine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00022021]	High-throughput incubation assays	n.a.	PMID: 29555994
Escherichia coli IAI1	Fluorometholone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005527231]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Rifabutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Doxycycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.58E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Chlortetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.02E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Tosufloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.77E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.91E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Minocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.87E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Meclocycline sulfosalicylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.06E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Demeclocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.99E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Methacycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.48E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Chlorhexidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Florfenicol	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.41E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Ciprofloxacin hydrochloride monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.53E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Rifapentine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.77E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Azithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.58E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Clindamycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.16E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Clarithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.43E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Clinafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.06E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Tetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Linezolid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.75E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Moxifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.91E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Thiamphenicol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.79E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Oxytetracycline dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Rifampicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Furazolidone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.00E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Niridazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.76E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Carbadox	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.47E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Benzylpenicillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.19E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Nadifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.04E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Gatifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.77E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Sarafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000407513]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Rifaximin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.03E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Furaltadone hydrochloride	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.49E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Meropenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.31E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Erythromycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Josamycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Lincomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Nifuroxazide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000166937]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Cefazolin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.11E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Piperacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.11E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Roxithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.67E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Hexachlorophene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.73E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Alexidine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.67E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Tylosin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.46E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Novobiocin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.78E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Ticarcillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.26E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Dirithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000200215]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Spiramycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.96E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Thimerosal	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.28E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Auranofin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.41E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Closantel	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Benzathine benzylpenicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.99E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Ampicillin trihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.44E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Cefotaxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.87E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Cefoperazone dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.01E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Amoxicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.07E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Fusidic acid sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.50E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Nitrofural	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.54E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.64E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Thiostrepton	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.25E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Ronidazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.11E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Talampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.07E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Sparfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.68E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Cephalothin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.51E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.05E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Cefdinir	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Rufloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002160053]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Ornidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.11E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Troleandomycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.31E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Ceforanide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000949381]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Imipenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Phenethicillin potassium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.70E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.14E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Cefoxitin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000273365]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Nifurtimox	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.58E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Secnidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.49E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Methyl benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.91E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Diacerein	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.08E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Monensin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.84E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Chloroxine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.08E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Pentamidine isethionate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.34E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Merbromin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.82E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Nitrofurantoin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003050721]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Cefuroxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.55E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Moxalactam disodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.66E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Ebselen	Therapeutic Substance	Investigational Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.37E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Cefepime hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.50E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Dicloxacillin sodium salt hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.99E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Cefotetan	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000180873]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Vancomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Azlocillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.44E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Bacitracin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.48E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Daunorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005040288]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Cefotiam hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Cefmetazole sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.61E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Clioquinol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.66E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Dequalinium dichloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009240568]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Flucloxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.81E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Loracarbef	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009959859]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Isoconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.15E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Clotrimazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Cloxacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.11E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Ceftazidime pentahydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Nafcillin sodium salt monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.61E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Miconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.19E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Oxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.63E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Flumequine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008468237]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Clofazimine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Bacampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.12E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Cefixime	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003586475]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Tioconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.03E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Oxethazaine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.60E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Econazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Thonzonium bromide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.61E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Streptozotocin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Lymecycline	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.69E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Colistin sulfate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003395309]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Cefsulodin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.58E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Oxiconazole Nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.44E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Pivampicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.77E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Bifonazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.79E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Terfenadine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000575937]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Butoconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.68E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Tamoxifen citrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006847773]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Sertaconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.14E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Loratadine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.80E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Clemizole hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.11E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Tazobactam	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003762061]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Sulconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.82E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Bepridil hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000213422]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Thioridazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000354051]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Enilconazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.87E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Perhexiline maleate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.65E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Clomiphene citrate (Z,E)	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000409922]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Avermectin B1a	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001196707]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Ketoconazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00171391]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Astemizole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002062169]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Entacapone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003959654]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Pinaverium bromide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000919651]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Methiothepin maleate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000587621]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Amiodarone hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000147452]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Stanozolol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005291612]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Sertindole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003077566]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Gefitinib	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001858081]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Fendiline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009434026]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Suloctidil	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.94E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Meclozine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001303223]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Zotepine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001711794]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004276717]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Zuclopenthixol dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005211733]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Butenafine Hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002639895]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Hexetidine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000285174]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Trifluoperazine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000767287]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Halofantrine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001229724]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Prenylamine lactate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001383791]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Azelastine HCl	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007897794]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Perphenazine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003200122]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Clofilium tosylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00386463]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Proadifen hydrochloride	Environmental Chemicals	Unclassified Substance	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003952581]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Sertraline	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008314918]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	GBR 12909 dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004498]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Thyroxine (L)	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001698405]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Norcyclobenzaprine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000421185]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Deptropine citrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002434065]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Dicyclomine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002806708]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] eligens	Dimethisoquin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004750396]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Rifabutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000378371]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Doxycycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000409003]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Chlortetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000361878]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Tosufloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000306383]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000170551]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Minocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000214078]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Meclocycline sulfosalicylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000974908]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Demeclocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017063]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Methacycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001033647]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Chlorhexidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000338955]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Florfenicol	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000172554]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Ciprofloxacin hydrochloride monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000898138]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Rifapentine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000262719]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Azithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00040424]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Clindamycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000355776]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Clarithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000166057]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Clinafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000935714]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Tetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000361878]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Linezolid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000273851]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Moxifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001400586]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Thiamphenicol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000169166]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Oxytetracycline dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000214299]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Rifampicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000399994]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Furazolidone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000162753]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Niridazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000265494]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Carbadox	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000221545]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Benzylpenicillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000209646]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Nadifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001837541]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Sarafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000691821]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Rifaximin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000165922]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Furaltadone hydrochloride	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000166057]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Meropenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000170551]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Erythromycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000353513]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Josamycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000355771]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Lincomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000213422]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Nifuroxazide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000399703]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Cefazolin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000988593]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Piperacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000170551]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Roxithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000168726]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Hexachlorophene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000165512]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Alexidine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000164611]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Tylosin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000165993]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Novobiocin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000166937]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Ticarcillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00021134]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Dirithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0004071]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Spiramycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000169084]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Niclosamide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001492278]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Thimerosal	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002294069]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Auranofin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000163771]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Closantel	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000271581]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Benzathine benzylpenicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001038111]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Ampicillin trihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000361878]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Cefotaxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000362657]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Cefoperazone dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000384931]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Amoxicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000387318]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Fusidic acid sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000382397]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Nitrofural	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000402648]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000166057]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Thiostrepton	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008421756]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Ronidazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000167597]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Talampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001040151]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Sparfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001923597]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Cephalothin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000168984]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000967328]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Cefdinir	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000401702]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Rufloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001080112]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Ornidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000167548]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Troleandomycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000976862]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Ceforanide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000271267]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Imipenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000412089]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Phenethicillin potassium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000170885]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000346097]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Cefoxitin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000169502]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Nifurtimox	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001055051]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Secnidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000165993]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Methyl benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000164898]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Diacerein	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000170513]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Monensin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000165512]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Chloroxine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00034623]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Pentamidine isethionate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000407731]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Merbromin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000168628]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Nitrofurantoin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000168706]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Cefuroxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000168435]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Moxalactam disodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000168822]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Ebselen	Therapeutic Substance	Investigational Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000165]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Cefepime hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000216184]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Dicloxacillin sodium salt hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000271872]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Cefotetan	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000271267]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Vancomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000403341]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Azlocillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00016811]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Bacitracin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017063]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Daunorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001199846]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Cefotiam hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000405409]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Cefmetazole sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0001689]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Clioquinol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000163962]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Triclosan	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000453083]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Dequalinium dichloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000372795]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Flucloxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001039356]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Enoxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001718902]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Loracarbef	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000230873]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Isoconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000350754]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Clotrimazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000202747]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Cloxacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000982525]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Ceftazidime pentahydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000407345]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Nafcillin sodium salt monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000171186]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Miconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000165993]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	5-fluorouracil	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005029022]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Benzbromarone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003862578]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Oxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000169084]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Clofazimine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003261408]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Bacampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000991355]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Cefixime	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000279971]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Tioconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000347934]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Oxethazaine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000166653]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Econazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000207066]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Thonzonium bromide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000169425]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Lymecycline	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001026634]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Trimethoprim	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000449161]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Colistin sulfate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002922821]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Cefsulodin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000168449]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Oxiconazole Nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000957735]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Pivampicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001224807]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Bifonazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000165081]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Pyrimethamine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002168721]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Terfenadine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001593325]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Cefaclor hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00079504]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Butoconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00028298]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Zafirlukast	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00811522]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Tamoxifen citrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003193652]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Etoposide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001445676]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Sertaconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000170773]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Loratadine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000905297]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Clemizole hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000166388]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Sulconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000162663]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Bepridil hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00166258]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Mefloquine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002765864]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Azaguanine-8	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000195813]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Troglitazone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003048825]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Thioridazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003451354]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Enilconazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001010013]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Methotrexate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001928589]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Perhexiline maleate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001468787]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Amethopterin (R,S)	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001557165]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Clomiphene citrate (Z,E)	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001929889]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Amikacin hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000556732]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Tobramycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003665325]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Avermectin B1a	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000569178]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Estradiol Valerate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002436407]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Ketoconazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000755219]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Efavirenz	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005069808]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Astemizole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000965664]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Pinaverium bromide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00029395]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Methiothepin maleate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001925619]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Amiodarone hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00126153]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Stanozolol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000439773]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Toremifene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002310188]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Sertindole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000282724]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Montelukast	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007492184]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Gefitinib	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000198323]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Fendiline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004664749]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Suloctidil	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003364809]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Meclozine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009134219]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Lansoprazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00073008]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Alfacalcidol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00282026]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Zotepine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001843987]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Pimozide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000219214]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006471855]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Apramycin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005453684]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Hexetidine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000769692]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Acarbose	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000460108]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Rabeprazole Sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00183633]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Trifluoperazine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003095836]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Prochlorperazine dimaleate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006409321]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Spectinomycin dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008337197]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Ivermectin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00339554]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Halofantrine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002281473]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Fluphenazine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003104732]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Prenylamine lactate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006182585]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Ethaverine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004729501]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Parbendazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005696752]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Saquinavir mesylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003173408]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Thiethylperazine dimalate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001757155]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Azelastine HCl	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0041032]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Vecuronium bromide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000301514]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Clofilium tosylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000200168]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Lidoflazine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001454241]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Sertraline	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001553159]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Asenapine maleate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003655819]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Indatraline hydrochloride	Environmental Chemicals	Unclassified Substance	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005829803]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Loperamide hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002894824]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Mebhydroline 1,5-naphtalenedisulfonate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002495343]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Triflupromazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008014017]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Folic acid	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001145843]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Fluspirilen	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009483084]	High-throughput incubation assays	n.a.	PMID: 29555994
[Eubacterium] rectale	Darifenacin hydrobromide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001015196]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Rifabutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Doxycycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Chlortetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.19E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Tosufloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Minocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.54E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Meclocycline sulfosalicylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Demeclocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.43E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Methacycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.81E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Chlorhexidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Florfenicol	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.09E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Ciprofloxacin hydrochloride monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Rifapentine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Azithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Clindamycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Clarithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.47E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Clinafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.17E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Tetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.04E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Linezolid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Moxifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Thiamphenicol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.72E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Oxytetracycline dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.54E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Rifampicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Benzylpenicillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.80E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Nadifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.56E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Gatifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Sarafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.06E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Rifaximin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.07E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Erythromycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Josamycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.38E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Lincomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.57E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Nifuroxazide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000473102]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Cefazolin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004079502]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Piperacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Roxithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.60E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Hexachlorophene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.52E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Alexidine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.28E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Tylosin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.46E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Novobiocin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Ticarcillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.56E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Dirithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Spiramycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.46E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Niclosamide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Thimerosal	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.46E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Auranofin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.16E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Closantel	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Benzathine benzylpenicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.89E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Ampicillin trihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.12E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Cefotaxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000312424]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Cefoperazone dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.43E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Amoxicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.83E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.48E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Thiostrepton	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Talampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000181202]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Sparfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.50E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Cephalothin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000686529]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Cefdinir	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.85E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Troleandomycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Phenethicillin potassium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.23E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Methyl benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.19E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Monensin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.81E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Chloroxine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000686521]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Pentamidine isethionate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001427007]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Cefuroxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.70E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Ebselen	Therapeutic Substance	Investigational Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Cefepime hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000711793]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Dicloxacillin sodium salt hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Azlocillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.02E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Bacitracin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.54E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Daunorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Cefotiam hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.07E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Triclosan	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008164124]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Dequalinium dichloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.19E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Flucloxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000949493]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Cloxacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.91E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Lomefloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000198677]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Nafcillin sodium salt monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.55E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Miconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003529462]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	5-fluorouracil	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.03E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Benzbromarone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007174905]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Oxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.05E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Clofazimine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001721254]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Bacampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005573957]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Oxethazaine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Econazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002834728]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Thonzonium bromide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001049058]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Ofloxacin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000149183]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Norfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003173959]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Trimethoprim	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Oxiconazole Nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004700317]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Pyrimethamine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000686935]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Doxorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.55E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Etoposide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.95E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Pyrvinium pamoate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004579591]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Loratadine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008854011]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Clemizole hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001957133]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Methotrexate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Amethopterin (R,S)	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Amikacin hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.72E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Tobramycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003224539]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Avermectin B1a	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001227586]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Tolnaftate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003395954]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Ivermectin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006102465]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Thyroxine (L)	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009357149]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Flucytosine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007454192]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Carvedilol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004253894]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Fadrozole hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007672282]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Betaxolol hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006477728]	High-throughput incubation assays	n.a.	PMID: 29555994
Lactobacillus paracasei	Iocetamic acid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.86E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Rifabutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Doxycycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Chlortetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Tosufloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Minocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Meclocycline sulfosalicylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.57E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Demeclocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Methacycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Chlorhexidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Florfenicol	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Ciprofloxacin hydrochloride monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Rifapentine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Azithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Clindamycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Clarithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Clinafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Tetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Linezolid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Moxifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Thiamphenicol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Oxytetracycline dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Rifampicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Furazolidone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Niridazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Carbadox	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Benzylpenicillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Nadifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Gatifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Sarafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Rifaximin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Furaltadone hydrochloride	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Meropenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.33E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Erythromycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Josamycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Lincomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Cefazolin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.57E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Piperacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Roxithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Hexachlorophene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Alexidine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Tylosin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Novobiocin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Ticarcillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Dirithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Spiramycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Niclosamide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Thimerosal	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001166423]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Auranofin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Closantel	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Benzathine benzylpenicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Ampicillin trihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Cefotaxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Cefoperazone dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Amoxicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Fusidic acid sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Nitrofural	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000270398]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Thiostrepton	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Ronidazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.23E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Talampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Sparfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Cephalothin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.57E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Cefdinir	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Rufloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Ornidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.23E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Troleandomycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.57E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Ceforanide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Imipenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Phenethicillin potassium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Cefoxitin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Nifurtimox	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Secnidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Methyl benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.62E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Diacerein	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Monensin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Chloroxine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Pentamidine isethionate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Merbromin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Nitrofurantoin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00021442]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Cefuroxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Moxalactam disodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Ebselen	Therapeutic Substance	Investigational Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002400165]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Cefepime hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.55E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Dicloxacillin sodium salt hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Cefotetan	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Azlocillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Daunorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Cefotiam hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Cefmetazole sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Clioquinol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Triclosan	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Dequalinium dichloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001063906]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Flucloxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Enoxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Loracarbef	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Cloxacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.95E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Lomefloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.88E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Ceftazidime pentahydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Nafcillin sodium salt monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	5-fluorouracil	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Benzbromarone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.01E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Oxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Flumequine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004208369]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Clofazimine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001074754]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Bacampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.65E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Cefixime	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Ofloxacin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000298156]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Streptozotocin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Lymecycline	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Norfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.65E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Trimethoprim	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.53E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Cefsulodin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Floxuridine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Pivampicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.28E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Pyrimethamine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.91E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Terfenadine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002107446]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Doxorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Hexestrol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Pefloxacine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.38E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Mafenide hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.29E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Dienestrol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Cefaclor hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Pyrvinium pamoate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00021713]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Diethylstilbestrol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.48E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Tazobactam	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Tiratricol, 3,3',5-triiodothyroacetic acid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002177626]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Mefloquine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000732883]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Zidovudine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.70E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Trifluridine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.96E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Anthralin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Promazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006814855]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Ethopropazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.11E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Efavirenz	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006094828]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Tolfenamic acid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001265417]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Methiothepin maleate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004225506]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Dicumarol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000511457]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Metixene hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000994849]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Aztreonam	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.19E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Moricizine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002627508]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Loxapine succinate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.54E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Trimeprazine tartrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006969853]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Toltrazuril	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003783935]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Hycanthone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001979002]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Quinacrine dihydrochloride dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000154227]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Idoxuridine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001120241]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Sulbactam	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Saquinavir mesylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003155935]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Flufenamic acid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004838187]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Clavulanate potassium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000334219]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Metergoline	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002160053]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Flunixin meglumine	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000691593]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Temozolomide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008274591]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Dantrolene sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002634804]	High-throughput incubation assays	n.a.	PMID: 29555994
Odoribacter splanchnicus	Doxazosin mesylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008264925]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Rifabutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Doxycycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Chlortetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Tosufloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Minocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.80E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Meclocycline sulfosalicylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.59E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Demeclocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Methacycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.25E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Chlorhexidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Florfenicol	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Ciprofloxacin hydrochloride monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Rifapentine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Azithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Clindamycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Clarithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.62E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Clinafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Tetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.44E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Linezolid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Moxifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Thiamphenicol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.78E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Oxytetracycline dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Rifampicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Furazolidone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.82E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Niridazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Carbadox	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Benzylpenicillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Nadifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Gatifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Sarafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.53E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Rifaximin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Furaltadone hydrochloride	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Meropenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.76E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Erythromycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.65E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Josamycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Lincomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Nifuroxazide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.33E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Cefazolin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.23E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Piperacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Roxithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.09E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Hexachlorophene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Alexidine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.47E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Tylosin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Novobiocin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Ticarcillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Dirithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Spiramycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.47E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Niclosamide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Thimerosal	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.17E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Auranofin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Closantel	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Benzathine benzylpenicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Ampicillin trihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.28E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Cefotaxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Cefoperazone dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.79E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Amoxicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.54E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Fusidic acid sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Nitrofural	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000453712]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.20E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Thiostrepton	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Ronidazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.62E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Talampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.76E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Sparfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Cephalothin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.87E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Cefdinir	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.16E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Rufloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.70E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Ornidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Troleandomycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Ceforanide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.71E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Phenethicillin potassium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.78E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.12E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Cefoxitin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.36E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Nifurtimox	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.44E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Secnidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.87E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Methyl benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.72E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Diacerein	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.94E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Monensin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Pentamidine isethionate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Merbromin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000646374]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Nitrofurantoin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000112269]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Cefuroxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Moxalactam disodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Ebselen	Therapeutic Substance	Investigational Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000199681]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Cefepime hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Cefotetan	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Azlocillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Bacitracin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.35E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Daunorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.22E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Cefmetazole sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Triclosan	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.78E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Dequalinium dichloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.67E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Enoxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003167824]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Loracarbef	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.93E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Isoconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.54E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Clotrimazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001800915]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Lomefloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000153415]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Ceftazidime pentahydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Miconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007636386]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	5-fluorouracil	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.85E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Benzbromarone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.82E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Cefixime	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Tioconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.94E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Oxethazaine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.03E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Econazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000192316]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Thonzonium bromide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.59E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Ofloxacin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.66E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Streptozotocin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.62E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Lymecycline	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.53E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Floxuridine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.23E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Terfenadine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000485641]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Doxorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000213793]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Hexestrol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.94E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Mafenide hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000407345]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Dienestrol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Zafirlukast	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.47E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Felodipine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.70E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Tamoxifen citrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.30E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Diethylstilbestrol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.66E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Tiratricol, 3,3',5-triiodothyroacetic acid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000970824]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Bepridil hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0023746]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Mefloquine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.02E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Thioridazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.73E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Clomiphene citrate (Z,E)	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008757232]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Promazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000112711]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Ethopropazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.55E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Efavirenz	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.03E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Aprepitant	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001985399]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Tolfenamic acid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.05E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Methiothepin maleate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004049483]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Dicumarol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000114306]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Toremifene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000479833]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Sertindole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.36E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Metixene hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Diclazuril	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000137683]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Montelukast	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Chlorprothixene hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000776517]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Moricizine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000165707]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Loxapine succinate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Zotepine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003256341]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Pimozide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009098165]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Trimeprazine tartrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.92E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Zuclopenthixol dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000575241]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Toltrazuril	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.75E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Butenafine Hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000999474]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Pimethixene maleate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007677224]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Trifluoperazine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001621938]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Prochlorperazine dimaleate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008917598]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Chlorpromazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003429568]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Promethazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Quinacrine dihydrochloride dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000100254]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Cilnidipine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002695836]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Meclofenamic acid sodium salt monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003019082]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Fluphenazine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005572399]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Perphenazine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001361982]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Telmisartan	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004467722]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Flufenamic acid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001149242]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Amodiaquin dihydrochloride dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.09E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Aripiprazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00018774]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Idebenone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003822923]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Simvastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000762378]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Etofenamate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000338854]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Mitotane	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003007578]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Racepinephrine HCl	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000111392]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	Pemirolast potassium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006799706]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides distasonis	R(-) Apomorphine hydrochloride hemihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00016442]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Rifabutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Doxycycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Chlortetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Tosufloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Minocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Meclocycline sulfosalicylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Demeclocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Methacycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Chlorhexidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Florfenicol	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Ciprofloxacin hydrochloride monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Rifapentine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Azithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Clindamycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Clarithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Clinafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Tetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Linezolid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Moxifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Thiamphenicol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Oxytetracycline dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Rifampicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Furazolidone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Niridazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Carbadox	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Benzylpenicillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Nadifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Gatifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Sarafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Rifaximin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Furaltadone hydrochloride	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.49E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Meropenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Erythromycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Josamycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Lincomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Nifuroxazide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.24E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Cefazolin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Piperacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.13E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Roxithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Hexachlorophene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Alexidine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Tylosin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Novobiocin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Ticarcillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Dirithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Spiramycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Niclosamide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Thimerosal	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Auranofin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Closantel	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Benzathine benzylpenicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Ampicillin trihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Cefotaxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Amoxicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Fusidic acid sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Nitrofural	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.30E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.93E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Thiostrepton	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Ronidazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Talampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Sparfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Cephalothin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.97E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Cefdinir	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Rufloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.90E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Ornidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Troleandomycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Ceforanide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.67E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Phenethicillin potassium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Cefoxitin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Nifurtimox	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.65E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Secnidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Methyl benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.37E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Diacerein	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Monensin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.21E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Chloroxine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.41E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Pentamidine isethionate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.47E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Merbromin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00034437]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Cefuroxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Ebselen	Therapeutic Substance	Investigational Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.61E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Cefepime hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Dicloxacillin sodium salt hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.58E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Cefotetan	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Vancomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000181202]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Azlocillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.76E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Bacitracin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Daunorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.81E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Cefotiam hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.06E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Clioquinol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.08E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Triclosan	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.59E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Dequalinium dichloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.73E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Flucloxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005381005]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Loracarbef	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Isoconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.73E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Clotrimazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.64E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Cloxacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003097339]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Lomefloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.30E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Ceftazidime pentahydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Miconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000170427]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	5-fluorouracil	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002584087]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Benzbromarone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.90E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Bacampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Cefixime	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Tioconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.63E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Econazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001809617]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Thonzonium bromide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Ofloxacin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Colistin sulfate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Oxiconazole Nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003093329]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Bifonazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002866397]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Terfenadine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000970824]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Hexestrol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Dienestrol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.23E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Zafirlukast	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007133259]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Felodipine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.97E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Tamoxifen citrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000403341]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Pyrvinium pamoate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Diethylstilbestrol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000151975]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Tazobactam	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001688439]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Tiratricol, 3,3',5-triiodothyroacetic acid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003190057]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Bepridil hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007296817]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Thioridazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000126222]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Anthralin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.01E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Estradiol Valerate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000997738]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Promazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.67E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Ethopropazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Efavirenz	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.12E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Tolfenamic acid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000141002]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Dicumarol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006860033]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Sertindole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002065448]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Metixene hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Diclazuril	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Chlorprothixene hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00216403]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Protriptyline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006955194]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Moricizine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.37E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Loxapine succinate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Trimeprazine tartrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.55E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Toltrazuril	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.03E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Butenafine Hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0018713]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Pimethixene maleate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000120861]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Chlorpromazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003605615]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Promethazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Cilnidipine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009525141]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Meclofenamic acid sodium salt monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000845062]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Cinoxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.79E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Flufenamic acid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008821497]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Lidoflazine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.06E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Amodiaquin dihydrochloride dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.40E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Ribavirin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003021836]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Mifepristone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.97E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Isosorbide dinitrate	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001898209]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Amoxapine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008486101]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Racepinephrine HCl	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005817496]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Pemirolast potassium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003849058]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Nicardipine hydrochloride	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005823836]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	Famprofazone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004960818]	High-throughput incubation assays	n.a.	PMID: 29555994
Parabacteroides merdae	N6-methyladenosine	Environmental Chemicals	Unclassified Substance	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004484062]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Rifabutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000105362]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Doxycycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000337554]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Chlortetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000204718]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Tosufloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.40E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.29E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Minocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.42E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Meclocycline sulfosalicylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.51E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Demeclocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000937349]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Methacycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002795386]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Chlorhexidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.36E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Florfenicol	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.76E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Ciprofloxacin hydrochloride monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006006895]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Rifapentine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.50E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Azithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000333615]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Clindamycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.47E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Clarithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.70E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Clinafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.56E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Linezolid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.55E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Moxifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.56E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Rifampicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000335395]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Furazolidone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.33E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Niridazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.29E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Carbadox	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.34E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Benzylpenicillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.84E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Nadifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000101163]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Gatifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.80E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Sarafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002363748]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Rifaximin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001576716]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Furaltadone hydrochloride	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.44E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Meropenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.46E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Erythromycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.56E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Josamycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.32E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Lincomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.03E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Nifuroxazide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005302486]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Cefazolin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.69E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Piperacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.31E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Roxithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.46E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Hexachlorophene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.32E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Alexidine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.44E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Tylosin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.65E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Novobiocin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.53E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Ticarcillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.73E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Spiramycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.72E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Niclosamide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.76E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Thimerosal	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000862574]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Auranofin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.24E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Closantel	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.44E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Benzathine benzylpenicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.78E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Ampicillin trihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.54E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Cefotaxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.51E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Cefoperazone dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000119098]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Amoxicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000102179]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Fusidic acid sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000103492]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Nitrofural	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000355466]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.36E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Thiostrepton	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000338971]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Ronidazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.87E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Talampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.58E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Sparfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.67E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Cephalothin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.52E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.65E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Cefdinir	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000312742]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Rufloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000877737]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Ornidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.61E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Troleandomycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.40E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Ceforanide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.35E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Imipenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000333376]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Phenethicillin potassium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.32E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.58E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Cefoxitin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.38E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Nifurtimox	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.78E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Secnidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.65E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Methyl benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.51E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Diacerein	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.04E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Monensin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00193131]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Chloroxine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.13E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Pentamidine isethionate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00216796]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Merbromin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.49E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Nitrofurantoin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.33E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Cefuroxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.53E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Moxalactam disodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.36E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Ebselen	Therapeutic Substance	Investigational Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.14E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Cefepime hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.63E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Dicloxacillin sodium salt hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.27E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Cefotetan	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.36E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Vancomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002799645]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Azlocillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.69E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Bacitracin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.35E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Daunorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00773707]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Cefotiam hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000322932]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Cefmetazole sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.74E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Clioquinol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.63E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Triclosan	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.14E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Flucloxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000129378]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Enoxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000348442]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Loracarbef	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.47E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Isoconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00048278]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Clotrimazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005092649]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Cloxacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.09E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Ceftazidime pentahydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000334037]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Nafcillin sodium salt monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000251723]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Miconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008944356]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Benzbromarone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002185392]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Oxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.89E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Flumequine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007296817]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Bacampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.67E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Cefixime	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.46E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Tioconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000660736]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Oxethazaine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.79E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Econazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003414426]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Thonzonium bromide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.73E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Colistin sulfate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002523703]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Cefsulodin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.60E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Floxuridine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000187809]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Bifonazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003915281]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Terfenadine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.10E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Hexestrol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0028704]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Dienestrol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000188147]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Zafirlukast	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000548876]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Felodipine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00027388]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Tamoxifen citrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003241269]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Sertaconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002796885]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Diethylstilbestrol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005071009]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Tazobactam	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.70E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Mefloquine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.35E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Troglitazone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00615387]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Thioridazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000180705]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Perhexiline maleate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000172153]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Trifluridine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000600373]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Estradiol Valerate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007431509]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Efavirenz	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001747188]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Astemizole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007611659]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Methiothepin maleate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000263044]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Amiodarone hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008678266]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Toremifene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003764233]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Sertindole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000955606]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Diclazuril	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.20E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Fendiline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008811167]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Chlorprothixene hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003321156]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Aztreonam	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000688403]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Zotepine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004271679]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Pimozide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004270959]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Azathioprine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000171237]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Zuclopenthixol dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002177626]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Toltrazuril	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001053227]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Trifluoperazine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000746972]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Prochlorperazine dimaleate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003039172]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Idoxuridine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006327976]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Fluphenazine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001603792]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Sulbactam	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000796508]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Haloprogin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003972536]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Thiethylperazine dimalate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000454427]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Mercaptopurine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000214679]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Sertraline	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002797396]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Aripiprazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008493167]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Cladribine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004324909]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Isosorbide dinitrate	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000673767]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Gemcitabine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000437895]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Iopanoic acid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000901834]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Nefazodone HCl	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006634379]	High-throughput incubation assays	n.a.	PMID: 29555994
Prevotella copri	Clomipramine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000642265]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Rifabutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.12E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Doxycycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.65E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Chlortetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.88E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Tosufloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.07E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.99E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Minocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000183397]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Meclocycline sulfosalicylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.56E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Demeclocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.94E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Methacycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.90E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Chlorhexidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.84E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Florfenicol	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.65E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Ciprofloxacin hydrochloride monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002785984]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Rifapentine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.45E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Azithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Clindamycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.97E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Clarithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Clinafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Tetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.93E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Linezolid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.36E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Moxifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00010614]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Thiamphenicol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.01E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Oxytetracycline dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000258893]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Rifampicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Furazolidone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Niridazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.21E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Carbadox	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.79E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Benzylpenicillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00023389]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Nadifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000114592]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Gatifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.18E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Rifaximin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.88E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Furaltadone hydrochloride	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.96E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Meropenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.84E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Erythromycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.89E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Josamycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.88E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Lincomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000232154]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Nifuroxazide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.68E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Cefazolin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Piperacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.96E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Roxithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.72E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Alexidine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Tylosin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Novobiocin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Ticarcillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000232311]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Dirithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Spiramycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.99E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Niclosamide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002579406]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Thimerosal	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000626908]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Auranofin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.57E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Benzathine benzylpenicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.74E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Ampicillin trihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.74E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Cefotaxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.81E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Cefoperazone dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.71E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Amoxicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.72E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Fusidic acid sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.92E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Nitrofural	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Thiostrepton	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.79E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Ronidazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001497261]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Talampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.82E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Cephalothin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.56E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.43E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Cefdinir	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.65E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Rufloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004555788]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Ornidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.89E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Troleandomycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.29E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Ceforanide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.21E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Imipenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.62E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Phenethicillin potassium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.76E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.81E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Cefoxitin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Nifurtimox	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.85E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Secnidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.72E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Methyl benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Diacerein	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Monensin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.93E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Chloroxine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000142897]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Pentamidine isethionate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.68E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Merbromin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Nitrofurantoin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.70E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Cefuroxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.75E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Moxalactam disodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Ebselen	Therapeutic Substance	Investigational Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002297368]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Cefepime hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000253591]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Dicloxacillin sodium salt hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.29E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Cefotetan	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.03E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Vancomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.70E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Azlocillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.68E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Bacitracin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Daunorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.55E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Cefotiam hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.62E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Cefmetazole sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.77E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Clioquinol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000964707]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Dequalinium dichloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.60E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Flucloxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.82E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Loracarbef	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.76E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Isoconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.69E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Clotrimazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002911093]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Cloxacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.44E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Ceftazidime pentahydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.64E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Nafcillin sodium salt monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Miconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	5-fluorouracil	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.27E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Oxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.76E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Flumequine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009830868]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Clofazimine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.44E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Bacampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.48E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Cefixime	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.29E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Tioconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.90E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Oxethazaine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.00E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Econazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000183536]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Thonzonium bromide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Streptozotocin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.88E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Colistin sulfate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000142269]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Cefsulodin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Oxiconazole Nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.42E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Floxuridine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.83E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Pivampicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.77E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Bifonazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000165427]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Terfenadine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.74E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Doxorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.32E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Cefaclor hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.59E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Butoconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.34E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Tamoxifen citrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000341198]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Etoposide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.47E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Sertaconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Pyrvinium pamoate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005257452]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Clemizole hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.80E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Sulconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.39E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Mefloquine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000103252]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Thioridazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000342803]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Zidovudine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.76E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Methotrexate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006374774]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Perhexiline maleate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001652559]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Amethopterin (R,S)	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009074269]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Clomiphene citrate (Z,E)	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000281831]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Trifluridine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.39E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Aprepitant	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001005864]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Pinaverium bromide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.08E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Methiothepin maleate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000271321]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Amiodarone hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000130393]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Cephalosporanic acid, 7-amino	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.31E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Toremifene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003428481]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Sertindole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.36E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Suloctidil	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000251723]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Pimozide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000404048]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Zuclopenthixol dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000835203]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Hycanthone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000688404]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Trifluoperazine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000360067]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Prochlorperazine dimaleate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005482844]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Propidium iodide	Environmental Chemicals	Unclassified Substance	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.76E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Halofantrine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007614793]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Quinacrine dihydrochloride dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000822814]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Fluphenazine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00250842]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Cyclosporin A	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.40E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Sulbactam	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000472372]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Saquinavir mesylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00602832]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Perphenazine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.66E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Clofilium tosylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000254099]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Lidoflazine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.05E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Cefadroxil	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002679627]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Amlodipine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00126153]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Metergoline	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002585901]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia hominis	Demecarium bromide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000207856]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Rifabutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000225141]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Doxycycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000406033]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Chlortetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000135092]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Tosufloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000164879]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000183586]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Minocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000681488]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Meclocycline sulfosalicylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000477981]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Demeclocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000183647]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Methacycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001195925]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Chlorhexidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000133856]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Florfenicol	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000151221]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Ciprofloxacin hydrochloride monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000416305]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Rifapentine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000160919]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Azithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000342522]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Clindamycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000131781]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Clarithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000141125]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Clinafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000468263]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Tetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000133224]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Linezolid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000169425]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Moxifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000241328]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Thiamphenicol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00018783]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Oxytetracycline dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000646073]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Rifampicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000325894]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Furazolidone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000239345]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Niridazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000179511]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Carbadox	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000132494]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Benzylpenicillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00066158]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Nadifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000345801]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Gatifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000536192]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Sarafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001243714]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Rifaximin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00018963]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Furaltadone hydrochloride	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000166377]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Meropenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000133365]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Erythromycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000138652]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Josamycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000133484]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Lincomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000691798]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Nifuroxazide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000309554]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Cefazolin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000686521]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Piperacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000185636]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Roxithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000209985]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Hexachlorophene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000159446]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Alexidine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000171847]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Tylosin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000133498]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Novobiocin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00021134]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Ticarcillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000658811]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Dirithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000323156]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Spiramycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000172121]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Niclosamide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000190957]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Thimerosal	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000750365]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Auranofin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000243363]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Closantel	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000179188]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Benzathine benzylpenicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000606965]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Ampicillin trihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000138933]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Cefotaxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000131781]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Cefoperazone dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000300773]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Amoxicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000253591]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Fusidic acid sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000233624]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Nitrofural	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000315934]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000128455]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Thiostrepton	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000346874]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Ronidazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000126331]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Talampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00095505]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Sparfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000602138]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Cephalothin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000135328]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000604897]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Cefdinir	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000320023]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Rufloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001211448]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Ornidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000166057]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Troleandomycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000925813]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Ceforanide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000172471]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Imipenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00033814]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Phenethicillin potassium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017552]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000144555]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Cefoxitin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000233624]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Nifurtimox	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000687091]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Secnidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000133324]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Methyl benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000131961]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Diacerein	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000202857]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Monensin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00015911]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Chloroxine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Pentamidine isethionate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000324492]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Merbromin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00018563]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Nitrofurantoin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000148521]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Cefuroxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000132382]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Moxalactam disodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000245651]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Ebselen	Therapeutic Substance	Investigational Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000166421]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Cefepime hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000681488]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Dicloxacillin sodium salt hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000175753]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Cefotetan	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000155772]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Vancomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000362476]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Azlocillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000216779]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Bacitracin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000185438]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Daunorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000422533]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Cefotiam hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000372124]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Cefmetazole sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000140634]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Clioquinol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000178834]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Triclosan	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000250692]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Dequalinium dichloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000424954]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Flucloxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000833633]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Enoxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004538411]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Loracarbef	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00015842]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Isoconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000133224]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Clotrimazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000635361]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Cloxacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000508555]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Ceftazidime pentahydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000333791]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Nafcillin sodium salt monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000216356]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Miconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0001943]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	5-fluorouracil	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001979002]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Benzbromarone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0064412]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Oxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000152121]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Flumequine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007277845]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Clofazimine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005828529]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Bacampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000563638]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Cefixime	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000177543]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Tioconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000133859]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Oxethazaine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00019455]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Econazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000665366]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Thonzonium bromide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000166653]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Streptozotocin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000175664]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Colistin sulfate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001187417]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Cefsulodin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00022602]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Oxiconazole Nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000543699]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Pivampicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000899543]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Bifonazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000160194]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Terfenadine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000132871]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Doxorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004838187]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Hexestrol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003185447]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Mafenide hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003522489]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Dienestrol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004038344]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Cefaclor hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000751703]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Butoconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000215102]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Zafirlukast	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000925335]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Felodipine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002287279]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Tamoxifen citrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000484892]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Etoposide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000800613]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Sertaconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000156512]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Loratadine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000426132]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Clemizole hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000142009]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Sulconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000246537]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Tiratricol, 3,3',5-triiodothyroacetic acid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008092593]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Bepridil hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002131008]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Mefloquine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00061337]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Troglitazone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001020538]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Thioridazine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00089262]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Enilconazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001194454]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Perhexiline maleate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000559087]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Clomiphene citrate (Z,E)	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000236766]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Amikacin hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000241562]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Tobramycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000336385]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Avermectin B1a	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000364452]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Ketoconazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000750365]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Astemizole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000930375]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Aprepitant	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000454054]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Pinaverium bromide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000151975]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Methiothepin maleate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000672828]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Amiodarone hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0002565]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Stanozolol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000269858]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Toremifene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000158052]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Sertindole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000223961]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Montelukast	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000673509]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Gefitinib	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000630469]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Fendiline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003134602]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Suloctidil	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00082887]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Meclozine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001403155]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Lansoprazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000428798]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Alfacalcidol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001149386]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Pimozide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001273328]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000750365]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Toltrazuril	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006747685]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Apramycin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000841542]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Butenafine Hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005890941]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Hexetidine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000580982]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Anethole-trithione	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000981846]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Lacidipine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006991061]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Rabeprazole Sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000854305]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Trifluoperazine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002532969]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Spectinomycin dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000311386]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Tolnaftate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007521944]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Ivermectin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00087023]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Halofantrine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000894084]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Fluphenazine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005479453]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Prenylamine lactate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004760197]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Ethaverine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001686706]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Parbendazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00080764]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Dihydrostreptomycin sulfate	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000428843]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Etomidate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008448038]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Thiethylperazine dimalate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004535848]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Azelastine HCl	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006525874]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Vardenafil	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000586538]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Clofilium tosylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004885272]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Lidoflazine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008916378]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001487911]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Gentamicine sulfate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008614335]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Epirizole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003382732]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	GBR 12909 dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007394277]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Iohexol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004750711]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Simvastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002620571]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Sisomicin sulfate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005840765]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Mitotane	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003977147]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Riluzole hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00913864]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Fluspirilen	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000392987]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Norgestimate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005430066]	High-throughput incubation assays	n.a.	PMID: 29555994
Roseburia intestinalis	Flunarizine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004676065]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Rifabutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.06E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Doxycycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Chlortetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.08E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Tosufloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.36E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Minocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Meclocycline sulfosalicylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.62E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Demeclocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Methacycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.49E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Chlorhexidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.05E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Florfenicol	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Ciprofloxacin hydrochloride monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000283578]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Rifapentine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.31E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Azithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Clindamycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.05E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Clarithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Clinafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.96E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Tetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.05E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Linezolid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.31E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Moxifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.37E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Thiamphenicol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Oxytetracycline dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Rifampicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Furazolidone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Niridazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.34E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Carbadox	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.96E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Benzylpenicillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Nadifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.01E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Gatifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.45E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Sarafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000132773]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Rifaximin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Furaltadone hydrochloride	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Meropenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Erythromycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.05E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Josamycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.03E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Lincomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Nifuroxazide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00122221]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Cefazolin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.62E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Piperacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Roxithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.79E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Hexachlorophene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Alexidine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.85E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Tylosin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Ticarcillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Dirithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Spiramycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Niclosamide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Thimerosal	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.47E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Auranofin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Closantel	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.30E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Benzathine benzylpenicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.50E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Ampicillin trihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.10E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Cefotaxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.10E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Cefoperazone dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.00E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Amoxicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.99E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Fusidic acid sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.99E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Nitrofural	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000651391]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Thiostrepton	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.16E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Ronidazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Talampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.52E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Cephalothin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.62E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Cefdinir	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Ornidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Troleandomycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.62E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Ceforanide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.30E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Imipenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Phenethicillin potassium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.05E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Cefoxitin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Nifurtimox	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.53E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Secnidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Methyl benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000271654]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Diacerein	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Monensin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.06E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Chloroxine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.09E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Pentamidine isethionate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.11E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Merbromin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Nitrofurantoin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000217512]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Cefuroxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Moxalactam disodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.79E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Ebselen	Therapeutic Substance	Investigational Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Cefepime hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Dicloxacillin sodium salt hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.31E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Cefotetan	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.30E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Vancomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.14E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Azlocillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Bacitracin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Daunorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.53E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Cefotiam hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.12E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Cefmetazole sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Clioquinol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Dequalinium dichloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000159192]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Flucloxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.49E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Loracarbef	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Isoconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.08E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Clotrimazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Cloxacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.62E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Ceftazidime pentahydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Nafcillin sodium salt monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001070784]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Miconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Benzbromarone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.42E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Oxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Clofazimine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.64E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Bacampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.63E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Cefixime	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.31E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Tioconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.21E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Oxethazaine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.03E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Econazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Lymecycline	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.10E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Cefsulodin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.11E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Oxiconazole Nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.62E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Pivampicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.50E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Bifonazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Cefaclor hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Butoconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.31E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Felodipine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004078377]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Sertaconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Loratadine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.23E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Clemizole hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Tazobactam	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.83E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Sulconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Troglitazone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001808803]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Enilconazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.50E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Amikacin hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.00E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Tobramycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.71E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Estradiol Valerate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Ketoconazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.64E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Efavirenz	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0002032]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Entacapone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.87E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Stanozolol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.52E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Gefitinib	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001950525]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Lansoprazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000152827]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000196508]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Apramycin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000238177]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Anethole-trithione	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.26E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Rabeprazole Sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001688439]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Chlorotrianisene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002425866]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Etomidate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002512885]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Isosorbide dinitrate	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.26E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Clavulanate potassium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008071607]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Acenocoumarol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006136303]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Erlotinib	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005683558]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Lynestrenol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000228354]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Diloxanide furoate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009077749]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Nicorandil	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002266077]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Pranlukast	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007658516]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Glafenine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.35E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Ruminococcus bromii	Testosterone propionate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000556732]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Rifabutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Doxycycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Chlortetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.69E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Tosufloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.86E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Minocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.10E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Meclocycline sulfosalicylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Demeclocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Methacycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Chlorhexidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.77E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Florfenicol	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Ciprofloxacin hydrochloride monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000314817]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Rifapentine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.77E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Azithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Clindamycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.72E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Clarithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Clinafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Tetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.71E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Linezolid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.77E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Moxifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.50E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Thiamphenicol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Oxytetracycline dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.13E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Rifampicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Furazolidone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Niridazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.76E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Carbadox	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.06E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Benzylpenicillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.13E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Nadifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Gatifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000172471]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Sarafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.57E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Rifaximin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Furaltadone hydrochloride	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.17E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Meropenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.71E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Erythromycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.69E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Josamycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.67E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Lincomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.13E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Nifuroxazide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.11E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Cefazolin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Piperacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Roxithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Hexachlorophene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Alexidine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Tylosin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Novobiocin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.66E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Ticarcillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.16E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Dirithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Spiramycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Niclosamide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000164947]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Thimerosal	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.51E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Auranofin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Closantel	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.77E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Benzathine benzylpenicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Ampicillin trihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.75E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Cefotaxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.79E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Cefoperazone dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Amoxicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Fusidic acid sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Nitrofural	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.34E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.24E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Thiostrepton	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Ronidazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.72E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Talampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Sparfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.81E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Cephalothin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Cefdinir	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Rufloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001636301]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Ornidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.66E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Troleandomycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000477981]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Ceforanide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.77E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Imipenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000798186]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Phenethicillin potassium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.66E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Cefoxitin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Nifurtimox	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Secnidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Methyl benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.11E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Diacerein	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.24E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Monensin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Chloroxine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.40E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Pentamidine isethionate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Merbromin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000151975]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Nitrofurantoin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001363477]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Cefuroxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Moxalactam disodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Ebselen	Therapeutic Substance	Investigational Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.73E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Cefepime hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.17E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Dicloxacillin sodium salt hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.77E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Vancomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Azlocillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Bacitracin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Daunorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000895076]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Cefotiam hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000133971]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Cefmetazole sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.15E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Clioquinol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.50E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Dequalinium dichloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.61E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Flucloxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Enoxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002313221]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Loracarbef	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Isoconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.74E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Clotrimazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.82E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Cloxacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Nafcillin sodium salt monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Miconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Benzbromarone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.26E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Oxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Clofazimine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003813771]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Bacampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Tioconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.66E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Oxethazaine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.17E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Econazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.16E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Thonzonium bromide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.56E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Streptozotocin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Lymecycline	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009392496]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Norfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003780078]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Trimethoprim	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.44E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Cefsulodin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Oxiconazole Nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.65E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Floxuridine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Pivampicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Bifonazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Terfenadine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000740599]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Hexestrol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009586657]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Mafenide hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009222294]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Dienestrol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Cefaclor hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009425311]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Butoconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.76E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Zafirlukast	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.75E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Tamoxifen citrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.71E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Etoposide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Sertaconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.71E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Pyrvinium pamoate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007923075]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Clemizole hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.36E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Sulconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Bepridil hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005475023]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Mefloquine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000473573]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Troglitazone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00446964]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Enilconazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.81E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Methotrexate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005149904]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Perhexiline maleate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001596797]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Amethopterin (R,S)	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000214389]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Clomiphene citrate (Z,E)	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000133859]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Amikacin hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001543463]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Astemizole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000919651]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Toremifene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001890094]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Montelukast	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000958761]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Halofantrine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006930773]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Vecuronium bromide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000543623]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	GBR 12909 dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000891288]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] gnavus	Iohexol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002666464]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Rifabutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.33E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Doxycycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Chlortetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.07E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Tosufloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.84E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.77E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Minocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Meclocycline sulfosalicylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.87E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Demeclocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.72E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Methacycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.82E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Chlorhexidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Florfenicol	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Ciprofloxacin hydrochloride monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Rifapentine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.40E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Azithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Clindamycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.54E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Clarithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.14E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Clinafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000150969]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Tetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Linezolid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.54E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Moxifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006468553]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Thiamphenicol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Oxytetracycline dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Rifampicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.51E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Furazolidone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.74E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Niridazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.39E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Carbadox	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Benzylpenicillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Nadifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.73E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Gatifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000778131]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Sarafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.48E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Rifaximin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.28E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Furaltadone hydrochloride	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000141893]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Meropenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.68E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Erythromycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Josamycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Lincomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Nifuroxazide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.47E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Cefazolin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.96E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Piperacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Roxithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Hexachlorophene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.64E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Alexidine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.22E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Tylosin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.19E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Novobiocin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.93E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Ticarcillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Dirithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Spiramycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.75E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Niclosamide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000404096]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Thimerosal	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000646322]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Auranofin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.77E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Closantel	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.19E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Benzathine benzylpenicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.05E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Ampicillin trihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.57E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Cefotaxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.57E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Cefoperazone dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.77E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Amoxicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.63E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Fusidic acid sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.65E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Nitrofural	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.44E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Thiostrepton	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Ronidazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.63E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Talampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.25E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Cephalothin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.33E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Cefdinir	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Rufloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008930242]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Ornidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.54E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Troleandomycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.91E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Ceforanide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.58E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Imipenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.46E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Phenethicillin potassium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Cefoxitin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.67E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Nifurtimox	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004828422]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Secnidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Methyl benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.19E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Diacerein	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.81E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Monensin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.47E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Chloroxine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.61E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Pentamidine isethionate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.65E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Merbromin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.24E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Cefuroxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.18E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Moxalactam disodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.34E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Ebselen	Therapeutic Substance	Investigational Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.87E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Cefepime hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Dicloxacillin sodium salt hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Cefotetan	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000787021]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Vancomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Azlocillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Bacitracin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.01E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Cefotiam hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.67E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Cefmetazole sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Clioquinol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.98E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Triclosan	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.98E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Dequalinium dichloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007772802]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Flucloxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.83E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Enoxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001391235]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Loracarbef	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000207669]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Isoconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.11E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Clotrimazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.25E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Cloxacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.86E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Nafcillin sodium salt monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Miconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.77E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Oxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.17E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Clofazimine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.61E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Bacampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.16E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Cefixime	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.56E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Tioconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Oxethazaine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.07E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Econazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.40E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Thonzonium bromide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000331598]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Streptozotocin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.46E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Lymecycline	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.13E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Norfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00358652]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Colistin sulfate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000244933]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Cefsulodin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.52E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Oxiconazole Nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.11E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Bifonazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.45E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Terfenadine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000118131]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Doxorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000240309]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Dienestrol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.34E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Butoconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.53E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Felodipine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009028298]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Tamoxifen citrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000360321]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Etoposide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.79E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Sertaconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000100649]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Loratadine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000561844]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Clemizole hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000273281]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Sulconazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Troglitazone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001354778]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Enilconazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000110537]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Amikacin hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.28E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Tobramycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.34E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Avermectin B1a	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.01E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Estradiol Valerate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000575241]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Ketoconazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.51E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Astemizole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000536906]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Entacapone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.66E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Pinaverium bromide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002561027]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Stanozolol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.55E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Gefitinib	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003385786]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Suloctidil	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001171004]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Lansoprazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.12E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.29E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Apramycin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.57E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Butenafine Hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007511804]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Hexetidine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000160806]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Anethole-trithione	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.20E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Rabeprazole Sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.36E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Chlorotrianisene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001283709]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Tolnaftate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000374146]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Ivermectin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.51E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Ethaverine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.16E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Parbendazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.60E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Dihydrostreptomycin sulfate	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000776173]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Etomidate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.42E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Vardenafil	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000390662]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Tenatoprazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.91E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Gentamicine sulfate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001548607]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Epirizole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.70E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Simvastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004017029]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Sisomicin sulfate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0001018]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Fenbendazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0001339]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Albendazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001083172]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Atovaquone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002191168]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Erlotinib	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002028454]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Riluzole hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000384151]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Nicardipine hydrochloride	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003157294]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Leflunomide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.77E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Nilutamide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000442687]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Lynestrenol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003709083]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Abacavir Sulfate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000584373]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Methiazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000164286]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Nimesulide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001019344]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Butamben	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001622822]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Salmeterol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002505954]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Butylparaben	Environmental Chemicals	Unclassified Substance	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000285497]	High-throughput incubation assays	n.a.	PMID: 29555994
[Ruminococcus] torques	Tracazolate hydrochloride	Environmental Chemicals	Unclassified Substance	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000232154]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Rifabutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.67E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Doxycycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.84E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Chlortetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Tosufloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.55E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Minocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Meclocycline sulfosalicylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Demeclocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Methacycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.96E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Chlorhexidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Florfenicol	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Ciprofloxacin hydrochloride monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Rifapentine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Azithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.92E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Clindamycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Clarithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Clinafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.71E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Tetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Linezolid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Moxifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Thiamphenicol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.46E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Oxytetracycline dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Rifampicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.89E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Furazolidone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.45E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Niridazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Carbadox	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Benzylpenicillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Nadifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.83E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Gatifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.00E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Sarafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.18E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Rifaximin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Furaltadone hydrochloride	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Meropenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Erythromycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Josamycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Lincomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Nifuroxazide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.08E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Cefazolin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Piperacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.53E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Roxithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Hexachlorophene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Alexidine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.45E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Tylosin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Novobiocin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Ticarcillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Dirithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.90E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Spiramycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Niclosamide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.85E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Thimerosal	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.84E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Auranofin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.14E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Closantel	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Benzathine benzylpenicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.08E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Ampicillin trihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Cefotaxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Cefoperazone dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.67E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Amoxicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.67E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Fusidic acid sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00127379]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Thiostrepton	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.91E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Talampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.11E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Sparfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.84E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Cephalothin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Cefdinir	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.92E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Rufloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001734051]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Troleandomycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Ceforanide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Imipenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.88E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Phenethicillin potassium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Cefoxitin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Methyl benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001708248]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Diacerein	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.82E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Monensin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Pentamidine isethionate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.92E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Merbromin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0005815]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Nitrofurantoin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.66E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Cefuroxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Moxalactam disodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Ebselen	Therapeutic Substance	Investigational Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.75E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Cefepime hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Dicloxacillin sodium salt hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Cefotetan	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Vancomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.92E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Azlocillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Bacitracin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Daunorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.79E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Cefotiam hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.89E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Cefmetazole sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Triclosan	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00406747]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Dequalinium dichloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000750268]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Flucloxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.08E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Loracarbef	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Cloxacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Lomefloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006240123]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Ceftazidime pentahydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.03E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Nafcillin sodium salt monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Miconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001963582]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Benzbromarone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000100118]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Oxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Bacampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Cefixime	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.53E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Oxethazaine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.54E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Ofloxacin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.40E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Lymecycline	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001859804]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Norfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00012336]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Cefsulodin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.20E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Floxuridine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.73E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Pivampicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.21E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Pyrimethamine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000596883]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Doxorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Cefaclor hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.52E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Zafirlukast	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000240274]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Felodipine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008363427]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Etoposide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.10E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Enilconazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009673022]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Methotrexate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Amethopterin (R,S)	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.91E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Amikacin hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000160215]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Tobramycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.07E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Dicumarol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.54E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Diclazuril	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008913545]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Alfacalcidol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005574865]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Apramycin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008830102]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Spectinomycin dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000358033]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Cilnidipine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009376224]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Dihydrostreptomycin sulfate	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000349122]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus parasanguinis	Gentamicine sulfate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009968201]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Rifabutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.82E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Doxycycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Chlortetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.71E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Tosufloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.67E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Minocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Meclocycline sulfosalicylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Demeclocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.83E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Methacycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Chlorhexidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.72E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Florfenicol	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Ciprofloxacin hydrochloride monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.69E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Rifapentine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Azithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Clindamycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.77E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Clarithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Clinafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Tetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.67E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Linezolid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Moxifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.71E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Thiamphenicol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Oxytetracycline dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Rifampicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Furazolidone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.95E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Niridazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.00E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Carbadox	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001009145]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Benzylpenicillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Nadifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.65E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Gatifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.25E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Sarafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.52E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Rifaximin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.56E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Furaltadone hydrochloride	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00357394]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Meropenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Erythromycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.67E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Josamycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.71E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Lincomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Nifuroxazide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.64E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Cefazolin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Piperacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.62E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Roxithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Hexachlorophene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.55E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Alexidine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.47E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Tylosin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.52E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Novobiocin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Ticarcillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Dirithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.00E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Spiramycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.60E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Niclosamide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Thimerosal	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Auranofin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.98E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Closantel	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Benzathine benzylpenicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Ampicillin trihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.72E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Cefotaxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.72E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Cefoperazone dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.54E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Amoxicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.54E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Fusidic acid sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.89E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.44E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Thiostrepton	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Talampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Sparfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Cephalothin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.59E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Cefdinir	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Troleandomycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Ceforanide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Imipenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.09E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Phenethicillin potassium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.56E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Cefoxitin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Methyl benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.07E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Diacerein	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.72E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Monensin sodium salt	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.55E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Pentamidine isethionate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.39E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Cefuroxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.52E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Moxalactam disodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Ebselen	Therapeutic Substance	Investigational Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000623909]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Cefepime hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Dicloxacillin sodium salt hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.67E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Cefotetan	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.67E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Vancomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Azlocillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Bacitracin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Daunorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Cefotiam hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Cefmetazole sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.52E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Triclosan	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.62E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Dequalinium dichloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.76E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Flucloxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Enoxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001329469]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Loracarbef	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Isoconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003205469]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Clotrimazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006108494]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Cloxacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Lomefloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000279971]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Ceftazidime pentahydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Nafcillin sodium salt monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Miconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006471536]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Benzbromarone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Oxacillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Clofazimine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004620385]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Bacampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Cefixime	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Tioconazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001995732]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Oxethazaine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.29E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Econazole nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004177971]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Ofloxacin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.25E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Lymecycline	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Norfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.84E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Cefsulodin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Oxiconazole Nitrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003427444]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Floxuridine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Pivampicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Doxorubicin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.72E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Hexestrol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001027956]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Cefaclor hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Zafirlukast	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Felodipine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004629765]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Tamoxifen citrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001510749]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Etoposide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Diethylstilbestrol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004139029]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Tiratricol, 3,3',5-triiodothyroacetic acid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Bepridil hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008500296]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Troglitazone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.61E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Methotrexate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.77E-07]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Amethopterin (R,S)	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.64E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Clomiphene citrate (Z,E)	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009110665]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Amikacin hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.70E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Tobramycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.44E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Avermectin B1a	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007766915]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Dicumarol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000465018]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Montelukast	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.92E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Meclozine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002196121]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Alfacalcidol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.93E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Apramycin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00394427]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Lacidipine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007635661]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Propidium iodide	Environmental Chemicals	Unclassified Substance	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.34E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Ivermectin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00248147]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Telmisartan	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006928984]	High-throughput incubation assays	n.a.	PMID: 29555994
Streptococcus salivarius	Albendazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003156937]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Rifabutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Doxycycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Chlortetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Tosufloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Minocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Meclocycline sulfosalicylate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Demeclocycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Methacycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Chlorhexidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Florfenicol	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Ciprofloxacin hydrochloride monohydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Rifapentine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Azithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.76E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Clindamycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Clarithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Clinafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Tetracycline hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Linezolid	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Moxifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Thiamphenicol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Oxytetracycline dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Rifampicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.87E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Furazolidone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Niridazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Carbadox	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Benzylpenicillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Nadifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Gatifloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Sarafloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Rifaximin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Furaltadone hydrochloride	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Meropenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Erythromycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Josamycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Lincomycin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Nifuroxazide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.93E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Cefazolin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.16E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Piperacillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Roxithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Hexachlorophene	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Alexidine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Tylosin	Therapeutic Substance; Herbal Substance	Approved Drug (veterinary medicine); Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Ticarcillin sodium	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Dirithromycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.36E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Spiramycin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Niclosamide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Thimerosal	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.91E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Auranofin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Closantel	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Benzathine benzylpenicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Ampicillin trihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Cefotaxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Cefoperazone dihydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Amoxicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Fusidic acid sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.16E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Nitrofural	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.80E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Thiostrepton	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.29E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Ronidazole	Therapeutic Substance	Approved Drug (veterinary medicine)	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Talampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Sparfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Cephalothin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Tinidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.93E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Cefdinir	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Rufloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Ornidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Ceforanide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Imipenem	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Phenethicillin potassium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Cefoxitin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Nifurtimox	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Secnidazole	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Methyl benzethonium chloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Diacerein	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Chloroxine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Pentamidine isethionate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.27E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Nitrofurantoin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Cefuroxime sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Moxalactam disodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Cefepime hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Cefotetan	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Azlocillin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Cefotiam hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.72E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Cefmetazole sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Clioquinol	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Dequalinium dichloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Enoxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Loracarbef	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Lomefloxacin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Ceftazidime pentahydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.16E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	5-fluorouracil	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Flumequine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Bacampicillin hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.86E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Cefixime	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Thonzonium bromide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Ofloxacin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Lymecycline	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.76E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Norfloxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Colistin sulfate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.19E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Cefsulodin sodium salt	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006092327]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Pivampicillin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Pyrimethamine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Terfenadine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002974409]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Pefloxacine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Mafenide hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000124422]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Cefaclor hydrate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Pyrvinium pamoate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.15E-05]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Methotrexate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Amethopterin (R,S)	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Anthralin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Fleroxacin	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Aprepitant	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008757071]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Pinaverium bromide	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Cephalosporanic acid, 7-amino	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001967198]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Suloctidil	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000149165]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Aztreonam	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Azathioprine	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002817096]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Cyclosporin A	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00310105]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Cyclobenzaprine hydrochloride	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008100327]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Hydrocortisone base	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008929837]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Zileuton	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000426281]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Spiperone	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000133269]	High-throughput incubation assays	n.a.	PMID: 29555994
Veillonella parvula	Mometasone furoate	Therapeutic Substance	Approved Drug	n.a.	Decrease	Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.46E-05]	High-throughput incubation assays	n.a.	PMID: 29555994